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Abstract: Formononetin, an isoflavone, is extracted from various medicinal plants and herbs,
including the red clover (Trifolium pratense) and Chinese medicinal plant Astragalus membranaceus.
Formononetin’s antioxidant and neuroprotective effects underscore its therapeutic use against
Alzheimer’s disease. Formononetin has been under intense investigation for the past decade as strong
evidence on promoting apoptosis and against proliferation suggests for its use as an anticancer agent
against diverse cancers. These anticancer properties are observed in multiple cancer cell models,
including breast, colorectal, and prostate cancer. Formononetin also attenuates metastasis and tumor
growth in various in vivo studies. The beneficial effects exuded by formononetin can be attributed
to its antiproliferative and cell cycle arrest inducing properties. Formononetin regulates various
transcription factors and growth-factor-mediated oncogenic pathways, consequently alleviating the
possible causes of chronic inflammation that are linked to cancer survival of neoplastic cells and their
resistance against chemotherapy. As such, this review summarizes and critically analyzes current
evidence on the potential of formononetin for therapy of various malignancies with special emphasis
on molecular targets.
Keywords: formononetin; cancer; preclinical models; cell signaling; angiogenesis
1. Introduction
Cancer refers to the disease that develops when abnormal cells proliferate uncontrollably, followed
by invasion into the surrounding tissues and eventually spreads to the organs or other parts of
the body via the circulatory and lymphatic systems [1]. The fundamental process that leads to the
development of cancer is the process of continuous, unregulated proliferation of cancer cells, resulting
in tumor development [2]. Cancer has claimed the lives of 8.8 million individuals in 2015, making
it the second leading cause of death worldwide after cardiovascular diseases [3,4]. In the past few
decades, numerous treatment methods have been developed against cancer after acquiring a deeper
understanding of multiple underlying signals and mechanisms that contribute to the survival and
progression of neoplastic cells. These treatment modalities include both adjuvant and neoadjuvant
chemotherapy, targeted therapy, immunotherapy, surgery, and radiotherapy. The incidence of cancer
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still remains high, with increasing mortality due to the disease progression despite significant progress
in treatment regimens [3,4]. This phenomenon can be largely attributed to the limited effects exhibited
by existing cancer therapies and the high cost of treatment, coupled with significant adverse effects [5].
Furthermore, conventional cytotoxic agents usually embody life-threatening toxicities [6]. There have
been nearly 500 cases of withdrawal of medicinal products from the market as a result of adverse drug
reactions over the past six decades, with the most common reason being hepatotoxicity [7]. In addition,
certain cancers, such as breast cancer, can still resurface after a dormant period of 15 years following
successful treatment [8], suggesting that there is a need to develop new and safe treatment options that
can be proven to be more efficacious.
Natural products and dietary agents have gained enormous popularity over the years to be used
in the clinical setting. They can be obtained from plants, microorganisms, or animals and have been
used medicinally for decades, usually in complementary and alternative medicine [9]. An example
would be Veregen, a topical ointment containing green tea extract sinecatechins, which is used to
treat external genital and perianal warts, and the herb Artemisia annua, from which pharmaceutical
scientist Tu Youyou managed to isolate artemisinin that is now used as a potent antimalarial drug [10].
These studies indicate the promising use of natural products for future discovery and development of
cancer preventive and anticancer drugs. In the past three decades, nearly 80% of the drugs approved
by the United States Food and Drug Administration for cancer therapy contain natural products or
imitate their functions [11,12]. Natural products have since then made their appearance and represent
a large portion of today’s pharmaceutical agents used in cancer therapy, including taxol, vinblastine
and camptothecin [13]. Over 60% of the current anticancer drugs are derived from natural sources [13],
and the impetus to discover more natural products for chemotherapy and chemoprevention has
become evident in the past decade as more agents are now in clinical trials.
Antitumorigenic activity can be found in compounds with different structural groups, including
isoprenoids (including terpenoids and carotenoids), isoflavones, etoposide, and teniposide [5,11,14–35].
They function through various mechanisms, including the induction of apoptosis via DNA cleavage
by inhibiting the activity of topoisomerase I or II, mitochondrial permeabilization, inhibiting crucial
enzymes in signal transduction (i.e., proteases), cellular metabolism, or by inhibiting tumor-induced
angiogenesis [9,36]. Certain isoflavones, such as isoliquiritigenin, have been shown to possess
antitumorigenic properties, including pro-apoptotic effect on human cancer cells [37]. In recent years,
there has been increasing evidence in preclinical and clinical studies that suggest that a dysregulated
inflammatory response plays a crucial role in cancer development and may even be a key driver of
cancer [38,39].
Chronic inflammation is also one of the hallmarks of cancer, and can drive the development of
cancer through increasing the production of pro-inflammatory mediators involved in various signaling
mechanisms, including cytokines, chemokines, reactive oxygen species/intermediates, increased expression
of oncogenes, cyclooxygenase-2, 5-lipoxygenase, matrix metalloproteinases (MMPs), and pro-inflammatory
transcription factors, such as nuclear factor-κB (NF-κB), signal transducer and activator of transcription
3 (STAT3), activator protein 1 (AP-1) and hypoxia-inducible factor 1α (HIF-1α) [38–66]. These factors
mediate the basis of cancer progression, such as the proliferation of tumor cells, metastasis, survival,
invasion, angiogenesis, chemoresistance and radio-resistance [38,47,61,64,67–71].
Targeting selected transcription factors and pathways increases the sensitivity of cancer cells to
chemotherapeutics and radiation, resulting in apoptosis [60]. Furthermore, the use of natural products,
such as farnesol, curcumin and celastrol, have been found to significantly enhance the anticancer effects
of chemotherapeutics, such as bortezomib and thalidomide, in multiple myeloma [57,72]. This suggests
that natural products can be used as adjunct cancer therapy. Despite the steady improvement of
current anticancer therapeutics, developing novel drugs remains a priority of cancer treatment due to
an overwhelming increase in resistance to chemotherapeutic drugs [9,73–76]. With greater knowledge
and constant advances in technology, there is a great prospect for safer and more efficacious treatment
options for cancer.
2
Cancers 2019, 11, 611
The red clover, Trifolium pratense (family: Fabaceae), is a legume known for its numerous health
benefits, and can hold a crucial role in the prevention and management of certain health conditions,
including type 2 diabetes, hyperlipidemia and hypertension [77]. It is a perennial herb that is commonly
found in Asia, Europe, and North America, and has been traditionally used to treat skin and respiratory
conditions, such as eczema, psoriasis, asthma and pertussis [78]. The isoflavones present in red clover
have estrogen-like activities and have been subjected to an intense research over the past two decades
due to their potential cancer-preventive, cardio-protective and anti-osteoporosis effects [78].
The extract from the red clover plant contains genistein, daidzein, formononetin (biochanin B),
and biochanin A. Formononetin [7-hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one], (Figure 1),
one of the main bioactive components extracted from the red clover, has been found to be the principal
compound that contributes the therapeutic effects observed in the extract. It is exclusively produced
by the Fabaceae family, and can be extracted from the roots of Astragalus membranaceus, T. pratense and
Glycyrrhiza glabra [79]. Since it is structurally similar to 17-estrogen, formononetin’s bioactivity mimics
the effect of estrogen and this compound is considered to be a phytoestrogen [80].
Figure 1. The chemical structure of formononetin.
Formononetin has shown beneficial effects in clinical trials for menopausal relief [81,82], reduction
in bone loss [83], and improved arterial compliance [84]. Formononetin has been used clinically in
China, in traditional medicine, as one of the fundamental herbs for treating carcinomas due to its
protective effects against certain malignant tumors [85]. Formononetin has become the subject of
intense research over the past decade due to its estrogenic effects and antitumorigenic properties.
This review will summarize and critically analyze current evidence on the potential of formononetin
for anticancer therapy with special emphasis on molecular targets.
2. Toxicity and Pharmacokinetics of Formononetin
A water-soluble derivative of formononetin, formononetin-3′-sulphonate (Sul-F, C16H12O7SNa), has
been shown to provide significant neuro- and cardio-protective effects both in vitro and in vivo [86,87].
Pro-estrogenic isoflavones, such as formononetin, can potentially be converted to more potent
phytoestrogens in the human body. Incubation of formononetin in human liver microsomes caused
demethylation, resulting in the production of formononetin derivatives and metabolites, including
daidzein [88]. Due to the fact that formononetin is a naturally occurring isoflavone and phytoestrogen,
it is associated with estrogen receptor (ER) binding. Phytoestrogens, especially isoflavones, can be
classified as endocrine disruptors and are known to modify or interfere with the endocrine function [80].
Formononetin and its metabolites can significantly enhance pro-inflammatory cytokines and
induce an allergic immune response. Interleukin-4 (IL-4) is closely associated with the CD4+ T helper
cells and EL4 T lymphoma cells (Mus musculus). An increase in IL-4 production is observed upon
administration of formononetin, daidzein, and equol due to an elevation in the activation of activator
protein 1 (AP-1) via the phosphoinositide 3-kinase (PI3K)/protein kinase C (PKC)/p38 mitogen activated
protein kinase (MAPK) signaling pathway. This suggests that formononetin and its metabolites may
potentially cause allergic responses through amplifying the production of IL-4 in T-cells [89]. Hence,
it may be a reasonable approach to restrict or limit the usage of formononetin in order to prevent
allergic responses.
3
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3. In Vitro Anticancer Pharmacological Properties of Formononetin
3.1. Antiproliferative Effects
The anticancer potential of formononetin has been explored in numerous in vitro models as
shown in Table 1. First and foremost, formononetin showed potential in inhibiting tumor growth and
proliferation. Uncontrolled proliferation is one of the primary hallmarks of cancer and represents one of
the most prominent factors associated with malignancy. This antiproliferative effect of formononetin has
been observed in multiple cancer models and is one of the main anticancer properties of formononetin.
As compared to other isoflavones, formononetin has been proven to possess the greatest antiproliferative
activity [90]. The antiproliferative property of formononetin has been observed in ER-positive breast cancer
cells, such as MCF-7 and T-47D [91,92], and displayed minimal effect against ER-negative breast cancer
cells, namely MDA-MB-231 and MDA-MB-435 [93]. It also demonstrated antiproliferative effects against
prostate cancer (PC-3, DU-145 and LNCaP) [94,95], non-small cell lung cancer (A549 and NCI-H23) [96],
cervical cancer (HeLa) [97], bladder cancer (T24) [98], osteosarcoma (U2OS), ovarian cancer (ES2 and
OV90) [99], glioma (C6), and colorectal cancer cells (HCT-116, SW1116 and RKO) [37,85].
For most cell lines, formononetin has been found to possess a concentration- and time-dependent
effect against tumor proliferation [85,94,96,98]. Antiproliferative effects of formononetin were
also demonstrated in cytokine-induced cancer models, such as multiple myeloma, where
formononetin attenuated the expression of inflammatory cytokines, including tumor necrosis factor-α
(TNF-α), transforming growth factor-β1 (TGF-β1), interleukin-6 (IL-6), and interleukin-8 (IL-8) by
downregulating hypoxia-inducible factor 1α (HIF-1α) [39,100] and nuclear factor-κB (NF-κB) [101].
Most studies conducted thus far indicate that formononetin has been able to prevent the proliferation
of tumor cells without causing serious adverse effects as compared to other chemotherapeutic drugs.
3.2. Proapoptotic Effects
For progression of abnormal cells into cancerous ones, it is crucial that the apoptosis pathway is
hijacked to allow promotion of growth and development of the damaged or abnormal cells. Cancer cells
have the ability to evade the apoptotic checkpoints, allowing them to proliferate uncontrollably [102].
As a result, the proapoptotic property of formononetin elevates its potential to be used as an anticancer
agent in cancer therapy. However, the underlying mechanisms of formononetin that promote cell
apoptosis differ among different cell lines as well as cancer models. Apoptosis observed in cells can be
classified into two different stages—early and late apoptosis—which can be differentiated through the
presence of propidium iodide [102]. Formononetin largely elevated the proportion of early apoptotic
cells in DU-145 prostate and U2SO osteosarcoma cell lines, and was found to be dose-dependent for
prostate PC-3 cells (25–100 μM) [103–105].
The influence of formononetin on apoptosis of different cancer cell lines may involve the
upregulation of specific transcription factors. The apoptotic mechanism in prostate DU-145 cells is
activated by upregulating dexamethasone-induced retrovirus associated DNA sequences (Ras)-related
protein 1 (maximum for 48 h before decreasing rapidly after) and Bcl-2-associated protein (Bax),
and simultaneously reducing B-cell lymphoma 2 (Bcl-2) levels, thereby causing the DU-145 cells
to display morphological changes indicative of the early apoptotic stage, and trigger apoptosis via
the mitochondrial apoptotic pathway [106]. On the contrary, high concentrations of formononetin
(>12.5μM) have been found to effectively inhibit proliferation and trigger apoptosis of PC-3 prostate
cancer cells by inhibiting the insulin-like growth factor 1 (IGF-1) receptor androgen-independent
pathway [104]. T24 human bladder cancer cells displayed morphological changes of apoptosis when
treated with formononetin, and there was a significant reduction in the expression of miR-21 and
phosphorylated protein kinase B (AKT). In addition, phosphatase and tensin homolog (PTEN), a
notable tumor suppressor gene, was upregulated in T24 cells after formononetin treatment, which
suppressed uncontrolled tumor proliferation [98]. Furthermore, a study by Zhang and colleagues [107]
suggested that formononetin did not elicit toxic effects on non-cancerous cell lines, indicating that it
may be a safe choice to halt cancerous cell growth.
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One of the primary factors associated with cell apoptosis is the Bax and Bcl-2 protein levels, usually
coupled with the AKT and extracellular signal regulated kinase (ERK) pathway. Bax protein is crucial
for apoptosis in normal cells to prevent excessive proliferation and possible tumor formation. However,
Bcl-2 functions in the opposite manner: enhancing cell survival by suppressing apoptosis [113].
Formononetin treatment reduced Bcl-2 protein levels and upregulated the pro-apoptotic proteins,
such as Bax and caspase-3, thereby increasing the Bax/Bcl-2 ratio and inducing apoptosis. This effect
was observed in several cancers, including prostate cancer (PC-3) [107], osteosarcoma (U2OS) [105],
non-small cell lung cancer (A549 and NCI-H23) [96], and colon carcinoma (HCT-116) [37], and was
sometimes coupled with caspase and phosphorylation activity. In PC-3 cells, increased phosphorylation
of p38 and blocked AKT phosphorylation accompanied the growth in the Bax/Bcl-2 ratio to induce
apoptosis [107]. An elevated activation and cleavage of caspase-3 was observed in A549 and
NCI-H23 non-small cell lung cancer cell lines [96], and antiapoptotic proteins Bcl-2 and Bcl-xL were
downregulated in HCT-116 colon cancer cells, along with caspase activation [37]. Furthermore,
the upstream regulator and a novel pro-apoptotic protein, non-steroidal anti-inflammatory drug
(NSAID)-activated gene (NAG-1) was found to be overexpressed in formononetin-treated HCT-116 cells,
potentially promoting the apoptotic effects of formononetin; however, it failed to induce phase-specific
cell cycle arrest [37]. In a recent study formononetin was found to inhibit the growth of osteogenic
sarcoma U2OS cells and induce apoptosis by modulating the intracellular miR-375/ERα-PI3K/AKT
signaling pathway [114].
Studies conducted thus far indicate that formononetin supports the apoptotic process of cancer
cells through intrinsic pathways, but the mechanism and pathways may differ between different cancers.
The most evident pathways suppressed by formononetin to induce apoptosis are the PI3K/AKT and
the extracellular signal regulated kinase (ERK) pathways, which are the main regulatory pathways
found dysregulated in many cancers. These pathways regulate the cell cycle and transmit signals
from the surface of the cell to the nuclear DNA [115,116]. Some examples include cervical cancer
(HeLa), osteosarcoma (U2OS) [90,105], and colorectal cancer (RKO) [101]. Other studies showed that
formononetin successfully promoted apoptosis in prostate cancer (DU-145 and PC-3) [104,106,107], breast
cancer (MCF-7 and MDA-MB-231) [92,93,108], non-small cell lung cancer (A549 and NCI-H23) [96],
colon cancer (HCT116 and SW1116) [37,85], and nasopharyngeal carcinoma (CNE1 and CNE2) [112]
via modulation of aforementioned pathways. Formononetin inactivated the MAPK signaling pathway,
causing apoptosis in MCF-7 breast cancer cells and increased expression levels of Bax in LNCaP
and PC-3 prostate cancer cells, leading to apoptosis [94]. Another commonly dysregulated pathway
in cancer is the STAT3 signaling pathway. Emerging evidence suggests that abnormal STAT3
signaling drives the initiation and progression of human cancers through the inhibition of apoptosis
and driving multiple pro-oncogenic functions [57,66,72,117–120]. Formononetin has been found to
suppress fibroblast growth factor 2 (FGF2)-induced STAT3 activation, successfully suppressing multiple
myeloma, leukemia, lymphoma and solid tumors that display constitutive STAT3 activation [121].
Furthermore, formononetin has been found to elicit greater antiproliferative and proapoptotic activity
as compared to other isoflavones, such as calycosin [90].
3.3. Induction of Cell Cycle Arrest
Treatment of various cancer cell lines using formononetin has been shown to attenuate cancer
cell proliferation via cell cycle arrest. Formononetin has been demonstrated to be highly effective in
suppressing the oncogenic PI3K/AKT pathway [122–132] and inducing cell cycle arrest in numerous
cell lines, including breast cancer (MCF-7), colorectal cancer (HCT-116 and SW1116) [85], non-small
cell lung cancer [96], and prostate cancer (PC-3 and DU-145) [95]. Formononetin can induce cell cycle
arrest at the G0/G1 phase by modifying the level of expression of cell cycle arrest-associated proteins
and growth factors, as observed in DU-145 and PC-3 prostate cancer cells [95], A549 and NCI-H23 lung
adenocarcinoma cells [96], ES2 and OV90 ovarian cancer cells [99], and MCF-7 breast cancer cells [91].
In non-small cell lung cancer, proliferation of A549 and NCI-H23 cells was significantly inhibited with
7
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treatment with formononetin. In human non-small cell lung cancer cells, formononetin induced cell
cycle arrest in the G1-phase and promoted apoptosis via increasing p21 expression and reducing cyclin
A and D1 expression in a time- and concentration-dependent manner [96].
Similarly, formononetin induced G1 arrest in PC-3 and DU-145 prostate cancer cells by
downregulating cyclin D1, protein kinase B (AKT), and cyclin dependent kinase 4 (CDK4) in a
concentration-dependent manner, and this phenomenon was observed to be more significant in PC-3
cells than DU-145 cells [95]. Inactivation of AKT facilitated the phosphorylation of glycogen synthase
kinase-3β (GSK-3β), which, coupled with the reduction of cyclin D1, can deter progression into
the G1/S phase [133]. Likewise, formononetin induced G0/G1 cell cycle arrest in MCF-7 cells by
inactivating the IGF-1/IGFR-PI3K/AKT pathway [91]. On the contrary, cell cycle arrest in SW1116
and HCT-116 colon carcinoma cells at the G0/G1 checkpoint was induced through the suppression
of cyclin D1 in a concentration-dependent manner, without changes in the expression levels of
cyclin B1, which propagated the number of cells undergoing G1 phase cell cycle arrest to 79.7% upon
treatment with 100 μM formononetin [85]. Collectively, these results suggest that the administration
of formononetin modulated the expression levels of crucial cell cycle regulators through different
pathways, consequently leading to cell cycle arrest at the G1 phase and apoptosis in various cancer
cell lines.
3.4. Antioxidant Effects
Formononetin has been investigated for its antioxidant properties and is known for being a potent
and effective natural antioxidant capable of protecting cells from most free radicals. This is a crucial
property of formononetin that may support its use as an anticancer agent because free radicals can
lead to cancer development [134]. Formononetin is also the most effective isoflavone in inhibiting lipid
peroxidation as it possesses the strongest antioxidant activity [135].
3.5. Angiogenesis-Modulating Effects
Tumor angiogenesis is an essential pathway for the development and progression of malignant
tumors [136], and studies have shown that the PI3K pathway may hold a vital role in this process [137].
It is a crucial process that leads to the growth and spread of cancer. The effect of formononetin
on angiogenesis differs for different cancers. In one study, formononetin downregulated the
expression of key pro-angiogenic factors, such as vascular endothelial growth factor (VEGF) and matrix
metalloproteinases (MMPs), in LoVo human colorectal adenocarcinoma cells and reduced xenografted
tumor size and the number of proliferating cells in the tumor tissues with decreased serum VEGF
level [109]. MMP-2 and MMP-9 are known to be directly associated with tumor angiogenesis [138].
The most well-known pathway involved in antiangiogenic therapies currently under evaluation in
clinical trials targets the VEGF pathway. However, there is a chance of the tumor acquiring resistance to
the VEGF-targeted therapy by shifting to other angiogenesis mechanisms [121], therefore rendering the
antiangiogenic treatment ineffective. Consequently, there is a need to develop alternative therapeutic
agents that inhibits other non-VEGF angiogenic pathways. Other angiogenesis inducers, apart from
VEGF, are the fibroblast growth factors basic fibroblast growth factor (b-FGF/FGF-2), making them a
potential drug target for cancer, such as melanoma [137,139]. Formononetin has been found to be a
novel FGF receptor 2 inhibitor as it suppressed the sprouting of FGF2-induced micro-vessel in rat aortic
rings and angiogenesis, specifically targeting the FGF receptor 2-mediated AKT signaling pathway,
resulting in the attenuation of tumor growth and angiogenesis [121]. As a result, formononetin could
be investigated in future studies as an angiogenesis inhibitor through targeting FGFs.
3.6. Metastasis-Regulatory Effects
When highly metastatic MDA-MB-231-luc and 4TI breast cancer cells were exposed to formononetin,
no significant difference in the cell viability was observed as compared to untreated cells [108]. However,
treatment with formononetin (2.5–40μmol/L) reduced the migration of MDA-MB-231 and 4TI cells in a
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concentration-dependent manner. Furthermore, formononetin reduced the invasion of MDA-MB-231
and 4T1 cells. Invasiveness of metastatic cancer was also attenuated in the LoVo human colon cancer
cell line [109]. This phenomenon may have been due to the reduced expression levels of MMPs.
MMP-2 and MMP-9 levels were reduced concentration-dependently with formononetin treatment,
and formononetin elevated the expression levels of tissue inhibitor of MMP-1 and MMP-2, which
are negative regulators of MMPs [108], suggesting that formononetin has the ability to influence the
expression levels of proteins and genes associated with proteolytic activation.
3.7. Anti-Inflammatory Effects
One of the hallmarks of cancer development is chronic inflammation. It can drive tumor progression
by regulating proliferation, invasion, metastasis, angiogenesis, chemoresistance, and radio-resistance
of tumor cells [1,2,38,60,61,102]. NF-κB, a pro-inflammatory transcription factor, is associated with
the inflammation and suppression of apoptosis, and is a key driver of different cellular processes
in multiple cancer models [21,50,60,62,64]. NF-κB can translocate into the nucleus and activate
numerous genes that are involved in multiple processes crucial for multistage carcinogenesis, including
proliferation, invasion, and angiogenesis, upon activation by cytokines or chemotherapeutic agents.
As a result, chemotherapeutics that can potentially inhibit NF-κB have a significant role in anticancer
therapy [5,12,21,38,50,58,60,62,102,129]. Formononetin demonstrated an inhibitory effect on NF-κB
activation, and NF-κB is a significant transcription factor for the induction of nitric oxide synthase to
decrease the production of nitric oxide in vitro [140]. The inhibition of NF-κB suggests the potential
crucial and therapeutic effect that formononetin may have in protecting against inflammation, which
may result in cancer development. Overall, the important oncogenic and pro-inflammatory pathways
affected by formononetin have been depicted in Figure 2.
 
Figure 2. Formononetin regulates major oncogenic pathways involved in cancer progression.
⊥, inhibition/downregulation; ↑ upregulation/activation.
3.8. Combinatorial Studies with Selected Chemotherapeutics
Previous clinical studies suggest that polysaccharides obtained from Astragalus plants can
counteract the adverse effects of chemotherapeutic drugs, including a significant reduction of
myelosuppression in cancer patients [141]. In addition to the antiproliferative and proapoptotic
properties of formononetin, the expression level of p53 was concentration-dependently upregulated
after treatment with formononetin through increased phosphorylation of p53 at Ser15 and Ser20,
enhancing its transcriptional activity [96]. For example, formononetin demonstrated synergy when
coupled with the use of other chemotherapeutic drugs. Temozolomide (TMZ) is an oral chemotherapy drug
often used in the treatment for certain brain cancers, such as glioblastoma multiforme. However, TMZ is a
chemotherapeutic drug that is known to causes adverse side effects, including hematologic complications
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and both intrinsic and acquired resistance [110,142]. Although results found that both formononetin
and TMZ alone were sufficient to inhibit the growth of C6 glioma cells concentration-dependently,
when formononetin is used in combination with TMZ, it displayed a synergistic effect on C6 cells.
The combination of both drugs increased Bax protein expression and cleaved caspase-3 and caspase-9,
attenuated Bcl-2 expression, and promoted tumor cell apoptosis [110]. Furthermore, the drug
combination prevented the migration of C6 glioma cells due to the down-regulated expression of
MMP-2 and MMP-9. This suggests the potential use of formononetin as a combination drug during
chemotherapy or as a post-operative adjuvant therapy to curb the adverse effects displayed by other
chemotherapeutic drugs, such as TMZ. Co-treatment consisting of formononetin with synthetic
inhibitors for ovarian cancer, such as LY294002 (PI3K inhibitor) or U0126 [mitogen activated protein
kinase kinase (MEK) inhibitor], further prevented the proliferative effects on ovarian cancer cells
(ES2 and OV90), thus increasing the occurrence of apoptosis in both cell lines [99].
Furthermore, a potent chemotherapy drug doxorubicin has been identified to induce
epithelial-mesenchymal transition (EMT) in glioma cells via elevated expression of vimentin
and reduced expression of E-cadherin in U87MG glioma cells [111]. Numerous studies have
suggested the important role that EMT holds in carcinogenicity, metastasis, progression, and acquired
chemoresistance [129,143–146]. Formononetin has been proven to be able to sensitize glioma cells to
doxorubicin, and combination therapy using doxorubicin and formononetin is able to successfully
reverse the induction of EMT by doxorubicin. In addition, histone deacetylase 5 (HDAC5) has been
identified to enhance glioma cell proliferation, and doxorubicin-treated glioma cells have been identified
to have significantly increased HDAC5 levels. However, co-treatment with formononetin reduced the
expression of HDAC5 in glioma cells. These results implied that co-treatment with formononetin and
other chemotherapeutic drugs, such as doxorubicin, potentially sensitizes cancer cells, such as glioma
cells, through the prevention of EMT and the inhibition of HDAC5 [111]. This further suggests that
formononetin could be considered as an adjuvant agent with existing chemotherapeutic drugs.
3.9. Novel Semi-Synthetic Hybrids of Formononetin
Several new bioactive derivatives of formononetin have been shown to have potent anti-cancer
activity. Ren et al., 2012 showed that formononetin nitrogen mustard derivative (IC50-3.8 μM)
exhibited potent antitumor activity against colorectal HCT-116 cells and was associated with G2/M
phase cell cycle arrest and induction of apoptosis [147]. In another study, formononetin-dithiocarbamate
hybrid (IC50-1.97 μM) inhibited androgen independent prostate cancer PC3 cell growth and induced
apoptosis by modulating the MAPK and wingless (Wnt) signaling pathway [148]. Several lines of
evidence suggest that epidermal growth factor receptor (EGFR) is an attractive target for non-small cell
lung cancer (NSCLC) therapy. Lin et al 2017 reported on a new series of formononetin derivatives
following the binding model of lapatinib to EGFR. Formononetin derivatives exhibited potent
anti-proliferative activity against triple negative breast cancer MDA-MB-231 cells and induced apoptosis
by down-regulating multiple EGFR/PI3K/Akt/Bcl-2-associated death promoter (Bad), EGFR/ERK
and EGFR/PI3K/Akt/β-catenin signaling pathways in breast cancer cells [149]. In another study
a formononetin 7-phosphoramidate derivative significantly induced early apoptosis in HepG-2
cells [150]. In a recent study by Chengli et al. [151] three new derivatives of formononetin were
shown to inhibit the growth, invasion and migration of A549 lung cancer cells. Furthermore,
Bohong et al. [152] demonstrated that multiwalled carbon nanotube–formononetin (MWCNT-FMN)
composite for sustained delivery induced apoptosis by activating reactive oxygen species (ROS)
production in cervical carcinoma HeLa cells.
4. In Vivo Anticancer Pharmacological Activities of Formononetin
The anticancer potential of formononetin has been demonstrated in numerous in vivo models as
shown in Table 2. First, formononetin has demonstrated the potential to inhibit tumor proliferation in
various murine models of cancers. As compared to controls, formononetin is able to significantly and
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dose-dependently inhibit local tumor growth in nude mice bearing MCF-7 human breast cancer [91].
The weight of the tumor in the formononetin-treated group was reduced significantly when compared
to the control, and this was substantiated with a reduction of 39.6% in tumor weight. Similar effects
have been observed using human colorectal cancer cell lines. HCT-116 nude mice xenografts (CCL-247)
treated with formononetin exhibited a large reduction in tumor volume and the number of proliferating
cells as compared to the vehicle-treated group [109]. Mortality and significant changes in body
weight were not observed in the formononetin-treated HCT-116 nude mice xenografts, indicating that
formononetin displayed tolerable toxicity while being able to significantly reduce tumor size and mass
in vivo. This observation was substantiated with comparable white blood cell counts between the
formononetin-treated and control group, suggesting that formononetin did not exhibit neutropenic
effects in preclinical models, unlike other common chemotherapeutic drugs [109]. Furthermore,
formononetin has been proven to successfully inhibit the growth of tumors in vivo through targeting
the TNF-α/NF-κB pathway in colorectal tumor bearing nude mice [101], and both tumor weight and
volume decreased dose-dependently after treatment with formononetin.
The antitumor potential of formononetin is also observed in human multiple myeloma xenografts
in nude mice, with a decrease in Ki-67 expression levels in tumor tissues [49]. Oxidative stress
induced through formononetin treatment impeded the expression of phosphorylated STAT3 and STAT5
through the STAT3 and STAT5 signaling axis by successfully removing the binding ability of both
transcription factors; thereby reversing their activation and consequently suppressing tumor growth
in multiple myeloma [49]. Similarly, the antiproliferative effect was also observed in vivo in U2OS
osteosarcoma and PC-3 and DU-145 prostate cancer nude mouse xenografts in a dose-dependent
manner through a significant reduction in tumor weight [95,105]. This further affirms the potential
application of formononetin as a cancer therapeutic agent. However, it is important to note that
varying concentrations of phytoestrogens may exude different effects on the proliferative and apoptotic
properties of different cancer models.
In vivo mouse metastasis models were used to study the inhibitory effects of formononetin on
metastatic breast cancer cells (MDA-MB-231-luc and 4T1) for lung metastasis [108]. Formononetin is
able to successfully diminish the development of lung metastasis in mouse xenografts with metastatic
breast cancer, which suggests that formononetin may possess antimigration and invasion properties on
breast cancer cells and therefore, can increase survival time in preclinical models. This is an important
finding that could promote the use of formononetin in clinical settings for chemotherapy because it
plays a protective role against breast cancer metastasis.
Formononetin has been investigated for its ability to exhibit antioxidant properties in in vivo
models. Antioxidant and estrogenic properties are important factors that could catalyze the development
of cancers as they are found to be involved in oxidative damage to the cellular macromolecules.
Several antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione
peroxidase (GSH-Px), are essential to counter the reactive oxygen species in vivo [153]. Preclinical
studies using ovariectomized mice supported the use of formononetin as a potent free radical scavenging
molecule that can prevent lipid peroxidation, which is a crucial factor in the progression of cancer [154].
The pharmacological property of formononetin in vivo is dependent on the level of estrogen
present, which can be proestrogenic or antiestrogenic [92]. As previously mentioned, free radicals
are highly reactive chemicals that can damage several major components of cells, especially the
DNA, playing a pivotal role in the development of cancer. The oxidative effects of formononetin
were monitored through the levels of SOD, GSH-Px, CAT, and malondialdehyde (MDA). A high and
low formononetin intake for 6 months was found to increase uterine weight and the levels of SOD,
GSH-Px, and CAT, and reduced MDA content in preclinical conditions, suggesting that formononetin
displayed obvious antioxidant and estrogenic effects in in vivo conditions, and the estrogenic property
of formononetin is not dose-dependent [153].
11
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Further studies conducted to analyze the estrogenic effects of formononetin showed that it
significantly elevated the expression of atrial ER subtype ERβ in ovariectomized mice [155]. Although
it has not been yet demonstrated that formononetin is able to negatively impact the ER in preclinical
models, this study provides us with insight that formononetin could likely affect the regulation of ERs,
which are essential in the development of hormone-sensitive cancers, such as breast and ovarian cancer.
Tumor angiogenesis is a crucial process for tumor growth and metastasis for the development of
cancer. The most well-established effect is the role of VEGF and VEGFR2. However, as mentioned earlier,
there is evidence that the tumor can become resistant to VEGF-targeted therapy and acquire resistance
against monotherapy with VEGFR inhibitors that manipulate other angiogenesis mechanisms [156].
The antiangiogenic property of formononetin is observed in nude mouse xenografts through the reduced
levels of VEGF in drug-treated animals when compared against controls [109]. In preclinical models,
formononetin displayed antiangiogenic properties in a myriad of cancers, especially colorectal cancer
(HCT-116) [109] and breast cancer (MDA-MB-231-luc) [108]. The HCT-116 human metastatic colorectal
adenocarcinoma cell line is known for its invasiveness and metastatic properties. Following treatment
with formononetin, HCT-116 tumor xenografts in mice displayed a notable reduction in the number of
invaded cells [109]. In another study, formononetin at doses of 25, 50 or 100 mg/kg administered for
14 days significantly suppressed the growth of subcutaneously implanted osteogenic sarcoma U2OS
tumor growth and was associated with the downregulation of miR-375 with concomitant upregulation
of Bax, Caspase-3, and Apaf-1 [114]. Further studies in preclinical models with small molecules have
been of interest in recent years as a therapeutic measure against cancer since multi-kinase inhibitors
targeting VEGFR have been proven effective in clinical settings against breast tumors. However, these
agents displayed signs of toxicity and did not exhibit high response rates. Formononetin derivative
when administered intraperitoneally (i.p.) for 21 days (5 mg/kg) was shown to significantly inhibit
breast tumor growth in a nude mice model when compared to EGFR inhibitors gefitinib or lapatinib
and was found to be well tolerated with no significant change in the body weight of the mice [149].
Further research in the preclinical setting has found evidence that formononetin could be
effective for antiangiogenesis treatment against human breast cancer (MDA-MB-231) xenografted in
nude mice by preventing tumor growth via inhibition of tumor angiogenesis [121]. Furthermore,
formononetin supplemented the effect of sunitinib, a receptor tyrosine kinase inhibitor that targets
VEGFR2, on tumor growth inhibition through largely decreasing the invasiveness of cancer cells
stimulated by tumor growth in vivo through the fibroblast growth factor receptor 2 (FGFR2)-mediated
AKT signaling pathway, attenuating tumor growth and angiogenesis [121,157]. The inhibition of
angiogenesis in xenografted human breast cancer (MDA-MB-231) by formononetin was found to
modulate FGF2-induced micro-vessel growth that suppressed the emergence of rat aortic rings and
angiogenesis through the repression of FGF2-initiated activation of FGFR2 and AKT signaling [121].
5. Formononetin in Clinical Studies
Formononetin has been tested in preclinical settings for other diseases, such as Alzheimer’s [158],
but clinical studies for the use of formononetin as a treatment method for cancer have yet to be
conducted. Jarred and colleagues [159] identified that treatment with a red clover-derived isoflavone
mixture was able to induce apoptosis in low- to moderate-grade human prostate carcinoma. Further
clinical research needs to be performed to ascertain the anti-cancer properties of formononetin in
multiple cancer types.
6. Conclusion and Future Perspectives
Evidence presented in this review provides a comprehensive summary on the potential anticancer
properties of formononetin in both in vitro and in vivo studies and the current progress of clinical studies.
Numerous molecular targets and mechanisms of actions are involved in the antitumorigenic property
(primarily on the induction of cell apoptosis and the inhibition of cell proliferation) of formononetin as
evidenced from numerous in vitro studies, whereas the safety and efficacy of formononetin and its
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metabolites in biological systems are further confirmed in in vivo studies. The tumor-inhibitory effects
of formononetin have been associated with the modulation of PI3K/AKT and STAT3 signaling pathways
in both in vitro and in vivo models. The various anticancer molecular targets of formononetin are
briefly summarized in Figure 3. In addition, formononetin has been found to possess additive and
synergistic effects with chemotherapeutic drugs, such as Sunitinib. The potential role for formononetin
to be used as an adjunct therapy and future prospective drug development for cancer patients are
supported through these findings. However, further studies need to be conducted (both in vivo
and clinical studies) to allow for further assessment of the efficacy and safety of formononetin for
prevention and treatment of various cancer types. This is crucial as various formononetin derivatives
and metabolites have varying pharmacokinetic properties and activities that need to be fully elucidated,
and this requires further investigation to ensure that this bioactive phytochemical is safe for clinical
development. The significant antitumor properties of formononetin make it a novel candidate for
anticancer drug development.
 
Figure 3. Molecular targets influenced by formononetin in cancer.
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Abbreviations
AKT protein kinase B
AP-1 activator protein 1
Bax Bcl-2-associated protein
Bcl-2 B-cell lymphoma 2
Bcl-xL B-cell lymphoma-extra-large
b-FGF basic fibroblast growth factor
CAT catalase
CDK cyclin-dependent kinase
CD4 cluster of differentiation 4
CREB cAMP response element-binding protein
DMSO dimethyl sulfoxide
EGR3 early growth response protein 3
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EMT epithelial-mesenchymal transition
ERK extracellular signal regulated kinase
FGF fibroblast growth factor
FGF2 fibroblast growth factor 2 receptor
GSH-Px glutathione peroxidase
GSK-3β glycogen synthase kinase 3β
HDAC5 histone deacetylase 5
HIF-1α hypoxia-inducible factor 1α
IGF-1 insulin-like growth factor 1












PTEN phosphatase and tensin homolog
ROCK Rho-associated protein kinase
siRNA small interfering ribonucleic acid
SOD superoxide dismutase
STAT3 signal transducer and activator of transcription 3
Sul-F formononetin-3′-sulphonate
TMZ temozolomide
TNF-α tumor necrosis factor-α
VCAM-1 vascular cell adhesion protein 1
VEGF vascular endothelial growth factor
VEGFR vascular endothelial growth factor receptor
Wnt Wingless
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Abstract: Malva pseudolavatera Webb & Berthel. is a plant from the Malvaceae family that has
long been included in the human diet due to its various curative effects. Many plant leaf extracts
from the various species of Malva genus have been reported to possess anti-cancer properties,
however, studies on M.pseudolavatera Webb & Berthel. leaves have documented anti-inflammatory
and anti-oxidant effects with no emphasis on their possible anti-cancer potential. The present study
explores the anti-cancer properties of Malva pseudolavatera Webb & Berthel. leaf extract on acute
myeloid leukemia (AML) cell lines in vitro and deciphers the underlying molecular mechanism.
Treatment of AML cell lines with M. pseudolavatera methanolic leaf extract showed a dose- and
time-dependent inhibition of proliferation and a dose-dependent increase in apoptotic hallmarks such
as an increase in phosphatidylserine on the outer membrane leaflet and membrane leakage in addition
to DNA fragmentation. The pro-apoptotic effect was induced by reactive oxygen species (ROS) as
well as an upregulation of cleaved poly(ADP-ribose) polymerase (PARP), increase in Bax/Bcl-2 ratio,
andrelease of cytochrome-c from the mitochondria. Major compounds of the extract included methyl
linolenate, phytol,γ-sitosterol, and stigmasterol as revealed by gas chromatography coupled with mass
spectrometry, and amino acids, amino acid derivatives, tiliroside, 13-hydroxyperoxyoctadecadienoic,
and quercitrin as detected by liquid chromatography coupled to mass spectrometry.
Keywords: Malva pseudolavatera Webb & Berthel.; apoptosis; acute myeloid leukemia; reactive
oxygen species
1. Introduction
Malva pseudolavatera Webb & Berthel. is an annual or biennial subshrub that grows in fields
and roadsides in coastal areas and low-altitude mountain regions [1]. Commonly known as “tree
mallow” in North America and “khubbaza” in the Middle East, it is a plant of the Malvaceae family [2].
Previously named Lavatera cretica (Malvaceae family), the species was transferred to the Malva genus
and is currently called M. pseudolavatera or Malva linnaei or Malva multiflora [3]. Malva pseudolavatera
Webb & Berthel. is the accepted name of the species as included on http://www.theplantlist.org [4].
Apart from being used as food in some regions such as in Turkey, Spain, and Pakistan, leaves of
the Malva genus plants have been traditionally used in folk medicine all around the world to treat
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a multitude of diseases, most commonly diarrhea, arthritis, inflammation, cough, and respiratory
infections [5]. Among the 50 species of Malva, M. pseudolavatera Webb & Berthel. is known for its
versatile uses [6]. In Spain, it is considered as a remedy for influenza, upper respiratory tract infections,
and cough [7], whereas in Portugal, it is used for its laxative, analgesic, and antiseptic effects [8].
In fact, studies showed that M. pseudolavatera Webb & Berthel. aqueous leaf extracts were able to
scavenge free radicals and inhibit lipoxygenase activity in vitro, indicating its potent antioxidant and
anti-inflammatory activities [9].
Malva species leaves have a lot of similarities in the overall morphology and anatomy, and only
differ in some characteristics such as the number of lobes, size of the blade, or margin dentation.
Leaves of many Malva species such as M. sylvestris and M. parviflora share a common basic chemical
composition as they all contain anthocyanins, flavonoids, essential oils, and tocopherols [10,11]. In fact,
many studies have shown the inhibitory effects of leaf extracts from Malva species on cancer cell
lines. The methanolic extract from M. sylvestris leaves exhibited a dose-dependent cytotoxicity on
melanoma and lymphoma cell lines in vitro [12]. Moreover, the ethanolic extract from M. parviflora
leaves showed mild cytotoxicity against the MCF-7 human breast adenocarcinoma cell line [13].
Other studies have reported that the hexane and methanol extracts from M. parviflora leaves inhibited
the proliferation of HeLa cervical carcinoma cells, but the aqueous extract did not cause any inhibition
of cell proliferation [14]. However, no studies have examined the anti-cancer potential of extracts from
M. pseudolavatera Webb & Berthel. leaves.
Acute myeloid leukemia (AML) is a type of cancer that starts in the bone marrow and quickly
moves undifferentiated myeloblasts into the blood [15]. It is an aggressive malignancy with incidence
levels still on the rise in several countries including Canada, UK, and Australia [16]. Chemotherapy is
the main treatment for AML [17] and plants have long been used as important sources for novel
chemotherapeutic drug characterization [18,19].
In the present study, we investigated the potential anti-cancer properties of M. pseudolavatera Webb
& Berthel. methanolic leaf extract (MMLE) on AML cell lines in vitro and deciphered the underlying
molecular mechanism.
2. Materials and Methods
2.1. Cell Culture
Acute myeloid leukemia cell lines, namely Mono-Mac-1, U937, and KG-1 (American Type Culture
Collection), were cultured in Roswell Park Memorial Institute medium (RPMI, Sigma-Aldrich, St. Louis,
MO, USA)supplemented with 10% fetal bovine serum (FBS) (GibcoTM, Dublin, Ireland) and 100 U/mL
penicillin and 100 μg/mL streptomycin (Lonza, Basel, Switzerland) in a humidified incubator at 5%
CO2 at 37 ◦C. Trypan blue exclusion method was used to count the cells before experimentation.
2.2. Isolation and Culture of Mesenchymal Stem Cells (MSCs) from Rat Bone Marrow
A single, 12-week-old rat was provided by the animal facility at the Lebanese American University.
The animal was maintained under optimal laboratory conditions and received food and water ad
libidum. All experiments were approved by the university’s Animal Care and Use Committee (ACUC)
and complied with the Guide for the Care and Use of Laboratory Animals (Committee for the Update
of the Guide for the Care and Use of Laboratory Animals, 2010) [20,21]. MSCs were isolated from rat
bone marrow according to a modified procedure. Briefly, the rat was sacrificed by CO2 asphyxiation
and both hind legs were aseptically removed. Femoral and tibial bones were then isolated and washed
with 70% ethanol and placed in sterile phosphate buffered saline (PBS, Lonza) supplemented with
100 U/mL penicillin and 100 μg/mL streptomycin (Lonza). After removing the bone epiphyses with
sterilized scissors, the bone marrows were flushed out using a needle filled with Dulbecco’s modified
Eagle medium (DMEM, Sigma-Aldrich) supplemented with 10% fetal bovine serum (GibcoTM) and
100 U/mL penicillin and 100 μg/mL streptomycin (Lonza). The cells collected were then incubated in
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vented flasks at 37 ◦C with 5% CO2. After 5 days of daily medium change, MSCs were identified by
their spindle-shaped morphology as observed using the ZOE fluorescent cell imager (Bio-Rad, Irvine,
CA, USA) [22–24].
2.3. Isolation and Culture of Normal Mononuclear Cells (MNCs) from Human Bone Marrow (BM)
Normal mononuclear cells were offered by Dr. Marwan El-Sabban’s Lab at the American University
of Beirut (AUB) as a kind gift. The normal MNCs were obtained originally from bone marrow aspirate
leftovers of healthy patients attending AUB Medical center (AUB-MC). BM aspirates were centrifuged
on Ficoll/Hypaque (GE Healthcare Life Sciences, Uppsala, Sweden), a density gradient step to separate
MNCs from red blood cells and neutrophils. Then the buffy coat was aspirated and seeded in petri
dishes using Dulbecco’s modified Eagle’s medium (DMEM)-low glucose (Sigma-Aldrich, Saint Louis,
MO, USA) supplemented with 10% FBS (Gibco, Dublin, Ireland) and 100 U/mL penicillin and 100 μg/mL
streptomycin (Lonza, Basel, Switzerland) in a humidified incubator at 37 ◦C and 5% CO2. One week
later, the cells in suspension were collected as a purified MNC population and cultured in the same
conditions as detailed by Zibara et al. [25].
2.4. Plant Material
Malva pseudolavatera Webb & Berthel. leaves were collected from Batroun, Lebanon (34.2498◦ N,
35.6643◦ E. 20 m above sea level), during January 2018, and identified according to the indications
and characteristics described by Edgecombe [2], and then identified by Dr. Nisrine Machaka-Houri,
plant researcher and expert on Lebanese flora [26]. A voucher specimen was deposited in the Beirut
Arab University Herbarium (ID-RCED2019-361).
2.5. Preparation of Crude Leaf Extract (MMLE)
Leaves were washed with distilled water, stored between paper towel sheets at 4 ◦C for 2 weeks
to dry out, then ground and left to shake in absolute methanol at 200 rpm for 1 week. The extract was
later filtered through a cheesecloth and centrifuged at 15,000 rpm to discard the pellet. Methanol was
evaporated using a rotary evaporator. The methanolic crude extract was weighed, then dissolved in
dimethyl sulfoxide (DMSO) and diluted with RPMI to a final concentration of 9 mg/mL. When applied
on the cell lines, the DMSO level maximally reached 0.8% at 360 μg/mL for KG-1 and Monomac-1 and
1% at 450 μg/mL for U937.
2.6. Cytotoxicity Assay
AML cells and MSCs were seeded in 96-well plates at a density of 0.5× 105 cells/well and incubated
overnight before treatment of triplicates of wells with increasing concentrations of M. pseudolavatera
Webb & Berthel. methanolic leaf extract (MMLE). After 24 or 48 h of incubation, WST-1 cell proliferation
reagent (Roche, Mannheim, Germany) was used to estimate cell viability according to the manufacturer’s
guidelines. Absorbance of each well was detected at 450 nm using a MultiskanTM FC microplate
photometer to quantify metabolically-active cells before calculating the percent proliferation relative to
the control untreated cells.
2.7. Cell Cycle Analysis
Monomac-1 cells were seeded in 6-well plates at a density of 1 × 105 cells/well and incubated
overnight before treatment with increasing concentrations of MMLE for 24 h. Cells were then fixed
overnight with ethanol, and the DNA was stained with propidium iodide (PI, Sigma-Aldrich) after the
enzymatic removal of RNA using RNase (Roche). DNA content was measured using an Accuri C6
flow cytometer to determine the distribution of cells in each cell cycle phase: pre-G0/G1 phase cells
had <2n, G0/G1 phase cells had 2n, S phase cells had between 2n and 4n, and G2/M phase cells had 4n.
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2.8. Apoptosis Detection Using Fluorescent Annexin V Staining
Monomac-1 and KG-1 cells were seeded in 24-well plates at a density of 1 × 105 cells/well and
incubated overnight before treatment with increasing concentrations of the MMLE for 24 h. Cells were
then stained with annexin V-FITC (Abcam, Cambridge, UK)and visualized with the ZOE fluorescent
cell imager under bright-field conditions then the filter was set for FITC before merging the images.
2.9. Apoptosis Quantification by Dual Annexin V/PI Staining
Monomac-1 cells were seeded in 6-well plates at a density of 2 × 105 cells/well and incubated
overnight before incubation with increasing concentrations of the MMLE for 24 h. Cells were then
stained with annexin V-FITC and PI (Abcam) according to the manufacturer’s instructions and analyzed
by the Accuri C6 flow cytometer. Annexin V binds to phosphatidylserine molecules translocated to
the outer layer of the cell membrane upon apoptosis induction. PI reaches the cellular DNA in cells
that have lost the cellular membrane integrity, so it stains late apoptotic and necrotic cells but not
viable and early apoptotic cells. This allowed for the discrimination between viable, early apoptotic,
late apoptotic, and necrotic cells.
2.10. Cell Death ELISA
Monomac-1 and KG-1 cells were seeded in 24-well plates at a density of 2 × 105 cells/well
and incubated overnight before treatment of duplicates of wells with increasing concentrations of
MMLE. Treatment with the chemotherapeutic drug, etoposide (Abcam) at a concentration of 100 μM
(58.85 μg/mL) was used as positive control. After 24 h, cells were collected and lysed in incubation
buffer before quantification of fragmented cytosolic histone-associated-DNA content using the Cell
Death ELISA kit according the manufacturer’s instructions (Roche). Extracted DNA was then incubated
in wells coated with biotin-associated anti-histone antibodies, followed by incubation with anti-DNA
antibodies linked to peroxidase enzyme, then washed with washing buffer before the addition of the
peroxidase substrate. Absorbance at 405 nm was measured by spectrophotometry using a MultiskanTM
FC microplate photometer and the DNA fragmentation enrichment factor (absorbance of treated
cells/absorbance of non-treated cells) was calculated as the ratio of absorbance in the treated samples
to that of the untreated controls.
2.11. Western Blot
Monomac-1 cells were plated in 6-well plates at a density of 5 × 105 cells/mL before treatment
with two increasing concentrations of MMLE for 24 h. The concentrations used were the closest to the
IC50. Total proteins were extracted using the Qproteome mammalian protein prep kit (Qiagen, Hilden,
Germany) and quantified using the Lowry method. Proteins were then separated by SDS-PAGE
(10%) and transferred to PVDF membranes that were blocked with 5% skimmed milk, then incubated
with primary antibodies: anti-β-actin (Santa Cruz Biotechnology, Dallas, Tx, USA), anti-cytochrome-c
and anti-cleaved poly(ADP-ribose) polymerase (PARP) (Abcam), anti-Bax and anti-Bcl2 (Elabscience,
Houston, TX, USA). β-actin was used as a loading control. Membranes were then washed and
incubated with a secondary antibody (Bio-Rad, Irvine, CA, USA) followed by exposure for image
development using Clarity™ Western ECL substrate (Abcam) on a ChemiDoc machine (Bio-Rad).
Quantification using the ImageJ program allowed us to calculate the relative expression of proteins,
as compared to the loading control.
2.12. Reactive Oxygen Species Detection
Using the DCFDA cellular ROS detection assay kit (Abcam), levels of ROS were quantified
in Monomac-1 and KG-1 cells treated with increasing concentrations of MMLE. Tert-butyl
hydrogen peroxide (TBHP) is a potent ROS inducer and was used as a positive control. DCFDA
(2′,7′-dichlorodihydrofluorescein diacetate) oxidative conversion to H2DCFDA upon ROS reduction
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was quantified by spectrofluorometry on the Varioskan™ LUX multimode microplate reader (Thermo
Fisher Scientific, Bremen, Germany).
2.13. Gas ChromatographyMass Spectrometry Analysis of the Methanolic Extract of M. Pseudolavatera Webb &
Berthel. Leaves
MMLE composition was analyzed using gas chromatography coupled with mass spectrometry
(GC-MS). The carrier gas used was helium with splitless injection and a flow rate of 1.2 mL/min was
applied. A temperature program consisted of 2 min at 70 ◦C, from 70 ◦C to 130 ◦C at 8 ◦C/min and hold
for 5 min, from 130 ◦C to 180 ◦C at 2 ◦C/min and hold for 10 min, from 180 ◦C to 220 ◦C at 15 ◦C/min
and hold for 2 min, and then from 220 ◦C to 280 ◦C at 15 ◦C/min and hold for 22 min. Preliminary
identification of the various compounds was performed by comparing their mass spectra with the
literature (NIST11 and Wiley9). Percentage composition was computed from GC peak areas.
2.14. Liquid ChromatographyMass Spectrometry Analysis of the Methanolic Extract of M. Pseudolavatera
Webb & Berthel. Leaves
A 2.5 μg sample was injected into C18 Gravity-SB Nucleodur (300 Å, 1.8 μm, 2 × 100 mm,
Macherey-Nagel, Düren, Germany) using a Dionex Ultimate 3000 analytical RSLC system (Dionex,
Germering, Germany) coupled to a heated electrospray source HESI source (Thermo Fisher Scientific,
Bremen, Germany). The separation was performed with flow rate of 300 μl/min by applying a gradient
of solvent B from 3% to 50% within 35 min, followed by column washing and re-equilibration steps.
Solvent A was composed of water with 0.1% formic acid, while solvent B consisted of acetonitrile with
0.1% formic acid. Eluting compounds were analyzed on a QExactive HF-HT-Orbitrap-FT-MS benchtop
instrument (Thermo Fisher Scientific, Bremen, Germany). MS1 scan was performed with 60,000
resolution, AGC (automatic gain control) of 3e6 and maximum injection time of 200 ms. MS2 scan
was performed in Top10 mode with 2 m/z isolation window, AGC of 5e5, 15 000 resolution, maximum
injection time of 50 ms, and averaging 2 μscans. Higher-energy collisional dissociation (HCD) was
used as the fragmentation method with normalized collision energy of 28%. For compound analysis,
mzCloud and ChemSpider database for chemicals were used.
2.15. Statistical Analysis
All experiments were repeated three times (n=3). Statistical analyses were performed using
GraphPad Prism 8. The data was reported as mean ± SEM and the p-values were calculated by
t-tests or two-way ANOVA depending on the experiment. Significant differences were reported with *
indicating a p-value of 0.01 < p < 0.05, ** indicating a p-value of 0.001 < p < 0.01, *** indicating a p-value
of 0.0001 < p < 0.001, and **** indicating a p-value of p < 0.0001.
3. Results
3.1. M. pseudolavatera Leaf Extract Exhibits Selective Anti-Proliferative Effects on AML Cell Lines
In order to detect the percent proliferation of AML cell lines, MSCs, and MNCs treated with
MMLE, WST-1 cell proliferation reagent was used. A dose-dependent and time-dependent significant
decrease in proliferation of the three AML cell lines, Monomac-1, KG-1, and U937 was observed with
an IC50 of 200 μg/mL and 86.80 μg/mL for Monomac-1 (Figure 1A), 207.9 μg/mL and 89.47 μg/mL for
KG-1 (Figure 1B), and 402 μg/mL and 229 μg/mL for U937 (Figure 1C) after 24 h and 48 h, respectively.
The extract had no significant cytotoxic effect on MSCs and MNCs (Figure 1D,E). This indicates that
MMLE exhibits selective anti-proliferative effects on all AML cancer cell lines used.
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Figure 1. Proliferation of Monomac-1 (A), KG-1 (B), U937 (C), mesenchymal stem cells (MSCs) (D),
and normal mononuclear cells MNCs (E), after 24 h and 48 h of treatment with methanolic leaf extract
(MMLE). A significant dose- and time-dependent inhibition of proliferation of the three AML cell lines
was noticed with increasing concentrations of MMLE. Significant differences were reported with *
indicating a p-value: 0.01 < p < 0.05, ** indicating a p-value: 0.001 < p < 0.01 and *** indicating a p-value:
0.0001 < p < 0.001.
3.2. M. pseudolavatera Leaf Extract Induces Cellular Fragmentation in AML Cell Lines
In order to elucidate the mechanism by which MMLE exerted its cytotoxic effect, PI staining was
performed. To check for any cell cycle arrest and analyze the cell cycle distribution of Monomac-1
cells treated with MMLE, DNA content was quantified by PI staining followed by cytometric analysis.
A dose-dependent increase in cellular fragmentation was detected as the cells gradually shifted
from the G0/G1, S, and G2/M stages to the pre-G0/G1 stage where cells are fragmented and contain
DNA <2n. In fact, the proportion of Monomac-1 cells in the pre-G0/G1 stage increased significantly
from 8.05% in the untreated cells to 74.9% in cells treated with 270 μg/mL (after IC50) (Figure 2).
This shows that MMLE does not induce a cell cycle arrest, but rather activates a mechanism leading to
cellular fragmentation.
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Figure 2. Cell cycle analysis of Monomac-1 treated with MMLE for 24 h (A). The percentage of the cells
in different phases of cell cycle was determined by C Flow software (B) A significant increase in the
pre-G and a decrease in G0/G1, S, and G2/M in a dose-dependent manner was obtained and indicated
an increase in DNA fragmentation in Monomac-1 cells upon MMLE treatment.
3.3. M. pseudolavatera Leaf Extract Significantly Induces Apoptosis in AML Cell Lines
To explore whether cell death is induced by apoptosis, annexin V staining was followed by
fluorescence microscopy. Upon treatment with increasing concentrations of MMLE, a marked increase
in annexin binding on Monomac-1 cells was observed, indicating a shift of phosphatidylserine from
the inner leaflet to the outer leaflet of the cell membrane, a major apoptotic event (Figure 3A).
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Figure 3. Annexin V (A) and annexin V/PI staining (B,C) of Monomac-1 cells treated for 24 h with
increasing concentrations of MMLE. A significant increase in positively stained cells was observed upon
24 h treatment with increasing concentrations of MMLE (A). A decrease in annexin-negative/PI-negative
stained cells and an increase in annexin-positive/PI-negative, annexin-positive/PI-positive, and
annexin-negative/PI-positive stained cells were noted in Monomac-1 treated with 90, 180, and 270 μg/mL
for 24 h.
To quantitatively assess the induction of apoptosis, flow cytometry analysis was carried out after
annexin V/PI staining and cells were distributed into four quadrants where the lower left quadrant
represents normal healthy cells, negatively staining for both annexin V and PI. The lower right quadrant
represents early apoptotic cells which stain positively only for annexin V. The upper right quadrant
represents the late apoptotic cells, staining positively for both annexin V and PI. The upper left quadrant
represents necrotic cells which stain positively for PI only. After 24 h of treatment with increasing
concentrations of MMLE, a decrease in Monomac-1 healthy cells from 84.3% in the control group to
18.2% at 270 μg/mL was coupled to a significant increase in early apoptotic cells from 17.8% in the
control to 44.9% when treated with 270 μg/mL MMLE. A significant increase in late apoptotic cells
from 4.5% to 27.7% was also observed upon treatment (Figure 3B,C). This shows that apoptosis is the
likely mechanism by which MMLE inhibits the proliferation of AML cell lines.
To validate apoptosis induction, DNA fragmentation was quantified by Cell Death ELISA
kit. A 5.0-fold and 12.8-fold significant increase in DNA fragmentation was observed upon 24 h
treatment of Monomac-1 with 180 μg/mL and 270 μg/mL, respectively (Figure 4A), which correspond
to concentrations below and above the IC50. A similar pattern of DNA fragmentation was noted in
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KG-1 cells with a 1.7-fold and 2.5-fold increase after 24 h treatment with 135 μg/mL and 270 μg/mL
respectively (Figure 4B). The increase of the dual stain fluorescence using annexin V/PI dual staining
and DNA fragmentation confirms that MMLE induces apoptosis in Monomac-1 and KG-1 cell lines in
a dose-dependent manner.
Figure 4. Cell Death ELISA on Monomac-1 (A) and KG-1 cells (B) treated with increasing concentrations
of MMLE and a positive control treated with etoposide for 24 h. A significant dose-dependent increase in
the enrichment factor was observed in both Monomac-1 and KG-1 cells when treated with concentrations
before and after IC50. Significance relative to the control was reported with * indicating a p-value:
0.01 < p < 0.05 and *** indicating a p-value: 0.0001 < p < 0.001.
3.4. M. pseudolavatera Leaf Extract Causes Upregulation of Pro-Apoptotic Proteins
Western blot analysis was then performed to determine the apoptotic signaling pathway induced
by MMLE on Monomac-1 cell line treated with 2 different concentrations, before and after the IC50,
for 24 h. Upon treatment of Monomac-1 cells with 270 μg/mL of MMLE, an upregulation of cleaved
PARP (c-PARP) was observed (Figure 5). This treatment also induced a downregulation of the
anti-apoptotic protein Bcl-2, coupled to an upregulation of the pro-apoptotic protein Bax indicating
an increase in the Bax/Bcl-2 ratio (Figure 5) leading to apoptosis. This was further confirmed by the
observed dose-dependent upregulation of cytochrome-c upon treatment of Monomac-1 with MMLE
(Figure 5).
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Figure 5. Western blot analysis and quantification of expression levels of apoptosis-regulating proteins
in Monomac-1 cells treated with MMLE for 24 h. Significant upregulation of pro-apoptotic proteins
such as cleaved poly(ADP-ribose) polymerase (PARP), Bax, and cytochrome-c and downregulation
of anti-apoptotic proteins such as Bcl-2 were observed upon treatment of Monomac-1 cells with 180
μg/mL and 270 μg/mL. Significance relative to the control was reported with * indicating a p-value: 0.01
< p < 0.05, ** indicating a p-value: 0.001 < p < 0.01, and *** indicating a p-value: 0.0001 < p < 0.001.
Detailed information of western blot can be found at Figure S1.
3.5. M. pseudolavatera Leaf Extract Induces Oxidative Stress in AML Cell Lines
Reactive oxygen species levels (ROS) in Monomac-1 and KG-1 treated with increasing
concentrations of MMLE were quantified using the DCFDA Cellular ROS Detection Assay kit.
The recorded ROS levels showed a significant upregulation reaching 1.608-fold increase and 1.351-fold
increase at 360 μg/mL for Monomac-1 and KG-1, respectively (Figure 6). This indicates that the extract
is inducing oxidative stress by production of excess ROS in AML cell lines.
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Figure 6. Fold change of ROS in Monomac-1 (A) and KG-1 cells (B) treated with increasing concentrations
of MMLE and a positive control treated with 20 μM of TBHP. ROS levels increased significantly with
increasing concentration of MMLE for both Monomac-1 (A) and KG-1 cells (B). Significance relative to
the negative control was reported with * indicating a p-value: 0.01 < p < 0.05, ** indicating a p-value:
0.001 < p < 0.01, and *** indicating a p-value: 0.0001 < p < 0.001.
3.6. Chemical Elucidation of M. pseudolavatera Leaf Extract Using GC-MS
The chemical composition of the extract was assessed using gas chromatography coupled
to mass spectrometry (GC-MS) (Figure 7). Table 1 shows the major and minor constituents of
the extract, some of which have been identified. The major compound (Peak 5: 31.7912%) was
(Z,Z,Z)-9,12,15-octadecatrienoic acid methyl ester and another omega-3 fatty acid ester that os
hexadecatrienoic acid was identified Peaks 7,10,13: (0.0463%). The second most abundant compound
was phytol (Peak 6: 19.3447%). γ-sitosterol also constituted an important portion of the extract (Peak
25: 13.2396%) along with stigmasterol (Peak 24: 5.3751%).
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Figure 7. Chromatogram of M. pseudolavatera Webb & Berthel. methanolic leaf extract elucidated by
GC-MS. Analysis of the different peaks obtained at different retention times with varying areas under
the peak showed the presence of many compounds in different amounts.
Table 1. Table showing the composition of the M. pseudolavatera Webb & Berthel. methanolic leaf
extract as elucidated by GC-MS.
Peak RT Compound %MMLE
1 5.751 Unidentified A 0.2141
2 28.7101 Hexadecanoic acid methyl ester 3.4385
3 35.0314 Unidentified B 1.4208
4 35.9573 (E,E)-9,11-Octadecadienoic acid methyl ester 2.7188
5 36.3974 Methyl linolenate 31.7912
6 36.8717 Phytol 19.3447
7 37.3804 Octadecanoic acid methyl ester 1.3903
8 38.7407 Unidentified C 0.124
9 38.7864 7,10,13-Hexadecatrienoic acid methyl ester 0.0463




12 53.607 Unidentified D 1.47
13 56.3158 Unidentified E 1.4302
14 56.4415 (Z,Z,Z)-9-(3-hexenylidenecyclopropylidene)-,2-hydroxy-1-(hydroxymethyl)nonanoic acid, ethyl ester 8.0675
15 56.584 Unidentified F 1.5
16 57.4074 Unidentified G 0.2354
17 57.505 Unidentified H 0.3
18 57.8875 Cyclotetracosane 0.6203
19 58.322 Unidentified I 0.31
20 59.5393 α-Tocopherol 0.3324
21 60.168 Unidentified J 0.3748
22 60.2195 Unidentified K 0.9207
23 60.3509 3-β-Ergost-5-en-3-ol 1.5331
24 60.6538 Stigmasterol 5.3751
25 61.2311 γ-Sitosterol 13.2396
26 61.4254 3-methoxy-19-Norpregna-1,3,5(10)-trien-17-ol 1.2401
27 64.94 Unidentified L 0.39
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3.7. Chemical Elucidation of M. Pseudolavatera Leaf Extract Using LC-MS
The chemical composition of the extract was assessed using liquid chromatography coupled with
mass spectrometry (LC-MS). Table 2 shows the major identified constituents of the extract. The two
major compounds detected were the amino acids DL-phenylalanine and DL-tryptophan (RT= 2.609 min
and 5.583 min, respectively). Other important abundant compounds were tiliroside (RT = 23.857 min),
13-hydroperoxyoctadecadienoic acid (RT = 35.512 min), and quercitrin (RT = 18.598 min). Many other
compounds were identified as well.
Table 2. Table showing the composition of the M. pseudolavatera Webb & Berthel. methanolic leaf
extract as elucidated by liquid chromatography coupled with mass spectrometry (LC-MS).
RT Compound Area Max
2.609 DL-phenylalanine 1.21 × 106
5.583 DL-tryptophan 1.10 × 106
23.857 Tiliroside 4.25 × 105
10.893 5-[(6,7,8-trimethoxy-4-quinazolinyl)amino]pentyl nitrate 3.12 × 105
35.512 13-hydroperoxyoctadecadienoic acid 1.95 × 105
14.915 N-acetyl-L-phenylalanine 1.12 × 105
18.865 3-amino-2-pyrazinecarboxylate 1.04 × 105
18.598 quercitrin 7.35 × 104
13.603 N-(4-{methyl[(1-methyl-1H-pyrazol-4-yl)methyl]sulfamoyl}phenyl)acetamide 7.21 × 104
26.441 Decyl hydrogen sulfate 6.97 × 104
14.775 Suberic acid 6.73 × 104
19.007 9-hydroxynonanoic acid 6.10 × 104
16.791 L-acetyltryptophan 5.12 × 104
14.082 5-(benzyloxy)-2-piperazinopyrimidine 5.05 × 104
4. Discussion
Natural products from plants have been widely considered an important source for identifying
drugs with anti-cancer properties since they are rich in bioactive components having multiple targets
with minimal side-effects [18,27]. In fact, of all pharmaceutical drugs present on the market, one-third
are plant-derived [28], and many chemotherapeutic drugs which have been isolated from plants
are now used as standard-of-care in cancer treatment regimens. In this study, the methanolic leaf
extract of M. pseudolavatera Webb & Berthel. was examined for its anti-proliferative and pro-apoptotic
effects on AML cell lines since leaves from other Malva species have shown cytotoxic effects on other
cancer types [12–14]. In a previous study by Solowey et al. (2014), the ethanolic extract from Urtica
membranacea showed potent anti-cancer effects at 750 μg/mL and 1500 μg/mL and these concentrations
showed to be therapeutically correlated to a mouse breast cancer model with no side-effects [29]. These
concentrations are higher than the concentrations of MMLE used to treat AML cells for 24 and 48 h.
For the rest of this study, all experiments were performed with 24 h incubation of the extract in order
to elucidate the mechanism of action of the extract in inhibiting cancer cell proliferation, although
therapeutic levels are best reached after 48 h of incubation.
Moreover, the inhibitory effect of MMLE on the proliferation of the AML cell lines was significantly
stronger than its effect on the growth of the MSCs and MNCs which exhibited resistance to the extract
with no significant toxicity. These results supported the promising effects of the extract in selectively
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targeting cancerous cells with minimal if any effects on normal healthy cells, which is a major advantage
of an effective chemotherapeutic drug exhibiting target selectivity [30].
An important mechanism by which chemotherapeutic drugs achieve their selective cytotoxicity is
by activating apoptosis or programmed cell death [31]. Many hallmarks of apoptosis were detected in
AML cell lines treated with MMLE among which were both membrane and nuclear changes typically
detected by flow cytometry and protein blots [32].
Another characteristic of apoptosis alongside DNA fragmentation and membrane moieties flipping
is the cleavage of poly(ADP-ribose) polymerase (PARP) [33]. PARP was previously reported to play an
important role in salvaging cells suffering from DNA damage because it is involved in DNA repair.
In fact, the cleaved fragment of PARP-1 binds to double strand breaks in the DNA preventing DNA
repair machinery from accessing the damage leading to apoptosis. So, upregulation of cleaved PARP
(c-PARP) in Monomac-1 treated with MMLE implies that DNA repair is no longer occurring, which
promotes cell death via apoptosis induction [34].
Bcl-2 and Bax are also involved in the control of cell survival by decreasing and increasing the
permeability of the outer mitochondrial membrane, respectively [35,36]. The reported increase in the
Bax/Bcl-2 ratio upon MMLE treatment confirms the increase in mitochondrial membrane permeability.
This promotes the release of cytochrome-c from the mitochondria, explaining its upregulation, which is
essential for the activation of caspases leading to apoptosis [37]. In fact, exploiting chemotherapeutic
effects on mitochondrial membrane leakage was shown to be effective in selectively triggering apoptosis
in cancer cells since metabolic reprogramming is an inherent step required for hyperproliferation of
cancer cells [38].
Another aspect of apoptotic cell death involves reactive oxygen species (ROS). Excess cellular ROS
levels cause oxidative stress which damages proteins, DNA, and cellular membranes and activates
death-receptor-mediated or mitochondrial apoptotic pathways [39]. However, a previous study
showed that aqueous extract from M. pseudolavatera Webb & Berthel. possesses antioxidant properties
by scavenging free radicals [9]. The differential effect of MMLE can be attributed to variation in its
concentration, implying its dose-dependent activity. In fact, in similar medicinal plants with anti-cancer
properties, extracts were shown to exhibit antioxidant activity at low concentration of the extract,
without achieving any cytotoxicity. At high concentrations, that same extract was shown to be cytotoxic
and induced ROS [40]. In MMLE, an antioxidant compound(s) may be present in high concentrations
and hence act to destroy the mitochondrial membrane and generate ROS. This mechanism was
described in green tea extract with the phenolic compound epigallocatechin gallate that can decrease
lipid peroxidation and enhance antioxidant capacity in hepatocytes at low concentrations and destroy
the mitochondrial membrane and generate intracellular oxidative stress at high concentrations [41].
The examination of the extract composition by GC-MS and LC-MS provided insight into some
of the potential compounds in MMLE responsible for its pro-apoptotic effects. Abundant identified
molecules included amino acids like-phenylalanine (Phe) and tryptophan (Trp) (detected by LC-MS)
as well as some of their acetylated derivatives. These two essential amino acids were not previously
shown to possess such activity. Omega-3 fatty acid esters (detected by GC-MS) and these two amino
acids (phe and trp) were previously shown to slow the growth of many types of cancers and increase
patient outcomes when included in a standard regimen of chemotherapy since they increase the
sensitivity of the cells to the conventional therapies. They also exhibit selective toxicity on cancer
cells of various types but not on normal cells [42,43]. This could explain the selective toxicity seen on
AML cell lines and not on MSCs and MNCs. Also, (13S)-hydroperoxyoctadecadienoic (13-HPODE)
detected by LC-MS, is a linoleic acid derivative previously shown to inhibit growth of a chronic myeloid
leukemia cell line K-562 [44]. In fact, the mechanism of action described was ROS-mediated and
caspase-dependent apoptosis which could explain the effects observed by MMLE on AML cell lines.
Phytol, another major compound detected by GC-MS, is a diterpene alcohol and it was previously
found to inhibit the growth of many cancer cell types, among which acute T-cell lymphoblastic
leukemia (Molt-4) cells in a dose- and time-dependent manner. The effects of phytol were attributed
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to apoptosis demonstrated by DNA fragmentation and formation of apoptotic bodies. In other
studies, phytol was found to have a synergistic effect with some used chemotherapeutic drugs
like β-caryophyllene, in addition to inducing apoptosis in epidermoid carcinoma cells (A431) and
immortalized keratinocytes (HaCaT cells) by ROS induction, activation of the apoptotic pathway
involving the release of cytochrome-c, the activation of the caspase pathway, cleavage of PARP, and an
increase in the Bax/Bcl-2 ratio [45,46]. These previously reported effects are consistent with the current
observed morphological and molecular changes in AML cell lines upon treatment with MMLE. Another
detected alcohol is quercitrin (by LC-MS). It is a plant-derived polyphenol found to enhance the
effect of topotecan in breast cancer cell lines [47,48]. It was also found to reduce the cytotoxicity and
genotoxicity of topotecan in bone marrow cells of mouse models in a dose-dependent manner [49].
Another important phytochemical detected by LC-MS is tiliroside. It is a glycosidic flavonoid
present in many edible plants [50]. It was found to be cytotoxic against human CML cell line K-562 [51]
and to inhibit cell proliferation and induce apoptosis via the extrinsic pathway in breast cancer cell
lines MCF-7 and T47D [52].
Phytosterols, particularly γ-sitosterol and stigmasterol, are also important constituents of the
extract (detected by GC-MS). γ-sitosterol was previously shown to be cytotoxic against colon and liver
cancer cell lines by downregulating c-myc and inducing apoptosis [53]. Moreover, stigmasterol was
formerly studied for activating apoptosis in hepatocellular carcinoma cell lines through upregulation of
the Bax protein and downregulation of the Bcl-2 protein [54]. In another study, stigmasterol inhibited
the proliferation of gastric cancer cell lines through a mitochondrial pathway [55], in accordance with
the effects MMLE exhibited on AML cell lines in this study.
All these findings suggest that MMLE contains many compounds which can potentially be acting
together as cancer growth inhibitors through inducing ROS and activating apoptosis in AML cell
lines. Many compounds detected by GC-MS and LC-MS were not previously known for their effects
on cancer cell lines and many other compounds were not identified. This should also be taken into
account when explaining the pro-apoptotic effect of MMLE on AML cells.
5. Conclusions
In conclusion, Malva pseudolavatera Webb & Berthel. methanolic leaf extract showed a promising
selective anti-proliferative and pro-apoptotic effect on acute myeloid leukemia cell lines, by cleaving
PARP, releasing cytochrome-c, and increasing the Bax/Bcl-2 ratio. Chemical analysis of the extract
showed that it is a ROS inducer and that it contains many compounds that are potentially anti-cancer
compounds. Future work aims at exploring the effect of the extract on other types of cancer cells,
fractionating the extract to identify the compounds with highest biological therapeutic activity and
confirming the efficacy of the extract in vivo.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/2/435/s1,
Figure S1: Western blot analysis and quantification of expression levels of apoptosis-regulating proteins in
Monomac-1 cells treated with MMLE for 24 h.
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Abstract: Obesity is a major risk factor for breast cancer (BC). Obesity-related metabolic alterations such
as inflammation and overactivation of the adipose renin–angiotensin system (RAS) may contribute to
the progression of BC. Clinically used antihypertensive drugs such as angiotensin-converting enzyme
inhibitors (ACE-I) and dietary bioactive components such as eicosapentaenoic acid (EPA) are known
for their anti-inflammatory and adipose RAS blocking properties. However, whether EPA enhances
the protective effects of ACE-I in lessening adipocyte inflammation on BC cells has not been studied.
We hypothesized that combined EPA and ACE-I would attenuate BC cell inflammation and migration
possibly via adipose RAS inhibition. To test our hypothesis, we examined the (i) direct effects of an
ACE-I (captopril (CAP)) or EPA, individually and combined, on MCF-7 and MDA-MB-231 human
BC cells, and the (ii) effects of conditioned medium (CM) from human adipocytes pretreated with
the abovementioned agents on BC cells. We demonstrated that CM from adipocytes pretreated
with EPA with or without captopril (but not direct treatments of BC cells) significantly reduced
proinflammatory cytokines expression in both BC cell lines. Additionally, cell migration was reduced
in MDA-MB-231 cells in response to both direct and CM-mediated CAP and/or EPA treatments. In
summary, our study provides a significant insight into added benefits of combining anti-inflammatory
EPA and antihypertensive ACE-I to attenuate the effects of adipocytes on breast cancer cell migration
and inflammation.
Keywords: obesity; breast cancer; renin–angiotensin system; eicosapentaenoic acid;
adipocyte inflammation
1. Introduction
Breast cancer (BC) is the most common type of cancer among U.S. women and has a lifetime
risk of more than 12% [1]. Obesity is one of the major modifiable risk factors for BC, especially
in postmenopausal women, and is associated with poor cancer outcomes and survival in patients
with BC [2,3]. Moreover, as inflammation is an important underlying basis for both diseases, it is
critical to understand its involvement in mechanism(s) of obesity-related BC [4]. In obesity, adipose
tissue expands and becomes hypertrophic and hypoxic, with invasion of proinflammatory M1-type
macrophages and exaggerated secretion of protumor adipocytokines [5]. Various proinflammatory
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adipocytokines such as interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1) can
promote the activation and transcription of many protumor signaling pathways such as nuclear factor
kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3), resulting in increased
migratory and invasive capacities in the adjacent cancer cells [6]. Additionally, cancer-associated
adipocytes form a proinflammatory microenvironment via induced macrophage invasion and thus
synergistically activate STAT3 and NF-κB pathways [7], which in turn leads to apoptosis inhibition and
cancer cell proliferation [8]. Moreover, aberrant STAT3 signaling also upregulates angiogenic vascular
endothelial growth factor (VEGF), leading to higher tumor angiogenesis [9]. Hence, obesity-associated
proinflammation increases cancer cell progression via their interaction with adjacent adipocytes [6].
Furthermore, obese adipocytes also overexpress metabolic markers such as fatty acid synthase (FASN),
which is associated with adipocyte hypertrophy and increased proinflammatory adipocytokine secretion
in obesity [10,11]. FASN provides an alternative energy source to proliferating cancer cells in the form
of free fatty acids helping their growth and proliferation [12]. This, in turn, facilitates the formation
of a toxic tumor microenvironment (TME) in the breast, which contributes to obesity-associated BC
progression [13].
The renin–angiotensin system (RAS) is classically known to regulate fluid balance and
blood pressure. Angiotensinogen (Agt) is the main precursor protein for the bioactive hormone
angiotensin II (Ang II). Agt is first cleaved by renin into Ang I, which is converted into
Ang II by the angiotensin-converting enzyme (ACE). Ang II mediates its effect via binding to
two major G-protein-coupled receptors, namely, type 1 receptor (AT1R) and type 2 receptor
(AT2R) [14,15]. Adipose RAS activation has multiple roles in obesity, such as increasing inflammatory,
prothrombotic, and angiogenic markers [16] that can also promote tumor growth, proliferation,
and invasion in the breast [17,18]. In addition, Ang II/AT1R signaling triggers production and
infiltration of tumor-associated macrophages (TAM) in different tumor models, while RAS inhibitors
can restrain tumor growth and TAM response [19]. Thus, RAS is a potential key player in
adipocyte–breast-cancer-cell interactions. RAS inhibitors such as angiotensin-converting enzyme
inhibitors (ACE-I) and AT1R blockers (ARB) have recently gained interest as possible anticancer agents
in both clinical and preclinical models of BC [17,18,20,21]. Some ACE-I and ARBs were found to reduce
BC risk in a time-dependent manner in BC patients [21].
RAS can also be downregulated by anti-inflammatory dietary bioactive compounds such as
omega-3 polyunsaturated fatty acids (n-3 PUFA) [22], which we have also shown to reduce Agt secretion
from adipocytes [23]. The dietary n-3 PUFAs eicosapentaenoic acid (EPA)-20:5n-3 and docosahexaenoic
acid (DHA)-22:5n-3 have potent anti-inflammatory properties that include reducing obesity-associated
systemic and adipose tissue inflammation, thus alleviating TME formation in adipocyte–BC-cell
crosstalk [24–27]. Therefore, given the promising anti-inflammatory and anticancer properties of
ACE-I and EPA, we hypothesized that ACE-I (captopril (CAP)) and EPA alone or in combination
would attenuate BC cell inflammation and migration, in part through inhibition of adipocyte RAS. We
examined both direct and adipose CM-mediated effects of captopril and EPA and their combination on
cultured BC cell genes and proteins as well as cell migration using wound healing analyses.
2. Results
2.1. Effect of Captopril and EPA on Markers of Fatty Acid Synthesis and Inflammation in BC Cells and Role of
Human Adipocyte-Conditioned Media (CM)
MDA-MB-231 and MCF-7 cells were treated with 100 μm of EPA or 100 μm of CAP with or
without EPA either directly or using CM from CAP, EPA, or both pretreated adipocytes for 48 h.
Direct treatments with EPA, CAP, or CAP + EPA did not alter most measured markers of cancer cell
growth and inflammation in MDA-MB-231 cells, with the exception of IL-8, which was significantly
reduced by EPA and CAP + EPA treatments for 48 h in MDA-MB-231 cells (p < 0.05) compared with
control (CT), while CAP alone had no effect. However, EPA and CAP + EPA had comparable effects,
indicating no additional effect of direct CAP + EPA combination on BC cell inflammatory markers
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(Figure 1E). Treatment of MDA-MB-231 cells with human adipocyte CM significantly increased all
tested markers of cell growth and inflammation after 48 h, as shown by increased mRNA levels of
FASN, STAT3, NF-κB, IL-6, and IL-8 compared with control (Figure 1A–E; also see Tables S1–S7)
(p < 0.05). However, treatment of MDA-MB-231 cells with CM from adipocytes pretreated with EPA,
CAP, and their combination significantly reduced the mRNA content of all measured markers of BC
cell growth and inflammation compared with treatment with CM derived from untreated adipocytes
(Figure 1A–E) (p < 0.05). However, no changes were observed in FASN, STAT3, NF-κB, and IL-8
mRNA transcription levels in MDA-MB-231 BC cells treated with CAP + EPA pretreated adipocyte CM,
compared with CAP-CM or EPA-CM (Figure 1A–C,E) (p < 0.05). Interestingly, CAP + EPA pretreated
CM reduced IL-6 mRNA levels to a greater extent in MDA-MB-231 cells compared with CAP-CM
and/or EPA-CM treatments, indicating potential additive anti-inflammatory effects of CAP and EPA
combination (Figure 1D) (p < 0.05). Exploratory factorial regression analyses performed to examine
the interactions of CAP and EPA when administered as a combination resulted in significant negative
regression coefficients for CM-CAP and CM-EPA factors but significant positive CM-CAP × EPA
interaction for mRNA levels of all measured markers of MDA-MB-231 cell growth and inflammation
(Tables S1–S5). This result suggests that CAP and EPA may act via a common pathway in reducing
mRNA expression in CM-treated MDA-MB-231 cells.
 
Figure 1. Eicosapentaenoic acid (EPA) and captopril (CAP) (angiotensin-converting enzyme inhibitors;
ACE-I) effects on mRNA expression in MDA-MB-231 cells. MDA-MB-231 cells were treated with
100 μm of CAP with or without 100 μm of EPA for 48 h. Human mesenchymal stem cells (HMSCs)
were differentiated into adipocytes and treated with 100 μm of CAP with or without 100 μm of EPA
for 24 h. Conditioned media (CM) was collected and transferred to breast cancer (BC) cells for 48 h.
Cells were harvested and changes in mRNA levels of fatty acid synthase (FASN) (A), signal transducer
and activator of transcription 3 (STAT3) (B), nuclear factor kappa B (NF-κB) (C), interleukin (IL)-6 (D),
and IL-8 (E) were measured (p < 0.05; N = 3; three replicates under each treatment group; bars with
different letters (a, b, c) indicate significance).
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On the other hand, CM from human adipocytes significantly increased markers of cell growth
and inflammation in MCF-7 cells after 48 h, as shown by increased mRNA levels of FASN, STAT3,
NF-κB, and IL-8 compared with CT (p < 0.05), while CM from adipocytes pretreated with EPA, CAP,
and CAP + EPA significantly reduced the abovementioned markers of cell growth and inflammation
after 48 h compared with CM-control (Figure 2A–C,E; Tables S8–S14) (p < 0.05). However, no changes
in the mRNA levels of the respective markers were observed between CAP and EPA treated groups
with or without CAP–EPA combination. Additionally, direct treatments with EPA and CAP + EPA
significantly reduced MCF-7 BC cell inflammation, as demonstrated by significantly lower IL-6 and
IL-8 mRNA transcription levels, while direct treatments with CAP reduced only IL-6 mRNA levels after
48 h compared with control in MCF-7 cells (Figure 2D,E) (p < 0.05). However, the changes were not
significant between EPA and CAP + EPA treated groups, indicating no additional effects of CAP–EPA
combination in MCF-7 cells compared with EPA alone or CAP alone.
Figure 2. EPA and captopril (ACE-I) effects on mRNA expression in MCF-7 cells. MCF-7 cells were
treated with 100 μm of CAP with or without 100 μm of EPA for 48 h. HMSCs were differentiated
into adipocytes and treated with 100 μm of CAP with or without 100 μm of EPA for 24 h. CM was
collected and transferred to BC cells for 48 h. Cells were harvested and mRNA level changes of FASN
(A), STAT3 (B), NF-κB (C), IL-6 (D), and IL-8 (E) were measured (p < 0.05; N = 3; three replicates under
each treatment group; bars with different letters (a, b, c) indicate significance).
Next, we measured proinflammatory IL-6 and IL-8 protein levels secreted by both MDA-MB-231
and MCF-7 cells after 48 h of EPA and CAP treatments. Medium was collected from both cell lines
after direct and adipocyte CM (with or without EPA, CAP, or combined EPA and CAP) treatments
for 48 h. Consistent with the above-described results (Figure 3A,B), no changes were observed in
secreted IL-6 and IL-8 levels in MDA-MB-231 cells with direct treatments of EPA, CAP, CAP + EPA for
48 h. In addition, increased IL-6 and IL-8 secretion in MDA-MB-231 cells were observed in response to
adipocyte CM treatments compared with CT and direct CAP ± EPA treatments (p < 0.05). Moreover,
significant reductions in both IL-6 and IL-8 protein levels were identified in MDA-MB-231 cells in
response to CM-EPA and CM-CAP treatments (with or without EPA) compared with CM-control
(p < 0.05) (Figure 3A,B). However, the changes were not significant between CM-EPA and CM-CAP
groups as well as compared to CT and direct CAP ± EPA treatments after 48 h (p < 0.05). Additionally,
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both IL-6 and IL-8 protein levels were undetectable (* nd) without CM treatments in MCF-7 cells, as
reported earlier by others [28] (Figure 3C,D). Interestingly, adipocyte CM with CAP + EPA significantly
reduced IL-6 secretion in MCF-7 cells compared with CM-control treatment, but no changes were
observed compared to CM-EPA or CM-CAP individual treatments (Figure 3C) (p < 0.05). However,
no significant changes were observed in secreted IL-8 levels by MCF-7 cells when treated with
adipocyte CM-EPA or CM-CAP (with or without EPA) (Figure 3D). Therefore, these results suggest
possible inflammatory-reducing benefits of CAP–EPA combination in triple-negative breast cancer
(TNBC) MDA-MB-231 cells but not in MCF-7 cells, indicating the potential role of n-3 PUFAs and
antihypertensive ACE inhibitors in attenuating the tumor-promoting proinflammatory effects of
adipocytes on breast cancer cells.
 
Figure 3. Adipose-CM with ACE-I with or without EPA reduced proinflammatory interleukins secretion
in BC cells. Mature human adipocytes were pretreated with 100 μm of CAP with or without 100 μm of
EPA for 24 h followed by CM collection and transferred to MDA-MB-231 (A,B) and MCF-7 (C,D) cells
for 48 h. Medium was collected, and secreted IL-6 and IL-8 levels were measured in response to direct
(no adipocyte CM) or CM-mediated CAP and EPA effects (p < 0.05; N = 3; and in each experiment, three
replicates were used for each treatment group; bars with different letters (a, b) indicate significance;);
nd: not detectable; ns: not significant).
2.2. Combined Effect of Captopril and EPA on Breast Cancer Cell Migration in Response to Treatment with
Adipocyte CM, Measured by a Wound Healing Assay
Since inflammation is associated with BC cell migration, we performed in vitro wound healing
assays to dissect the effects of both direct and human adipocyte-mediated effects of CAP ± EPA
treatments in MDA-MB-231 cells. First, MDA-MB-231 cells were treated directly with CAP with or
without EPA and images of wound closure were taken at various times up to 48 h (Figure 4A,B; also
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see Tables S15 and S16). No significant effects of direct CAP treatment were found in MDA-MB-231
cells at any of the time points tested (p < 0.05) (Figure 4A,B). Intriguingly, a significantly higher percent
wound area (or lower percent wound healing) was observed in response to direct EPA and CAP + EPA
treatments at 4, 8, 12, 24, and 36 h time points when compared with bovine serum albumin (BSA)-control
(p < 0.05), indicating reduced wound healing cell migration with EPA and CAP + EPA. However, the
reductions in wound healing were not significant between EPA and CAP + EPA treatments at the
respective time points (p < 0.05), indicating no additional effect of CAP when combined with EPA on
MDA-MB-231 cell wound-healing capacity (Figure 4A,B).
Figure 4. Direct effect of captopril and EPA on cell migration in MDA-MB-231 cells. Representative
wound healing images at 0, 4, 8, 12, 24, 36, and 48 h. Wounds were inflicted with a 200 uL pipette tip on
MDA-MB-231 (A,B) cells in confluent monolayers. Graphical representation of migrating MDA-MB-231
(A,B) cells in response to CAP with or without EPA treatments of BC cells. Cells treated with regular
Dulbecco’s Modified Eagle’s Medium (DMEM) with 1% bovine serum albumin (BSA) conjugation
were used as controls (BSA). Bars represent mean of the percent wound area in MDA-MB-231 (A,B)
cells in the two independent experiments ± SEM. p < 0.05 (comparison between 0 and 48 h; N = 2
combined experiments, in which each had three replicates per treatment group). Different letters (a, b)
indicate significance.
Next, we identified the adipocyte-CM-mediated effects of CAP ± EPA treatments in MDA-MB-231
cells. Mature human adipocytes were pretreated with CAP with or without EPA for 24 h and medium
was transferred to MDA-MB-231 cells, followed by capturing time-dependent images, as described
above (Figure 5A,B). Cell migration, as denoted by the changes in percent wound area due to closure,
was significantly increased in response to CM-mediated EPA, CAP, and CAP + EPA treatments
compared with CM-control in MDA-MB-231 cells at all time points tested, such as 4, 8, 12, 24, 36, and
48 h (p < 0.05) (Figure 5A,B), whereas CM-CAP + EPA effects were not significantly different from
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CM-EPA or CM-CAP, indicating no additional effect of CAP and EPA combination on MDA-MB-231
cell migration (Figure 5A,B). When time was modeled as a continuous variable, the wound area with
CM treatment decreased by 2.13% per hour. This rate of reduction of wound area was hindered by
treatment of adipocyte CM with each of EPA, CAP, and their combination as evidenced by significant
positive interactions (Table S16). The subsequent factorial model revealed a significant positive effect
of EPA and CAP but a significant negative interaction of CAP and EPA; these findings suggest that
EPA and CAP may act via a common pathway in slowing down cell MDA-MB-231 cell migration
(Tables S17 and S18). We did not perform wound healing assays in MCF-7 cells since the inflammatory
markers were expressed and secreted at a lower level in MCF-7 compared with the MDA-MB-231 cell
line we used. In addition, we observed greater changes in these markers, such as IL-6 in MDA-MB-231
cells, in response to both direct and CM-mediated treatments of CAP and EPA. These results further
confirm our previous observation that CAP and EPA effects may be mediated by a common pathway
to reduce expression of mRNA biomarkers of MDA-MB-231 cell proliferation.
Figure 5. CM-mediated effect of captopril and EPA on cell migration in MDA-MB-231 cells.
Representative wound healing images at 0, 4, 8, 12, 24, 36, and 48 h. Wounds were inflicted with a 200 uL
pipette tip on MDA-MB-231 (A,B) cells in confluent monolayers. Graphical representation of migrating
MDA-MB-231 (A,B) cells in response to CM-EPA and CM-CAP with or without EPA treatments of BC
cells. Cells treated with human adipose conditioned medium were used as controls (CM). Bars represent
mean of the percent wound area in MDA-MB-231 (A,B) cells in the two independent experiments ±
SEM. p < 0.05 (comparison between 0 and 48 h; N = combined experiments, in which each had three
replicates per treatment group). Different letters (a, b) indicate significance.
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3. Discussion
The aim of the current study was to provide new insights into adipocyte–BC interaction through
inhibition of RAS in adipocytes. We previously showed protective effects of n-3 PUFAs in adipocyte–BC
cell interactions [27]. Moreover, we demonstrated that n-3 PUFAs reduce Agt secretion from adipocytes
and reduce both systemic and adipose tissue inflammation [29]. Hence, we proposed to determine
whether an n-3 PUFA (EPA), individually or in combination with ACE-I, would reduce BC cell
inflammation and migration directly on BC cells or via adipose RAS inhibition. In this study, we
demonstrated reduced BC cell inflammation and motility in response to CM-derived EPA, CAP, and
CAP + EPA treatments while no changes were observed among these treatments, indicating that
the combination of CAP and EPA had no synergistic effects in attenuating adipocyte RAS effects on
BC cells.
The doses of EPA and CAP that we used were within or lower than ranges used in human studies,
making our findings translatable to humans. For omega-3 fatty acids, doses ranging from 1 to 6 g of
EPA per day have been used in various human cancer studies and are associated with both improved
cardiovascular and cancer outcomes [30,31]. Researchers reported that a ≥150 μg/mL (~150 μm) plasma
EPA level was linked to benefits in preventing cardiovascular disease (CVD) outcomes [32]. In addition,
plasma EPA concentrations in healthy subjects taking 2–4 g/day of EPA ethyl ester for 28 days increased
up to a mean of 366 μg/mL, without any adverse events [33]. Although it is difficult to translate in vitro
doses into actual human intake, the above mentioned reports clearly indicate that our 100 μm of EPA
dose was lower than doses that can be reached in human plasma levels with prescribed fish oil or
EPA. Moreover, other cell studies used doses of fatty acids up to 5 times higher than our dose [34,35].
For captopril, it has been used safely at doses up to 450 mg/day in humans [36], which may lead to
plasma doses likely higher than the 100 μm dose we used for cell treatments. Captopril was given at
150 mg/day to lung cancer patients [37] and lisinopril (another ACE-I) given as 10 mg tablets to breast
cancer patients to prevent cardiotoxicity [38]. We were unable to find data regarding this drug’s plasma
level concentration in cancer patients since ACE-I is only prescribed as antihypertensive medication for
cancer patients and not as an anticancer agent. Hence, the suitable dose for preventing breast cancer
is not known. However, earlier research reported plasma captopril levels in normal versus chronic
renal failure subjects as 364 and 347 μm, respectively, after 1 h, but it was undetectable in blood after
6 h [39]. In addition, we previously performed a cell viability (MTT) assay with both 100 μm of EPA
and 100 μm of captopril and found no toxic effects against breast cancer cell viability.
Adipose tissue is a major component of the breast tissue and is actively involved in forming TME;
thus, adipose tissue through its inflammatory and lipogenic activities may increase the risk of BC
development [3,40]. Human adipose CM is a source of various growth factors, several adipocyte secretory
hormones, cytokines, and metabolites [41], which are immensely responsible for inducing expression of
markers associated with breast cancer cell signaling, motility, and metastases [42,43]. Consistent with
this, we have found increased inflammatory, IL-6, IL-8, NF-κB, and STAT3 mRNA expression as well as
induced expression of the lipogenic enzyme FASN in both MCF-7 and MDA-MB-231 cells in response to
human adipocyte CM. Overexpression of FASN plays an important role in tumorigenesis and is thus
a vital target of obesity-mediated BC therapy [44]. Additionally, selective FASN inhibitors are potent
antitumor agents showing antiproliferative and apoptosis inhibition effects in in vitro and in vivo models
of receptor-positive (ER/HER2+) BC [45].
Moreover, two metabolically different BC cell lines, MCF-7 and MDA-MB-231, were used in the
current study to identify the presence of any metabolic responses of these cell lines to n-3 PUFA or
ACE-I. While the observed changes in mRNA levels between two cell lines were almost identical, their
cytokine secretory profiles varied in response to direct or CM treatments. Both IL-6 and IL-8 levels
were below detection in response to direct EPA/CAP treatments in MCF-7 cells, which is in agreement
with other studies investigating the basal protein secretion levels by different BC cell lines [46,47].
Furthermore, we observed higher IL-6/IL-8 secretion by MDA-MB-231 cells compared with MCF-7
cells, which is consistent with previous studies indicating a stronger secretory profile in MDA-MB-231
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TNBC cells compared with its less aggressive counterpart MCF-7 cells [48]. Another possible reason
for the differential proinflammatory profile of MCF-7 versus MDA-MB-231 could be the intrinsically
reduced transcriptional/post-transcriptional and/or translational/post-translational IL-6/IL-8 profile of
MCF-7 cells in vitro compared with MDA-MB-231 cells [48].
Moreover, IL-6 activates STAT3 and NF-κB by (i) autocrine and paracrine signaling [8] and (ii)
via synergistic crosstalk between the pathways in BC cells [7], resulting in cancer cell proliferation
and apoptosis evasion [8]. By contrast, EPA is a natural anti-inflammatory bioactive compound
previously reported to reduce IL-6 production, in part by inhibiting NF-κB activation [49] and through
its downstream anti-inflammatory lipid mediators such as E-resolvins [50]. Consistent with this, we
have also shown reduced mRNA levels of IL-6/STAT3/NF-κB in response to EPA-CM treatments. On
the other hand, EPA also reduces both inflammation and Agt secretion from adipocytes both in vivo
and in vitro [22,29]. Hence, when combining EPA with ACE-I (captopril), we observed reduced IL-6
inflammation in both MDA-MB-231 and MCF-7 BC cells as indicated by lower IL-6 mRNA and protein
levels, respectively. Interestingly, the effect of EPA and ACE-I combination was more pronounced
in reducing TNBC cell inflammation as shown by reduced IL-6 levels in MDA-MB-231 cells, which
could be attributed to the more aggressive, inflammatory, and metastatic nature of MDA-MB-231 cells
compared with MCF-7 cells [51]. Similarly, EPA and EPA-derived ethanol amines were more potent in
reducing cell proliferation, migration, and invasion of MDA-MB-231 cells compared with non-invasive
MCF-7 cells in vitro, which is in agreement with our present study [52]. We did not observe any
synergistic effects of ACE-I and EPA combination in BC cell proliferation and migration, possibly
due to their competitive anti-inflammatory in vitro mechanisms of action via EGFR and/or NF-κB
(Rel-A) signaling pathways [19,53]. Moreover, many preclinical studies reported antihypertensive and
anti-inflammatory roles of n-3 PUFAs respectively via ACE-2 upregulation, Ang II downregulation,
and partly via GPCR-mediated NF-κB modulation [22,54,55]. Importantly, to our knowledge, we are
the first to report the potential anti-inflammatory roles of ACE-I and EPA combination in targeting
adipocyte and BC cell interactions. Despite this knowledge, potential mechanisms of ACE-I and EPA
interactions in lessening the effects of adipocytes on BC cells remain unknown. Clinical studies are also
lacking to understand the crosstalk between RAS inhibitors and n-3 PUFAs or other anti-inflammatory
bioactive compounds to improve obesity-mediated cancer outcomes.
Inflammation is positively associated with BC cell motility and wound healing, although their
mechanistic inter-relationship requires further studies [56]. Adipose CM contains various cytokines,
including IL-6 and IL-8, which could be responsible for increased BC cell motility and wound healing,
as reported by others [57]. We found a similar induced wound-healing capacity in MDA-MB-231 cells
in response to human adipose CM. On the contrary, given the anti-inflammatory and antiproliferative
effects of EPA on MDA-MB-231 cell motility [27] and the proposed similar effects for ACE-I, we
combined them to identify their synergistic or additive effects in MDA-MB-231 TNBC. Surprisingly,
both direct and CM-mediated EPA and ACE-I combination were ineffective in reducing TNBC cell
motility compared with either EPA or ACE-I alone. This is in disagreement with Krusche et al., who
reported the synergistic inhibitory effect of ACE-I and a Chinese herb (artesunate) on human umbilical
vein endothelial cells (HUVEC) motility [58]. This might be due to the competitiveness between EPA
and captopril to target common inflammatory mechanisms of action such as NF-κB downregulation
and/or inactivation [59]. Taken together, despite some protective anti-inflammatory effects of EPA and
ACE-I combination, such as attenuating IL-6, the underlying mechanisms require further studies in
both in vitro and in vivo models of obesity-induced breast cancer.
4. Materials and Methods
4.1. Cell Culture Experiments
Human breast cancer cells such as MDA-MB-231 (HTB-26; Lot: 700792) TNBC and ER/PR positive
MCF-7 (HTB-22; Lot: 64125078) BC cells were purchased from the American Type Culture collection
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(ATCC) (Manassas, VA, USA). MDA-MB-231 and MCF-7 cells were seeded at a density of 50,000 cells
per well and maintained under standard culture conditions at 37 ◦C in a humid atmosphere of 5%
CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM). The medium was supplemented with 10%
fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, MA, USA) and antibiotics (50 μg/mL
penicillin, 50 μg/mL streptomycin, and 100 ug/mL neomycin) (Thermo Fisher Scientific, Waltham, MA,
USA). Bone-marrow-derived human mesenchymal stem cells (HMSCs) (PT-2501; Lot: 0000483199)
were purchased from Lonza (Allendale, NJ, USA). These cells were differentiated into mature human
adipocytes according to the optimized published protocol [60] and maintained under standard culture
conditions at 37 ◦C and 5% CO2 in DMEM: Nutrient Mixture F-12 (DMEM/F-12) (Thermo Fisher
Scientific, Waltham, MA USA). Following differentiation, cells were transferred to regular DMEM with
10% FBS for 24 h and CM experiments were performed. EPA (Nu-Check Prep, Waterville, MN, USA)
and/or captopril (Sigma-Aldrich, St. Louis, MO, USA) was conjugated with 1% BSA (Sigma-Aldrich,
St. Louis, MO, USA) for 2 h in a shaking water bath at 37 ◦C prior to cell treatment. Since fatty acids
are found in the circulation as attached to albumin, many studies used BSA as a complex medium
for EPA and other fatty acids in in vitro culture experiments [61]. For consistency, all treatments were
performed in a BSA complexed medium.
4.2. Treatment with ACE Inhibitor, Captopril, and Eicosapentaenoic Acid for Conditioned Medium Experiments
MDA-MB-231 and MCF-7 cells were starved with 1% BSA for 2 h prior to CAP ± EPA experiments.
The BC cells were treated directly with the ACE inhibitor CAP (100 μm) with or without EPA (100 μm)
combination for 48 h to identify their individual/combined effect in modulating BC cell metabolism
(Figure S1). The time and dose of our current treatments (CAP and EPA) were based on our previous
work using EPA alone [27] or CAP alone (manuscript under review) against adipocyte–BC-cell
interactions. CM experiments were performed between differentiated human adipocytes (HMSCs)
and BC cells. Prior to the treatments, differentiated mature adipocytes were starved with 1% BSA
for 2 h. Following starvation, mature adipocytes were treated with 100 μm of CAP ± 100 μm of EPA
complexed with BSA, and BSA alone was used as the control. Conditioned media from differentiated
adipocytes were collected after 24 h and centrifuged at 10,000× g for 10 min, then filter-sterilized to
remove any cell debris. MDA-MB-231 and MCF-7 cells were seeded in six-well plates and then at 70%
confluency exposed to CM from human adipocytes for 48 h. BC cells and media were collected and
stored at −80 ◦C for further analyses (Figure S1).
4.3. Enzyme-Linked Immunosorbent Assay (ELISA)
Quantification of secreted IL-6 and IL-8 levels were determined by ELISA (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s protocol.
4.4. RNA Isolation and Real-Time Quatitative Polymerase Chain Reaction (RT-qPCR)
RNA was purified using the Quick RNA mini kit (Zymo Research, Irvine, CA, USA) according to the
established manufacturer’s protocol followed by cDNA synthesis. cDNA was reverse-transcribed using
Maxima reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, USA). mRNA transcription
levels were assessed with RT-qPCR using the Sybr green master mix (Thermo Fisher Scientific, Waltham,
MA, USA). All genes were normalized to two housekeeping genes (18S ribosomal RNA and TBP (TATA
box binding protein)). We used both 18S and TBP as our reference genes for normalization of RT-qPCR
data, both were normalized to each other, and we did not see any regulatory effects in response to our
proposed treatment conditions.
Sequences of the primers (Sigma Aldrich, St. Louis, MO, USA) are listed as follows
(forward, reverse):
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18S (5′-CTACCACATCCAAGGAAGCA-3′, 5’-TTTTTCGTCACTACCTCCCCG-3′), and
TBP (5′-ATGGTGGTGTTGTGAGAAGATG-3′, 5′-CAGATAGCAGCACGGTATGAG-3′).
4.5. Wound Healing Assay
MDA-MB-231 cells were seeded (50,000 cells per well) in six-well plates. At 95% confluence,
cells were washed with phosphate-buffered saline (PBS) (Thermo Fisher Scientific, Waltham, MA,
USA) and starved with 0.5% FBS in DMEM overnight to inhibit cell proliferation, thereby ensuring
wound closure was due to cell migration only. Using a sterilized 200 μL pipette tip, two straight
scratches were made through the cell’s monolayer, stimulating wound. Cells were first rinsed once
gently with PBS, then subjected to treatments described in the results, such as CAP with or without
EPA. Images were taken at 0, 4, 8, 12, 24, 36, and 48 h using the EVOS Cell Imaging System (Thermo
Fisher Scientific, Waltham, MA, USA) and data were analyzed using the in-house Cellular Growth
Analyzer for Windows software (version 2.2). The in-house analyzer program was used to change
the original image into black (the scratch) and the cell area into white (inside cells). The detection
parameter assigned in the program was the pixel size, and the program checked along the x direction
and later along the y direction, moving from left to right and counting the number of black pixels it
came across. This stopped when it encountered a white pixel. This worked on the basis that the wound
area (black) was the largest gap visible in the scratch assay.
4.6. Statistical Analysis
Data obtained from the experiments were normalized and analyzed using IBM SPSS (version
20, 2015) and R statistical software (version 3.5.3), and graphs were made using GraphPad Prism
(Version 8.0). Statistical significance between groups (control vs. treatments) was tested using one-way
ANOVA and subsequent pairwise post hoc comparisons adjusted using Tukey’s correction. Differences
were considered statistically significant for a Tukey-corrected p-value < 0.05. All experiments were
performed at least two times and results are expressed as mean ± SEM of three independent biological
replicates. Additional exploratory factorial regression analyses were performed to examine the
interactions between EPA and CAP on all measured biomarkers.
For the wound healing assays, the data were analyzed separately for BSA and CM-treated
conditions using two-way ANOVA models. The two-way ANOVA models were constructed to
examine for the main effects of treatment (i.e., EPA, CAP, and combination), time modeled as a
categorical variable, and their interaction. To determine the effect of each treatment on each biomarker
per unit time, additional exploratory linear regression analyses were performed to modeling time
as a continuous variable and the treatment condition as a categorical variable and their interaction.
The interactions of EPA and CAP on temporal trends of biomarkers were examined in factorial
regression analyses.
5. Conclusions
In conclusion, our study reported significant protective roles of EPA with and without ACE-I
combination in attenuating adipocyte-induced proinflammation and cancer cell migration. To our
knowledge, our study is the first to report inflammatory IL-6 downregulation effects of captopril and
EPA combination in both MDA-MB-231 and MCF-7 BC cells. One acknowledged limitation of our
study is that we only established a proof of principle for protective effects of CAP–EPA combination
against adipocyte–BC-cell interaction, possibly via modulation of inflammation. This provided us a
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basis for future more in-depth mechanistic studies to further dissect effects of adipocytes on cancer cell
proliferation and motility in response to CAP and EPA treatments in the tumor microenvironment.
Additionally, we did not see any differences between individual and combined ACE-I and EPA
treatments except for IL-6. This indicates the need for more in-depth mechanistic studies possibly
via knockdown of inflammatory signaling pathways in adipocytes and BC cells such as RAS and
IL-6/STAT3/NF-κB pathways. Moreover, comparison of the efficacy of other ACE-I such as lisinopril,
ARBs such as telmisartan, losartan, and/or n-3 PUFAs such as DHA or fish oil is necessary to better
understand how these affect adipocyte–BC-cell interactions. Hence, our present study provides a novel
significant validation for future mechanistic studies to combine diet and antihypertensive medication
as a potential therapeutic approach for obesity-associated BC. More research is warranted to identify
the possible mechanism of action and synergy of this unique combination of ACE-I and EPA or other
n-3 PUFAs in obesity and breast cancer.
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Abbreviations
Agt Angiotensinogen
Ang I Angiotensin I
Ang II Angiotensin II
ACE Angiotensin-converting enzyme
ACE-I Angiotensin-converting enzyme inhibitor
ARB Angiotensin receptor type I blocker
AT1R Angiotensin receptor type I
AT2R Angiotensin receptor type II







DMEM Dulbecco’s Modified Eagle’s Medium
ELISA Enzyme-linked immunosorbent assay
EPA Eicosapentaenoic acid
FBS Fetal bovine serum
FASN Fatty acid synthase
ER Estrogen receptor
ER+ Estrogen receptor positive
ER- Estrogen receptor negative
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HER2+ Human epidermal growth factor receptor-2 positive
HMSC Human mesenchymal stem cells
HUVEC Human umbilical vein endothelial cells
IL-6 Interleukin-6
IL-8 Interleukin-8
MCP-1 Monocyte chemoattractant protein 1
MMP Matrix metalloproteinase
n-3 PUFA Omega-3 polyunsaturated fatty acid




RT-qPCR Real-time quantitative polymerase chain reaction
STAT3 Signal transducer and activator of transcription 3
TAM Tumor-associated macrophage
TME Tumor microenvironment
TNBC Triple-negative breast cancer
VEGF Vascular endothelial growth factor
References
1. Stewart, B.; Wild, C.P. World Cancer Report 2014; World Health Organization (WHO): Geneva, Switzerland,
2017.
2. Carmichael, A.R. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG Int. J.
Obstet. Gynaecol. 2006, 113, 1160–1166. [CrossRef] [PubMed]
3. Ahn, J.; Schatzkin, A.; Lacey, J.V.; Albanes, D.; Ballard-Barbash, R.; Adams, K.F.; Kipnis, V.; Mouw, T.;
Hollenbeck, A.R.; Leitzmann, M.F. Adiposity, Adult Weight Change, and Postmenopausal Breast Cancer
Risk. Arch. Intern. Med. 2007, 167, 2091. [CrossRef] [PubMed]
55
Cancers 2020, 12, 220
4. Simone, V.; D’avenia, M.; Argentiero, A.; Felici, C.; Rizzo, F.M.; De Pergola, G.; Silvestris, F. Obesity and
breast cancer: Molecular interconnections and potential clinical applications. Oncologist 2016, 21, 404–417.
[CrossRef]
5. Deng, T.; Lyon, C.J.; Bergin, S.; Caligiuri, M.A.; Hsueh, W.A. Obesity, Inflammation, and Cancer. Annu. Rev.
Pathol. Mech. Dis. 2016, 11, 421–449. [CrossRef]
6. Dirat, B.; Bochet, L.; Dabek, M.; Daviaud, D.; Dauvillier, S.; Majed, B.; Wang, Y.Y.; Meulle, A.; Salles, B.; Le
Gonidec, S.; et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast
cancer invasion. Cancer Res. 2011, 71, 2455–2465. [CrossRef]
7. De Simone, V.; Franze, E.; Ronchetti, G.; Colantoni, A.; Fantini, M.C.; Di Fusco, D.; Sica, G.S.; Sileri, P.;
MacDonald, T.T.; Pallone, F.; et al. Th17-type cytokines, IL-6 and TNF-alpha synergistically activate STAT3
and NF-kB to promote colorectal cancer cell growth. Oncogene 2015, 34, 3493–3503. [CrossRef]
8. Hodge, D.R.; Hurt, E.M.; Farrar, W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur. J. Cancer
2005, 41, 2502–2512. [CrossRef]
9. Banerjee, K.; Resat, H. Constitutive activation of STAT3 in breast cancer cells: A review. Int. J. Cancer 2016,
138, 2570–2578. [CrossRef]
10. Wang, Y.; Kuhajda, F.P.; Li, J.N.; Pizer, E.S.; Han, W.F.; Sokoll, L.J.; Chan, D.W. Fatty acid synthase (FAS)
expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 2001,
167, 99–104. [CrossRef]
11. Berndt, J.; Kovacs, P.; Ruschke, K.; Kloting, N.; Fasshauer, M.; Schon, M.R.; Korner, A.; Stumvoll, M.;
Bluher, M. Fatty acid synthase gene expression in human adipose tissue: Association with obesity and type 2
diabetes. Diabetologia 2007, 50, 1472–1480. [CrossRef] [PubMed]
12. Wang, D.; Dubois, R.N. Associations between obesity and cancer: The role of fatty acid synthase. J. Natl.
Cancer Inst. 2012, 104, 343–345. [CrossRef] [PubMed]
13. Iyengar, P.; Combs, T.P.; Shah, S.J.; Gouon-Evans, V.; Pollard, J.W.; Albanese, C.; Flanagan, L.; Tenniswood, M.P.;
Guha, C.; Lisanti, M.P.; et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis
through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene
2003, 22, 6408–6423. [CrossRef] [PubMed]
14. Kalupahana, N.S.; Moustaid-Moussa, N. The adipose tissue renin-angiotensin system and metabolic disorders:
A review of molecular mechanisms. Crit. Rev. Biochem. Mol. Biol. 2012, 47, 379–390. [CrossRef]
15. Jing, F.; Mogi, M.; Horiuchi, M. Role of renin–angiotensin–aldosterone system in adipose tissue dysfunction.
Mol. Cell. Endocrinol. 2013, 378, 23–28. [CrossRef] [PubMed]
16. Ramalingam, L.; Menikdiwela, K.; LeMieux, M.; Dufour, J.M.; Kaur, G.; Kalupahana, N.; Moustaid-Moussa, N.
The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance.
Biochim. et Biophys. Acta Mol. Basis Dis. 2017, 1863, 1106–1114. [CrossRef] [PubMed]
17. Namazi, S.; Rostami-Yalmeh, J.; Sahebi, E.; Jaberipour, M.; Razmkhah, M.; Hosseini, A. The role of captopril
and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7:
An in vitro study. Biomed. Pharmacother. 2014, 68, 565–571. [CrossRef]
18. Muscella, A.; Greco, S.; Elia, M.G.; Storelli, C.; Marsigliante, S. Angiotensin II stimulation of Na+/K+ATPase
activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J. Endocrinol. 2002,
173, 315–323. [CrossRef]
19. Pinter, M.; Jain, R.K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for
immunotherapy. Sci. Transl. Med. 2017, 9, eaan5616. [CrossRef]
20. Rodrigues-Ferreira, S.; Nahmias, C. G-protein coupled receptors of the renin-angiotensin system: New
targets against breast cancer? Front. Pharmacol. 2015, 6, 24. [CrossRef]
21. Ni, H.; Rui, Q.; Zhu, X.; Yu, Z.; Gao, R.; Liu, H. Antihypertensive drug use and breast cancer risk: A
meta-analysis of observational studies. Oncotarget 2017, 8, 62545. [CrossRef]
22. Ulu, A.; Harris, T.R.; Morisseau, C.; Miyabe, C.; Inoue, H.; Schuster, G.; Dong, H.; Iosif, A.M.; Liu, J.Y.;
Weiss, R.H.; et al. Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble epoxide
hydrolase inhibitors in angiotensin-II-dependent hypertension. J. Cardiovasc. Pharmacol. 2013, 62, 285–297.
[CrossRef] [PubMed]
23. Fabian, C.J.; Kimler, B.F.; Hursting, S.D. Omega-3 fatty acids for breast cancer prevention and survivorship.
Breast Cancer Res. 2015, 17, 62. [CrossRef]
56
Cancers 2020, 12, 220
24. Kalupahana, N.S.; Claycombe, K.; Newman, S.J.; Stewart, T.; Siriwardhana, N.; Matthan, N.; Lichtenstein, A.H.;
Moustaid-Moussa, N. Eicosapentaenoic Acid Prevents and Reverses Insulin Resistance in High-Fat
Diet-Induced Obese Mice via Modulation of Adipose Tissue Inflammation. J. Nutr. 2010, 140, 1915–1922.
[CrossRef] [PubMed]
25. Kalupahana, N.S.; Claycombe, K.J.; Moustaid-Moussa, N. (n-3) Fatty Acids Alleviate Adipose Tissue
Inflammation and Insulin Resistance: Mechanistic Insights. Adv. Nutr. 2011, 2, 304–316. [CrossRef]
[PubMed]
26. Al-Jawadi, A.; Moussa, H.; Ramalingam, L.; Dharmawardhane, S.; Gollahon, L.; Gunaratne, P.;
Layeequr Rahman, R.; Moustaid-Moussa, N. Protective properties of n-3 fatty acids and implications
in obesity-associated breast cancer. J. Nutr. Biochem. 2018, 53, 1–8. [CrossRef] [PubMed]
27. Al-Jawadi, A.; Rasha, F.; Ramalingam, L.; Alhaj, S.; Moussa, H.; Gollahon, L.; Dharmawardhane, S.;
Moustaid-Moussa, N. Protective effects of eicosapentaenoic acid in adipocyte-breast cancer cell cross talk. J.
Nutr. Biochem. 2020, 75, 108244. [CrossRef]
28. Freund, A.; Jolivel, V.; Durand, S.; Kersual, N.; Chalbos, D.; Chavey, C.; Vignon, F.; Lazennec, G. Mechanisms
underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 2004, 23, 6105–6114.
[CrossRef]
29. Siriwardhana, N.; Kalupahana, N.S.; Fletcher, S.; Xin, W.; Claycombe, K.J.; Quignard-Boulange, A.; Zhao, L.;
Saxton, A.M.; Moustaid-Moussa, N. n-3 and n-6 polyunsaturated fatty acids differentially regulate adipose
angiotensinogen and other inflammatory adipokines in part via NF-κB-dependent mechanisms. J. Nutr.
Biochem. 2012, 23, 1661–1667. [CrossRef]
30. Brinton, E.A.; Mason, R.P. Prescription omega-3 fatty acid products containing highly purified
eicosapentaenoic acid (EPA). Lipids Health Dis. 2017, 16, 23. [CrossRef]
31. Superko, H.R.; Superko, A.R.; Lundberg, G.P.; Margolis, B.; Garrett, B.C.; Nasir, K.; Agatston, A.S. Omega-3
Fatty Acid Blood Levels Clinical Significance Update. Curr. Cardiovasc. Risk Rep. 2014, 8, 407. [CrossRef]
32. Itakura, H.; Yokoyama, M.; Matsuzaki, M.; Saito, Y.; Origasa, H.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.;
Hishida, H.; Kita, T.; et al. Relationships between plasma fatty acid composition and coronary artery disease.
J. Atheroscler. Thromb. 2011, 18, 99–107. [CrossRef]
33. Braeckman, R.A.; Stirtan, W.G.; Soni, P.N. Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red
Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin. Pharmacol. Drug Dev.
2014, 3, 101–108. [CrossRef]
34. Song, J.; Li, C.; Lv, Y.; Zhang, Y.; Amakye, W.K.; Mao, L. DHA increases adiponectin expression more
effectively than EPA at relative low concentrations by regulating PPARγ and its phosphorylation at Ser273 in
3T3-L1 adipocytes. Nutr. Metab. 2017, 14, 52. [CrossRef]
35. Mansara, P.P.; Deshpande, R.A.; Vaidya, M.M.; Kaul-Ghanekar, R. Differential Ratios of Omega Fatty Acids
(AA/EPA+DHA) Modulate Growth, Lipid Peroxidation and Expression of Tumor Regulatory MARBPs in
Breast Cancer Cell Lines MCF7 and MDA-MB-231. PLoS ONE 2015, 10, e0136542. [CrossRef]
36. Cunha, J.P. Consumer_Captopril_Capoten. Available online: https://www.rxlist.com/consumer_captopril_
capoten/drugs-condition.htm (accessed on 3 January 2020).
37. Small, W., Jr.; James, J.L.; Moore, T.D.; Fintel, D.J.; Lutz, S.T.; Movsas, B.; Suntharalingam, M.; Garces, Y.I.;
Ivker, R.; Moulder, J.; et al. Utility of the ACE Inhibitor Captopril in Mitigating Radiation-associated
Pulmonary Toxicity in Lung Cancer: Results From NRG Oncology RTOG 0123. Am. J. Clin. Oncol. 2018, 41,
396–401. [CrossRef]
38. Guglin, M.; Munster, P.; Fink, A.; Krischer, J. Lisinopril or Coreg CR in reducing cardiotoxicity in women
with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial. Am. Heart J.
2017, 188, 87–92. [CrossRef]
39. Onoyama, K.; Hirakata, H.; Iseki, K.; Fujimi, S.; Omae, T.; Kobayashi, M.; Kawahara, Y. Blood concentration
and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension 1981, 3,
456–459. [CrossRef]
40. Iyengar, N.M.; Gucalp, A.; Dannenberg, A.J.; Hudis, C.A. Obesity and Cancer Mechanisms: Tumor
Microenvironment and Inflammation. J. Clin. Oncol. 2016, 34, 4270–4276. [CrossRef] [PubMed]
41. Sagaradze, G.; Grigorieva, O.; Nimiritsky, P.; Basalova, N.; Kalinina, N.; Akopyan, Z.; Efimenko, A.
Conditioned Medium from Human Mesenchymal Stromal Cells: Towards the Clinical Translation. Int. J.
Mol. Sci. 2019, 20, 1656. [CrossRef] [PubMed]
57
Cancers 2020, 12, 220
42. Nieman, K.M.; Romero, I.L.; Van Houten, B.; Lengyel, E. Adipose tissue and adipocytes support tumorigenesis
and metastasis. Biochim. Biophys. Acta 2013, 1831, 1533–1541. [CrossRef] [PubMed]
43. Carter, J.C.; Church, F.C. Mature breast adipocytes promote breast cancer cell motility. Exp. Mol. Pathol.
2012, 92, 312–317. [CrossRef] [PubMed]
44. Vazquez-Martin, A.; Colomer, R.; Brunet, J.; Lupu, R.; Menendez, J.A. Overexpression of fatty acid synthase
gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif. 2008, 41,
59–85. [CrossRef] [PubMed]
45. Alwarawrah, Y.; Hughes, P.; Loiselle, D.; Carlson, D.A.; Darr, D.B.; Jordan, J.L.; Xiong, J.; Hunter, L.M.;
Dubois, L.G.; Thompson, J.W.; et al. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity
in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem. Biol. 2016, 23, 678–688. [CrossRef] [PubMed]
46. Faggioli, L.; Costanzo, C.; Merola, M.; Bianchini, E.; Furia, A.; Carsana, A.; Palmieri, M. Nuclear factor kappa
B (NF-kappa B), nuclear factor interleukin-6 (NFIL-6 or C/EBP beta) and nuclear factor interleukin-6 beta
(NFIL6-beta or C/EBP delta) are not sufficient to activate the endogenous interleukin-6 gene in the human
breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing
human breast carcinoma cell line. Eur. J. Biochem. 1996, 239, 624–631. [PubMed]
47. Chavey, C.; Muhlbauer, M.; Bossard, C.; Freund, A.; Durand, S.; Jorgensen, C.; Jobin, C.; Lazennec, G.
Interleukin-8 expression is regulated by histone deacetylases through the nuclear factor-kappaB pathway in
breast cancer. Mol. Pharmacol. 2008, 74, 1359–1366. [CrossRef]
48. Bravata, V.; Minafra, L.; Forte, G.I.; Cammarata, F.P.; Russo, G.; Di Maggio, F.M.; Augello, G.; Lio, D.;
Gilardi, M.C. Cytokine profile of breast cell lines after different radiation doses. Int. J. Radiat. Biol. 2017, 93,
1217–1226. [CrossRef]
49. Trebble, T.; Arden, N.K.; Stroud, M.A.; Wootton, S.A.; Burdge, G.C.; Miles, E.A.; Ballinger, A.B.;
Thompson, R.L.; Calder, P.C. Inhibition of tumour necrosis factor-a and interleukin-6 production by
mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant
co-supplementation. Br. J. Nutr. 2003, 90, 405–412. [CrossRef]
50. Duvall, M.G.; Levy, B. DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation.
Eur. J. Pharmacol. 2016, 785, 144–155. [CrossRef]
51. Illan-Cabeza, N.A.; Jimenez-Pulido, S.B.; Hueso-Urena, F.; Ramirez-Exposito, M.J.; Sanchez-Sanchez, P.;
Martinez-Martos, J.M.; Moreno-Carretero, M.N. Effects on estrogen-dependent and triple negative
breast cancer cells growth of Ni(II), Zn(II) and Cd(II) complexes with the Schiff base derived from
pyridine-2-carboxaldehyde and 5,6-diamino-1,3-dimethyluracil explored through the renin-angiotensin
system (RAS)-regulating aminopeptidases. J. Inorg. Biochem. 2018, 185, 52–62. [CrossRef]
52. Brown, I.; Lee, J.; Sneddon, A.A.; Cascio, M.G.; Pertwee, R.G.; Wahle, K.W.; Rotondo, D.; Heys, S.D. Anticancer
effects of n-3 EPA and DHA and their endocannabinoid derivatives on breast cancer cell growth and invasion.
Prostaglandins Leukot. Essent. Fat. Acids 2019. [CrossRef] [PubMed]
53. Weng, W.H.; Leung, W.H.; Pang, Y.J.; Kuo, L.W.; Hsu, H.H. EPA significantly improves anti-EGFR targeted
therapy by regulating miR-378 expression in colorectal cancer. Oncol. Lett. 2018, 16, 6188–6194. [CrossRef]
[PubMed]
54. Niazi, Z.R.; Silva, G.C.; Ribeiro, T.P.; Leon-Gonzalez, A.J.; Kassem, M.; Mirajkar, A.; Alvi, A.; Abbas, M.;
Zgheel, F.; Schini-Kerth, V.B.; et al. EPA:DHA 6:1 prevents angiotensin II-induced hypertension and
endothelial dysfunction in rats: Role of NADPH oxidase- and COX-derived oxidative stress. Hypertens. Res.
Off. J. Jpn. Soc. Hypertens. 2017, 40, 966–975. [CrossRef] [PubMed]
55. Ulu, A.; Stephen Lee, K.S.; Miyabe, C.; Yang, J.; Hammock, B.G.; Dong, H.; Hammock, B.D. An omega-3
epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. J.
Cardiovasc. Pharmacol. 2014, 64, 87–99. [CrossRef] [PubMed]
56. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [CrossRef]
57. Chang, Q.; Bournazou, E.; Sansone, P.; Berishaj, M.; Gao, S.P.; Daly, L.; Wels, J.; Theilen, T.; Granitto, S.;
Zhang, X.; et al. The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis. Neoplasia
2013, 15, 848–862. [CrossRef]
58. Krusche, B.; Arend, J.; Efferth, T. Synergistic inhibition of angiogenesis by artesunate and captopril in vitro
and in vivo. Evid. Based Complement. Alternat. Med. 2013, 2013, 454783. [CrossRef]
58
Cancers 2020, 12, 220
59. Miguel-Carrasco, J.L.; Zambrano, S.; Blanca, A.J.; Mate, A.; Vazquez, C.M. Captopril reduces cardiac
inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J. Inflamm. 2010, 7, 21.
[CrossRef]
60. Lee, M.J.; Fried, S.K. Optimal protocol for the differentiation and metabolic analysis of human adipose
stromal cells. Methods Enzymol. 2014, 538, 49–65. [CrossRef]
61. Wortman, P.; Miyazaki, Y.; Kalupahana, N.S.; Kim, S.; Hansen-Petrik, M.; Saxton, A.M.; Claycombe, K.J.;
Voy, B.H.; Whelan, J.; Moustaid-Moussa, N. n3 and n6 polyunsaturated fatty acids differentially modulate
prostaglandin E secretion but not markers of lipogenesis in adipocytes. Nutr. Metab. 2009, 6, 5. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution





Isobolographic Analysis Demonstrates the Additive
and Synergistic Effects of Gemcitabine Combined
with Fucoidan in Uterine Sarcomas and
Carcinosarcoma Cells
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Abstract: Background: Uterine sarcomas and carcinosarcoma are associated with unfavorable
prognosis. The regimens that are used in chemotherapy are associated with high incidence of side
effects and usually do not significantly increase patients’ survival rates. In this study we investigated
the activity and interactions between gemcitabine and fucoidan, the natural compound known for
its anti-tumor properties, in human sarcomas and carcinosarcoma cell models. Methods: SK-UT-1,
SK-UT1-B (carcinosarcoma), MES-SA (leiomyosarcoma), and ESS-1 (endometrial stromal sarcoma) cell
lines were used for the experiments. Cells were incubated in the presence of gemcitabine, fucoidan,
and mixtures, after the incubation the MTT tests were performed. In order to assess the interactions
between tested compounds isobolographic analysis was performed. Additional assessments of
apoptosis and cell cycle were done. Results: Additive effect of combined treatment with gemcitabine
and fucoidan was observed in ESS-1 and SK-UT-1 cell line. Although the supra-additive (synergistic)
effect noticed in SK-UT-1B cell line. It was not possible to determine the interactions of fucoidan and
gemcitabine in MES-SA cell line due to insufficient response to treatment. Addition of fucoidan to
gemcitabine enhances its proapoptotic activity, what was observed especially in ESS-1 and SK-UT-1B
cell lines. The arrest of cell cycle induced by mixture of gemcitabine and fucoidan, superior comparing
gemcitabine alone was observed in SK-UT-1B. Conclusions: Obtained data showed that a combination
of fucoidan and gemcitabine in uterine endometrial stromal sarcoma and carcinosarcoma cell lines
has additive or even synergistic effect in decreasing cell viability. Furthermore, this drug combination
induces apoptosis and arrest of cell cycle. The resistance of uterine leiomyosarcoma cell line, justifies
searching for other drugs combinations to improve therapy efficacy.
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1. Introduction
Uterine sarcomas are a group of malignancies consist of various types of tumors arising from
mesenchymal tissue. The most common type of uterine sarcomas is leiomyosarcoma (about 60%
of cases), less common types are endometrial stromal sarcoma (low and high grade), liposarcoma,
rhabdomyosarcoma, and many other rare types [1]. The incidence of uterine sarcomas remains low
respectively to epithelial malignancies (3–7% of all uterine malignancies) [2]. The diagnosis of uterine
sarcoma is associated with bad prognosis and low rate of response to chemotherapy. Carciosarcoma is
a type of tumor consisting of both mesenchymal and epithelial cells, that nowadays is considered as a
type of endometrial cancer. These tumors are associated with bad prognosis and, similarly to uterine
sarcomas, the results of its systemic treatment remain unsatisfactory. Systemic treatment of uterine
mesenchymal tumors is based on cytostatic agents such as doxorubicine, gemcitabine, docetaxel,
dacrbazine, and ifosfamde [3].
The exceptions from the above characteristics are endometrial stromal sarcomas, associated with
indolent clinical behavior and favorable prognosis. The majority of these tumors express estrogen
receptors and usually respond to hormonal treatment [2].
The retrospective trial comparing gemcitabine plus docetaxel, ifosfamide plus cisplatin,
doxorubicin plus ifosfamide, ifosfamide alone, topotecan alone, and observation only in stage I
and II leiomyosarcoma revealed no significant differences between groups in recurrence rate [4]. Due
to the rarity of uterine sarcomas, the number of completed, randomized, prospective trials is limited.
The response rates among patients suffering from uterine sarcomas, in prospective trials assessing the
efficacy of various combinations of gemcitabine, docetaxel, and bevacizumab were between 25% and
35.8% [5–7].
The results obtained in systemic therapy of sarcomas are unsatisfactory. Most authors strongly
recommend conducting clinical and pre-clinical trials in this field. The situation described above led to
a search for new agents to be active against uterine sarcomas. Fucoidan is sulphated polysaccharide
derived from brown seaweed, that recently gained attention due to its biological activities. It is known
to affect multiple pathways in cancer cells including PI3K/AKT, MAPK, PTEN, VEGF, and caspases. Its
effectiveness was proven in various models including lymphoma, leukemia, prostate cancer, breast
cancer, hepatic cancer [8]. Recently we reported the anti-proliferative and pro-apoptotic activity of
fucoidan in monotherapy among uterine sarcoma and carcinosarcoma cell lines. Simultaneously we
confirmed previous observations that fucoidan do not affect normal (benign) human cells. Additionally,
fucoidan is widely using as a dietary supplement. The characteristics listed above allow it to be
considered as a safe product [8–10].
Obtained results led us to question the activity of fucoidan in combination with standard
chemotherapy among uterine sarcomas. Gemcitabine was selected to be investigated together with
fucoidan. Gemcitabine is commonly used anti-tumor drug belonging to the group of antimetabolites. It
express antimetabolic effect by interruption of DNA synthesis. It is widely used as an option of standard
approach for the systemic therapy in most of uterine sarcomas subtypes [3,11,12]. Furthermore, it is
a comparator in many ongoing clinical trials enrolling uterine sarcoma patients [12]. Combinations
of gemcitabine with novel agents including olaratumab, nivolumab, and pazopanib are under
investigation in phases II–III of clinical trials [13].
This study was aimed to test if the combination of gemcitabine and fucoidan will have better
therapeutic effect in uterine sarcomas and carcinosarcomas cell lines than the compounds applied
alone and to assess the type of interactions between them in concomitant treatment.
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2. Materials and Methods
2.1. Reagents
Gemcitabine (100 mg/mL, 0.38 mMol/mL) was purchased from Accord Healthcare (UK), and
fucoidan (Undaria pinnatifida) was obtained from Sigma-Aldrich (St. Louis, MO, USA). Fucoidan was
diluted in respective complete culture medium at a concentration of 10 mg/mL just before use.
The Roswell Park Memorial Institute 1640 (RPMI-1640), Eagle’s Minimum Essential
Medium (MEM), McCoy’s 5a Medium Modified, fetal bovine serum (FBS), trypsin-EDTA
were purchased from PAN-Biotech (Aidenbach, Germany), penicillin-streptomycin and MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were obtained from Sigma-Aldrich
(St. Louis, MO, USA). The Cell Proliferation ELISA System assay kit was purchased from Roche
(Molecular Biochemicals, Manneihm, Germany). PE Active Caspase-3 Apoptosis Kit and Propidium
iodide utilizing the PI/RNase Staining Buffer were obtained from Becton Dickinson Biosciences (San
Jose, CA, USA).
2.2. Cell Lines and Cultures
Carcinosarcoma cell lines (SK-UT-1, SK-UT1-B), uterine leiomyosarcoma cell line (MES-SA), and
endometrial stromal sarcoma cell line (ESS-1) were obtained from the Laboratorio de Investigación
Traslacional (MD Anderson Cancer Center, Madrid). The selection of cell lines was done in order
to assess the differences in response to tested compounds among wide range of uterine sarcomas.
Each cell line used for experiments is a model of particular tumor what makes obtained data more
reproducible and comparable with other research.
The cells were cultured in MEM (SK-UT-1, SK-UT1-B), McCoy’s 5a Medium Modified (MES-SA),
RPMI-1640 (ESS-1), containing 10% (SK-UT-1, SK-UT-1B, MES-SA) or 20% (ESS-1) FBS and 1%
penicillin-streptomycin at 37 ◦C in a humidified 5% CO2 atmosphere. Cells from the 4th to 9th passage
were used for all experiments.
Detailed characteristic of cell lines is presented in Table 1.
Table 1. The characteristics of used cell lines [14,15].
Cell line: SKUT-1 * SKUT-1B * MES-SA ESS-1
Organism: Homo sapiens, human Homo sapiens, human Homo sapiens, human Homo sapiens,human
Tissue: uterus uterus/endometrium uterus uterus
Culture
properties:















Age: 75 years 75 years 56 years 76 years
Gender: female female female female
Ethnicity: Caucasian Caucasian Caucasian Caucasian
* SKUT-1 and SKUT-1B cell lines were derived from the same patient from different sites of tumor SKUT-1 line is a
model of sarcomatous part of the tumor (forms spindle cell sarcomas), SKUT-1B is a model of carcinomatous part of
the tumor (forms well differentiated adenocarcinomas).
2.3. Cell Viability Assay
Cells were platted on 96-well microplates SK-UT-1, SK-UT-1B, MES-SA, and ESS-1
(3 × 104 cells/mL) and cells were incubated in the presence of gemcitabine (0.1–200 ng/mL), fucoidan
(0.01–5 mg/mL) and mixtures of both compounds for 96 h. The maximum concentration of gemcitabine
achieved in human serum was 26.79 ± 10.06 μg/mL, reported by Wang et al. so the concentrations used
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in our experiments were much lower comparing to ones available in vivo [16]. The safe concentrations
of fucoidan in human serum are still under investigations and no conclusive data are available up to
date. Afterwards, the cells were incubated for 3 h with the MTT. During the time MTT was metabolized
by living cells to purple formazan crystals, which were later solubilized in SDS buffer (10% SDS in
0.01 N HCl) overnight. Separate experiments were performed in triplicate. The optical density of
the product was measured at 570 nm with the use of an ELX-800 plate reader (Bio-Tek, Instruments,
Winooski, VT, USA) and analyzed using Gen5 software (Bio-Tek, Instruments, Winooski, VT, USA).
2.4. Assessment of Apoptosis
Cell lines were treated with tested compounds and mixtures for 48 h, as a control cells without
treatment were used. Afterwards cells were harvested, fixed and permeabilized using the Cytofix. All
of experiments were performed according to the manufacturer’s instructions of PE Active Caspase-3
Apoptosis Kit (BD Biosciences, San Jose, CA, USA). Labeled cells were analyzed by flow cytometer
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA), operating with CellQuest software (BD
Biosciences, San Jose, CA, USA) to quantitatively assess the caspase-3 activity. The methodology of
apoptosis assessment were described in detail elsewhere [9].
2.5. Cell Cycle Analysis
Cell lines were treated with tested compound and mixture for 48 h (as a control we used cells
without exposure to tested compounds) and then fixed in 80% ethanol at −20 ◦C for 24 h. The
experiment was conducted by utilizing PI/RNase Staining Buffer (BD Biosciences, USA) according to
the manufacturer’s instructions. Cell cycle analysis was performed using flow cytometry (FACSCalibur
(Becton Dickinson, USA). Acquisition rate was at least 60 events/sec in low acquisition mode and
at least 10,000 events were measured. Methodology of cell cycle analysis was presented in detail
previously [10].
2.6. Isobolographic and Statistical Analysis
In order to determine the inhibition rate of cell viability, measured by MTT assay, per dose of
gemcitabine and fucoidan, log-probit linear regression analysis was performed according to method
described by Litchfield and Wilcoxon [17,18]. Median inhibitory concentrations (IC50) for gemcitabine
and fucoidan in ESS-1, SK-UT-1, and SK-UT-1B cell lines were calculated according to method
previously described [19]. Due to lack of cells response, the IC50 was not achievable for fucoidan in
MES-SA cell line [10]. Parallelism between dose–response curves for gemcitabine and fucoidan in
ESS-1, SK-UT-1, and SK-UT-1B cell lines was confirmed by log-probit method, as it was described in
detail previously [18]. Next, isobolographic analysis of interactions between drugs for the combination
of gemcitabine and fucoidan in tested cell lines were performed according to the method presented by
i.a. Tallarida et al. [20]. The median additive inhibitory concentrations (IC50 add) for two-drug mixtures
were theoretically calculated according to the method described elsewhere [20]. The calculated values
were used for performing MTT tests on ESS-1, SK-UT-1, and SK-UT-1B cell lines—the assessment of
experimentally derived IC50 mix values for tested drug combinations in a fixed 1:1 ratio. The particular
drug concentrations (gemcitabine and fucoidan) in the mixture were calculated by multiplying IC50 mix
values accordingly to proportions in additive mixture. Detailed description of isobolographic method
was introduced by Tallarida, Grabovsky and Luszczki [20–22]. The results of MTT test were analyzed
by one-way ANOVA test, Tukey’s Multiple Comparison Post-test using GraphPad Prism 5.0 (GraphPad
Softwere Inc., San Diego, CA, USA). The p < 0.05 was considered as statistically significant.
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3. Results
3.1. Cell Viability Assay
Anti-proliferative effects of gemcitabine on tested cell lines is presented on Figure 1. Experimentally
determined IC50 values for gemcitabine in SK-UT-1, SK-UT-1B, ESS-1, and MES-SA cell lines, were 31.173,
25.243, 13.875, and 72.482 ng/mL respectively.
As we previously reported fucoidan significantly affects SK-UT-1, SK-UT-1B, and ESS-1 cell lines,
meanwhile MES-SA cells seem to be resistant for this agent. IC50 was 0.966, 3.348, and 0.848 mg/mL
respectively, it was not possible to determine IC50 for fucoidan in MES-SA cell line due to insufficient
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Figure 1. The influence of gemcitabine on the proliferation of carcinosarcoma cell lines (SK-UT-1 (A),
SK-UT1-B (B)), endometrial stromal sarcoma cell line (ESS-1 (C)) and uterine leiomyosarcoma cell
line (MES-SA (D)). The cells were treated with the gemcitabine at various concentrations for 96 h.
(** p < 0.01, *** p < 0.001 were considered as statistically significant).
3.2. Isobolographic Anaysis
Additive effect of the combined treatment with gemcitabine and fucoidan was observed in ESS-1
and SK-UT-1 cell lines. Although the supra-additive (synergistic) effect was noticed in SK-UT-1B
cell line.
The details of results obtained in isobolographic analysis are presented on Figures 2–4.
In Figures 2–4 the median inhibitory concentrations (IC50) for gemcitabine (GEM) and fucoidan
(FUK) are plotted on the X- and Y-axes, respectively. The solid lines on both axes reflect the S.E.M.
for the IC50 values for the studied drugs, when administered alone. The lower and upper isoboles of
additivity represent the curves connecting the IC50 values for GEM and FUK administered alone. The
dotted line illustrates the fixed-ratio of 1:1 for the combination of GEM with FUK. The points A’ and A”
depict the theoretically calculated IC50 add values for both, lower and upper isoboles of additivity. The
point M reflects the experimentally-derived IC50 mix value for total dose of the mixture expressed as
proportions of GEM and FUK that produced a 50% anti-proliferative effect (50% isobole) in the cancer
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cell line (SK-UT-1, SK-UT-1B, and ESS-1, respectively for Figures 2–4) measured in vitro by the MTT
assay. On the graph, the S.E.M. values are presented as horizontal and vertical error bars for every IC50
value. Type I isobolographic analysis of interactions are presented in Supplementary Table S2. The
effect of combined fucoidan and gemcitabine on the proliferation of tested cell lines were presented of
Figure 5.
Figure 2. Isobologram showing interaction between gemcitabine (GEM) and fucoidan (FUK) with
respect to their anti-proliferative effects in the cancer cell line (SK-UT-1) measured in vitro by the MTT
assay. The experimentally-derived IC50 mix value is placed within the area of additivity and indicates
additive interaction between GEM and FUK in this cancer cell line.
Figure 3. Isobologram showing interaction between gemcitabine (GEM) and fucoidan (FUK) with
respect to their anti-proliferative effects in the cancer cell line (SK-UT-1B) measured in vitro by the MTT
assay. Because the experimentally-derived IC50 mix value is placed significantly below the point A’,
the interaction between GEM and FUK for the cancer cell line SK-UT-1B is supra-additive (synergistic).
* p < 0.05 vs. the respective IC50 add values.
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Figure 4. Isobologram showing interaction between gemcitabine (GEM) and fucoidan (FUK) with
respect to their anti-proliferative effects in the cancer cell line (ESS-1) measured in vitro by the MTT
assay. Although the experimentally-derived IC50 mix value is placed below, but near to the point A’,
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Figure 5. The influence of combined fucoidan and gemcitabine on the proliferation of carcinosarcoma
cell lines (SK-UT-1 (A), SK-UT-1B (B)) and endometrial stromal sarcoma cell line (ESS-1 (C)). The cells
were treated with fucoidan and gemcitabine at various concentrations for 96 h. (** p < 0.01, *** p < 0.001
were considered as statistically significant). The values on axis X represent the multiplicity of calculated
IC50. The combinations of gemcitabine and fucoidan were mixed 1:1 before added to cells.
3.3. Assessment of Apoptosis
The impact of gemcitabine and its combination with fucoidan on apoptosis, measured as a number
of cells with activated caspase 9, is presented on Figure 6A–C. Gemcitabine was used in concentration
of IC50. Results obtained in isobolographic analysis were used to select appropriate concentrations
of mixture for apoptosis assessment. For SK-UT-1 and SK-UT-1B concentrations of 0.5 IC50 for both
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Figure 6. Effects of gemcitabine (in IC50 concentration) and mixture of fucoidan and gemcitabine (in
concentrations of 0.5 IC50 for SK-UT-1 and SK-UT-1B and 0,05 IC50 for ESS-1) on caspase-3 activation in
SK-UT-1 (A), SK-UT-1B (B), and ESS-1 (C) cells. Results are expressed as mean ± SD of three separate
experiments (* p < 0.05, ** p < 0.01, *** p < 0.001 versus the control, one-way ANOVA test).
The strongest induction of apoptosis by both gemcitabine and mixture gemcitabine + fucoidan
was observed in ESS-1 cell line. This effect was also observed in SK-UT-1B cells. Although the induction
of apoptosis in SK-UT-1 cell line of both single agent and combination was very weak. Statistical
significance was observed between single agent and combination but the differences comparing to
control were not significant.
3.4. Cell Cycle
The results of cell cycle analysis of cells treated with gemcitabine and its mixture with fucoidan
are presented in Figure 7. Statistical significance of differences between each phase of cell cycle
in treatments and control are listed in Supplementary Table S3. Tested compounds were used in
concentration as in apoptosis assessments.
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Figure 7. Effects of gemcitabine (in IC50 concentration) and mixture of fucoidan and gemcitabine (in
concentrations of 0.5 IC50 for SK-UT-1 and SK-UT-1B and 0.05 IC50 for ESS-1) on cell cycle progression
in SK-UT-1 (A), SK-UT1-B (B), and ESS-1 (C) cell lines. The results are presented as mean ± SD from
three separate experiments.
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The most significant impact of concomitant treatment with gemcitabine and fucoidan on cell cycle
arrest (measured as percent of cells in phases pre-G1 and G0/G1) was detected in the SK-UT-1 B cell line
(comparing to both control and gemcitabine treatment). In the ESS-1 cell line significant differences
were noted between cells treated with gemcitabine and control, with no such differences between
gemcitabine and mixture. The differences in number of cells in each phase of cell cycle in SK-UT-1
cells exposed to investigated agents were very small in spite of statistical significance observed in
particular phases.
4. Discussion
This paper for our knowledge is the first report of interactions between fucoidan and gemcitabine
in any model. The results obtained in our experiments show that both gemcitabine and fucoidan
significantly affect cell viability in all tested cell lines (with exception of fucoidan in MES-SA cell line).
The problem of MES-SA cell line resistance to fucoidan have been discussed previously [10]. In present
study we observed also the worst response of MES-SA to gemcitabine among all of tested cell lines.
Interestingly we used regular MES-SA line, but not its multidrug resistant variant MES-SA/Dx5. The
mechanism of relative resistance of MES-SA cell line to fucoidan and gemcitabine is not known and
requires further investigations. For our best knowledge the phenomenon of spontaneous MES-SA
resistance to gemcitabine have not been published yet. Resistance to gemcitabine was artificially
induced by genetic modifications (transfection) in gene coding deoxynucleoside kinase in MES-SA,
although such modifications were not performed in the cell line we used [23]. Occurrence of some
spontaneous mutations in deoxynucleoside kinase gene at least in part of cells could possibly explain
our observation. The occurrence of serious side effects combined with limited activity makes systemic
therapy of uterine sarcomas doubtful [13]. The most common unwanted results of chemotherapy are
hematologic toxicities (leucopoenia, neutropenia, thrombocytopenia), fever, and concomitant infectious,
that appear in the majority of treated patients [24]. Side effects of drugs are mostly dose-dependent, so
it could be limited by the reduction of dosage, on the other hand, reduction of dose would decrease the
therapeutic effect.
In multidrug regimens, in assumption, lower doses of multiple drugs may cause fewer side effects
(or its lower intensity) without decreasing effectiveness or even increasing it [13]. But in clinical practice
such approaches are commonly associated with higher rate of adverse events.
The rarity and heterogeneity of uterine sarcomas limit the possibilities of conducting clinical trials,
which may be considered as a cause of the poor results of its treatment up to date. Even in preclinical
studies number of research aimed to test new drugs combinations in this group of tumors is limited.
Coley et al. tested the combination of seliciclib (cyclin-dependent kinases (CDK)-inhibitor) and
paclitaxel among selection of uterine sarcomas cell lines. Using isobolography, they observed synergism
between both drugs. Interestingly, differences in activity depending on the sequence of each drug
administration were reported. Although the study is interesting, seliciclib is not registered for the
treatment of uterine sarcomas. Furthermore, paclitaxel in monotherapy is not recommended among
this type of malignancies [25].
In the present study we propose a combination of standard chemotherapy with a natural compound
that is known to be safe; its intake is not associated with serious adverse events [26]. Both substances
were administered at the same time in order to avoid a “drug sequence effect” observed by Coley
at al. that could influence the results. Isobolographic analysis showed additive interaction between
gemcitabine and fucoidan in SK-UT-1 and ESS-1 cell lines and even supra-additive (synergy) in
SK-UT-1B. No antagonism between tested substances was observed.
Cell viability was decreased equally or more than the sum of effects of single agents. If these
observations are confirmed in animal models, clinical trials of fucoidan as an addition to treatment
with gemcitabine may allow a decrease of its dose. Fucoidan is nowadays used as dietary supplement,
and seaweeds containing it are widely used in Asian cuisine [26]. There are many researches aimed at
checking its activity in various types of cancer. Some of them regard a combination of fucoidan and
72
Cancers 2020, 12, 107
other agents (including cytostatics), and the results of most of them are promising. In our study we
assessed the type of interactions between fucoidan and a cytostatic agent, using an isobolographic
method, and calculated IC50 for the mixture. Significantly lower doses of therapeutic compounds may
be associated with lower risk of adverse events. Furthermore, it may solve another problem that was
widely discussed previously— the bioavailability of fucoidan. That is currently still under investigation
both in animal models as well as in clinical trials—the results of these studies are awaited [27–29].
IC50 values for fucoidan obtained in combination with gemcitabine are much lower than 1 mg/mL:
Such concentrations seem to be achievable in vivo. The doubtful concentrations were around 5
mg/mL. Although a few studies in this field were performed, precise determination of available serum
concentrations among human are still under investigation [29,30].
Quite similar results were obtained by Mathew et al. who assessed IC50 for various types of
fucoidan from 0.3 to 1.3 mg/mL (depending on plant that it was derived from). In this study they
also performed analysis of fucoidans’ impact on CYP450 and COMT (catechol-O-methyltransferase)
pathways, concluding that it is limited, which might be considered as a confirmation of its safety [31].
Our findings are comparable with other studies assessing activity of fucoidan and cytotoxic drugs.
Burney et al. assessed activity of 2 types of fucoidan in combination with paclitaxel and tamoxifen on
mouse models of human breast or ovarian cancer. They concluded that interaction between tested
compounds were additive or supra-additive (depending on combination and model used) [32].
Similar observations were taken by Zhang et al. who tested combinations of fucoidan with
cisplatin, tamoxifen, and paclitaxel in breast cancer cell lines. They concluded that fucoidan “enhances
the anti-cancer activity” of tested cytostatic drugs. Furthermore, they observed the induction of
apoptosis and cell cycle arrest among cells treated with fucoidan what corresponds with our previous
findings [9,33].
Observed additive and supra-additive interactions between various fucoidans and
chemotherapeutic drugs require explanation. The mechanism of fucoidans’ activity is not fully
investigated. As it was mentioned above there are various cellular pathways that are affected by
this compound. Its multipotential activity is, on the one hand, promising, and does not allow the
overcoming of single pathway change, but on the other it is very difficult to understand completely. One
of possible mechanism of synergistic interaction with chemotherapeutics is the ability to down-regulate
expression of Bcl-xL and Mcl-1, known as anti-apoptotic proteins [34]. The addition of fucoidan to
gemcitabine enhances its ability to induce apoptosis. This effect is especially noticeable in ESS-1 cell
line where, even if mixture was added in concentration 0.05 of IC50, almost 80% of cells enter apoptosis
and the difference between gemcitabine in monotherapy and the mixture reaches almost 20%. Weaker
effect was observed in SK-UT-1B cells. In the SK-UT-1 cell line almost no impact of gemcitabine and
fucoidan to apoptosis was noted, even if agents were used in concentration of 0.5 of IC50. Abudabbus
et al. compared the ability of fucoidan in combination with cisplatin, doxorubicin and taxol, to induce
apoptosis and to arrest the cell cycle among benign and malignant breast cells [35]. They reported a
strong impact to cell cycle arrest and induction of apoptosis in malignant cells but no significant effect
in normal cells. A comparable effect of fucoidan in monotherapy was described by Arumugam et al.
in hepatoblastoma cell line [36]. So, our results confirm proapoptotic features of fucoidan in selected
models. Interestingly, observations taken in experiments assessing apoptosis were confirmed also in
cell cycle analysis. The strongest effect of combination of gemcitabine and fucoidan was observed
in ESS-1 line. Moderate and weak changes in number of cells in particular cell cycle phases were
observed in SK-UT-1 and SK-UT-1B cell lines respectively.
Gemcitabine is known to affect the cell cycle in various cell models and in vivo; this feature is the
consequence of its mechanism of action by DNA damaging [37]. The process of gemcitabine-induced
cell cycle arrest can by interrupted by activity of DNA repairing mechanisms such as Chk1 [38]. Such a
mechanism might be responsible for the limited changes in cells distribution among cell cycle phases
observed in SK-UT-1 and SK-UT-1B treated with gemcitabine.
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Park et al. reported the effect of cell cycle arrest by fucoidan treatment in bladder cancer
cells. They also revealed the its association with down-regulation of cyclin D1, cyclin E, and
cyclin-dependent-kinases (Cdks) in a concentration-dependent manner, without any change in Cdk
inhibitors (p21, p27) [39]. Interestingly Han et al. experimented on a colon cancer model and observed
cell cycle arrest associated with an increased expression of p21 [40]. Different mechanisms of cell cycle
arrest induced by fucoidan in different models, combined with potential activity of DNA repairing
factors affecting activity of gemcitabine, can explain differences among tested cell lines, we observed. So
far, no studies assessing the impact of combination of gemcitabine and fucoidan have been published.
The results and survey of literature indicate that testing multicompound regimens gives promising
results and further research in the field could reveal a combination that could be beneficial for patients
suffering from uterine sarcomas.
The study is not without limitations and should be considered carefully. The main limitation
of the study is a cancer model that was used, 2D cell cultures, which do not allow investigation of
the tumor microenvironment and may not fully reflect the response of tumor cells in vivo. Although
promising, obtained results require clinical studies to be considered in practice.
The results obtained in our study indicate 3 potential directions for further investigations:
• Analysis of the mechanisms of the MES-SA cell line relative resistance to fucoidan and
gemcitabine that may lead to identification of such mechanisms in tumors and make progress for
overcoming them.
• Due to similarities in clinical course between carcinosarcomas and endometrial carcinomas the
results obtained on SK-UT-1 and SK-UT-1B cell lines might be replicated on carcinomas cell lines
and extend indications for future practical applications.
• Studies on 3D cell cultures or animal models have to be performed in order to confirm the activity
of proposed combination on tissue models and to assess how the tumor microenvironment
affects it.
5. Conclusions
Obtained data showed additive and supra-additive effect of fucoidan combined with gemcitabine
in uterine endometrial stromal sarcoma (ESS-1) and carcinosarcoma (SK-UT-1, SK-UT-1B) cell lines,
what confirms it has better or at least equal performance comparing to sum of effects of monotherapies.
The addition of fucoidan to gemcitabine enhances proapoptotic effect of gemcitabine in endometrial
stromal sarcoma cells (ESS-1) but not in carcinosarcoma (SK-UT-1, SK-UT-1B) cell lines.
Gemcitabine in monotherapy do not induce cell cycle arrest in carcinosarcoma (SK-UT-1, SK-UT-1B)
cell lines. Although the addition of fucoidan to gemcitabine induces it in model of carcinomatous part
of carcinosarcoma (SK-UT-1B).
Differences in response to applied treatment among tested cell lines (in cell viability apoptosis
and cell cycle distribution) can be explained by the multipotential and not-fully-investigated activity
of fucoidan as well as differences in cellular mechanisms (such as DNA repairing) in selected models.
The relative resistance of uterine leiomyosarcoma cell line (MES-SA) to applied drugs combination
justify searching for other therapeutic regimens to improve therapy efficacy.
Taking into consideration the disappointingly low effectiveness of systemic therapy among these
types of cancer, a combination of gemcitabine and fucoidan seems to be a promising alternative, having
the potential to increase effectiveness and safety of the treatment.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/1/107/s1,
Table S1: Anti-proliferative effects of gemcitabine (GEM) and fucoidan (FUK) administered singly in cancer cell
lines ESS-1, SKUT-1, SKUT-1B and MES-SA, as measured in vitro by the MTT assay, Table S2: Type I isobolographic
analysis of interactions (for non-parallel dose-response effects) between gemcitabine (GEM) and fucoidan (FUK)
in three cancer cell lines ESS-1, SKUT-1 and SKUT-1B, as measured in vitro by the MTT assay, Table S3: Statistical
significance of differences in percents of cells in each cell cycle phases among cells treated with gemcitabine or
mixture (gemcitabine and fucoidan) and control (no treatment). The results were analyzed by one-way ANOVA
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test, Tukey’s Multiple Comparison Post-test, p < 0.05 was considered as statistically significant. The results of
experiment are presented on Figure 7.
Author Contributions: Conceptualization, M.B., W.B. and J.K.; methodology, K.O. and M.D.-G.; validation, A.W.,
M.D.-G.; formal analysis, J.K.; investigation, K.O., A.W. and M.D.-G.; resources, W.B. and G.M.-B.; data curation,
J.Ł.; writing—original draft preparation, M.B.; writing—review and editing, K.O. and R.T.; supervision, J.K.;
project administration, M.B.; funding acquisition, W.B., J.K. and R.T. All authors have read and agreed to the
published version of the manuscript.
Funding: The research was founded by Medical University of Lublin (grants No. DS 120, DS 121 and MNmd129).
Acknowledgments: The research was performed in collaboration under umbrella of ENITEC (European Network
of Individual Treatment in Endometrial Cancer), the research group established by ESGO (European Society of
Gynaecological Oncology).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. El-Khalfaoui, K.; du Bois, A.; Heitz, F. Current and future options in the management and treatment of
uterine sarcoma. Ther. Adv. Med. Oncol. 2014, 6, 21–28. [CrossRef] [PubMed]
2. Benson, C.; Miah, A. Uterine sarcoma–current perspectives. Int. J. Womens Health 2017, 9, 597–606. [CrossRef]
[PubMed]
3. National Comprehensive Cancer Network. Uterine Neoplasms (Version: 3.2019-February 11, 2019). Available
online: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf (accessed on 21 March 2019).
4. Ricci, S.; Giuntoli, R.L., II; Eisenhauer, E.; Lopez, M.A.; Krill, L.; Tanner, E.J., III; Gehrig, P.A.; Havrilesky, L.J.;
Secord, A.A.; Levinson, K.; et al. Does adjuvant chemotherapy improve survival for women with early-stage
uterine leiomyosarcoma? Gynecol. Oncol. 2013, 131, 629–633. [CrossRef] [PubMed]
5. Hensley, M.L.; Maki, R.; Venkatraman, E.; Geller, G.; Lovegren, M.; Aghajanian, C.; Sabbatini, P.; Tong, W.;
Barakat, R.; Spriggs, D.R. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results
of a phase II trial. J. Clin. Oncol. 2002, 20, 2824–2831. [CrossRef]
6. Seddon, B.; Scurr, M.; Jones, R.L.; Wood, Z.; Propert-Lewis, C.; Fisher, C.; Flanagan, A.; Sunkersing, J.;
A’Hern, R.; Whelan, J.; et al. A phase II trial to assess the activity of gemcitabine and docetaxel as first
line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin. Sarcoma Res. 2015, 5, 13.
[CrossRef]
7. Hensley, M.L.; Miller, A.; O’Malley, D.M.; Mannel, R.S.; Behbakht, K.; Bakkum-Gamez, J.N.; Michael, H.
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment
for metastatic uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study. J. Clin.
Oncol. 2015, 33, 1180–1185. [CrossRef]
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Abstract: Cigarette smoking is associated with an increased risk of melanoma metastasis. Smokers
show higher PD-L1 expression and better responses to PD-1/PD-L1 inhibitors than nonsmokers.
Here, we investigate whether nicotine, a primary constituent of tobacco, induces PD-L1 expression
and promotes melanoma cell proliferation and migration, which is mediated by the α9 nicotinic
acetylcholine receptor (α9-nAChR). α9-nAChR overexpression in melanoma using melanoma cell
lines, human melanoma tissues, and assessment of publicly available databases. α9-nAChR
expression was significantly correlated with PD-L1 expression, clinical stage, lymph node status,
and overall survival (OS). Overexpressing or knocking down α9-nAChR in melanoma cells up- or
downregulated PD-L1 expression, respectively, and affected melanoma cell proliferation and migration.
Nicotine-induced α9-nAChR activity promoted melanoma cell proliferation through stimulation
of the α9-nAChR-mediated AKT and ERK signaling pathways. In addition, nicotine-induced
α9-nAchR activity promoted melanoma cell migration via activation of epithelial-mesenchymal
transition (EMT). Moreover, PD-L1 expression was upregulated in melanoma cells after nicotine
treatment via the transcription factor STAT3 binding to the PD-L1 promoter. These results highlight
that nicotine-induced α9-nAChR activity promotes melanoma cell proliferation, migration, and
PD-L1 upregulation. This study may reveal important insights into the mechanisms underlying
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nicotine-induced melanoma growth and metastasis through α9-nAChR-mediated carcinogenic signals
and PD-L1 expression.
Keywords: melanoma cells; nicotine; α9-nAChR; PD-L1; STAT3
1. Introduction
Melanoma is the most aggressive and lethal form of skin cancer, accounting for fewer than 5% of
all malignant skin tumors, but 75% of all skin cancer deaths in the United States [1]. Melanomas are
transformed, abnormal developments of melanocytes [2]. Unlike melanocytes, melanoma cells grow
uncontrollably and create a thick mass with or without ulceration [3]. As melanomas become thicker and
invade deeper, melanoma cells may spread into the dermal layer, nearby tissues and other parts of the
body [4]. Melanoma is divided into various histopathological subtypes, including superficial spreading,
nodular, lentigo maligna, acral lentiginous, desmoplastic, muscosal and amelanotic melanoma [5].
The different subtypes of melanoma can vary substantially in their molecular characterization and
pathogenesis [5]. Melanoma is the most dangerous type of skin cancer because it is the type most
likely to metastasize if not diagnosed in an early stage [6]. Programmed cell death protein 1 (PD-1)
blockade is the first-line therapy for advanced melanoma patients [7,8]. The mechanism of melanoma
tumorigenesis is not clear and may involve a combination of environment and genetic factors [9].
Nicotinic acetylcholine receptors (nAChRs) are common ligand-activated neurotransmitter
receptors located throughout the body [10]. Several subtypes of nAChRs have been demonstrated to
be closely correlated to the formation and progression of tumors [10]. α9-nAChR is one of the most
recently discovered nAChR subtypes [11]. At first, α9-nAChR was found in the outer hair cells of the
cochlea where it is involved in auditory functions [11,12]. Subsequently, many biological functions
of α9-nAChR have been identified, including keratinocyte adhesion [13], inflammation [14], chronic
pain [15,16], immune responses [17], endocrine activities [18], homeostasis of osteocytes and bone
mass regulation [19], and breast epithelial cancer formation [20]. α9-nAChR expression levels in breast
cancer patients are strongly correlated with staging and 5-year disease-specific survival rate, and highly
expresses (7.84-fold higher than the level in normal tissue) in 186 (67.3%) of the 276 breast cancer paired
samples [20]. α9-nAChR short interfering RNA in MDA-MB-231 cells inhibits cell proliferation in vitro
and tumor growth in vivo [20]. The α9-nAChR expression is essential for mediating tumor metastasis
through epithelial-mesenchymal transition (EMT) [21,22]. Expression of EMT-related gene α9-nAChR
is increased in metastasis in triple-negative breast cancer [21,22]. Notably, Chun-Yu Lin et al. reported
α9-nAChR subunit could potentially correlate with 38 cancer-related pathways in 15 cancer types
and interact with 64 proteins to play important roles in biological functions related to human cancer
development [23]. These studies suggest that α9-nAChR may initiate signal transduction pathways,
thus inducing melanoma growth and metastasis during tumor progression.
Tobacco is a known cause of cancer mortality [24]. Tobacco smoke contains 7000 toxic
and carcinogenic chemicals, and various classes, such as tobacco-specific nitrosamines, polycyclic
aromatic hydrocarbon, and aldehydes, are capable of inducing DNA damage response that initiates
turmorigenesis and enhances metastasis [25]. Exposure to tobacco smoke is an independent risk
factor for cancer [25]. The risk and severity of cancer depend on the duration of exposure and the
amount of tobacco smoking [26]. In melanoma, tobacco smoking supports metastasis of melanoma
cells, leading to a significant decrease in 5-year disease-free and overall survival (OS) in smokers
compared to nonsmokers [27]. The correlation between current smoking and nodal metastasis of
primary cutaneous melanoma is direct and positive [28]. This correlation is independent of tumor
thickness, ulceration, and other risk factors [28]. An epidemiological cohort study to assess the
clinical significance of α9-nAChR expression in breast tumors of different stages and to correlate
α9-nAChR expression with smoking history among Taiwanese women [20]. The results revealed the
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increased expression of α9-nAChR mRNA in tumor tissues from current smokers relative to those from
passive smokers and nonsmokers (6.62-fold vs. 2.8-fold or 1.51-fold, respectively) [20]. Nicotine is an
important and common component of tobacco responsible for addiction [29]. Many studies indicate
that nicotine induces breast cancer growth and metastasis in vitro and in vivo through binding to
and activating α9-nAChR [20,23,30,31]. Long-term exposure to extremely low doses of nicotine and
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induced nonmalignant breast epithelial cell
transformation through activation of the α9-nAChR-mediated signaling pathways [32]. However,
the mechanisms by which nicotine-induced α9-nAChR activity promotes melanoma growth and
metastasis are not fully understood.
Programmed death-ligand 1 (PD-L1) is a type 1 transmembrane protein that is encoded by the
CD274 gene in humans and is overexpressed in some kinds of cancers [33]. The overexpression of
PD-L1 in tumors serves as an indicator of progression and a poor prognosis [34]. In contrast, PD-L1
expression is associated with an increased response to PD-1/PD-L1 inhibitor treatment [35]. PD-1 is an
inhibitory receptor that is encoded by the PDCD1 gene and is located on the surface of all T cells [35].
The PD-1 receptor on activated T cells functions in the regulation of the immune system during various
physiological responses, including autoimmune disease and cancer [36]. The binding of PD-1 to PD-L1
on the surface of cancer cells leads to an immunosuppressive effect based on the interaction between
phosphatases (SHP-1 or SHP-2) and an immunoreceptor tyrosine-based switch motif (ITSM) [36]. PD-L1
not only has roles in the suppression of the immune system but also has distinct tumor-intrinsic roles
in growth, metastasis, and resistance to therapy [37]. Tobacco smoking-related carcinogenesis affects
cancer risk by increasing the somatic mutation load [38], thereby creating neoantigens which are strongly
correlated with decreased progression-free survival in cancers [39]. In contrast, neoantigens are able to
stimulate immune responses and pave the way for efficacious PD-1/PD-L1 immunotherapy [40]. Several
recent studies have shown positive correlations between smoking and PD-L1 expression or PD-1/PD-L1
immune checkpoint inhibitor efficacy [41]. Some clinical trials have reported that the smoking status
influences OS in anti-PD-1/PD-L1-treated lung cancer patients [42]. Tobacco-smoking patients show
higher PD-L1 expression [43] and better treatment responses to anti-PD-1/PD-L1 immunotherapy than
patients with lung cancer who have never smoked [41]. The overall response rate to anti-PD-1/PD-L1
antibodies is lower in patients who have never smoked than in former/current smokers [41]. Recently,
Wang et al. found that tobacco smoke induced PD-L1 expression in lung epithelial cells and the main
tobacco carcinogens benzo(a)pyrene (BaP), dibenz[a, h]anthracence (DbA), and benzo[g, h, I]perylene
(BzP) upregulated PD-L1 expression [44]. The above results suggest the possibility that nicotine may
induce a mechanism that drives expression of PD-L1 in melanoma cells through α9-nAChR.
In this study, we demonstrated that α9-nAChR expression was upregulated in melanoma and
associated with PD-L1 expression at the mRNA and protein levels. Overexpression of α9-nAChR
in melanoma cells upregulated PD-L1 expression and enhanced melanoma cell proliferation and
migration. In contrast, knocking down α9-nAChR in melanoma cells reduced PD-L1 expression and
inhibited melanoma cell proliferation and migration. Nicotine-induced α9-nAChR activity upregulated
PD-L1 expression and promoted melanoma cell proliferation and migration. Our results indicate novel
functions for α9-nAChR in melanoma cell proliferation, migration, and PD-L1 regulation.
2. Results
2.1. α9-nAChR Is Overexpressed in Melanoma
To evaluate the expression of nAChR subunits in three melanoma cell lines (A375, A2058, and
MDA-MB 435) and a primary melanocyte cell line (HEMn-LP), we performed reverse transcriptase
polymerase chain reaction (RT-PCR) to detect the mRNA levels of all alpha nAChR subunits. We found
overexpression of α2-10 nAChR subunits in the A375, A2058, and MDA-MB 435 melanoma cells
compared to the HEMn-LP melanocytes (Figure 1A). Quantification of the α1-10 nAChR mRNA levels
in the A375, A2058, and MDA-MB 435 melanoma cells was performed based on intensities, and we
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found that α9-nAChR mRNA expression was more prominent than that of the other subunits of alpha
nAChRs (* p < 0.05) (Figure 1B). α9-nAChR expression was detected in the three melanoma cell lines
(A375, A2058 and MDA-MB 435) and primary melanocyte cell line (HEMn-LP) by RT-PCR (Figure 1A)
and western blotting (Figure 1D and Figure S1).
Figure 1. α9-nAChR expression levels and their correlations with clinicopathological parameters in
multiple melanoma databases. (A) Detection of nAChR subunits in the primary epidermal melanocyte
cell line HEMn-LP and the melanoma cell lines A375, A2058, and MDA-MB 435 by RT-PCR. (B) Relative
mRNA expression of α1-10 nAChR subunits in the A375, A2058, and MDA-MB 435 melanoma cell
lines. (C) Relative α9-nAChR mRNA expression in the HEMn-LP, A375, A2058, and MDA-MB 435 cell
lines. (D,E) Determination of α9-nAChR mRNA levels using western blotting and statistical analysis of
α9-nAChR protein levels. (F) The mRNA expression of α9-nAChR in two datasets from the public R2
MegaSampler platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi) comprising melanocyte cell lines
(n = 3) and primary (n = 5), and metastatic (n = 58) melanoma cell lines. (G) Screening of melanoma
cell line datasets (http://www.jurno.ch/php/genehunter.html) for the mRNA expression of α9-nAChR.
These cell lines were further subdivided into proliferative (n = 101) and invasive (n = 90) phenotypes.
(H) α9-nAChR gene expression level in the TCGA-SKCM cohort (n = 472) downloaded from the UCSC
Xena browser (https://xenabrowser.net/heatmap/). Melanoma patients were further divided into two
groups based on the mean value of α9-nAChR mRNA expression, low α9-nAChR expression (n = 169)
and high α9-nAChR expression (n = 291). Bar plots show the proportions of five subcategories of lymph
node status in the high and low α9-nAChR level groups. (I) The frequencies of stages of I/II and III/IV in
the high and low α9-nAChR level groups of the TCGA-SKCM cohort. (J) The differences in α9-nAChR
expression between primary (n = 211) and metastatic (n = 201) groups. The result for the TCGA-SKCM
cohort was processed using the UCSC Xena browser. (K) Kaplan–Meier analysis for melanoma patients
based on the result from the public R2: Kaplan Meier Scanner software (https://hgserver1.amc.nl)
showing a borderline difference between the groups with high (red, 433 samples) and low (black,
35 samples) α9-nAChR expression levels in the TCGA-SKCM cohort with the optimal cut-off value.
(C,E) Results are shown as mean± standard deviation (SD) of three individual experiments. *** p< 0.001,
Student’s t-test. (F,G,J) The data were analyzed by the Mann-Whitney test. The median of α9-nAChR
expression in each group is shown by a horizontal line. ns, not significant; ** p < 0.01; *** p < 0.001.
(H,I) The two groups’ qualitative data were compared using the χ2 test; * p < 0.05, ** p < 0.01.
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Statistical analysis found that theα9-nAChR mRNA (Figure 1C) and protein levels (Figure 1E) were
obviously elevated in the three melanoma cells compared to the HEMn-LP melanocytes (* p < 0.05).
Melanoma cell line datasets from the public R2 MegaSampler platform (http://hgserver1.amc.nl/
cgi-bin/r2/main.cgi) were evaluated. We found that α9-nAChR mRNA expression in melanoma cell
lines was significantly higher than that in melanocyte cell lines (*** p < 0.001) (Figure 1F). In addition,
α9-nAChR mRNA expression in metastatic melanoma cell lines was higher than that in primary
melanoma cell lines (** p < 0.01) (Figure 1F).
Melanoma cell lines stratified into either a proliferative or an invasive phenotype using the
melanoma cell line datasets from HOPP Database (http://www.jurmo.ch/hopp/hopp_mpse.php) were
defined by a specific gene expression pattern [45]. We analyzed α9-nAChR mRNA levels and found
that they were significantly upregulated in the melanoma cells (n = 176) with the invasive phenotype
(n = 90) compared to those with the proliferative phenotype (n = 101) (*** p < 0.001) (Figure 1G).
We examined α9-nAChR expression of human skin cutaneous melanoma (SKCM) using the
data obtained from The Cancer Genome Atlas (TCGA) from the University of California Santa
Cruz (UCSC) Xena browser (https://xenabrowser.net/). The samples were divided into primary and
metastatic groups according to the TNM classification for malignant melanoma staging. We found
that the metastatic group had higher α9-nAChR mRNA levels than the primary group (* p = 0.01)
(Figure 1J). Moreover, Kaplan-Meier analysis based on the result from R2: Kaplan Meier Scanner
software (https://hgserver1.amc.nl) to analyze the OS of TCGA-SKMC cohort stratified according to
α9-nAChR mRNA expression with an optimal cut-off value. TCGA-SKCM cohort divided into high
α9-nAChR mRNA expression (433 samples) and low α9-nAChR mRNA expression (35 samples) groups
(Figure 1K). 0.9 is the ratio of high α9-nAChR mRNA expression samples (433 samples) to the total
amount of samples (468 samples). The results showed that the patients with high α9-nAChR expression
were shorter OS than patients with low α9-nAChR mRNA expression (* p = 0.033) (Figure 1K).
We evaluated the immunohistochemistry (IHC) staining of α9-nAChR in tissue microarray
specimens using the IHC scoring system, and the scoring system was determined as no staining (0),
weak (1+), moderate (2+), and strong (3+) based on α9-nAChR intensity (Figure 2A). Histological
analysis of α9-nAChR expression in melanoma tissues (Mel, n = 176) and normal skin tissues (NS,
n = 16) indicated that there were significantly upregulated in melanoma tissues compared with normal
skin tissues (*** p < 0.001) (Figure 2C,D). Taken together, these results suggested that α9-nAChR is
overexpressed in melanoma and correlates with melanoma stage and phenotype.
2.2. Correlation of α9-nAChR Levels with Clinicopathological Features in Melanoma
To investigate the relationships between α9-nAChR and clinicopathological parameters in
melanoma, we downloaded α9-nAChR gene expression data for the TCGA-SKMC cohort. We divided
the patients into two groups according to the mean level of α9-nAChR. The first group expressed low
levels of α9-nAChR, and the second group expressed high levels of α9-nAChR. Table 1 summarizes
the associations of α9-nAChR with melanoma clinicopathological parameters (age, sex, ulceration,
Breslow depth, Clark level, tumor size, lymph node status, distant metastasis status, and stage of
disease). High α9-nAChR mRNA expression was significantly associated with sex (* p = 0.04) (Table 1),
and α9-nAChR mRNA expression was significantly higher in female groups than that in male group
(* p < 0.05) (Figure S2); however, no strong relationships were found for age, ulceration, Breslow depth
or Clark level.
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Figure 2. Correlations between α9-nAChR and PD-L1 in melanoma. (A,B) Representative images
for α9-nAChR and PD-L1 immunohistochemistry (IHC) scoring system in the melanoma tissues and
normal skin tissues. The scoring system was determined as no staining (0), weak (1+), moderate
(2+), and strong (3+) based on α9-nAChR and PD-L1 intensity. (C) The α9-nAChR (red lines) and
PD-L1 (green lines) expression profiles of melanoma tissues (n = 176) and normal skin tissues (n = 16)
were detected by IHC staining based on H-score value. (D,F) Histological analysis of α9-nAChR
and PD-L1 expression in melanoma tissues (Mel, n = 176) compared with normal skin tissues (NS,
n = 16). (E,G) Histological analysis of α9-nAChR and PD-L1 expression in the tissue microarrays
(n = 192) based on H-score value. The tissues were divided into two groups based on the mean value
of α9-nAChR or PD-L1 H-score, low α9-nAChR (n = 97) or high α9-nAChR (n = 95) and low PD-L1
(n = 104) or high PD-L1 (n = 88). (H) The association between α9-nAChR and PD-L1 expression in the
tissue microarrays (n = 192) as categorical variables. The χ2 test was employed to assess the correlation
between a9-nAChR and PD-L1 expression in samples. *** p < 0.001. (I) Correlation between α9-nAChR
and PD-L1 expression in the melanoma tissue microarrays (n = 192). Pearson’s rank correlation
measured the strength of the association between α9-nAChR and PD-L1 expression. *** p < 0.001.
(J) PD-L1 expression levels in melanoma tissues with high α9-nAChR (n = 89) or low α9-nAChR
(n = 87) expression. The melanoma tissues were divided into low or high α9-nAChR based on the mean
value of α9-nAChR. (K) α9-nAChR and PD-L1 mRNA levels detected by PT-PCR. (L) α9-nAChR and
PD-L1 protein levels detected by western blotting. The data are presented as the mean ± SD, ** p < 0.01,
*** p < 0.001, Student’s t-test.
84
Cancers 2019, 11, 1991
Table 1. Correlations between α9-nAChR mRNA expression and clinicopathological parameters of







Age (year) ≥40 147 (32%) 257 (55%) 0.33
<40 18 (4%) 42 (9%)
Sex
Female 114 (24%) 179 (38%)
0.04 *Male 53 (11%) 126 (27%)
Ulceration
Yes 61 (19%) 106 (34%)
0.08No 40 (13%) 107 (34%)
Breslow depth (mm) ≥2 76 (21%) 145 (40%) 0.8
<2 46 (13%) 93 (26%)
Clark level
I-III 32 (10%) 69 (21%)
0.24IV-V 85 (26%) 136 (42%)
Tumor size
T1 14 (3%) 27 (7%)
0.87
T2 27 (7%) 52 (13%)
T3 32 (8%) 59 (14%)
T4 60 (15%) 93 (23%)
Unknown 15 (4%) 32 (8%)
Lymph node status
N0 94 (21%) 141 (31%)
0.035 *
N1 20 (4%) 54 (12%)
N2 17 (4%) 32 (7%)
N3 22 (5%) 34 (8%)
Unknown 6 (1%) 30 (7%)
Distant metastasis status
M0 148 (33%) 270 (61%)
0.39M1 10 (2%) 15 (3%)
Stage I-II 94 (25%) 123 (30%) 0.009 **III-IV 64 (15%) 131 (32%)
Clinicopathological parameters were assessed using the χ2 test analysis. * p < 0.05, ** p < 0.01. We divided the
patients into two groups according to the mean level of α9-nAChR mRNA expression. The first group expressed
low levels of α9-nAChR, and the second group expressed high levels of α9-nAChR.
We next explored the correlations between α9-nAChR mRNA expression and tumor staging and
observed that high α9-nAChR expression was significantly associated with lymph node metastasis
(* p = 0.035) (Figure 1H and Table 1) and clinical stage (** p = 0.009) (Figure 1I and Table 1); however,
no significant associations were found for tumor size or distant metastasis status in the TCGA-SKCM
cohort. From these results, we suggest that α9-nAChR correlates with sex, lymph node metastasis
status and clinical stage.
2.3. Correlation Between α9-nAChR and PD-L1 in Melanoma
We investigate whether the correlation between α9-nAChR and PD-L1 in melanoma. We analyzed
the expression of α9-nAChR and PD-L1 in the melanoma tissues (n = 176) and normal skin tissues
(n = 16) using the IHC staining (Figure 2A–C). The expression levels of α9-nAChR and PD-L1
were significantly increased in melanoma tissues compared with skin normal tissues (Figure 2D,F).
The patient tissues were divided into two groups based on the mean value of the α9-nAChR H-score,
low α9-nAChR H-score (n = 97) and high α9-nAChR H-score (n = 95) or PD-L1 H-score, low PD-L1
H-score (n = 104) and high PD-L1 H-score (n = 88). 14 cases of the normal skin tissues (n = 14/16) had a
low α9-nAChR H-score (Figure 2C,E) and 15 cases of the normal skin tissues (n = 15/16) had a low
PD-L1 H-score (Figure 2C,G). The chi-square (χ2) test was applied to assess the correlation between
α9-nAChR and PD-L1 mRNA expression in samples as categorical variables (Table S1). We found that
α9-nAChR expression was significantly associated with PD-L1 expression in the tissue microarrays
(*** p < 0.001) (Figure 2H). Subsequently, we identified a strong correlation between α9-nAChR and
PD-L1 expression levels in the tissue microarray data (r = 0.7, *** p < 0.001) (Figure 2I).
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To further evaluate the correlation between α9-nAChR and PD-L1 mRNA expression, we analyzed
the melanoma cell line datasets (n = 176) and TCGA-SKCM cohort (n = 472). We found that the mRNA
expression of α9-nAChR was significantly associated with PD-L1 expression in the melanoma cell line
datasets (*** p< 0.001) (Figure S3A,B) and TCGA-SKCM cohort (** p< 0.01) (Figure S4A,B). Furthermore,
we identified a moderate correlation melanoma cell line datasets (r = 0.22, ** p = 0.003) (Figure S3C)
and weak correlation between α9-nAChR and PD-L1 mRNA levels in the TCGA-SKCM cohort
(r = 0.115, * p = 0.012) (Figure S4C). Melanoma is classified into various histopathological subtypes,
and distinct subtypes can vary substantially in their molecular characterization and pathogenesis,
which TCGA-SKCM cohort has not mentioned. Therefore, the distinct subtypes of melanoma might
have different correlations between α9-nAChR and PD-L1 mRNA levels led to a weak correlation in
TCGA-SKCM cohort (r = 0.115, * p = 0.012) (Figure 2H).
To gain more insight about the correlation of α9-nAChR and PD-L1 expression, RT-PCR and
western blotting were performed in HEMn-LP, A375, A2058, and MDA-MB 435 cells using α9-nAChR
and PD-L1-specific primers and antibodies, respectively. GAPDH was used as a loading control.
α9-nAChR and PD-L1 expression were prominently higher in the A375, A2058, and MDA-MB 435
melanoma cells than in the HEMn-LP melanocytes at the mRNA (Figure 2K) and protein levels
(Figure 2L and Figure S7). α9-nAChR expression was coupled with PD-L1 expression in the HEMn-LP,
A375, A2058, and MDA-MB 435 cells at the mRNA (Figure 2K) and protein levels (Figure 2L and
Figure S7). These experiments were repeated three times per cell line. Band intensities were measured
using ImageJ software, and the amounts of α9-nAChR and PD-L1 at the mRNA and protein levels in
the A375, A2058, and MDA-MB 435 melanoma cells were normalized to the α9-nAChR and PD-L1
mRNA and protein levels in the HEMn-LP cells. We found strong correlations between α9-nAChR
and PD-L1 at the mRNA (r = 0.96, *** p < 0.001) (Figure S5A) and protein levels (r = 0.66, * p = 0.02)
(Figure S5B) in the HEMn-LP, A375, A2058, and MDA-MB 435 cells.
On the other hand, we compared PD-L1 expression levels between the low α9-nAChR (melanoma
tissue microarrays, n = 87; TCGA-SKCM cohort, n = 167; melanoma cell line datasets, n = 156) and high
α9-nAChR (melanoma tissue microarrays, n = 89; TCGA-SKCM cohort, n = 305; melanoma cell line
datasets, n = 20) expression groups and found that PD-L1 expression levels were significantly higher
in the samples with high α9-nAChR expression than in the samples with low α9-nAChR expression
(** p < 0.01, *** p < 0.001) (Figure 2J, Figures S3D and S4D). According to the results, we suggest that
α9-nAChR expression correlates with the PD-L1 expression in melanoma.
2.4. α9-nAChR Induces PD-L1 Expression and Regulates in Proliferation and Migration
The results for the melanoma databases, cell lines, and tissue microarrays indicated that α9-nAChR
was highly associated with tumor growth, metastasis, and PD-L1 expression in melanoma patients
and with cell proliferation, migration, and PD-L1 expression in melanoma cell lines. To evaluate the
roles of α9-nAChR in the proliferation, migration and PD-L1 upregulation of melanoma cells, we
generated stable α9-nAChR-siRNA-expressing A2058 cells, α9-nAChR-overexpressing A2058 cells
and α9-nAChR-overexpressing MDA-MB 435 cells by transfection with α9-nAChR-small interfering
RNA (siRNA) or pcDNA3.1-α9-nAChR overexpression vectors. Stable scrambled siRNA-A2058 cells,
pcDNA3.1-A2058 cells, and pcDNA3.1-MDA-MB 435 cells were used as control groups. The protein
levels of α9-nAChR expression in the cells with α9-nAChR knockdown or overexpression were
compared to the protein levels in the control cells (Figures 3A and 4A, Figures S8 and S10). α9-nAChR
overexpression significantly increased cell proliferation in the A2058 (Figure 3B) and MDA-MB 435 cells
(Figure 3C) after five days incubation by a cell count assay (*** p < 0.001). These results were confirmed
by a soft-agar colony assay at 21 days (ns, not significant; * p < 0.05; *** p < 0.001) (Figure 3D,E).
In contrast, compared to stable scrambled siRNA-A2058 cells, stable α9-nAChR-siRNA-expressing
A2058 cells substantially decreased the numbers of cells and colonies after 5 and 21 days, respectively
(*** p < 0.001) (Figure 4C,D). Together, these data demonstrate that α9-nAChR regulates melanoma
cell proliferation in vitro.
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Figure 3. α9-nAChR overexpression induces PD-L1 upregulation and promotes melanoma cell
proliferation and migration. (A) Overexpression of α9-nAChR activated the phosphorylation of AKT,
ERK, and STAT3 and induced PD-L1, Snail-1, and Twist-1 protein levels in A2058 and MDA-MB-435 cells,
which were evaluated by western blotting. (B,C) α9-nAChR overexpression significantly increased the
proliferation of A2058 and MDA-MB435 cells compared to control cells, as determined by a cell count
assay. (D) Soft-agar growth assays were performed with A2058 and MDA-MB-435 cells transfected
with pcDNA3.1 or pcDNA3.1-α9-nAChR overexpression vectors. (E) Colony numbers were quantified
and presented in the histogram. (F) Cell morphology of A2058 and MDA-MD-435 cells transfected with
pcDNA3.1 or pcDNA3.1-α9-nAChR overexpression vector. (G,H) Representative micrographs and
statistical analysis demonstrated that α9-nAChR overexpression increased the migration areas of A2058
and MDA-MB 435 cells at 24 h after scratching. (I,K) Percentages of cell proliferation for the A2058
cells, pcDNA3.1-A2058 cells, and α9-nAChR-overexpressing A2058 cells were treated with or without
the PI3K inhibitor LY294002 (10 μm) or MEK inhibitor PD98059 (10 μm) for 48 h determined by an
MTT assay. (J,L) Western blotting to detect the protein levels of P-AKT and P-ERK in pcDNA3.1-A2058
cells and α9-nAChR-overexpressing A2058 cells with or without LY294002 or PD98059 treatment. The
data are presented as the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p <
0.001, Student’s t-test.
We performed a scratch-wound healing assay to examine whether α9-nAChR affects the migration
of melanoma cells. After scratching, cells along the wound-edge migrated into the empty space
continuously so that the migration area, as indicated by comparing the distance between the opposite
cell edges at 0 h and 24 h, became wider over time. We compared stable α9-nAChR-overexpressing
A2058 cells to stable pcDNA3.1-A2058 cells and showed apparent increases in the migration areas at
24 h after scratching (ns, not significant; ** p < 0.01) (Figure 3G). For stable α9-nAChR-overexpressing
MDA-MB 435 cells, the migration areas were also significantly larger than those of pcDNA3.1-MDA-MB
435 cells at 24 h after scratching (ns, not significant; * p < 0.05) (Figure 3H). In contrast, compared
to corresponding stable scrambled siRNA-A2058 cells, stable α9-nAChR-siRNA-expressing A2058
cells exhibited substantially reduced migration areas at 24 h after scratching (Figure 4E, right panel).
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Statistical analysis demonstrated that the migration areas of the stable α9-nAChR-siRNA-expressing
A2058 cells were significantly narrower than those of the stable scrambled siRNA-A2058 cells at
24 h after scratching (* p < 0.05) (Figure 4E, left panel). Taken together, our results demonstrate that
α9-nAChR positively regulates melanoma cell migration.
Figure 4. Knocking down α9-nAChR expression inhibits melanoma cell proliferation and migration
and affects the protein level of PD-L1. (A) Western blotting results showing the protein level changes
in α9-nAChR, PD-L1, P-STAT3, P-AKT, P-ERK, Snail-1 and Twist-1 after knocking down α9-nAChR
expression in A2058 cells. GAPDH served as a control. (B) Fluorescence micrographs showing GFP
expression (bottom panels) of α9-nAChR-siRNA-expressing or scrambled siRNA-A2058 cells at 48 h
after pSUPER-α9-nAChR-si or pSUPER-α9-nAChR-scramble vector transfection, and corresponding
phase-contrast microscopy images showing cell morphology (top panels). (C) Cell proliferation of
α9-nAChR-siRNA-expressing A2058 cells monitored by a cell count assay. (D) Cell proliferation of
α9-siRNA-expressing A2058 cells assessed by a soft-agar growth assay. The colonies formed in the low
density seeding assay were counted after 21 days (left panels). The amounts, sizes, and fluorescence
microscopy images of colonies are shown (right panels). (E) Migratory capacity measured at 24 h
using a wound-healing assay with A2058 cells stably expressing α9-nAChR-siRNA (si), scrambled
siRNA (sc) or wild-type (wt) (left panels). Quantification of the migratory areas (right panels) were
measured using ImageJ software. (F) The STAT3 binding site of the PD-L1 promoter and targets of
STAT3 phosphorylation inhibitor Stattic and STAT3 DNA-binding inhibitor NSC74859. (G) Effects of
treatment with the inhibitors Stattic and NSC74858 on P-STAT3, and PD-L1 protein levels in A2058
cells evaluated by western blotting. GAPDH served as a control. (H,I) Inhibitors Stattic and NSC74859
inhibited A2058 cell proliferation. (J,K) ChIP assay using STAT3-precipitated DNA samples from
wild-type, scrambled siRNA, and α9-nAChR-siRNA-expressing A2058 cells. The DNA fragments
were subjected to RT-PCR and real-time PCR (qPCR) using PD-L1 promoter primer pairs as shown in
Table S2. In RT-PCR, a rabbit IgG antibody was used as a negative control, and total genomic DNA was
used as a positive control. In qPCR, relative fold enrichments of PD-L1 promoter region were calculated
after normalization to GAPDH. Each of the immunoprecipitations was replicated three times, and each
sample was quantified at least in triplicate. The data are presented as the mean ± SD of independent
experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, Student’s t-test.
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α9-nAChR expression correlated with PD-L1 expression in melanoma (Figure 2 and Figures S3–S5).
To further understand the relationship between α9-nAChR and PD-L1 in melanoma cells, we
performed western blotting to assess PD-L1 protein levels in stable α9-nAChR-knockdown and
α9-nAChR-overexpressing cells. We found that the protein level of PD-L1 was significantly upregulated
in stableα9-nAChR-overexpressing A2058 and MDA-MB 435 cells compared to the corresponding stable
pcDNA3.1-expressing A2058 and MDA-MB 435 cells (Figure 3A and Figure S8). On the other hand,
the protein level of PD-L1 was substantially downregulated in the stable α9-nAChR-siRNA-expressing
A2058 cells compared to the stable scrambled siRNA-A2058 cells (Figure 4A and Figure S10). According
to these results, we suggest that α9-nAChR induces melanoma cell proliferation, migration, and
PD-L1 upregulation.
2.5. α9-nAChR Regulates Melanoma Cell Proliferation via the AKT and ERK Signaling Pathways
To investigate the mechanisms by which α9-nAChR regulates proliferation, western blot analysis
was performed with melanoma cells to detect the protein levels of AKT and ERK, which are
well-documented signaling molecules associated with tumor growth [2]. We found that α9-nAChR
affected the phosphorylated forms of AKT and ERK1/2 in α9-nAChR-siRNA-expressing A2058 cells,
α9-nAChR-overexpressing A2058 cells and α9-nAChR-overexpressing MDA-MB 435 cells (Figures
3A and 4A, Figures S8 and S10). As shown in Figure 3A and Figure S8, overexpression of α9-nAChR
in A2058 cells and MDA-MB 435 cells substantially promoted the activation of the AKT and ERK
signaling pathways. In contrast, α9-nAChR depletion in A2058 cells significantly decreased AKT and
ERK activation (Figure 4A and Figure S10).
To elucidate the role of α9-nAChR in promoting melanoma cell proliferation via the AKT and
ERK signaling pathways, we examined the proliferative ability of stable α9-nAChR-overexpressing
A2058 cells treated with the PIK3 inhibitor LY 294002 (10 μm) or MEK inhibitor PD 98059 (10 μm) for
48 h and compared the proliferation of these cells to that of stable pcDNA3.1-A2058 cells treated with
the inhibitors. Western blotting was performed to evaluate the inhibitory control of PIK3 inhibitor
LY 294002 or MEK inhibitor PD 98059 on the phosphorylation of AKT and ERK (Figure 3J,L and
Figure S9). We found that an inhibitory effect on the proliferation of the A2058 cells when α9-nAChR
overexpression was combined with the PI3K or MEK inhibitor (*** p < 0.001) (Figure 3I,K). Together,
these data suggest that α9-nAChR plays a role in the proliferation of melanoma cells through the
activation of the AKT and ERK signaling pathways.
2.6. α9-nAChR Promotes Melanoma Cell Migration through EMT
The fact that α9-nAChR overexpression/knockdown greatly affected melanoma cell movement
strongly suggested a major function for α9-nAChR in controlling melanoma cell migration. To elucidate
the underlying mechanism, we observed morphological changes in cells withα9-nAChR overexpression
or knockdown compared to cells transfected with control vectors. The results demonstrated that
α9-nAChR overexpression in A2058 and MDA-MB 435 cells induced mesenchymal-like melanoma
cells with loss of cell-cell adhesions junctions (Figure 3F). Conversely, α9-nAChR knockdown in
A2058 cells resulted in increased cell-cell adhesions junctions and epithelial-like melanoma cells
(Figure 4B). The molecular changes in the levels of EMT markers (Twist-1 and Snail-1) which are pivotal
in controlling cancer cell migration via cell transformation [46], also indicated the occurrence of EMT in
cells with α9-nAChR overexpression/knockdown. Moreover, it is known that MEK and PI3K cascades
promote EMT by upregulating Twist-1 and Snail-1 expression [46]. The western blot analysis clearly
showed that compared to stable scrambled siRNA-A2058 cells, stable α9-nAChR-siRNA-expressing
A2058 cells inhibited the activation of AKT and EKR phosphorylation and significantly downregulated
the expression of the EMT markers Twist-1 and Snail-1 (Figure 4A and Figure S10). In contrast,
compared to pcDNA3.1-A2058 cells and pcDNA3.1-MDA-MB 435 cells, α9-nAChR overexpressing
A2058 cells and α9-nAChR overexpressing MDA-MB 435 cells exhibited activated MEK and PI3K
signaling pathways and substantially increased expression of EMT markers, including Twist-1 and
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Snail-1, at the protein level (Figure 3A and Figure S8). Based on these results, we suggest that α9-nAChR
regulates melanoma cell migration through EMT.
2.7. α9-nAChR Regulates PD-L1 Expression via the STAT3 Signaling Pathway
We investigate whether the STAT3 signaling pathway regulates PD-L1 expression. We treated
A2058 cells with the STAT3 phosphorylation inhibitor Stattic (2.5 μm or 5 μm) and STAT3 DNA-binding
inhibitor NSC74859 (10 μm or 25 μm) to inhibit STAT3 activation (Figure 4F). Western blotting and
MTT assay were performed to evaluate the PD-L1 expression and cell growth, respectively. Stattic and
NSC74859 significantly inhibited STAT3 activation, leading to the suppression of PD-L1 expression
(Figure 4G and Figure S11) and cell growth (Figure 4H,I) in A2058 cells. From this evidence, we
conclude that STAT3 signaling pathway regulates cell growth and PD-L1 expression in melanoma cells.
We examined the role of the α9-nAChR-mediated STAT3 signaling pathway in regulating PD-L1
expression. We found that α9-nAChR overexpression in A2058 and MDA-MB 435 cells substantially
increased phosphorylated STAT3 expression (Figure 3A and Figure S8). In contrast, knocking down
α9-nAChR in A2058 cells significantly decreased phosphorylated STAT3 expression (Figure 4A and
Figure S10).
Several recent findings have mentioned that -337 to -118 fragment of the PD-L1 core promoter
is enriched with consensus binding sites for STAT3, which is known to regulate PD-L1 expression
transcriptionally (Figure 4F) [47,48]. To investigate the mechanism involving the transcription factor
STAT3 in α9-nAChR-mediated PD-L1 expression, we performed a chromatin immunoprecipitation
(ChIP) assay with an anti-STAT3 rabbit polyclonal antibody and primer pairs specific for the PD-L1
gene promoter to compare stable α9-nAChR-siRNA-expressing A2058 cells with stable scrambled
siRNA-A2058 cells. The expression of PD-L1 was evaluated by RT-PCR and qPCR. We found that the
transcription factor STAT3 directly bound to the promoter of PD-LP at -337 to -118 region (Figure 4J).
Moreover, knocking down α9-nAChR expression decreased the PD-L1 level by reducing STAT3 binding
to the PD-L1 promoter (*** p < 0.001) (Figure 4K). Thus, we suggest that PD-L1 expression is directly
regulated by the STAT3 downstream signaling transduction pathway activated by α9-nAChR.
2.8. Nicotine-Induced α9-nAChR Activity Upregulates PD-L1 Expression and Promotes Melanoma Cell
Proliferation and Migration
We examined the effects of nicotine-induced α9-nAChR activity on cell proliferation in the
HEMn-LP melanocytes and A375, A2058, and MDA-MB 435 melanoma cells using nicotine at final
concentrations of 0.001–1 μm to treat the cells for 24–72 h. As shown in Figure 5A,B and Figure S12,
we found that nicotine-induced α9-nAChR activity significantly promoted cell proliferation in a
concentration and time-dependent manner in the three melanoma cell lines (A375, A2058, and
MDA-MB 435), with maximal proliferation occurring with the 1 μm dose (ns, not significant; * p < 0.05;
** p< 0.01; *** p< 0.001). However, we found no significant effect of nicotine-induced α9-nAChR activity
on HEMn-LP melanocyte growth (ns, not significant) (Figure 5A, Figures S6 and S18). Compared with
that in stable scrambled siRNA-A2058 cells, α9-nAChR-siRNA-expressing A2058 cells showed an
inhibition of nicotine-stimulated proliferation (Figure 6K,L and Figure S17). These results suggest that
nicotine-induced α9-nAChR activity promotes melanoma cell proliferation.
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Figure 5. Nicotine-induced α9-nAChR activity promotes melanoma cell proliferation, migration,
and PD-L1 upregulation. (A) Nicotine induced melanoma cell proliferation. Cell count assays were
performed with the A375, A2058, and MDA-MB 435 melanoma cells and HEMn-LP melanocytes, and
the cells were treated with nicotine at the final concentrations of 0.001–1 μm for 24–72 h. (B) Melanoma
cells were exposed to nicotine at the indicated concentrations for indicated time periods. α9-nAChR
and PD-L1 protein levels were determined by western blotting. (C) Nicotine promoted melanoma
cell migration. Cell migration capabilities were evaluated using a wound-healing assay. Cells were
scratched using 10 or 100 μL tips and treated with nicotine at the indicated concentrations for 24 h.
(D) Comparing migration area among the A375, A2058, and MDA-MB 435 melanoma cells. The data
are presented as the mean ± SD of three independent experiments. ns, not significant; * p < 0.05;
** p < 0.01; *** p < 0.001; Student’s t-test.
To examine the effects of nicotine on migration in the A375, A2058, and MDA-MB 435 melanoma
cells, we performed a scratch-wound healing assay. After scratching, the cells were treated with nicotine
at a final concentration of 0.1 or 1 μm for 24 h. By comparing migration areas at 0 h and 24 h, we found
that the migration areas were significantly larger in the nicotine treatment groups than in the groups
without nicotine treatment after 24 h (* p < 0.05, ** p < 0.01, *** p < 0.001) (Figure 5C). When comparing
migration area among the three cell lines, the migration areas of the A2058 cells were the largest (ns,
not significant; * p < 0.05; ** p < 0.01; *** p < 0.001) (Figure 5D). Moreover, exposure of all three cell
lines to nicotine induced increases in Twist-1 and Snail-1 protein levels (Figure 6B and Figure S14).
These results suggest that exposure to nicotine induces EMT and promotes cell migration through
α9-nAChR in the A375, A2058, and MDA-MB 435 melanoma cells. To investigate nicotine-induced
α9-nAChR and PD-L1 upregulation, we performed western blotting to detect α9-nAChR and PD-L1
protein levels in the A375, A2058 and MDA-MB 435 melanoma cells treated with nicotine at final
concentrations of 0.001–1 μm for 24 h or at a concentration of 1 μm for 12–72 h. We found that nicotine
induced both α9-nAChR and PD-L1 upregulation in a concentration- and time-dependent manner
(Figure 5B and Figure S12). However, in the HEMn-LP melanocytes, nicotine-induced α9-nAChR
activity did not upregulate PD-L1 expression (Figures S6 and S18).
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Figure 6. α9-nAChR mediates nicotine-induced PD-L1 expression and regulates melanoma cell
proliferation. (A) Nicotine increased STAT3, AKT, and ERK phosphorylation in a time-dependent
manner in the A375, A2058, and MDA-MB-435 cells, as assessed by western blotting. (B) Nicotine
induced the phosphorylation of STAT3, AKT, and ERK and upregulated the protein levels of α9-nAChR,
PD-L1, Snail-1 and Twist-1 in a dose-dependent manner. The results were determined by western
blotting. (C–J) A2058 cells were pretreated with the inhibitor LY294002 (10 μm or 25 μm), PD98059
(10 μm or 25 μm), Stattic (2.5 μm or 5 μm) or NSC74859 (10 μm or 25 μm) for 3-24 h and subsequently
treated with or without nicotine (1 μm) for additional 24-48 h. Western blot analysis was used to detect
protein levels. Cell proliferation was assessed by an MTT assay. (K,L) Wild-type, scrambled siRNA,
and α9-nAChR-si-expressing A2058 cells were treated with or without 1 μm nicotine. Western blot
analysis was used to assess protein levels. Cell growth was assessed by an MTT assay. (M,N) After
A2058 cells were exposed to 0.1 μm or 1 μm nicotine for 24 h, a ChIP assay was performed using
an anti-STAT3 antibody. The protein-chromatin immunoprecipitates were subjected to RT-PCR and
qPCR. In RT-PCR, a rabbit IgG antibody was used as a negative control, and total genomic DNA was
used as a positive control. In qPCR, relative enrichments of PD-L1 promoter region were calculated
after normalization to GAPDH. Each of the immunoprecipitations was replicated three times, and
each sample was quantified at least in triplicate. The data are presented as the mean ± SD of three
independent experiments. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; Student’s t-test.
Wild-type, scrambled siRNA, and α9-nAChR-siRNA-expressing A2058 cells were treated with or
without 1 μm nicotine. After 24 h, we compared α9-nAChR-siRNA-expressing A2058 cells treated
with 1 μm nicotine to those not treat with 1 μm nicotine. We found that knocking down α9-nAChR
led to an inhibition of nicotine-induced PD-L1 protein levels through α9-nAChR-mediated STAT3
signaling pathway (Figure 6K and Figure S17). Together, these results suggest that α9-nAChR mediates
nicotine-induced PD-L1 expression.
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2.9. Nicotine-Induced α9-nAChR Activity Significantly Increases Melanoma Cell Proliferation via the AKT and
ERK Signaling Pathways
To examine the mechanisms by which the AKT and ERK signaling pathways induced
nicotine-stimulated α9-nAChR activity promote proliferation in the A375, A2058, and MDA-MB
435 melanoma cells, we treated cells with 1 μm nicotine at the indicated time points (Figure 6A and
Figure S13). Nicotine increased AKT and ERK phosphorylation in a time-dependent manner in the A375,
A2058 and MDA-MB 435 melanoma cells, as assessed by immunoblotting with anti–phospho-AKT
and anti–phospho-ERK antibodies (Figure 6A and Figure S13). To evaluate concentration-dependent
responses to nicotine, we treated cells with nicotine at final concentrations of 0.1–1 μm for 24 h.
We found that nicotine increased the phosphorylation of AKT and ERK level in the three cell lines in a
concentration-dependent manner (Figure 6B and Figure S14).
To examine the potential roles of PI3K and MEK inhibitors in the prevention of nicotine-induced
melanoma cell proliferation, we pretreated A2058 cells with LY 294002 (10 μm and 25 μm) or PD
98059 (10 μm and 25 μm) for 3 h and then treated the cells with or without 1 μm nicotine for
24–48 h. As shown in Figure 6C–F and Figure S15, LY294002 and PD98059 significantly inhibited
the activation of the AKT and ERK signaling pathways, leading to the inhibition of nicotine-induced
melanoma cell proliferation. Moreover, knocking down α9-nAChR expression led to an inhibition
of the nicotine-induced proliferation mediated by the AKT and ERK signaling pathways (Figure 6L).
Together, these data indicate that nicotine-induced α9-nAChR activity significantly increases melanoma
cell proliferation via the AKT and ERK signaling pathways.
2.10. Nicotine-Induced α9-nAChR Activity Upregulates PD-L1 Expression via STAT3 Signaling Pathway
The transcription factor STAT3 is required for regulating PD-L1 expression. To examine
whether nicotine-induced α9-nAChR activity activated the transcription factor STAT3 in response
to PD-L1 upregulation, we performed western blotting and ChIP assays. Nicotine induced STAT3
phosphorylation and upregulated PD-L1 protein levels in a time- and dose-dependent manner
(Figures 5B and 6A,B, Figures S12–S14)). Pretreatment of A2058 cells with the STAT3 phosphorylation
inhibitor Stattic (2.5 μm or 5 μm) or STAT3 DNA-binding inhibitor NSC74859 (10 μm or 25 μm) to
block the activation of the STAT3 signaling pathway was performed for 24 h prior to a coincubation
with or without 1 μm nicotine stimulation. As shown in Figure 6H,J and Figure S16, the inhibitors
Stattic and NSC74859 significantly inhibited the stimulation of the nicotine-activated STAT3 signaling
pathway that leads to PD-L1 upregulation. Moreover, the inhibitors Stattic and NSC74859 prevented
the nicotine-induced melanoma cell proliferation (Figure 6G,I). Knocking down α9-nAChR expression
led to an inhibition of the nicotine-induced PD-L1 protein level through the STAT3 signaling pathway
(Figure 6K and Figure S17). We added 0.1 or 1 μm nicotine to A2058 cells for 24 h, and then performed
a ChIP assay with an anti-STAT3 antibody and primer pairs specific for the PD-L1 gene promoter.
The expression of PD-L1 was evaluated by RT-PCR and qPCR. We found that nicotine activated the
transcription factor STAT3, which directly bound to the promoter of PD-L1 in -337 to -118 region
(Figure 6M). Moreover, nicotine upregulated PD-L1 levels by increasing STAT3 binding to the PD-L1
promoter in a dose-dependent manner (* p < 0.05, *** p < 0.001) (Figure 6N). Together, these results
indicate that nicotine-induced α9-nAChR activity activates the STAT3 signaling pathway that influences
melanoma cell proliferation and upregulates PD-L1 expression, and the STAT3 inhibitors Stattic and
NSC74859 prevent nicotine-induced PD-L1 expression and proliferation.
3. Discussion
Smoking is the leading cause of premature death and causes so many types of cancers [49].
Increasing evidence indicates that nicotine, which is one of the harshest substances in tobacco
smoke, contributes to carcinogenesis in various cancer types, affects cancer progression and results
in a poor prognosis in patients [30]. Nicotine binds to nAChRs and induces various downstream
signaling pathways involved in cancer promotion, progression, and malignancy [30]. Recently,
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various epidemiological studies reported that tobacco smoking significantly increases metastasis in
melanoma [27,28]. Moreover, a previous study indicated that α9-nAChR had important roles in
promoting breast cancer growth and metastasis in vitro and in vivo [20]. In our results, we showed, for
the first time, the associations of α9-nAChR expression with clinicopathological features of melanoma
patients, including clinical staging, lymph node status and OS (Figure 1 and Table 1). α9-nAChR
expression was significantly higher in melanoma cells than in melanocytes based on four cell lines (A375,
A2058, and MDA-MB 435 melanoma cell lines and HEMN-LP melanocyte cell line) and melanoma
cell line datasets (Figure 1). α9-nAChR mRNA level was higher in melanoma cells with the invasive
phenotype than in those with the proliferative phenotype (Figure 1). In the TCGA-SKCM cohort, the
metastatic patient group had higher α9-nAChR mRNA level than the primary patient group. In vitro,
overexpression of α9-nAChR via transfection substantially increased melanoma cell proliferation and
migration (Figure 3). By contrast, the suppression of α9-nAChR expression significantly inhibited
melanoma cell growth and migration (Figure 4). Taken together, these findings suggest that α9-nAChR
expression is not only relevant to melanoma growth and metastasis but also an unfavorable prognostic
factor in melanoma patients.
α9-nAChR mRNA expression significantly associated with sex (* p = 0.04) (Table 1), and female
had a higher α9-nAChR mRNA expression as compared to male (* p < 0.05) (Figure S2). 17β-estradiol
upregulated α9-nAChR expression via the phosphorylation of estrogen receptor-alpha (ERα)-mediated
the binding of AP1 and transcription factors to the α9-nAChR gene promoter, and –induced α9-nAChR
protein production in breast cancer cells [31]. This study may provide us the clues to explain the
mechanism of female sex hormone-induced α9-nAChR expression.
Numerous findings indicate that PD-L1 is present in tumor cells [50]. Tumor-expressed PD-L1
binds to PD-1-expressed on T cells, leading to the alterations of tumor immunopathogenesis which
helps tumor cells evade the immune response [50]. Furthermore, the roles for tumor-intrinsic-PD-L1 in
the regulation of EMT, cancer stemness, tumor development, metastasis, and resistance to therapy
have recently been discovered [37]. PD-L1 overexpression, knockdown or knockout in glioblastoma
multiforme was investigated, and the results demonstrated that PD-L1 promoted cancer cell growth
and metastasis in vitro and in vivo [51]. In our study, the expression of PD-L1 is overexpressed in
melanoma cells and tissues compared with melanocytes and normal skin tissues, respectively (Figure 2);
and the positive correlation between α9-nAChR and PD-L1 expression by using melanoma cell lines,
tissue microarrays, and public databases (Figure 2 and Figures S3–S5). In particular, α9-nAChR
knockdown or overexpression induced changes in PD-L1 expression (Figures 3 and 4). We suggest
that α9-nAChR promotes melanoma cell proliferation and migration through the regulation of PD-L1.
The transcription factor STAT3 plays a key role in the regulation of PD-L1 expression in various
cancer types [52]. In non-Hodgkin lymphoma, STAT3 binds to the PD-L1 gene promoter, resulting
in upregulation of PD-L1 expression in vitro and in vivo [53]. STAT3 suppression decreases PD-L1
expression in ALK-positive anaplastic large cell lymphoma (ALCL) [54] and KRAS-mutant non-small
cell lung cancer (NSCLC) cells [55]. In our study, STAT3 was activated and regulated by α9-nAChR
(Figures 3 and 4). Moreover, we found that STAT3 bound to the PD-L1 promoter in melanoma cells,
and knocking down α9-nAChR expression inhibited STAT3 binding to the PD-L1 promoter, leading to
PD-L1 downregulation (Figure 4). In contrast, the stimulation of α9-nAChR expression with nicotine
increases STAT3 binding to PD-L1 promoter, leading to PD-L1 upregulation (Figure 6).
α9-nAChR synergizes mainly with epidermal growth factor (EGF) receptor, insulin-like growth
factor 1 (IGF-1) receptor, vascular endothelial growth factor (VEGF) receptor in lung cancer cells [56],
and estrogen receptor α (ERα) in breast cancer cells [31]. Moreover, EGFR has been shown to
regulate the expression of PD-L1 through the activation of the IL6/JAK/STAT3 pathway in NSCLC [57].
17β-Estradiol-induced PD-L1 expression through ERα-mediated AKT signaling [58]. We suggest that
not only is STAT3 activated through α9-nAChR, but the interaction of α9-nAChR with other receptors
also regulates PD-L1 expression.
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PD-L1 expression can be inducible or constitutive and may change over time in response to
different stimuli such as EGF, cytokines, interferon-gamma (IFNγ), 17β-estradiol, BaP, DbA, and
BzP [44,58,59]. In our study, we found that nicotine remarkably increased PD-L1 protein expression in
a dose- and time-dependent manner through α9-nAChR (Figure 5), suggesting that nicotine-induced
α9-nAChR activity can regulate anti-cancer immunity. In addition, nicotine-induced α9-nAChR
stimulated cancer cell proliferation and migration to drive cancer development and progression
(Figure 5). Our study suggested that a new role for nicotine in suppressing anticancer immunity
through α9-nAChR-induced PD-L1 expression in melanoma.
The ERK, AKT and STAT3 signaling pathways have been previously described to regulate
melanoma cell proliferation [2,60]. In this study, we found MEK, AKT and STAT3 inhibitors interfered
with melanoma cell proliferation and attenuated nicotine-induced melanoma cell proliferation (Figures 3,
4 and 6). α9-nAChR regulated melanoma cell proliferation (Figures 3 and 4). Stimulation of α9-nAChR
with nicotine or overexpression of α9-nAChR promoted the activation of the AKT, ERK and STAT3
signaling pathways (Figures 3, 5 and 6). In contrast, knocking down α9-nAChR expression inhibited
the AKT, ERK and STAT3 signaling pathways (Figures 4 and 6). These observations, along with the
rest of the results in this study, suggest an important role for the α9-nAChR-mediated AKT, ERK and
STAT3 signaling pathways in regulating melanoma cell proliferation.
In a previous study, Chernyavsky et al. found that stimulation ofα9-nAChR initiated cell migration
in epidermal keratinocytes through activation of the phosphorylation of intercellular junction proteins
(desmoglein 3 and β-catenin), and focal adhesion proteins (paxillin and focal adhesion kinase (FAK)),
thereby separating cell-cell adhesion complexes; in contrast, knocking down α9-nAChR expression
inhibited the phosphorylation of adhesion and cytoskeletal proteins [61]. Moreover, α9-nAChR
regulated the shape and adhesion of keratinocytes through the activation of several kinases, including
EGFR, Scr, PLC, and PKC, and GTPases (Rho and Rac) [61]. Recently, Chun et al. found that α9-nAChR
in breast cancer cells interacted with EGFR and EEBB2, and these genes were coexpressed with
numerous downregulated genes, such as nectin-3 (NECTIN3) in the adherens junction pathway [23].
In our present study, we also investigated the participation of α9-nAChR in the regulation of melanoma
cell migration (Figures 3 and 4), and stimulation of α9-nAChR by nicotine significantly increased
melanoma cell migration (Figure 5). Furthermore, we found that the protein levels of the EMT markers
Twist-1 and Snail-1 and morphological changes were affected by the overexpression or suppression of
α9-nAChR (Figures 3 and 4). These observations suggest that the α9-nAChR network is significantly
associated with migration in melanoma cells.
Snail and Twist-1 transcription factors contribute to repression of the epithelial phenotype and
activation of the mesenchymal phenotype [62]. Snail-1 and Twist-1 EMT markers are not enough for
proving EMT program, but their expression is activated early in EMT, and they thus have central roles in
metastatic cancer [62]. In many previous studied, researchers mentioned that AKT and EKR signaling
pathways promote EMT markers, including Snail-1 and Twist-1 [62] and cigarette smoking-induced
AKT and ERK signaling pathways promotes the EMT program in cancers [63]. Nicotine/ α9-nAChR
activates AKT, ERK pathways and EMT markers in melanoma cells (Figures 3, 4 and 6). We suggest
that nicotine/ α9-nAChR may induce the EMT program through AKT or ERK pathways, or both.
In this study, the expression of α9-nAChR was significantly associated with metastasis and
OS. α9-nAChR had roles in inducing PD-L1 expression and regulating melanoma cell proliferation
and migration. Notably, nicotine-induced α9-nAChR activity promoted melanoma cell proliferation
through stimulation of the α9-nAChR-mediated AKT, ERK and STAT3 signaling pathways. In addition,
nicotine-induced α9-nAchR activity promoted melanoma cell migration by activating the EMT pathway.
PD-L1 expression was upregulated in melanoma cells after nicotine treatment via α9-nAchR-mediated
activation of the binding of the transcription factor STAT3 to the PD-L1 promoter.
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4. Materials and Methods
4.1. Cell Culture
The human primary neonatal foreskin melanocyte cell line HEMn-LP from a lightly pigmented
donor was cultured at 37 ◦C and 5% CO2 in Medium 254 supplemented with human melanocyte growth
supplement (HMGS). Melanocyte cell line, medium, and supplement listed above were purchased
from Invitrogen (Carlsbad, CA, USA). The human melanoma cell line MDA-MB 435 was purchased
from the American Tissue Cell Culture Collection (ATCC, Manassas, VA, USA), and the melanoma cell
lines A2058 and A375 were obtained from Dr. Shing-Chuan Shen (Taipei Medical University, Taipei,
Taiwan). All melanoma cell lines were maintained at 37 ◦C and 5% CO2 in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS,
Gibco) and 1% penicillin-streptomycin-neomycin (PSN) antibiotic mixture (Gibco).
4.2. Bioinformatics Analysis
4.2.1. Melanoma Cell Line Dataset Analysis
Cell line datasets from the public R2 MegaSampler platform (https://hgserver1.amc.nl/cgi-bin/
r2/main.cgi) were used to screen α9-nAChR mRNA expression in melanocyte, primary melanoma,
and metastatic melanoma groups. We compared the α9-nAChR mRNA expression among the groups
in the cell line datasets. Data from six different datasets in the melanoma cell phenotype-specific
gene expression database (HOPP Database) (http://www.jurmo.ch/php/ genehunter.html) were used to
assess α9-nAChR mRNA expression and PD-L1 expression in melanoma cell lines [45]. The melanoma
cell lines from these datasets were divided into proliferative and invasive phenotypes. We conducted a
statistical comparison of α9-nAChR mRNA expression values between the two phenotype groups
using the nonparametric Mann-Whitney U-test. In addition, α9-nAChR and PD-L1 expression was
used to divide the melanoma cell lines into high and low expression groups based on the mean
level of α9-nAChR or PD-L1 expression. The χ2 test was used to analyze the correlation between
α9-nAChR (low or high) and PD-L1 (low or high) expression. Pearson and Spearman’s rank correlation
analysis was used to evaluate the strength of the association between α9-nAChR and PD-L1 expression.
A p-value <0.05 was considered statistically significant.
4.2.2. TCGA-SKCM Cohort Analysis
We downloaded gene expression data from the cancer genomic browser of UCSC (https://
xenabrowser.net/). We selected gene expression of α9-nAChR and PD-L1, and then clinicopathological
parameters (sex, age, ulceration, Breslow depth, Clerk level, tumor size, lymph node status, distant
metastasis status, stage) were selected from the phenotype search option. All patient data were
downloaded. Furthermore, OS time and events were also obtained. α9-nAChR and PD-L1 mRNA
expression were used to divide the patients into high and low expression groups according to the
mean level of α9-nAChR or PD-L1 mRNA expression. The χ2 test was used to analyze the correlations
between α9-nAChR (low or high) mRNA expression, PD-L1 (low or high) mRNA expression, and
clinicopathological parameters. Pearson and Spearman’s rank correlation analysis was used to evaluate
the strength of the association between α9-nAChR and PD-L1 mRNA expression. A p-value <0.05 was
considered statistically significant.
4.3. Kaplan-Meier Analysis
Kaplan-Meier analysis based on the result from publicly available R2: Kaplan Meier Scanner
software (https://hgserver1.amc.nl), selected the TCGA-SKCM cohort, then selected the optimal cut-off
value to separate α9-nAChR mRNA expression into high or low group, and finally selected OS.
A p-value <0.05 was considered statistically significant.
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4.4. Nicotine Treatment
Cells were seeded in 60 mm dishes or 6-well plates at 5 × 105 cells per dish or 5 × 104 cells
per well, respectively. Nicotine was purchased from Sigma-Aldrich (St. Louis, MO, USA, Catalog
#54-11-5). The final concentrations were 0.001, 0.001, 0.01, 0.1 and 1 μm/mL, and cells were treated for
the indicated time periods. The cells were harvested and analyzed by a cell count assay and western
blotting at the indicated time points.
4.5. Inhibitor Treatment
Cells were seeded at 5 × 105 cells per dish in 60 mm dishes or 5 × 103 cells per well in 96-well
plates. These cells were pretreated with 10–25 μm LY 294002 (#1130), 10–25 μm PD 98059 (#1231),
2.5–5 μm Stattic (#2798) or 5–10 μm NSC74859 (#4655) for 3–24 h and then cultured in the presence
or absence of nicotine (1 μm) for 24–48 h. All inhibitors were purchased from TOCRIS Bioscience
(Minneapolis, MN, USA). The cells were harvested to assess cell proliferation and viability as well as
protein expression, which was analyzed by western blotting.
4.6. Cell Proliferation and Viability Assays
4.6.1. Cell Counting Assay
Cell numbers were determined by a cell counting assay. Cells were seeded in a 6-well plate at a
density of 5 × 104 cells per well and then incubated in medium for the indicated times. The cells were
collected and suspended in a growth medium. After staining with trypan blue, the cell number was
counted with a hemocytometer. This assay was repeated four times with duplicate samples.
4.6.2. MTT Assay
Cell growth and viability were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
(MTT) assay. Cells were seeded in triplicate in 96-well plates at a density of 5000 cells per well.
Cells were treated with a compound at the indicated concentration for the indicated time periods.
The medium was changed every two to three days. The optical density at 570 nm was measured using
the SynergyTM HT Multi-Detection Microplate Reader (BioTek Instruments, Winooski, VT, USA).
The assay was repeated three times with duplicate samples.
4.6.3. Soft-Agar Growth Assay
Anchorage-independent cell growth was analyzed using a soft-agar colony formation assay.
Cells were seeded in a 0.4% top agarose II (Amresco, Solon, OH, USA) solution in growth medium over
a base layer of 0.9% agarose II in 6-well plates at a density of 1 × 104 cells/mL. Soft-agar cultures were
maintained at 37 ◦C for an additional 21 days and observed for the appearance of the colonies using
the Leica DMI 4000 B Microscope Imaging System (Leica Microsystems, Wetzlar, Germany). The assay
was repeated four times with duplicate samples. Images were acquired using a BioSpectrumTM 500
Imaging system, and colonies were counted under a light microscope.
4.7. Wound healing Scratch Assay
Cell migration was evaluated by a scratch-wound healing assay. In total, 5× 105 cells per well were
seeded in 12-well plates. After the cells grew to approximately 90% confluence, the cell monolayers
were wounded by manually scraping the monolayers with a 10 μL or 100 μL sterile pipette tips.
Then cells were washed three times with 1× PBS and fresh medium was added. Migrated cells were
observed and captured by using the Leica DMI 4000 B Microscope Imaging System. This assay was
performed at 0 h and 24 h after wounding. Wound closure was quantified as a percentage (versus the
control set to 100%) that indicated the relative distance between the two scratch edges (scratch wound)
using ImageJ software.
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4.8. Construction of Vectors
4.8.1. α9-nAChR siRNA
The sequences of the α9-nAChR-scramble and α9-nAChR-siRNA primers are shown in Table S2.
α9-nAChR-siRNA was constructed using two independent siRNAs. The scrambled siRNA sequence
was used as a control. After BLAST analysis to verify the absence of significant sequence homology
with other genes, the selected sequences were inserted into the pSUPER vector and digested with bglII
and HindIII to generate the pSUPER-α9-nAChR-siRNA and pSUPER- α9-nAChR-scramble vectors.
4.8.2. α9-nAChR Overexpression
The sequences of the α9-specific overexpression primers are shown in Table S2. After BLAST
analysis to verify the absence of significant sequence homology with other human genes, the selected
sequences were inserted into the pcDNA3.1 vector (Invitrogen) and digested with bglII and HindIII to
generate pcDNA3.1-α9-nAChR overexpression vectors. The identity of the construct was confirmed
by DNA sequence analysis.
4.9. Generation of Stable Cell Lines
For stable transfections, 5 × 106 cells were washed twice with 1× PBS and mixed with 10 μg
of vectors (pSUPER-α9-nAChR-siRNA, pSUPER-α9-nAChR-scramble, pcDNA3.1 or pcDNA3.1-α9
nAChR overexpression vector). The mixtures were transfected using the pipette-type microporator
MP-100 electroporation (Invitrogen). After 48 h, the selection medium supplemented with G418
concentration of 5 mg/mL (A2058 cells) or 2 mg/mL (MDA-MB 435 cells) was added to the transfected
cells. Every 2–3 days, the selection medium was replaced with new selection medium. After 30 days,
the clones were isolated and evaluated for knockdown or overexpression at protein levels, and these
clones were compared with scramble clones by western blotting.
4.10. RNA Isolation and RT-PCR Analysis
Total RNA was isolated from human cell lines using TRIzol (Invitrogen) according to the
manufacturer’s protocol. The specific primers were synthesized as shown in Table S2. The PCR
amplicons were analyzed on 1.2% agarose gels (Amresco) stained with ethidium bromide. Images
were acquired by an INFINITY-a digital imaging system (Vilber Lourmet, France), and the intensities of
the bands were quantified using ImageJ software. The relative mRNA levels were normalized against
the GAPDH mRNA levels.
4.11. Protein Extraction, Western Blotting, and Antibody
To determine protein expression, we harvested cellular proteins for western blotting as previously
described [20]. Cells were washed three times with ice-cold 1× PBS and lysed on ice in a cell lysis
buffer (50 mM Tris-HCl, pH 8.0; 120 mM NaCl2; 0.5% NP-40; 100 mM sodium fluoride; and 200 M
sodium orthovanadate) supplemented with protease inhibitors. Proteins (50 μg per lane) were
separated by gel electrophoresis on 10% SDS-PAGE gels, transferred to nitrocellulose membrane
by electroblotting. The membranes were probed with appropriate primary antibodies against
α9-nAChR (Thermo Fisher Scientific, Rockford, IL, USA, #PA5-46826), PD-L1 (Genetex, Irvine, CA, USA,
#GTX104763; Thermo Fisher Scientific, #14-5983-82; Santa Cruz Biotechnology, Santa Cruz, CA, USA,
#sc-293425), total-AKT (Genetex, #GTX121937), phospho-AKT (Cell Signaling Technology, Beverly,
MA, USA, #9271), total-ERK1/2 (Genetex, #GTX113094), phospho-ERK1/2 (Santa Cruz Biotechnology,
#sc-7383), total-STAT3 (Santa Cruz Biotechnology, #sc-8059), phospho-STAT3 (Cell Signaling Technology,
#9145), Snail-1 (Cell signaling Technology, #6615), Twist-1 (Santa Cruz Biotechnology, #sc-81417) and
GAPDH (Genetex, #GTX627408) followed by incubation with an HRP-conjugated secondary antibody.
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Band intensity was quantified using ImageJ software. The relative protein levels were normalized
against the GAPDH protein levels.
4.12. ChIP Assay
ChIP assays of the cultured cells were performed as described previously [31]. In brief, cells
were cross-linked with a final concentration of 1% formaldehyde at 25 ◦C for 15 min and quenched
with 0.125 M glycine for 5 min. Chromatin was sheared by sonication to average lengths of 500 bp.
Chromatin was immunoprecipitated using 10 μg of anti-STAT3 monoclonal antibody (mAb) and
protein A agarose beads at 4 ◦C overnight. DNA was recovered from the protein A complex using
an elution buffer (10 mmol/L Tris, 10 mmol/L EDTA, 1% SDS, 150 mmol/L NaCl, and 5 mmol/L
DTT, pH 8.0) and purified using a Macherey-Nagel PCR Clean-up kit. The DNA fragments were
subjected to RT-PCR and qPCR using PD-L1 promoter primer pairs as shown in Supplemental Table S2.
Nonimmunoprecipitated lysates (input) and immunoprecipitates obtained with an anti-rabbit IgG
(Santa Cruz Biotechnology, #sc-2007) served as positive and negative controls, respectively. Relative
enrichments of PD-L1 promoter region were calculated after normalization to GAPDH. Each of the
immunoprecipitations was replicated three times, and each sample was quantified at least in triplicate.
4.13. IHC Staining and Scoring System
4.13.1. IHC Staining
Tissue microarrays used in the present study were purchased from US Biomax, Inc. (Rockville, MD,
USA). The tissue microarrays have 192 specimens, including 112 specimens of malignant melanoma,
64 specimens of metastatic malignant melanoma, eight specimens of adjacent normal skin tissue, and
eight specimens of skin normal tissue. Each core of the tissue microarrays represents a specimen.
US Biomax, Inc. also provided patient information concerning age, gender, clinical stage, TNM, and
pathological diagnosis. Standard immunohistochemical procedures were implemented as follows:
Paraffin sections were baked at 60 ◦C for 1h, de-paraffinized in xylene, rehydrated through graded
ethanol, quenched for endogenous peroxidase activity in 3% hydrogen peroxide for 10 min, and
processed for antigen retrieval by high pressure cooking in citrate antigen retrieval solution (pH = 6.0)
for about 30 min. Sections was blocked with normal serum at room temperature for 30 min. Then,
the samples on the slides were incubated at 37 ◦C for 2 h with rabbit polyclonal antibodies against
α9-nAchR (1:100, Thermo Fisher Scientific, #PA5-77511) and mouse monoclonal antibodies against
PD-L1 (1:100, Santa Cruz Biotechnology, #sc-293425) in a moist chamber. The slides were subsequently
incubated with goat anti-Mouse/Rabbit IgG VisUCyte HRP Polymer Antibody (VC002, R&D Systems,
Minneapolis, MN, USA) for 1 h at room temperature. Immunostaining was performed using the
Liquid DAB-Substrate Chromogen System (K3468, Dako, Glostrup, Denmark), which resulted in
a brown-colored precipitate at the antigen site. Subsequently, sections were counterstained with
hematoxylin and the procedure of dehydration was implemented. Finally, covers slips were applied in
a non-aqueous mounting medium.
4.13.2. Immunohistochemistry Score
The staining scores were evaluated independently by two investigators, who were blinded to the
information on the microarrays. For IHC analysis, the results were analyzed using Image-Pro Plus 6.0
software. The expression of each protein expression was evaluated by intensity scoring on scale of “0”
to “3+” (0: no staining, +: weak staining, 2+: moderate staining, 3+: high staining) and proportion (0%,
1–24%, 25–50%, >50%). The final immunoreactive score was determined by multiplying the intensity
score by the proportion of positive cells.
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4.14. Statistical Analysis
Data were analyzed using SPSS version 22.0 (SPSS Inc., Chicago, IL, USA) and SigmaPlot graphing
software (San Jose, CA, USA). Continuous variables are presented as the mean± standard deviation and
were analyzed by two-tailed unpaired Student’s t-test for two groups. Nonmormally distributed data
are expressed as the median and were assessed by the nonparametric Mann-Whitney U-test. The χ2
test analysis was used to study the associations between α9-nAChR (low or high) and PD-L1 (low or
high) expression or different clinicopathological features. Pearson and Spearman’s rank correlation
analysis was used for the association between α9-nAChR and PD-L1 expression levels. Kaplan-Meier
analysis was used to plot survival curves, which were compared by the log-rank test. A p-value <0.05
(two-sided) was considered statistically significant.
5. Conclusions
This study may reveal important insights into the mechanisms underlying nicotine-induced
melanoma cell proliferation and migration mediated through α9-nAChR-initiated carcinogenic
signaling and PD-L1 expression. α9-nAChR could serve as a therapeutic target to decrease the
growth and metastasis in melanoma (Figure 7).
Figure 7. A schematic molecular model of nicotine-induced α9-nAChR activity in melanoma cells.
α9-nAChR mediates nicotine-induced PD-L1 expression and regulates melanoma cell proliferation
and migration. Nicotine-induced α9-nAChR activity upregulates Snail-1 and Twist-1 expression and
activates the phosphorylation of AKT, ERK, and STAT3.
Supplementary Materials: The following material is available online at http://www.mdpi.com/2072-6694/11/12/
1991/s1, Table S1: The chi-square test was employed to assess the correlation between a9-nChAR and PD-L1
expression in the tissue microarrays (n = 192) as categorical variables, Table S2: RT-PCR primers, Figure S1:
Uncropped scans with size marker indications of western blots shown in Figure 1D, Figure S2: α9-nAChR mRNA
level in female (n = 179) and male (n = 293) groups, Figure S3: Correlation between α9-nAChR and PD-L1 mRNA
expression in the melanoma cell line datasets, Figure S4: Correlation between α9-nAChR and PD-L1 mRNA
expression in the TCGA-SKCM cohort, Figure S5: Correlations between α9-nAChR and PD-L1 in melanoma cell
lines, Figure S6: Nicotine-induced α9-nAChR activity did not influence PD-L1 protein levels in the HEMn-LP
melanocytes, and densitometry readings/intensity ratios, Figure S7: Uncropped scans with size marker indications
of western blots shown in Figure 2L, and densitometry readings/intensity ratios, Figure S8: Uncropped scans
with size marker indications of western blots shown in Figure 3A, and densitometry readings/intensity ratios,
Figure S9: Uncropped scans with size marker indications of western blots shown in Figure 3J,L, and densitometry
readings/intensity ratios, Figure S10: Uncropped scans with size marker indications of western blots shown in
Figure 4A, and densitometry readings/intensity ratios, Figure S11: Uncropped scans with size marker indications
of western blots shown in Figure 4G, and densitometry readings/intensity ratios, Figure S12: Uncropped scans
with size marker indications of western blots shown in Figure 5B, and densitometry readings/intensity ratios,
Figure S13: Uncropped scans with size marker indications of western blots shown in Figure 6A, and densitometry
readings/intensity ratios, Figure S14: Uncropped scans with size marker indications of western blots shown in
Figure 6B, and densitometry readings/intensity ratios, Figure S15: Uncropped scans with size marker indications
of western blots shown in Figure 6D,F, and densitometry readings/intensity ratios, Figure S16: Uncropped scans
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with size marker indications of western blots shown in Figure 6H,J, and densitometry readings/intensity ratios,
Figure S17: Uncropped scans with size marker indications of western blots shown in Figure 6K, and densitometry
readings/intensity ratios, Figure S18: Uncropped scans with size marker indications of western blots shown in
Figure S6, and densitometry readings/intensity ratios.
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Abstract: New and effective anticancer compounds are much needed as the incidence of cancer
continues to rise. Microorganisms from a variety of environments are promising sources of new
drugs; Streptomyces sp. MUM256, which was isolated from mangrove soil in Malaysia as part of
our ongoing efforts to study mangrove resources, was shown to produce bioactive metabolites with
chemopreventive potential. This present study is a continuation of our previous efforts and aimed
to investigate the underlying mechanisms of the ethyl acetate fraction of MUM256 crude extract
(MUM256 EA) in inhibiting the proliferation of HCT116 cells. Our data showed that MUM256 EA
reduced proliferation of HCT116 cells via induction of cell-cycle arrest. Molecular studies revealed
that MUM256 EA regulated the expression level of several important cell-cycle regulatory proteins.
The results also demonstrated that MUM256 EA induced apoptosis in HCT116 cells mediated
through the intrinsic pathway. Gas chromatography-mass spectrometry (GC-MS) analysis detected
several chemical compounds present in MUM256 EA, including cyclic dipeptides which previous
literature has reported to demonstrate various pharmacological properties. The cyclic dipeptides
were further shown to inhibit HCT116 cells while exerting little to no toxicity on normal colon cells in
this study. Taken together, the findings of this project highlight the important role of exploring the
mangrove microorganisms as a bioresource which hold tremendous promise for the development of
chemopreventive drugs against colorectal cancer.
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1. Introduction
Colorectal cancer (CRC) constitutes the third most common cancer diagnosed and the fourth leading
cause of cancer mortality globally [1]. According to Arnold et al. [2], CRC incidence and mortality is
correlated well to human development levels. The study described that the rate of CRC cases is increasing
rapidly in many low-income and middle-income countries while stable or decreasing trends are seen in
highly developed countries [2]. Treatment of CRC usually involves surgical removal alone when detected
early whereas late stage of advanced or metastasized CRC requires radiotherapy or chemotherapy [3].
However, chemotherapy suffers from significant limitations including insufficient selectivity for tumor
cells, leading to many adverse side effects [4,5]. Although targeted therapies have been regarded as
the most successful treatments of cancer for the past few decades, genetic mutations greatly affect
the efficacy of various targeted drug therapies and leading to mutation-driven resistance of targeted
therapy [6–8]. Thus, there is an urgent need to search for alternative chemotherapeutic/chemoprevention
agents which may overcome the limitations of chemotherapy, and natural products are an excellent
resource to explore [9].
Natural products have provided the inspiration for the development of alternative agents for the
prevention or therapy of cancer, and using natural products to reduce cancer prevalence has received
substantial attention [10–14]. The natural products of interest can be found in fruits, vegetables, herbs
and medicinal plants [15–19]. Aside from plant-based natural products, microorganisms are also
reported to be a useful source of bioactive compounds, including chemotherapeutic agents [20–23].
For instance, actinomycin was discovered as the first microbial metabolite isolated from the bacterium
Streptomyces antibioticus in 1940 [24] to be used in cancer therapy. Since then, many more microbial
metabolites with antitumor properties were discovered including anthracyclines, bleomycin, mitosanes,
mithramycin, pentostatin and calicheamicins [25]. Currently, there is evidence demonstrating that the
mangrove derived microbial metabolites could be the next bioresources for potential cancer therapeutic
agents [26–29]. Thus, we explored the potential of Streptomyces isolated from Malaysian mangrove soil
with a focus on its ability to produce metabolites exhibiting chemopreventive activity.
This work represents part of an ongoing project to discover anticancer compounds from mangrove
resources, and our screening of the various isolated Streptomyces strains led to the discovery of
Streptomyces sp. MUM256 which possesses the potential to produce active metabolites that induced
cell-cycle arrest and apoptosis. In the earlier study [30], we demonstrated that the methanol extract
of Streptomyces sp. MUM256 exhibited antioxidant and cytotoxic properties. The present study is
a continuation of this work aiming to investigate the underlying mechanisms of the cytotoxic and
antiproliferative effects of the ethyl acetate fraction of Streptomyces sp. MUM256 crude extract (MUM256
EA) against the HCT116 cell line. We demonstrated that the MUM256 EA induced cell-cycle arrest by
downregulating several important cell-cycle regulatory proteins and induced apoptosis via interactions
with the intrinsic pathway in colon cancer cells (Figure 1). Thus, we believe these results provide new
insight into the development of mangrove-derived Streptomyces metabolites against CRC.
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Figure 1. The summarized flow chart of this study. The figure illustrates the fermentation, crude
extract extraction, fractionation and elucidated mechanisms of MUM256 EA in cell-cycle arrest and
apoptosis induction.
2. Results
2.1. Phylogenetic Analysis of Streptomyces sp. MUM256
Given that the publicly available database for 16S rRNA gene sequence, such as Ezbiocloud, is
regularly updated by adding new bacteria species with validly published names, a new phylogenetic
tree was constructed for strain MUM256 based on its 16S rRNA gene sequence (GenBank accession
number KT459477) (Figure 2). Based on the blast result of the Ezbiocloud database, the 16S rRNA
gene sequence of strain MUM256 demonstrated highest similarity to S. hydrogenans NBRC13475T
(99.70%), S. daghestanicus NRRL B-5418T (99.70%), S. albidoflavus DSM40455T (99.70%), S. violascens
ISP5183T (99.70%) followed by S. koyangensis VK-A60T (99.48%). According to Figure 2, the 16S rRNA
sequence of strain MUM256 formed a distinct clade with strains S. koyangensis VK-A60T, S. hydrogenans
NBRC13475T, S. daghestanicus NRRL B-5418T, S. albidoflavus DSM40455T and S. violascens ISP5183T at
bootstrap value of 82%, showing relatively high confidence level of the association (Figure 2).
107
Cancers 2019, 11, 1742
Figure 2. Neighbour-joining phylogenetic tree based on 16S rRNA gene sequence of strain MUM256
(1343bp). The tree illustrates the relationship between strain MUM256 and closely related strains.
Numbers at nodes indicate percentages of 1000 bootstrap re-samplings. Bar, 0.001 substitutions per site.
2.2. To Examine the Cytotoxic Effect of Streptomyces sp. MUM256 Fractions against Colon Cancer
Cell HCT116
Three different fractions were obtained from the methanolic MUM256 extract after being subjected
to sequential fractionation with three types of solvents, namely hexane, ethyl acetate and water.
Figure 3a demonstrates the cell viability of HCT116 after exposure to MUM256 extract and the
respective fractions for 72 h. The ethyl acetate fraction of MUM256 extract was shown to exhibit the
highest cytotoxicity towards HCT116 among the fractions tested, followed by the hexane fraction and
the aqueous fraction as the least toxic against HCT116 cells. The toxicity of MUM256 EA was also
evaluated on a normal colon cell line CCD-18Co. The MUM256 EA exhibits significantly lesser toxicity
towards a normal colon cell (CCD-18Co) at all the concentrations tested in this study (Figure 3b).
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The IC50 of MUM256 EA towards CCD-18Co was measured at 215 μg/mL which is 1.72 higher than its
cytotoxicity towards colon cancer cell (HCT116) with IC50 of 88.44 μg/mL. This result demonstrates
that the MUM256 EA displays a slight preferential cytotoxicity against HCT116 colon cancer cells over
a CCD-18Co normal colon cell.
Figure 3. Cytotoxic and antiproliferative properties of MUM256 EA against HCT116 cells. (a) Cytotoxic
effect of MUM256 crude extract (MeOH: methanol) and 3 different fractions (H2O: water; Hex: hexane;
EtOAc: ethyl acetate) against HCT116 cells at a series of concentrations after 72 h treatment, (n = 4,
* p < 0.05). (b) The toxicity of MUM256 EA towards CCD-18Co as compared to its cytotoxicity against
HCT116 after 72 h exposure, (n = 4, * p < 0.05). (c) Cytotoxic effect of MUM256 EA at a series of
concentrations against HCT116 cells after 24, 48 and 72 h of exposure, (n = 4, * p < 0.05). (d) Line
graph shows the inhibitory effect of MUM256 EA fraction on HCT116 cells. Bar graph illustrates the
relative percentage of number of viable cells after exposure to MUM256 EA fraction after normalized to
100% for number of viable cells exposed to vehicle control (0.5% dimethyl sulfoxide (DMSO)) (n = 3),
* p < 0.05 indicates significant difference between the untreated and the treated cells. (e) Images of
colony formation after 7 days of control and MUM256 EA pre-treated cells in 6 well-plate. Crystal
violet staining was used for visualization and quantification of colonies. The area of colonies formed
are shown as bar graph with the mean relative mean colony area to control ± standard deviation (SD)
(n = 3, * p < 0.05).
2.3. MUM256 EA Suppresses Cell Viability and Proliferation in HCT116 Cells
To further examine the cytotoxic effects of MUM256 EA using MTT assay, the HCT116 cells were
treated with increasing concentrations of MUM256 EA for 24, 48 and 72 h. As shown in Figure 3c,
when treated for 24, 48 or 72 h in the concentration range of 25 to 400 μg/mL, MUM256 EA reduced the
cell viability of HCT116 cells; MUM256 EA demonstrated cytotoxic effect against HCT116 cells in a
significant dose-dependent manner at both 48 and 72 h timepoints. At 400 μg/mL, the cell viability of
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HCT116 was reduced by MUM256 EA in a time-dependent manner. The concentrations of MUM256
EA required to produce a 50% reduction in cell viability (IC50) were determined by a regression
analysis; the value of the half maximal inhibitory concentration (IC50) decreases according to the time
of treatment (IC50-24 h: 246.47 μg/mL > IC50-48 h: 102.37 μg/mL > IC50-72 h: 88.44 μg/mL).
Trypan blue dye exclusion assay showed that the growth of HCT116 cells were reduced upon
MUM256 EA treatment as demonstrated by the lower number of viable HCT116 cells in the wells
treated with MUM256 EA when compared to the wells with untreated cells (Figure 3d). According to
Figure 3d, a significantly lower number of viable cells were detected following exposure to 200 μg/mL
MUM256 EA: 59.7%, 51.7% and 33.6% at 24, 48 and 72 h, respectively, when compared to control.
To further evaluate MUM256 EA’s inhibitory effects on cancer cell proliferation, we performed
colony formation/clonogenic survival assay on HCT116 cells upon exposure to MUM256 EA treatment,
as a test reflecting long-term effect/toxicity [31]. The assay clearly demonstrated that clone formation
of HCT116 cells was reduced in a dose-dependent manner (Figure 3e). Treatment with MUM256 EA
resulted in a reduction in both numbers of colonies formed as well as the size of the colonies-colony
numbers for treated samples were significantly reduced and appeared smaller than those of the
control. Therefore, these results confirm that MUM256 EA is cytotoxic and anti-proliferative towards
HCT116 cells.
2.4. Morphological Changes Induced by MUM256 EA
The morphological examination revealed that the treatment of MUM256 EA visibly altered the
cell morphology of the viable HCT116 cells. In Figure 4a, most of the untreated HCT116 cells (control)
appeared as normal angular and spindle shapes, but most of the cells lost these features after treatment
with MUM256 EA. For example, it was observed that the treatment caused rounding and detachment
of HCT116 cells. In addition, reduced number of cells and cell shrinkage with lesser cytoplasm mass
were also observed (indicated by arrows) in Figure 4a. These abnormal morphological changes of the
cells upon exposure to MUM256 EA has provided some insight on its cytotoxic effect towards the
HCT116 cells.
Furthermore, flow cytometry was also utilized to examine the morphological changes of the cells
after treatment with MUM256 EA. The results showed a decrease in forward light scatter (Figure 4b);
the median channel fluorescence was lowered in the treated cells with increasing dose of treatment.
Meanwhile, the side light scatter was increased in the treated cells significantly with a 1.48-fold increase in
the median channel fluorescence compared to the control (Figure 4b). The reduced forward light scatter
indicates cell shrinkage, whereas the increased side scatter may be caused by chromatin condensation,
nuclear fragmentation and crosslinking of cytoplasmic proteins by activated transglutamine, resulting
in the cell becoming more reflective and refractive [32].
Figure 4. Cont.
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Figure 4. Morphological changes of HCT116 cells after exposure to MUM256 EA treatment. (a) Phase
contrast microscopic evaluation of HCT116 cells under×10 magnification. Decreased number of HCT116
cells were observed across the 3 timepoints with increasing concentration of MUM256 EA treatment.
Furthermore, arrows indicate the rounded cells due to cytoplasmic shrinkage and detached cells which
was increased in number with increasing concentration of MUM256 EA treatment. (b) Representative
forward scatter/side scatter (FSC/SSC) dot plot of HCT116 cells after exposure to MUM256 EA at
different concentrations. The x-axis shows a decreasing FSC in HCT116 cells treated with increasing
concentrations of MUM256 EA. The FSC represents the diffracted light and it is related to cell size.
The y-axis shows an increasing SSC in HCT116 treated with increasing concentrations of MUM256 EA.
The SSC represent the reflected and refracted light and is related to cell granularity and complexity.
The bar graphs show the relative median FSC and SSC fluorescence signals of treated cell population as
compared to control ± SD (n = 3, * p < 0.05).
2.5. Cell Cycle Arrest Effect of MUM256 EA in HCT116 Cells
In Figure 5a, exposure of HCT116 to 200 μg/mL of MUM256 EA resulted in a statistically
significant increase in the percentage of cells in G0/G1 phase from 44.7% (untreated cells) to 67.4%, with
a concomitant decrease in percentage of cells in the G2 phase from 32.68% (untreated cells) to 14.31%.
However, by 48 h, cells started accumulating in the G2 phase from 13.74% to 22.13% and followed
by accumulation from 11.14% to 22.39% by 72 h (Figure 5a). These results suggested that MUM256
EA hampers cell-cycle progression by arresting the cells in G1 and G2/M phase, subsequently lead to
inhibition of cell proliferation.
Expressions of Cell-Cycle Regulatory Proteins
After treatment with MUM256 EA for 24, 48 and 72 h, both reverse-transcription polymerase
chain reaction (RT-PCR) and Western blotting analysis showed the expression levels of p21Waf1/Cip1
were significantly elevated as compared to untreated HCT116 cells (Figure 5b,c). As one of the
transcriptional targets of p53, the expressions of p21Waf1/Cip1 could be regulated by p53 [33–35]. Thus,
the changes of p53 in response to MUM256 EA in HCT116 was also investigated using intracellular
flow cytometry. The p53 protein expression was shown to be increased upon treatment with MUM256
EA for 24 h (Figure 8c). This result supports that p53 activation plays a role in MUM256 EA-induced
p21 up-regulation in HCT116 cells.
Besides that, this study also demonstrated that the MUM256 EA treatment downregulated several
important cell cycle regulator genes, including CDK2, CDK4 and cdc25A phosphatase (Figure 5b).
Western blot analysis also showed that MUM256 EA induced reduction in cyclin B1 protein levels in
the HCT116 cells after 24, 48 and 72 h of exposure (Figure 5c).
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Figure 5. Cell-cycle arrest at G1 and G2 phase induced by MUM256 EA through modulation of cell
cycle regulatory proteins. (a) Effect of MUM256 EA on cell cycle distribution. HCT116 cells were treated
with 200 μg/mL of MUM256 EA for indicated durations (24, 48 and 72 h). Cells were harvested and
fixed with ice-cold 70% ethanol overnight. Before flow cytometric analysis, the cells were incubated
in phosphate-buffered saline (PBS) containing 25 μg/mL PI, 0.1% Triton-X-100 and 100 μg/mL RNase
A for 30 min in the dark at room temperature. The cellular DNA content was determined by flow
cytometry. Representative of histograms showing X-axis, DNA contents; y-axis, cell population (%).
Each bar represents at least three individual experiments, (* p < 0.05). (b) Real-time polymerase chain
reaction (PCR) analysis of p21, CDK2, CDK4 and cdc25A expressions in HCT116 cells treated with
200μg/mL MUM256 EA. The fold change of the gene was normalized against 18S rRNA expression
using the formula 2−ΔΔCT. Bar graph represents the comparison between treatment and control by
t-test, * p < 0.05 (n = 3). (c) The levels of p21 and cyclin B1 proteins were determined by Western
blotting. HCT116 cells were treated with DMSO and MUM256 EA at 200 μg/mL for indicated durations
and the expression of p21 and cyclin B1 were determined by Western blotting with specific antibody.
One representative Western blot of three is presented (Figure S1). Each has the expression of β-actin as
the internal control. Protein expression was quantified by the densitometry analysis using Image J and
normalized against β-actin expression. The values above each band indicate the densitometry ratio of
each protein of interest normalized against respective β-actin expression. Bar graph represents the
comparison between treatment and control by t-test, * p < 0.05 (n = 3).
2.6. Nuclear Condensation and DNA Fragmentation
Differences were observed in the nuclei of treated and untreated HCT116 after staining with
Hoechst 33258 (Figure 6a). The Hoechst 33258 dye stains morphologically normal nuclei dimly blue,
whereas treated cells demonstrate smaller nuclei with brilliant blue staining due to nuclear condensation
(yellow arrows). This result demonstrated that MUM256 EA induces morphological changes with
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characteristics of apoptotic cell death. This result is also consistent with the detection of a significantly
increased percentage of subG1 cell populations as an index of the apoptotic DNA fragmentation.
Figure 6. Apoptosis evaluation of MUM256 EA on HCT116 cells. (a) Nuclear morphology of HCT116
stained by Hoechst 33342 dye. Comparison of the nuclear morphological features of untreated and treated
HCT116 under fluorescence microscope. Arrow indicates the abnormal nuclear morphological features
(nuclear shrinkage or condensation shown by the bright-blue fluorescent and nuclear fragmentation)
resulted from the cytotoxic effect of MUM256 EA fraction, indicating sign of apoptosis. (b) Bar graph
represents the mean percentage of subG1 population ± S.D. (n = 3, * p < 0.05). (c) The apoptosis-inducing
effect of MUM256 EA fraction was examined by flow cytometric analysis using double staining of
Annexin V-FITC and PI on HCT116 cells for 24, 48 and 72 h. Quantification of early apoptosis (LR)
(Annexin V positive/PI negative) and late apoptosis (UR) (Annexin V positive/PI positive) are shown by
the representative four quadrants plot. The bar graph represents the mean percentage of population ±
S.D., (n = 3, * p < 0.05). (d) Both the early apoptotic portion and the late apoptotic portion were included
as the total apoptotic cells upon treatment for 24, 48 and 72 h. The bar graph represents the mean
percentage of apoptotic cells ± S.D, (n = 3, * p < 0.05). (e) Flow cytometry analysis of caspase-3/7 and
9 activities in HCT116 cells using a non-cytotoxic fluorescent labelled inhibitors of caspase-3/7 and 9.
HCT116 cells were treated with 200 μg/mL MUM256 EA fraction for various times as indicated, or with
DMSO as a control, then stained with FAM-DEVD-FMK or FAM-LEHD-FMK which recognizes and
binds to active caspase-3/7 or 9, respectively, before analysed by flow cytometry (BD FacVerse). The bar
graph represents the median of fluorescence intensity (MFI) of active caspase-3/7 or 9 straining in treated
cells normalized to control ± SD. (n = 3, * p < 0.05).
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MUM256 EA treatment increased the percentage of cells in the subG1 phase after treatment for 24,
48 and 72 h, respectively, as compared to control (Figure 6b). Intranucleosomal DNA fragmentation is
a major hallmark of apoptosis [36,37]. PI is a fluorescent dye that binds stoichiometrically to nucleic
acids [38]; and as fluorescence emission is proportional to DNA content of the cells, it allows the
analysis of a cell population’s replication state. Hence, cells undergoing apoptosis can be identified
from the DNA content histograms as those with lower fluorescent signal due to the low molecular
weight of DNA fragments present in these cells compared to the G1 cells [37]. These data suggest that
the reduced cell proliferation by MUM256 EA could be contributed by the induction of apoptosis.
2.7. Exposure of Phosphatidylserine
In this study, additional evidence for the occurrence of apoptosis was obtained by double staining
of the cells with propidium iodide (PI) and Annexin V-FITC. Annexin V is a protein that binds with high
affinity to phosphatidylserine (PS), which is translocated from the inner to the outer membrane leaflet
during early apoptosis. Meanwhile, the healthy cells have phosphatidylserines on the inner leaflet of
the plasma membrane. This technique is then combined with DNA binding dye (propidium iodide)
which is impenetrable to intact membrane, hence allowing for the determination of the apoptotic state
of a cell. As shown in Figure 6c, the percentage of the early apoptotic cells (PS positive and PI negative
cells) increased in response to treatment with MUM256 EA for 24, 48 and 72 h. Overall, the percentage
of apoptotic cells (PS positive cells) were increased in HCT116 cells treated with MUM256 EA for 24,
48 and 72 h (Figure 6d).
2.8. Caspase Activation
To investigate the effect of MUM256 EA in activation of caspases, flow cytometric analysis was
performed using non-cytotoxic fluorescent labelled inhibitors, FAM-DEVD-FMK and FAM-LEHD-FMK
that bind irreversibly to cysteine of the active center of caspase-3/7 or caspase-9 in the cells, respectively,
hence allowing accurate quantification of the caspase activity in the cells. The results showed that
the expression of active caspase-3/7 in HCT116 cells were significantly increased upon treatment with
MUM256 EA for 24, 48 and 72 h as demonstrated by the increased median fluorescence intensity
(MFI) (Figure 6e). Similarly, the flow-cytometric analysis demonstrated that MUM256 EA induced
an increasing trend of caspase-9 activation in HCT116 cells (Figure 6e). Thus, MUM256 EA-induced
cell death was accompanied by an increase in caspase activities, which then stimulated the molecular
cascade of apoptosis. To further validate the apoptosis inducing effect of MUM256 EA, pretreatment of
cells with either z-VAD-fmk, a broad-spectrum caspase inhibitor, or z-DEVD-fmk, a caspase-3 inhibitor,
diminished the cell death induced by MUM256 EA (Figure 7). These data suggest that the MUM256
EA-induced apoptosis involves a caspase-dependent pathway in HCT116 cells.
Figure 7. Cont.
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Figure 7. Effect of caspase inhibitors on MUM256 EA induced apoptosis in HCT116 cells. (a) Cells were
pretreated with either z-VAD-fmk (25μg/mL) or z-DEVD-fmk (25μg/mL) for 1 h, then treated as described
(Control—0.5% DMSO, with or without—200 μg/mL MUM256 EA) for 24 h. Cell viability was measured
by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, (n = 4, * p < 0.05). (b)
Morphological changes of HCT116 cells upon indicated treatments were observed by phase-contrast
microscopy (magnification ×20). Arrows indicate the treated cells with apoptotic morphology.
2.9. Mitochondrial Membrane Potential (MMP)
To determine whether the caspase-dependent apoptosis in HCT116 cells was mediated through
the mitochondrial apoptotic pathway in response to MUM256 EA treatment, the effect of MUM256
EA on the mitochondrial membrane permeability was investigated. JC-1 dye was used to assess the
mitochondrial transmembrane potential of HCT116 cells in response to the treatment with MUM256
EA. JC-1 dye exhibits variable characteristics when bound to the membrane of apoptotic cells versus
non-apoptotic cells. In non-apoptotic cells, JC-1 dye appears in aggregate form, emitting orange
fluorescence at 590 nm when bound on polarized mitochondrial membrane with high membrane
potential; but exists in monomeric form that emits green fluorescence at 527 nm in cells with disrupted
mitochondrial potential [39]. The results of flow cytometry showed that treatment of HCT116 cells
with MUM256 EA resulted in the increase of green-fluorescence-positive cells as well as the decrease
in the JC-1 orange/green ratio in treated cells, suggesting depolarization of MMP (Figure 8a). This
result suggested that the MUM256 EA induced cell apoptosis by causing the collapse of mitochondrial
transmembrane potential in HCT116 cells.
2.10. Bax Pro-Apoptotic Protein Expressions
Given that mitochondrial transmembrane permeabilization represents a process of point-of-no-
return, it is highly regulated, largely by members of the BCL-2 protein family [40]. Thus, we investigated
the effect of MUM256 EA on the expression levels of Bax—which is a member of the BCL-2 family—in
HCT116 cells. As shown in Figure 8b, RT-PCR analysis showed that treatment of HCT116 cells with
MUM256 EA led to significantly increased expression of Bax at 24, 48 and 72 h. In line with the RNA
expression result, the intracellular flow cytometry analysis showed the level of proapoptotic protein
Bax in HCT116 cells was increased significantly upon treatment with MUM256 EA for 24, 48 and
72 h. This result suggested that the overall increase in Bax expressions could be the contributor to the
mitochondrial mediated apoptosis induced by MUM256 EA in HCT116 cells.
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Figure 8. Effect of MUM256 EA on the mitochondrial membrane potential, proapoptotic protein (Bax)
and p53 status in HCT116 cells. (a) HCT116 cells were treated with MUM256 EA for indicated durations
and then were stained with JC-1 dye to detect the change of MMP by flow cytometry. Dot plots are
representative of three independent experiments. Bar graph shows the ratio of JC-1 orange/green
normalized to control, decrease in the ratio indicating MMP depolarization upon treatment, * p < 0.05
(n = 3). (b) Real-time PCR analysis of Bax expression in HCT116 cells treated with 200 μg/mL MUM256
EA fraction. The fold change of the gene was normalized against porphobilinogen deaminase (PBGD)
expression using the formula 2−ΔΔCT. Flow cytometry analysis of Bax protein expression in HCT116
cells using intracellular immunofluorescence staining method. Representative overlay of histograms
showing Bax-associated fluorescence intensity after exposure to MUM256 EA fraction at 200 μg/mL
for 24, 48 and 72 h. Bar graph represents the relative expression levels of Bax protein in treated
HCT116 cells compared to control. Values are mean percentage of cells with expressed Bax ± SD.
of three independent experiments. Asterisks indicate a significant difference compared to control
(* p < 0.05). (c) Flow cytometry analysis of p53 protein expression in HCT116 cells using intracellular
immunofluorescence staining method. Representative overlay of histograms showing p53-associated
fluorescence intensity after exposure to MUM256 EA fraction at 200 μg/mL for 24, 48 and 72 h. Relative
expression levels of p53 protein in HCT116 cells. Values are median fluorescence intensity ± SD of three
independent experiments. Asterisks indicate a significant difference compared to control (* p < 0.05).
2.11. Detection of Bioactive Constituents in Streptomyces sp. MUM256 EA Extract Using Gas
Chromatography-Mass Spectrometry
To further elucidate the potential chemical compounds that may have contributed to the antioxidant
and cytotoxic properties, gas chromatography-mass spectrometry (GC-MS) was used to detect the
chemical compounds present in MUM256 EA. GC-MS has been widely used as the analytical tool for
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molecular detection and identification in drug discovery. Numerous studies also utilized GC-MS to
profile the bioactive compounds present in the secondary metabolites of Streptomyces bacteria [41–43].
The results of GC-MS analysis revealed that MUM256 EA contains several groups of chemical
compounds, including the pyrrole, pyrazine and cyclic dipeptides. The identification of the chemical
compounds was performed by comparing their mass spectra to standard mass spectra available in
the database of NIST 05 Spectral library. Table 1 tabulates the retention time, molecular weight and
molecular formula of the chemical compounds. Figure 9a,b depicts the GC chromatogram and chemical
structures detected in MUM256 EA, respectively.












1 5-Pyrrolidino-2-pyrrolidone 54.839 C8H14N2O
Heterocyclic,
pyrrolidine 154 93.8
2 5-Isopropylidene-3,3-dimethyl-dihydrofuran-2-one 58.047 C9H14O2
Heterocyclic,
cyclic ether 154 98.2
3 Pyrrolo[1,2-a]pyrazine-1,4-dione,hexahydro-3-(2-methylpropyl)- 58.654 C11H18N2O2
Cyclic
dipeptides 210 91.6
4 4(1H)-Pyrimidinone, 6-amino-2-methyl-5-nitroso- 58.957 C5H6N4O2
Heterocyclic,
pyridine 154 95.9
5 Pyrrolidine-2-carboxamide,1-benzyloxycarbonyl-N-(4-tolyl)- 70.314 C20H22N2O3
Heterocyclic,
pyrrolidine 338 96.6
6 Pyrrolo[1,2-a]pyrazine-1,4-dione,hexahydro-3-(phenylmethyl)- 71.593 C14H16N2O2
Cyclic
dipeptides 244 99.0
Figure 9. Gas chromatography-mass spectrometry (GC-MS) analysis of MUM256 EA. (a) The GC
chromatogram of MUM256 EA. (b) The chemical structures of the detected constituents present in
MUM256 EA. The identification of the chemical compounds was performed by comparing their mass
spectra to standard mass spectra available in the database of NIST 05 Spectral library.
2.12. The Cytotoxic Effects of the Two Main Bioactive Constituents Detected by Gas Chromatography-Mass
Spectrometry (GC-MS) against HCT116 and CCD-18Co Cells
To examine the cytotoxic properties of the chemical compounds in MUM256 EA, pure Compounds
(3) and (6) were obtained and tested against HCT116 colon cancer cells and the CCD-18Co normal colon
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cells. Based on the results, Compound (6) showed stronger cytotoxic effect against HCT116 cells as
compared to Compound (3) after 72 h exposure (Figure 10a). Interestingly, both compounds were not
toxic towards the CCD-18Co cells with no significant reduction in cell viability at all the concentrations
tested after 72 h of exposure (Figure 10b), except Compound (3) reduced the cell viability of CCD-18Co
to 86% at 400 μg/mL. Both compounds also showed cytotoxic effect against another colon cancer
(HT-29 cells) (Figure S2). To investigate potential combination effects between Compounds (3) and (6),
HCT116 cells were treated with Compounds (3) and (6) at a ratio of 3:5 based on peak height shown in
the GC-MS total ion chromatogram. However, the results did not indicate any significant combined
effect of both compounds against HCT116 (Figure 10c).
Figure 10. Cytotoxic effects of the two main Compounds (3) and (6) on HCT116 and CCD-18Co
cells. (a) Cytotoxic effect of pyrrolo [1,2-a] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- (3) and
pyrrolo [1,2-a] pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)- (6) against HCT116 cells at a series of
concentrations after 72 h treatment, (n= 5, * p< 0.05). (b) The toxicity of pyrrolo [1,2-a] pyrazine-1,4-dione,
hexahydro-3-(2-methylpropyl)- (3) and pyrrolo [1,2-a]pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)-
(6) towards CCD-18Co after 72 h exposure, (n = 5, * p < 0.05). (c) The combined effect of Compounds (3)
and (6) on HCT116 at respective concentrations after 72 h treatment, (n = 5, * p < 0.5).
3. Discussion
Actinobacteria, including the genus Streptomyces, from unexplored ecosystems, such as mangrove
environments, represent a prolific source of bioactive compounds which can contribute immensely to
humans in various biotechnological and pharmaceutical applications [44–48]. The capability of these
mangrove-derived Streptomyces to produce unique secondary metabolites with interesting bioactivities
has been linked to the highly dynamic mangrove ecosystem that exerts significant influence on bacterial
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metabolic and physiological adaptations [26,49]. In the present study, Streptomyces sp. MUM256
was demonstrated to produce bioactive compounds—present in the ethyl acetate fraction of crude
extract—which exhibited promising antiproliferative activity against colon cancer cells.
In this study, MUM256 EA demonstrated the strongest cytotoxicity effects on HCT116 cells as
examined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay which
measures the mitochondrial activity in viable cells [50]. Based on the morphological changes assessed
by phase-contrast microscopy and flow cytometry, MUM256 EA is suggested to exert its cytotoxic effect
by causing the reduced viability of HCT116 through mechanisms associated to apoptotic cell death. This
is because among the predominant features of apoptotic cells were their diminished size, condensation
of chromatin, segregation of nucleoli, nuclear fragmentation and formation of apoptotic bodies [51,52],
features which we observed in treated cells. However, the decreased forward light-scatter signal is not a
specific marker of apoptosis since mechanically broken and fragmented cells, isolated cell nuclei, and
necrotic cells also have reduced light-scatter properties. Therefore, a more specific assay should be
accompanied with these observations to determine the mode of cell death.
Carcinogenesis is a result of cell-cycle disorganization, leading to uncontrolled cellular
proliferation [53]. Regulatory proteins like the cyclins, cyclin-dependent kinases (CDK) and their
substrate proteins, CDK inhibitors and tumor-suppressor genes are major proteins that control the
cell-cycle progression [54]. In tumors, these cell cycle regulators are altered, resulting in failure to
control the correct entry and progression through the cell cycles; thus agents that suppress proliferation
of cancer cells by regulating these cell cycle regulators have therapeutic value [55]. In the present study,
we demonstrated that MUM256 EA reduced the proliferation of colon cancer cells by arresting cells at
G1 and G2 phases through the modulation of cell-cycle regulatory proteins including p21, cyclin B1,
CDK2, CDK4 and cdc25A phosphatase.
CDK inhibitory protein, p21, is an essential signaling molecule in regulating the cell-cycle
progression by interacting directly with cyclin/CDK complexes. It inhibits CDK activities, which in turn
results in decreased cell proliferation. Hence, the expression of CDK inhibitory protein p21 has been
exploited in the development of chemotherapeutic drugs that disrupt carcinogenesis by impeding the
cell cycle in cancer cells [56]. Consistent with this notion, the increased p21 expression level in response
to MUM256 EA treatment was accompanied by the decreased expression levels of CDK2 and CDK4 in
HCT116 cells. CDK4 associates with cyclin D to regulate the cell-cycle progression in the G1 phase; the
cyclin D/CDK4 senses cell mitogenic signals and prompts the cells to initiate DNA synthesis [55,57].
Similarly, CDK2 associates with cyclins E/A to form complexes which activate the downstream targets,
including Rb and E2F transcription factor, hence facilitating the transition of G1 to S phase and DNA
synthesis [58]. Thus, the accumulation of HCT116 cells in G1 phase in response to MUM256 EA could
be due to the downregulation of CDK2 and CDK4 which are crucial in controlling G1/S transition and
G1 progression.
The cdc25A is found to be involved in both early G1/S and late G2/M transitions. In the regulation of
S phase entry, it activates CDK2 through its dephosphorylating action [59]. Meanwhile, overexpression
of cdc25A was also found to mediate mitosis through the regulation of G2/M transition by activating the
cyclin B1/CDK1 complexes [60,61]. Thus, we examined the expression levels of cdc25A and cyclin B1 in
HCT116 cells upon treatment with MUM256 EA. The expression of cdc25A phosphatase was reduced
in HCT116 cells upon treatment with MUM256 EA. Furthermore, a previous study demonstrated that
p21 plays an important role in mediating the degradation of cyclin B1 in response to DNA damage and
is necessary for the maintenance of G2 cell-cycle arrest in HCT116 cells [62]. Thus, the upregulation of
p21 and downregulation of cdc25A in response to MUM256 EA may be involved in the downregulation
of cyclin B1 which lead to G2/M cell-cycle arrest in HCT116 cells.
Dysregulation of the apoptotic mechanism has been associated with carcinogenesis. Therefore,
any defects along the apoptotic pathway can lead to unchecked cell proliferation, development and
progression of cancer and cancer resistance to drug therapies. Thus, apoptosis induction in cancer
cells by modulating the pro-apoptotic proteins involved in the apoptotic pathways is an effective
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strategy for cancer treatment. We demonstrated that MUM256 EA induced cell death in HCT116 via
apoptosis as shown by the increased number of Annexin-V positive cells. Furthermore, the use of
fluorescent labelled inhibitors, FAM-DEVD-FMK and FAM-LEHD-FMK and the use of caspase
inhibitors (benzoylcarbonyl-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (z-VAD-fmk)
and benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethylketone (z-DEVD-fmk)) further
confirmed the role of caspases in MUM256 EA-induced apoptosis. Activated initiator caspases cleave
and activate effector caspases, which are involved in cleavage of multiple cellular protein substrates,
resulting in triggering of apoptosis [40].
Our data showed that MUM256 EA treatment resulted in increased HCT116 cells with depolarised
MMP as compared to the untreated of HCT116 cells. The loss of mitochondrial membrane potential is
one of the hallmarks of apoptosis [63]. This result suggests that MUM256 EA-induced cell apoptosis is
mediated by mitochondrial-dependent pathways in HCT116 cells. Nevertheless, the occurrence of
mitochondrial depolarization also could be a consequence of apoptosis induced by MUM256 EA.
The apoptotic mitochondrial events are tightly regulated by the members of Bcl-2 family of
proteins [64]. As a proapoptotic protein, the active Bax functions to permeabilise the mitochondrial
outer membrane through the formation of oligomers which induce pore formation at the mitochondrial
outer membrane [65]. It is also well established that Bax accumulation causes the release of cytochrome
c from mitochondria, leading to the activation of caspase cascade [66,67]. The present findings indicate
that MUM256 EA treatment elevated both RNA and protein expression of Bax in HCT116 cells which
confirmed the involvement of intrinsic pathway of apoptosis in HCT116 cells.
Literature shows that p53 mediated G1 and G2 cell cycle arrest could also be accomplished through
transcriptional activation of its downstream targets p21, GADD45α, 14-3-3ε [68]. Our results also
support this notion that p53 activation may be involved in the cell cycle arrest in HCT116 cells mediated
by MUM256 EA-induced p21 up-regulation. Furthermore, p53 plays an important role in apoptosis via
induction of pro-apoptotic Bax protein in response to cellular stress responses. Thus, the increased p53
protein expression suggests that p53 activation may also play an important in the MUM256 EA-induced
apoptosis in HCT116 cells. Overall, these data suggest that MUM256 EA triggers sequential activation
of p53/Bax/caspase-9/caspase-3/7 cascade to induce the mitochondrial-mediated apoptotic cell death
program in HCT116 cells.
According to GC-MS analysis, several groups of chemical compounds such as pyrrole, pyrazine
and cyclic dipeptides were detected in the MUM256 EA. The chemical compounds detected in this
study also have been evidenced previously in the microbial fermentation broth/extracts, including those
isolated from Actinobacteria and the genus Streptomyces. For example, 5-pyrrolidino-2-pyrrolidone
(1) [43], pyrrolo [1,2-a] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- (3) [69,70], pyrrolo [1,2-a]
pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)- (6) [70].
Both pyrrolo [1,2-a] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- (3) and pyrrolo [1,2-a]
pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)- (6) were detected and they belong to the chemical
group of proline-containing cyclic dipeptide or 2,5-diketopiperazines (DKP). They appear to be the two
major constituents present in MUM256 EA (Figure 9a). DKP consists of a group of the simplest peptide
derivatives that are found ubiquitously in nature [71]. Numerous studies have also pointed out the
detection of these peptides in the fermentation culture of microorganisms [72–74]. Previous studies also
reported that these cyclic dipeptide compounds possess antioxidant and cytotoxic properties [75–78].
A number of previous studies also elucidated the underlying mechanism of action of pyrrolo [1,2a]
pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)- (6) in killing cancer cells [79–81]. To sum up the
results of GC-MS analysis, several chemical compounds were detected which have been noted to
have pharmacological properties by previous studies, suggesting that the anti-colon cancer properties
of MUM256 EA could be contributed by these chemical compounds. In this study, both pyrrolo
[1,2-a] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- (3) and pyrrolo [1,2a] pyrazine-1,4-dione,
hexahydro-3-(phenylmethyl)- (6) were demonstrated to inhibit the growth of HCT116 cells, indicating
that these compounds may have been responsible for the anti-colon cancer properties of MUM256 EA.
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However, the efficacy of these compounds and their combined effect was not as strong as MUM256
EA against HCT116 colon cells, and this may be due to possible interactions between Compounds (1),
(2), (4) and (5) in MUM256 EA with the cancer cells. Thus, future study should further identify and
validate the potential lead compound as well as elucidate the mechanisms underlying the cell cycle
arrest and apoptosis induction. Nonetheless, this study has shed light on the Streptomyces sp. strain
MUM256 as a promising source for bioactive compounds with anti-colon cancer activities.
4. Materials and Methods
4.1. Phylogenetic Analysis of Strain MUM256
The 16S rRNA gene of strain MUM256 (GenBank accession number KT459477) was subjected to
multiple alignment analysis using CLUSTAL-X software with representative sequences of related type
strains in genus Streptomyces [82]. The reference sequences were obtained from the GenBank/European
Molecular Biology Laboratory (EMBL)/DNA Data Bank of Japan (DDBJ) databases on 20th June 2019.
The phylogenetic tree was reconstructed according to neighbor-joining algorithm with the use of MEGA
version 6.0 software. Kimura’s two-parameter model was selected for computing the evolutionary
distances of neighbor-joining algorithm [83]. Bootstrap analysis based on 1000 resamplings method
of Felsentein was performed to evaluate the topology of the constructed phylogenetic tree [84]. The
sequence similarities were calculated based on Ezbiocloud server (http://www.ezbiocloud.net/) [85].
4.2. Fermentation and Preparation of Extracts for Bioactivities Screening
A 14-day culture of Streptomyces sp. MUM256 in TSB was used as the inoculum for fermentation
process using Han’s fermentation media 1 (HFM1) as the fermentative medium [49,86]. Fermentation
was carried out in an Erlenmeyer flask containing 200 mL of HFM1 for 7–10 days at 28 ◦C with shaking
speed at 200 rpm. The resulting HFM1 medium was subjected to centrifugation at 12,000× g for 15 min.
The supernatant was filtered and freeze-dried before proceeding to extraction with methanol. After 72 h
of extraction with methanol, the supernatant was filtered and collected. The residue was re-extracted
twice under the same conditions. A rotary vacuum evaporator was used to remove the methanol from
the crude extract at 40 ◦C, and DMSO was used to dissolve the crude extract prior to assay.
4.3. Fractionation of Methanolic Crude Extract of Streptomyces sp. MUM256
The MUM256 crude extract was subjected to sequential fractionation using selected solvents
namely hexane, ethyl acetate and water. The solid methanolic MUM256 extract was suspended and
macerated with hexane solvent. The hexane fraction was obtained after filtration through filter paper.
The residue was partitioned between equal volumes of ethyl acetate and distilled water. Both the hexane
and ethyl acetate fractions were concentrated using a rotary evaporator while the aqueous fraction
was subjected to freeze drying. The dried fractions were suspended in DMSO before further analysis.
4.4. Cell Culture
Both human colon cancer (HCT116, HT-29) and normal colon (CCD-18Co) cell lines were purchased
from American Type Culture Collection (ATCC, Virginia, VA, USA). The cells were cultured in
RPMI (Roswell Park Memorial Institute)-1640 (Gibco, Life Technologies, Gaithersburg, MD, USA)
supplemented with 10% fetal bovine serum and 1× antibiotic-antimycotic (Gibco) at 37 ◦C in a humidified
incubator containing 5% CO2 and 95% air. The cultures were viewed using an inverted microscope to
assess the degree of confluency and to ensure they were free from bacterial and fungal contamination.
4.5. Cell Viability Test Using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) Assay
The cytotoxic effect of the extract/fractions on HCT116, HT-29 and CCD-18Co cell lines were
determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [87].
The cells (5 × 103 cells/well) were seeded into 96-well plates and left to adhere overnight in
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the incubator. Streptomyces extract/fraction was added into each well in a series of concentrations
(25 to 400 μg/mL) in the presence or absence of apoptosis inhibitors (z-VAD-fmk or z-DEVD-fmk).
Pyrrolo [1,2-a] pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl)- (Henan Tianfu Chemical Co., Ltd.,
Zhengzhou, China) and pyrrolo [1,2-a] pyrazine-1,4-dione, hexahydro-3-(phenylmethyl)- (Chemieliva
Pharmaceutical Co., Ltd., Chongqing, China) were added into each well in a series of concentrations.
DMSO (0.5% (v/v)) was used as the solvent and the negative control in all the experiments. The treatment
of cells was conducted according to the indicated durations. MTT assay was performed with the addition
of 20 μL of 5 mg/mL of MTT (Sigma, Saint Louis, MO, USA) into each well and incubated at 37 ◦C in
a humid atmosphere with 5% CO2, 95% air for 4 h. The formazan crystals were dissolved in DMSO
(100 μL) after the removal of the medium. The absorbance of dissolved formazan solution was measured
spectrophotometrically at 570 nm (with 650 nm as reference wavelength) using a microplate reader.
4.6. Trypan Blue Exclusion Assay
Trypan blue was used to stain and differentiate live and dead cells. Under phase contrast
microscopy, the live cells appear colorless and bright while the dead cells stained blue after exposure
to trypan blue. The live cells were counted using a haemocytometer.
4.7. Clonogenic Survival Assay
HCT116 cells were seeded in 6-well plates at 1500 cells/well, and the indicated concentrations
of MUM256 EA were added the following day. After 24 h of treatment, the media containing the
MUM256 EA was aspirated and rinsed with phosphate-buffered saline (PBS). Fresh culture media was
added, and the cells were left for 1 week to form colonies [88]. The culture media was replaced with
fresh culture media every 2 days. Colonies were fixed in ice-cold methanol and subsequently stained
with 0.01% crystal violet in dH2O for 10 min. Excess stain was rinsed twice with dH2O and allowed to
air dry. Images of each well were taken, and the colony area was quantitated using the ‘colony area’
plugin of ImageJ software [89].
4.8. Phase Contrast Microscopy
The effect of MUM256 EA on the HCT116 cells was examined morphologically with an inverted
light microscope.
4.9. Flow Cytometry
Flow cytometric analysis was performed on a BD FACSVerseTM flow cytometer (BD Bioscience,
San Jose, CA, USA). For phenotypic characterization of cells, the cells were harvested and washed twice
with PBS after treatment. The aliquots of cell suspension were analysed according to cell size (as defined
by FSC value) and their granularity (as defined by SSC value) using the FSC/SSC dot plot diagram.
A total of 10,000 events were acquired for each sample and presented on the FSC/SSC dot plot.
4.10. Cell-Cycle Analysis Using Propidium Iodide (PI)
DNA content and cell cycle distribution were evaluated using propidium iodide (PI) staining [90].
After exposure to MUM256 EA for a designated period, the cells were harvested and washed with PBS
before being fixed with 70% ice-cold ethanol at −20 ◦C overnight. Fixed cells were washed twice and
stained in a buffer containing 25 μg/mL PI, 0.1% Triton-X-100 and 100 μg/mL RNase A for 30 min in a
dark at room temperature. The PI-stained cells were acquired up to 10,000 events and analysed using
BD FACSVerseTM flow cytometer (BD Bioscience, San Jose, CA, USA).
4.11. Quantification of Gene Expression Using Reverse-Transcription Quantitative Polymerase Chain
Reaction (PCR)
To investigate the antiproliferative and apoptotic effects of the Streptomyces sp. MUM256 EA, the
expression of genes associated with apoptosis and cell cycle regulation were examined using qPCR. After
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treatment, the total RNA from cancer cells was extracted using TRIZOL reagent. The RNA concentration
was determined by ultraviolet (UV) spectrophotometry. Reverse transcription of the extracted RNA
was performed using a commercial cDNA reverse transcription kit. Quantitative real-time PCR was
conducted in a reaction mixture containing cDNA, specific primers and SYBR Green qPCR master
mix. The following primer pair sequences were used: CDK2, 5′-GGTCCTCCACCGAGACCTTAA-3′
(forward) and 5′-CAGGGACTCCAAAAGCTCTGG-3′ (reverse); CDK4, 5′-CAGTGTACAAGGCCCGT
GATC-3′ (forward) and 5′-ACGAACTGTGCTGATGGGAAG-3′ (reverse); cdc25A, 5′-CCCCAAAGG
AACCATTGAGA-3′ (forward) and 5′-CTGATGTTTCCCAGCAACTG-3′ (reverse); p21WAF1/CIP1,
5′-GGACAGCAGAGGAAGACCATGT-3′ (forward) and 5′-GCCGTTTTCGACCCTGAGA-3′ (reverse);
18S rRNA, 5′-GGCCCTGTAATTGGAATGAGTC-3′ (forward) and 5′-CCAAGATCCAACTACGA
GCTT-3′ (reverse); Bax, 5′-GTCGCCCTTTTCTACTTTGCCAG-3′ (forward) and 5′-TCCAGCCCAACA
GCCGCTCC-3′ (reverse); PBGD, 5′-ACCATCGGAGCCATCTGCAAG-3′ (forward) and 5′-CCCACC
ACACTCTTCTCTGGCA-3′ (reverse). Primers specificity was confirmed by peak melt curve before
use. The amplification was then performed as described by Goh, et al. [91]. The RNA expression level
of the genes of interest was then analysed and normalized to the house keeping genes (18SrRNA and
PBGD) expression levels.
4.12. Western Blot Analysis
The cells were harvested and lysed in cold radioimmunoprecipitation assay (RIPA) buffer containing
protease and phosphatase inhibitors after treatment with MUM256 EA for designated periods. The total
content of protein was quantified using bicinchoninic acid (BCA) assay. Twenty-five micrograms of total
protein were loaded into 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and transferred onto a nitrocellulose membrane. The membrane was blocked with skim milk for 1 h
prior to incubation with primary antibodies (p21, cyclin B1 and β-actin, Cell Signaling Technology,
Denver, MA, USA) overnight at 4 ◦C. After substantial washing, the membrane was reacted with
anti-rabbit/mouse immunoglobulin G-horseradish peroxidase-labelled secondary antibodies for 1 h at
room temperature. The membrane was stained with enhanced chemiluminescence (ECL) detection
kit prior to detection using gel documentation system. Image J was used to analyse and quantify the
band intensities.
4.13. Hoechst 33342 Nuclear Staining
Hoechst 33342 nuclear stain was used to detect the apoptotic cells by observing the apoptotic
nuclear morphology using fluorescence microscopy. After treatment, the cells were harvested in PBS
and then exposed to 0.05 g/L Hoechst 33342 dye in PBS for 30 min at room temperature. The samples
were observed and analysed under fluorescence microscope [90].
4.14. Externalization of Phosphatidylserine Detection by Flow Cytometry
The cells were harvested after treatment with MUM256 EA. A cell suspension at a density of
1 × 106 /mL was prepared and subjected to centrifugation to obtain the cell pellet. The cell pellet was
washed with pre-cooled PBS prior to the staining with Annexin V-FITC and propidium iodide in
the 1X binding buffer [90]. After incubation at room temperature for 15 minutes in the dark, cells
were analyzed by flow cytometry. A total of 10,000 events were collected and analysed using BD
FACSVerseTM flow cytometer (BD Bioscience, San Jose, CA, USA).
4.15. Measurement of Caspases-3/7 and -9 Activities
Using Carboxyfluorescein FLICA Apoptosis Detection Kit (Immunochemistry technologies, LLC),
the caspases-3/7 and -9 activities were measured in HCT116 cells after treatment by flow cytometer.
The treated cells were harvested and incubated with 1x FAM-DEVD-FMK or FAM-LEHD-FMK reagent for
1 h at 37 ◦C. The stained cells were washed twice with washing solution before subjected to 10,000 events
acquisition and analysis by using FACSVerseTM flow cytometer (BD Bioscience, San Jose, CA, USA).
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4.16. Mitochondrial Membrane Potential Analysis
JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetrathylbenzimidazolcarbocyanine iodide) dye from BDTM
MitoScreen kit ((BD Bioscience, San Jose, CA, USA) was used to evaluate the status of mitochondrial
membrane potential of the cells. After exposure to Streptomyces sp. MUM256 EA for a designated
period, cells were harvested and washed twice before being subjected to 10,000 events acquisition and
analysis by using BD FACSVerseTM flow cytometer (BD Bioscience, San Jose, CA, USA).
4.17. Measurement of p53 and Bax Proteins by Flow Cytometry
The expression level of p53 and Bax proteins was determined by immunofluorescence staining
using flow cytometry. After the treatment with MUM256 EA, cells were washed twice with PBS, fixed
and subsequently permeabilized using Cytofix/Cytoperm™ kit (BD Biosciences, San Jose, CA, USA).
The cells were resuspended in 500 μL of fixation/permeabilization solution and incubated at 4 ◦C for
20 min. The cells were washed twice with Perm/Wash™ buffer and incubated for another 15 min in 1 mL
of Perm/Wash™ buffer. For the detection of Bax or p53 proteins, the fixed and permeabilized cells were
incubated with 100 μL of Perm/Wash™ buffer containing corresponding antibodies. Briefly, the indirect
antibodies staining was conducted by incubating the cells with mouse anti-human monoclonal antibody
(p53, Bax) (Santa Cruz, TX, USA) at 4 ◦C in the dark for 30 min. After the washing procedure, the
cells were further incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG1
(Santa Cruz, USA) at 4 ◦C in the dark for 30 min. Finally, the cells were then washed with Perm/Wash™
buffer before being subjected to 10,000 events acquisition and analysis by using FACSVerseTM flow
cytometer (BD Bioscience). FITC-conjugated normal mouse IgG1 (Santa Cruz, USA) was used as the
isotype control to differentiate non-specific background signal.
4.18. Chemical Profiling of MUM256 EA Using GC-MS
Gas chromatography-mass spectrometry (GC-MS) analysis was performed to profile the
constituents present in MUM256 EA [92]. The analysis was conducted using Agilent technologies
6980N (GC) equipped with 5979 Mass Selective Detector (MS), HP-5MS (5% phenyl methyl siloxane)
capillary column of dimensions 30.0 m × 250 μm × 0.25 μm and helium was used as the carrier gas
at 1 mL/ min. For the initial 10 min, the column was operated at 40 ºC, followed by an increase of
3 ◦C/min to 250 ◦C and was kept isothermal for 5 min. The MS was operating at 70 eV. Identification
was performed by comparing the mass spectral data of the detected constituents in MUM256 EA with
those available in the database NIST 05 Spectral library.
4.19. Statistical Analysis
All the experiments were performed at least in triplicate. The results were expressed as mean ±
standard deviation (SD) and analysed using SPSS statistical analysis software. One-way analysis of
variance (ANOVA) and Student′s t-test were performed to determine if there was a significant difference
between the treated and untreated groups. A difference was considered statistically significant when
p ≤ 0.05.
5. Conclusions
In summary, these findings show that MUM256 EA has an inhibitory effect on the proliferating
and colony-forming abilities of HCT116 cells. Our work demonstrates that MUM256 EA induced
G1 and G2/M cell-cycle arrest in HCT116 cells possibly linked to upregulation of p21 and p53 and
downregulation of cyclin B1, CDK2, CDK4 and cdc25A phosphatase. Morphological changes observed
suggest the occurrence of apoptosis in HCT116 cells upon treatment with MUM256 EA. The results
demonstrated that MUM256 EA induced apoptosis in HCT116 cells mediated through intrinsic pathway
with activation of p53, Bax, caspases-9 and -3/7. GC-MS analysis of MUM256 EA detected the presence
of cyclic dipeptides which were demonstrated to have various pharmacological properties from
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previous literature suggesting that these compounds may have contributed to the cytotoxic properties
of MUM256 EA. Furthermore, the proline-based cyclic dipeptides detected in MUM256 EA inhibited
the growth HCT116 cells while showing little to no toxicity towards CCD-18Co normal colon cells.
Taken together, these findings highlight the important role of exploring the microorganisms from the
mangrove as a bioresource, especially for proline-based cyclic dipeptides. Further characterization of
the lead compounds in this fraction may yield bioactive agents which hold tremendous promise for
the development of chemopreventive drugs, and in vivo investigation of MUM256 EA is underway.
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Abstract: Marine sponge-derived manoalide has a potent anti-inflammatory effect, but its potential
application as an anti-cancer drug has not yet been extensively investigated. The purpose of this
study is to evaluate the antiproliferative effects of manoalide on oral cancer cells. MTS assay at 24 h
showed that manoalide inhibited the proliferation of six types of oral cancer cell lines (SCC9, HSC3,
OC2, OECM-1, Ca9-22, and CAL 27) but did not affect the proliferation of normal oral cell line (human
gingival fibroblasts (HGF-1)). Manoalide also inhibits the ATP production from 3D sphere formation
of Ca9-22 and CAL 27 cells. Mechanically, manoalide induces subG1 accumulation in oral cancer cells.
Manoalide also induces more annexin V expression in oral cancer Ca9-22 and CAL 27 cells than that
of HGF-1 cells. Manoalide induces activation of caspase 3 (Cas 3), which is a hallmark of apoptosis in
oral cancer cells, Ca9-22 and CAL 27. Inhibitors of Cas 8 and Cas 9 suppress manoalide-induced Cas
3 activation. Manoalide induces higher reactive oxygen species (ROS) productions in Ca9-22 and CAL
27 cells than in HGF-1 cells. This oxidative stress induction by manoalide is further supported by
mitochondrial superoxide (MitoSOX) production and mitochondrial membrane potential (MitoMP)
destruction in oral cancer cells. Subsequently, manoalide-induced oxidative stress leads to DNA
damages, such as γH2AX and 8-oxo-2’-deoxyguanosine (8-oxodG), in oral cancer cells. Effects, such
as enhanced antiproliferation, apoptosis, oxidative stress, and DNA damage, in manoalide-treated
oral cancer cells were suppressed by inhibitors of oxidative stress or apoptosis, or both, such as
N-acetylcysteine (NAC) and Z-VAD-FMK (Z-VAD). Moreover, mitochondria-targeted superoxide
inhibitor MitoTEMPO suppresses manoalide-induced MitoSOX generation and γH2AX/8-oxodG
DNA damages. This study validates the preferential antiproliferation effect of manoalide and explores
the oxidative stress-dependent mechanisms in anti-oral cancer treatment.
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1. Introduction
Oral cancer is one of the high incidence cancers worldwide [1], especially in Southeast Asia and
Taiwan. Betel quid chewing, smoking, and alcohol consumption are high risk factors for oral cancer [2].
Oral cancer causes serious morbidity and mortality [3]. Current therapies for oral cancer patients
include surgery or chemoradiation, or both. However, chemoradiation commonly shows severe side
effects in oral cancer patients [4]. Therefore, continuous drug screening and development for oral
cancer therapy remains a challenge.
Marine natural products provide an abundant resource for development of anti-cancer agents [5–8].
Besides corals, marine sponges provide diverse sources of natural products from the ocean. Marine sponges
are marine resources with a wide range of bioactive compounds and secondary metabolites with potential
therapeutic effects [9–11]. Bioactive compounds of marine sponges and their microbial consortia are known
for their anticancer, anti-inflammatory, antiviral, and antibiotic effects [11,12].
In 1980, manoalide, an antibiotic sesterterpenoid isolated from the marine sponge Luffariella
variabilis, was discovered [13]. In 1999, manoalide was reported to function as an analgesic and
anti-inflammatory agent [14]. This anti-inflammatory effect may be caused by the inhibition of
phospholipase A2 (PLA2) by manoalide [14]. Moreover, manoalide also functions as inhibitors for
phospholipase C (PLC) [15,16] and calcium channels [17]. Manoalide reached Phase II (antipsoriatic)
clinical trial, although it was discontinued due to formulation problems [18].
In addition to anti-inflammatory effects, the anti-cancer effects of manoalide have not been
extensively studied. For example, manoalide showed a cytotoxic effect against murine lymphoma
LI210 and human epidermoid carcinoma KB cells [19]. However, the anticancer effect against oral
cancer cells was not studied as yet.
Natural products, such as marine sponges, commonly showed antioxidant properties [20,21].
Some marine sponge-derived natural products showed both cytotoxic and antioxidant activities [22–24].
Manoalide inhibits superoxide production in colon cancer cells (HT29-D4) [25], suggesting that
manoalide may have an antioxidant potential. Interestingly, antioxidants possess double-edge sword
activities to regulate cellular reactive oxygen species (ROS). For example, antioxidants at physiological
concentrations may decrease ROS and benefit cell health but induce ROS that damage cells at high
concentrations [26]. Hence, the ROS modulating effect of manoalide on oral cancer cells warrants
further investigation. Furthermore, drugs with inducing ROS generation ability may preferentially
kill cancer cells but show little damage to normal cells [27]. Whether manoalide causes a preferential
killing to oral cancer cells needs further to be examined.
In this study, we hypothesized that manoalide may preferentially inhibit the proliferation of
oral cancer cells. To examine this hypothesis, the preferential antiproliferation effect of manoalide
on oral cancer cells was studied by analyzing cell survival, cell cycle, apoptosis, oxidative stress,
and DNA damage.
2. Results
2.1. Cell Viability of Manoalide-Treated Oral Cancer and Normal Oral Cells with or Without Pretreatments of
NAC or Z-VAD
Cell viability was determined by mitochondrial enzyme activity-based MTS assay. Figure 1A
shows that manoalide dose-responsively decreases the viability (%) of oral cancer cells (CAL 27, Ca9-22,
HSC3, OECM-1, SCC9, and OC-2), but it only slightly decreases oral normal cells (human gingival
fibroblasts (HGF-1)), i.e., their IC50 values of manoalide are 7.8, 9.1, 14.9, 17.4, and 18.5 μM at 24 h MTS
assay. Among the oral cancer cells, Ca9-22 and CAL 27 cells belong to different oral locations (gingival
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and tongue) and show higher cytotoxicity upon manoalide treatment. Accordingly, Ca9-22 and CAL
27 cells were selected for the following assays to investigate the detailed mechanisms of anti-oral
cancer cells by manoalide. Figure 1B shows that 48 and 72 h treatments of manoalide dose-responsively
decrease the viability (%) of oral cancer cells, but it only slightly decreases oral normal cells (HGF-1),
i.e., the IC50 values of manoalide-treated oral cancer Ca9-22 and CAL 27 cells are 5.3 versus 14.0 μM
and 3.1 versus 7.5 μM at 48 and 72 h MTS assay, respectively. Furthermore, the photo images of 3D
sphere formation pattern of oral cancer cells are provided (Figure S1A). Its cell viability needs to be
determined by ATP detection. As shown in Figure 1C, the ATP-detected 3D sphere formation ability of
oral cancer cells (Ca9-22 and CAL 27) was decreased by manoalide treatment.
To address the role of oxidative stress and apoptosis in cell viability, the ROS scavenger
N-acetylcysteine (NAC) [28,29] and apoptosis inhibitor Z-VAD-FMK (Z-VAD) [30] were used. The cell
morphologies were abnormal in manoalide-treated oral cancer (Ca9-22 and CAL 27) cells, especially
at higher concentrations (Figure S1B). However, these manoalide-induced abnormal changes on
morphologies were recovered by NAC pretreatment and partly recovered by Z-VAD pretreatment
(Figure S1B). Moreover, manoalide-suppressed cell viabilities in oral cancer cells were completely
inhibited by a NAC pretreatment and partly inhibited by a Z-VAD pretreatment (Figure 1D).
Figure 1. Cell viabilities of oral cancer cells after manoalide treatment and its N-acetylcysteine
(NAC)/apoptosis inhibitor Z-VAD-FMK (Z-VAD) effects. Cells were treated with 0, 5, 10, and 20 μM of
manoalide. All treatments have the same concentration of DMSO. (A) MTS assay-based cell viabilities
for 24 h. Oral cancer (CAL 27, Ca9-22, OECM-1, OC-2, HSC 3, and SCC9) cells and oral normal
(HGF-1) cells were included. (B) MTS assay-based cell viabilities for 48 and 72 h for oral cancer
(CAL 27 and Ca9-22) and oral normal (HGF-1) cells. (C) Statistical of 3D spheroid formation for
manoalide-treated oral cancer (Ca9-22 and CAL 27) cells for 72 h. (D) NAC and Z-VAD effects on MTS
viability of manoalide-treated oral cancer cells. Pretreatment conditions were 8 mM, 1 h for NAC and
100 μM, 2 h for Z-VAD. Following pretreatment or not, oral cancer (Ca9-22 and CAL 27) cells were
post-incubated with 5 and 10 μM manoalide for 24 h. Data, means ± SDs (n = 3). Data were analyzed
by one-way ANOVA with Tukey HSD Post Hoc Test. Data showing the same small lettersrepresent
nonsignificant differences whereas data showing no overlapping same small letters are significant
difference (p < 0.05–0.001).
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2.2. Cell Cycle Changes of Manoalide-Treated Oral Cancer Cells with or Without Pretreatments of NAC
or Z-VAD
7-Aminoactinomycin D (7AAD) is a DNA staining dye for measuring the different cell cycle
phases. Figure S2A shows the pattern changes of cell cycle progression for oral cancer cells (Ca9-22 and
CAL 27) after manoalide treatment. The subG1 and > 4N populations appear at 10 and 20 μM of
manoalide for Ca9-22 cells and at 20 μM for CAL 27 cells. Figure 2A shows that the subG1 populations
are increased after manoalide treatment.
To address the role of oxidative stress and apoptosis in cell cycle distribution, the NAC and Z-VAD
were used. Figure S2B shows the effect of NAC and Z-VAD pretreatments on pattern of cell cycle
progression for manoalide-treated oral cancer cells and shows cell cycle disturbances (subG1 and >
4N populations). Figure 2B shows these manoalide-induced subG1 accumulations were recovered by
NAC pretreatment and partly recovered by Z-VAD pretreatment.
Figure 2. Cell cycle changes of manoalide-treated oral cancer (Ca9-22 and CAL 27) cells. (A) Statistical
results of the subG1 (%) for manoalide-treated oral cancer cells in Figure S2A. Cells were treated with
0, 5, 10, and 20 μM of manoalide for 24 h. (B) Statistical result of the subG1 (%) for NAC, Z-VAD,
and/or manoalide-treated oral cancer cells in Figure S2B. Cells were pretreated with 8 mM, 1 h for NAC
or 100 μM and 2 h for Z-VAD, and they were then post-incubated with 10 μM of manoalide for 24 h.
Data, means ± SDs (n = 3). Data were analyzed by one-way ANOVA with Tukey HSD Post Hoc Test.
Data showing no overlapping same small letters represent significant difference (p < 0.05–0.001).
2.3. Apoptosis of Manoalide-Treated Oral Cancer Cells with or Without Pretreatments of NAC or Z-VAD
Apoptosis was detected by the annexin V/7AAD method. Figure S3A shows that the populations
of oral cancer (Ca9-22 and CAL 27) cells shift from annexin V (−)/7ADD (−) to annexin V (+)/7ADD (−)
at 5 μM of manoalide and further shift to annexin V (+)/7ADD (+) at 10 and 20 μM. In contrast, normal
oral cells (HGF-1) show only a slight shift to apoptosis region. Therefore, cell populations of oral
cancer cells shift from alive, early apoptosis, to late apoptosis when the concentrations of manoalide
increase. Figure 3A shows that manoalide mainly induces early apoptosis at 5 μM, moderately
induces late apoptosis at 10 μM, and mainly induces late apoptosis at 20 μM in oral cancer cells.
However, manoalide-treated HGF-1 cells induce little apoptosis, which is undetectable at 5 and 10 μM
and is less than 15% for early apoptosis at 20 μM.
The involvement of oxidative stress in the apoptosis for manoalide-treated oral cancer cells
were further examined (Figure S3B and Figure 3B). Figure S3B shows that the populations of
manoalide-induced late apoptosis shift to early apoptosis or living status by NAC or Z-VAD
pretreatment. Figure 3B shows that NAC or Z-VAD pretreatments decrease the manoalide-induced
apoptosis for both oral cancer cells, Ca9-22 and CAL 27.
To further validate that apoptosis is induced by manoalide in oral cancer cells, western blotting
analysis was performed. Figure 3C shows that manoalide induces overexpression of cleaved forms of
caspase 3 (c-Cas 3) in both oral cancer cells, Ca9-22 and CAL 27. Figure S4A showing the procaspase
3 and c-Cas 3 patterns also supports this finding. Moreover, this manoalide-induced c-Cas 3 is
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suppressed by NAC or Z-VAD pretreatments in both oral cancer cells, Ca9-22 and CAL 27 (Figure 3D).
All the raw data for western blotting are provided (Figures S4B and S5).
To identify the initiator caspase responsible for the activation of Cas-3, the involvements of Cas
8 and Cas 9 were examined by using its inhibitors [31]. Figure S6A shows that the immunofluorescence of
c-Cas 8- and c-Cas 9-staining of manoalide-treated oral cancer cells is higher than the control. Figure S6B
shows that the populations of manoalide-induced c-Cas 3 shift to a low level by pretreatments of
Cas 8 or Cas 9 inhibitors. Figure 3E shows that Cas 8 or Cas 9 inhibitor pretreatments decrease
the manoalide-induced c-Cas 3 activation for both oral cancer cells, Ca9-22 and CAL 27, suggesting
that initiator caspase, such as both Cas 8 and Cas 9, are responsible for the c-Cas-3 activation in
manoalide-treated oral cancer cells.
Figure 3. Apoptosis changes in manoalide-treated oral cancer (Ca9-22 and CAL 27) cells and normal
oral (HGF-1) cells. (A) Statistical results of the annexin V/7AAD method in manoalide-treated oral
cancer cells and normal oral (HGF-1) cells in Figure S3A. Cells were treated with different concentrations
of manoalide for 24 h. Early and late apoptosis were, respectively, counted by the populations in the
annexin V (+)/7AAD (−) and annexin V (+)/7AAD (+) regions, i.e., Q3 and Q2. (B) Statistics results of
annexin V/7AAD method in NAC, Z-VAD, and/or manoalide-treated oral cells in Figure S3B. Cells were
pretreated with NAC (8 mM, 1 h) or Z-VAD (100 μM, 2 h), and posttreated with manoalide (10 μM,
24 h). Apoptosis was represented by the sum of early and late apoptosis, i.e., annexin V (+)/7AAD (+
or −). (C) Western blotting for detecting apoptosis in manoalide-treated oral cancer cells. (D) Western
blotting for detecting apoptosis in NAC, Z-VAD, and/or manoalide-treated oral cells. Cleaved forms
caspase 3 (c-Cas 3) were used to detect apoptosis. Actin was the internal control. (E) Statistical results of
c-Cas 3 positive levels in Cas 8 inhibitor, Cas 9 inhibitor, and/or manoalide-treated oral cells in Figure S6.
Cells were pretreated with Cas 8 inhibitor Z-IETD-FMK (100 μM, 2 h) or Cas 9 inhibitor Z-LEHD-FMK
(100 μM, 2 h), and posttreated with manoalide (10 μM, 24 h). Data were analyzed by one-way ANOVA
with Tukey HSD Post Hoc Test. Data, means ± SDs (n = 3). Data showing no overlapping same small
letters represent significant difference (p < 0.05–0.001).
2.4. ROS Production of Manoalide-Treated Oral Cancer and Normal Oral Cells
2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA) can react with ROS to generate products
for flow cytometry detection [32]. Figure S7A shows the ROS patterns of manoalide-treated oral cancer
(Ca9-22 and CAL 27) and normal oral (HGF-1) cells. Figure 4A shows that the ROS productions of
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Ca9-22 and CAL 27 cells are dramatically induced when the concentrations of manoalide increase.
In contrast, the ROS productions of HGF-1 cells stay unchanged at 5%, at less than 10 μM and slightly
increased to 25% at 20 μM.
To address the role of oxidative stress and apoptosis in manoalide-induced ROS production,
pretreatments of NAC and Z-VAD were used, and its ROS patterns were shown in Figure S7B. Figure 4B
shows that the manoalide-induced ROS productions are inhibited by NAC and Z-VAD pretreatments
for both oral cancer cells, Ca9-22 and CAL 27.
Figure 4. ROS changes in manoalide-treated oral cancer (Ca9-22 and CAL 27) and normal oral (HGF-1)
cells. Cells were treated with different concentrations of manoalide for 10 min. (A). Statistical results
of ROS (+) (%) for manoalide-treated oral cancer and oral normal cells in Figure S7A. (B) Statistical
results in NAC, Z-VAD, and/or manoalide-treated oral cells in Figure S7B. Cells were pretreated with
NAC (8 mM, 1 h) or Z-VAD (100 μM, 2 h), and posttreated with manoalide (10 μM, 10 min). Data were
analyzed by one-way ANOVA with Tukey HSD Post Hoc Test. Data, means ± SDs (n = 3). Data showing
no overlapping same small letters represent significant differences (p < 0.05–0.001).
2.5. Mitochondrial Superoxide (MitoSOX) Production of Manoalide-Treated Oral Cancer Cells with or Without
Pretreatment of MitoTEMPO
MitoSOX™ Red can react with intra-mitochondrial superoxide to generate products for flow
cytometry detection [33]. Figure S8A shows the populations of oral cancer (Ca9-22 and CAL 27) cells
shift to MitoSOX (+) region when the concentrations of manoalide increase. Figure 5A shows that the
MitoSOX production of Ca9-22 and CAL 27 cells dramatically increase. Figure S8B shows the positive
control treatment (betulinic acid; BA) [34] for MitoSOX patterns in oral cancer. Figure 5B shows that
the manoalide induces more MitoSOX productions than that of BA in Ca9-22 and CAL 27 cells.
Moreover, the involvement of MitoSOX in manoalide-treated oral cancer cells was further
validated using MitoSOX inhibitor (MitoTEMPO). Figure S8C shows the MitoSOX patterns of
MitoTEMPO pretreatment effects against manoalide-treated oral cancer cells. Figure 5C shows
that MitoTEMPO pretreatment decreases the manoalide-induced MitoSOX production for both oral
cancer cells, Ca9-22 and CAL 27.
136
Cancers 2019, 11, 1303
Figure 5. Change of mitochondrial superoxide (MitoSOX) production in manoalide-treated oral cancer
(Ca9-22 and CAL 27) cells. (A) Statistical results of MitoSOX (+) (%) for manoalide-treated oral cancer
cells in Figure S8A. Cells were treated with different concentrations of manoalide for 24 h. (B) Statistical
results of positive control of MitoSOX (+) (%) for oral cancer cells in Figure S8B. Cells were treated
with betulinic acid (BA; 25 μM, 24 h) as the positive control treatment for comparison to manoalide
(10 μM, 24 h). (C) Statistical results of MitoSOX (+) (%) in MitoSOX inhibitor (MitoTEMPO) and/or
manoalide-treated oral cells in Figure S8C. Cells were pretreated with MitoTEMPO (20 μM, 1 h) and
posttreated with manoalide (10 μM, 24 h). Data were analyzed by one-way ANOVA with Tukey HSD
Post Hoc Test. Data, means ± SDs (n = 3). Data showing no overlapping same small letters represent
significant difference (p < 0.05–0.001).
2.6. Membrane Potential (MitoMP) of Manoalide-Treated Oral Cancer Cells with or Without Pretreatments of
NAC or Z-VAD
JC-1 aggregate (red fluorescent) form can concentrate at mitochondria, and JC-1 monomer
form (green fluorescent) escape from mitochondria, reflecting the intact and depolarized MitoMP,
respectively [35]. These fluorescent signals were detected by flow cytometry. Figure S9A shows that
the populations of oral cancer (Ca9-22 and CAL 27) cells shift from JC-1 aggregates MitoMP (+) to
JC-1 monomers MitoMP (−) region when the concentrations of manoalide increase. Figure 6A shows
that the JC-1 monomers MitoMP (−) population is dose-responsively increased in manoalide-treated
oral cancer cells. Figure S9B shows the positive control treatment (betulinic acid; BA) for MitoMP
patterns in oral cancer. Figure 6B shows that the manoalide induces more JC-1 monomers MitoMP (−)
productions than that of BA in Ca9-22 and CAL 27 cells.
To address the role of oxidative stress and apoptosis in manoalide-suppressed MitoMP,
pretreatments of NAC and Z-VAD were used and its MitoMP patterns are shown in Figure S9C.
137
Cancers 2019, 11, 1303
Figure 6C shows that the manoalide-induced JC-1 monomer generations are inhibited by NAC and
Z-VAD pretreatments for both oral cancer cells, Ca9-22 and CAL 27.
Figure 6. Change of membrane potential (MitoMP) in manoalide-treated oral cancer (Ca9-22 and
CAL 27) cells. (A) Statistical results of JC-1 monomers (%) for manoalide-treated oral cancer cells in
Figure S9A. Cells were treated with different concentrations of manoalide for 24 h. High JC-1 monomers
(%) indicates low MitoMP, i.e., the MitoMP depolarization. (B) Statistical results of positive control of
low MitoMP for oral cancer cells in Figure S9B. Cells were treated with betulinic acid (BA; 25 μM, 24 h)
as the positive control treatment for comparison to manoalide (10 μM, 24 h). (C) Statistical results of
JC-1 monomers (%) for NAC, Z-VAD, and/or manoalide-treated oral cells in Figure S9C. Cells were
pretreated with NAC (8 mM, 1 h) or Z-VAD (100 μM, 2 h) and posttreated with manoalide (10 μM,
24 h). Data, means ± SDs (n = 3). Data were analyzed by one-way ANOVA with Tukey HSD Post Hoc
Test. Data showing no overlapping same small letters represent significant difference (p < 0.05–0.001).
2.7. Flow Cytometry-Based DNA Damage Changes of Manoalide-Treated Oral Cancer Cells with or Without
Pretreatments of NAC or Z-VAD
γH2AX is known as a DNA double strand break marker [36]. Figure S10A shows the populations
of oral cancer (Ca9-22 and CAL 27) cells shift to γH2AX (+) region when the concentration of
manoalide increases. Figure 7A shows that the γH2AX (+) population is dose-responsively increased
in manoalide-treated oral cancer cells. To address the role of oxidative stress and apoptosis in
manoalide-induced γH2AX, pretreatments of NAC and Z-VAD were used, and its γH2AX patterns are
shown in Figure S10B. Figure 7B shows that the manoalide-inducedγH2AX (+) (%) are inhibited by NAC
and Z-VAD pretreatments for both oral cancer cells, Ca9-22 and CAL 27. Moreover, the involvement of
MitoSOX for manoalide-induced γH2AX in oral cancer cells was further examined using MitoSOX
inhibitor (MitoTEMPO). Figure S10C shows the γH2AX patterns of MitoTEMPO pretreatment effects
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against manoalide-treated oral cancer cells. Figure 7C shows that MitoTEMPO pretreatment decreases
the manoalide-induced γH2AX (+) (%) for both oral cancer cells, Ca9-22 and CAL 27.
Figure 7. Change of γH2AX DNA damage in manoalide-treated oral cancer (Ca9-22 and CAL 27)
cells. Cells were treated with the indicated concentrations of manoalide for 24 h. (A) Statistical results
of γH2AX (+) (%) for manoalide-treated oral cancer cells in Figure S10A. (B) Statistical results of
γH2AX (+) (%) in NAC, Z-VAD, and/or manoalide-treated oral cancer cells in Figure S10B. Cells were
pretreated with 8 mM, 1 h for NAC or 100 μM, 2 h for Z-VAD, and then post-incubated with 10 μM of
manoalide for 24 h. (C) Statistical results of γH2AX (+) (%) in MitoSOX inhibitor (MitoTEMPO) and/or
manoalide-treated oral cancer cells in Figure S10C. Cells were pretreated with MitoTEMPO (20 μM,
1 h) and posttreated with manoalide (10 μM, 24 h). Data were analyzed by one-way ANOVA with
Tukey HSD Post Hoc Test. Data, means ± SDs (n = 3). Data showing no overlapping same small letters
represent significant difference (p < 0.05–0.001).
8-Oxo-2’-deoxyguanosine (8-oxodG) is one of the typical types of oxidative DNA damage [37].
Figure S11A shows the populations of oral cancer (Ca9-22 and CAL 27) cells shift to the 8-oxodG (+)
region when the concentrations of manoalide increase, while the populations of 8-oxodG (+) in normal
oral (HGF-1) cells are few. Figure 8A shows that the 8-oxodG (+) population is dose-responsively
increased in manoalide-treated oral cancer cells; however, 8-oxodG (+) was rarely appeared in normal
oral (HGF-1) cells. To address the role of oxidative stress and apoptosis in manoalide-induced 8-oxodG,
pretreatments of NAC and Z-VAD were used and its 8-oxodG patterns are shown in Figure S11B.
Figure 8B shows that the manoalide-induced 8-oxodG (+) (%) is inhibited by NAC and Z-VAD
pretreatments for both oral cancer cells, Ca9-22 and CAL 27. Moreover, the involvement of MitoSOX
for manoalide-induced 8-oxodG in oral cancer cells was further examined using MitoSOX inhibitor
(MitoTEMPO). Figure S11C shows the 8-oxodG patterns of MitoTEMPO pretreatment effects against
manoalide-treated oral cancer cells. Figure 8C shows that MitoTEMPO pretreatment decreases the
manoalide-induced 8-oxodG (+) (%) for both oral cancer cells, Ca9-22 and CAL 27.
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Figure 8. Change of 8-oxodG DNA damage in manoalide-treated oral cancer (Ca9-22 and CAL 27)
and normal oral (HGF-1) cells. Cells were treated with the indicated concentrations of manoalide for
24 h. (A) Statistical results of 8-oxodG (+) (%) for manoalide-treated oral cancer cells in Figure S11A.
(B) Statistical results of 8-oxodG (+) (%) in NAC, Z-VAD, and/or manoalide-treated oral cancer cells
in Figure S11B. Cells were pretreated with 8 mM, 1 h for NAC or 100 μM, 2 h for Z-VAD, and then
post-incubated with 10 μM of manoalide for 24 h. (C) Statistical results of 8-oxodG (+) (%) in MitoSOX
inhibitor (MitoTEMPO) and/or manoalide-treated oral cancer cells in Figure S11C. Cells were pretreated
with MitoTEMPO (20 μM, 1 h) and posttreated with manoalide (10 μM, 24 h). Data were analyzed
by one-way ANOVA with Tukey HSD Post Hoc Test. Data, means ± SDs (n = 3). Data showing no
overlapping same small letters represent significant difference (p < 0.05–0.001).
3. Discussion
The hypothesis that manoalide may preferentially inhibit the proliferation of oral cancer cells was
validated in this study. In the following, we compare the manoalide sensitivity in different cancer cells
and discuss the role of oxidative stress in preferential killing, apoptosis, and DNA damage in oral
cancer cells.
3.1. Manoalide Sensitivity in Different Cancer Cells
Manoalide showed a cytotoxic effect against human epidermoid carcinoma KB cells (IC50 =
0.725 μM) [19] without providing information for treatment time and methods. Moreover, KB cells
were reported as misidentified; these were HeLa cells, rather than oral cancer cells [38]. In the current
study, oral cancer Ca9-22, CAL 27, OECM1, OC2, and HSC3 cells, respectively, show the IC50 values of
manoalide with 7.8, 9.1, 14.9, 17.4, and 18.5 μM at 24 h MTS assay. It is noted that the drug safety for
manoalide in normal cell lines was firstly demonstrated in normal oral cells (HGF-1), which remained
healthy below 25 μM in a 24 h MTS assay. These results suggest that manoalide provides a preferentially
killing effect to oral cancer cells and shows little damage to normal oral cells.
3.2. Manoalide Induced Oxidative Stress Contributes to Preferential Killing Against Oral Cancer Cells
Both 2,2-azinobis (3-ethyl-benzothiazoline-6-sulfonic acid) (ABTS) and hydroxyl scavenging
activities of manoalide showed IC50 values for 14.3 and 18 μM (Figure S12), suggesting that manoalide
causes the antioxidant abilities. Recently, antioxidants were reported to display dual concentration
effects [26,39], i.e., low and high concentrations, respectively, decrease and increase intracellular ROS
levels. Similarly, we found that manoalide differentially induced ROS production between oral cancer
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cells and normal oral cells, i.e., manoalide induces higher ROS production in oral cancer cells than in
normal oral cells (Figure 4). Moreover, manoalide also induces other types of oxidative stresses, such
as MitoSOX production and MitoMP depolarization (Figures 5 and 6). Using NAC or MitoTEMPO
pretreatments, oxidative stresses, such as ROS generation (Figure 4B), MitoSOX production (Figure 5C),
and MitoMP depolarization (Figure 6C), as well as antiproliferation, were suppressed (Figure 1D).
Therefore, the preferential killing effect of manoalide is oxidative stress-dependent in oral cancer cells.
This finding also supports the rationale that ROS-modulating drugs provided preferential killing effects
against several types of cancer cells [27,40,41].
Manoalide displays a preferential killing against oral cancer cells with little damage to normal
oral cells. Similarly, betulinic acid (BA) selectively inhibits proliferation against a number of cancer
cells but not on normal cells (peripheral blood lymphoblast) [42,43], and therefore BA was chosen
as a positive control. Like manoalide, BA induces ROS generation, apoptosis, and proliferation,
and these effects are suppressed by NAC treatment [34]. As shown in Figures 5B and 6B, manoalide
induces more MitoSOX generation and MitoMP depletion (JC-1 monomers generation) than that of BA,
suggesting that manoalide is an effective oxidative stress inducer compared to BA in oral cancer cells.
The anticancer effect of BA was independent on p53 mutant or wild types [42,43]. In the current study,
all oral cancer cell lines harboring mutant p53 [44,45] and the role of p53 status warrants detailed
investigation in future.
3.3. Manoalide Induced Oxidative stress Contributes to Apoptosis and DNA Damage Against Oral
Cancer Cells
ROS-modulating drugs commonly induce apoptosis [29,40,41,46–49]. This is indicated by NAC
and Z-VAD as apoptosis inhibitors. In our study, both show the suppressing effect on manoalide-induces
subG1 accumulation and apoptosis (Figures 2B and 3B), suggesting that oxidative stress plays a vital
role in manoalide-induced apoptosis. Additionally, we found that Cas 8 and Cas 9 inhibitors suppressed
the manoalide-induced c-Cas 3 activation using flow cytometry (Figure 3E). Accordingly, the role of
extrinsic and intrinsic apoptosis may be involved in manoalide-induced apoptosis, and it warrants
detailed investigation in future.
It is noted that apoptosis inhibitor Z-VAD cannot completely recover the manoalide-induced
antiproliferation against oral cancer cells. Half and one-third of cell viabilities for Ca9-22 and CAL
27 cells were unable to be recovered (Figure 1D). These results suggest that apoptosis cannot completely
attribute to antiproliferation effects of manoalide-treated oral cancer cells. Detailed studies of the
involvement of other non-apoptosis mechanisms after manoalide treatment are warranted.
Moreover, oxidative stress is a high risk factor for inducing DNA damage [41,47].
Consistently, DNA double strand breaks (γH2AX) and oxidative DNA damage (8-oxodG) were induced
in oral cancer cells upon manoalide exposure. Both γH2AX and 8-oxodG levels in manoalide-treated
oral cancer cells were suppressed by NAC pretreatments (Figures 7B and 8B). DNA damage also has a
potential to induce apoptosis [50]. Accordingly, oxidative stress may induce DNA damage and lead to
apoptosis. It is noted that the manoalide-induced γH2AX/8-oxodG expressions (Figures 7B and 8B)
and ROS production (Figure 4B) were also suppressed by Z-VAD pretreatments, suggesting that
apoptosis may crosstalk to DNA damage in addition to oxidative stress.
It was reported that superoxide anion, such as MitoSOX, cannot cross the mitochondrial
membrane [51]. However, we found that manoalide-induced MitoSOX generation andγH2AX/8-oxodG
expressions (Figures 7C and 8C) were suppressed by MitoTEMPO pretreatment. Since MitoTEMPO is
the mitochondria-targeted superoxide inhibitor [52], the role of MitoSOX on DNA damage is explored
by MitoTEMPO pretreatment. Our finding suggests that MitoSOX may directly or indirectly induce
DNA double strand breaks and oxidative DNA damage. Accordingly, the validation and mechanism of
MitoSOX-induced DNA damage warrants detailed investigation in future. Therefore, both intracellular
ROS and mitochondrial superoxide (MitoSOX) may contribute to the manoalide-induced DNA damage
in oral cancer cells.
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The possible mechanism for preferential killing of manoalide against oral cancer cells but less
damage to normal oral cells is discussed as follows. In HGF-1 cells, the ROS production is few
(Figure 4A), leads to fewer annexin V-detected apoptosis (Figure 3A) and 8-oxodG DNA damage
(Figure 8A) than that of oral cancer cells, and causes the oral cancer cell death but keeps normal oral
cells alive.
3.4. Potential Target Molecules of Manoalide
Manoalide is known as an irreversible inhibitor for PLC [16] and PLA2 [53], as well as calcium
channel blockers (CCBs) [17]. PLC inhibitors, such as U73122, were reported to induce apoptosis
of human umbilical vein endothelial cells (HUVEC) [54]. PLA2 inhibitors, such as quercetin, were
also summarized to inhibit inflammation and cancer proliferation [55]. CCBs, such as verapamil and
diltiazem, have been reviewed for antiproliferation against several types of cancer cells in vitro and
in vivo [56]. Accordingly, PLC, PLA2, and CCBs are the potential targets for manoalide. It warrants
detailed investigation to explore the role of these potential targets between oral cancer and normal oral
cells in future.
4. Materials and Methods
4.1. Cell and Drug Information
All human oral cancer cell lines (Ca9-22, CAL 27, HSC-3, OC-2, and SCC-9) and a normal oral cell
line (HGF-1) were used from Health Science Research Resources Bank (HSRRB) (Osaka, Japan) and
American Type Culture Collection (ATCC; Manassas, VA, USA) except for OECM1 [57], a generous gift
from Dr. Wan-Chi Tsai (Kaohsiung Medical University, Taiwan). Cells were cultured in 5% CO2 at 37
◦C with humidity and maintained by regular formula (Gibco, Grand Island, NY, USA) with 10% fetal
bovine serum as previously described [49].
Manoalide (CAYMAN CHEMICAL, Ann Arbor, MI, USA) was dissolved in dimethyl sulfoxide
(DMSO) for treatment. A ROS scavenger N-acetylcysteine (NAC) [58] (Sigma-Aldrich; St. Louis, MO,
USA) was dissolved in double distilled water. The mitochondrial superoxide inhibitor MitoTEMPO [59]
(Cayman Chemical, Ann Arbor, MI, USA), panapoptosis inhibitor Z-VAD-FMK [60], Cas 8 inhibitor
Z-IETD-FMK, and Cas 9 inhibitor Z-LEHD-FMK (Selleckchem.com; Houston, TX, USA) was dissolved
in DMSO. All experiments contain the same concentration of DMSO.
4.2. Cell Viability Assay
After drug treatment, the mitochondrial activity-based cell viability was determined by MTS assay
(CellTiter 96 Aqueous One Solution, Promega, Madison, WI, USA) at 24 h [61], and the 3D microtissue
spheroids viability of oral cancer cells was measured by the CellTiter-Glo® 3D Cell Viability Assay
(Promega, Madison, WI, USA) coupling with ATP level detection at 72 h [62].
4.3. Cell Cycle Assay
7AAD (Biotium, Inc., Hayward, CA, USA), a DNA dye, was applied to cell cycle analysis [63].
Briefly, drugs-treated cells were stained with 7AAD (1 μg/mL, 37 ◦C, 30 min). Finally, the cell cycle
change was analyzed by Accuri™ C6 flow cytometry (Becton-Dickinson, Mansfield, MA, USA).
4.4. Annexin V/7AAD Assay for Apoptosis
Annexin V (Strong Biotech Corporation, Taipei, Taiwan) coupled with 7AAD was used for apoptosis
analysis [64]. Briefly, drugs-treated cells were incubated with the mixture of annexin V-fluorescein
isothiocyanate (FITC) (10 μg/mL) and 7AAD (1 μg/mL) at 37 ◦C for 30 min. Finally, the apoptosis
expression was analyzed by Accuri™ C6 flow cytometry.
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4.5. Western Blotting and c-Cas 3-Based Flow Cytometry for Apoptosis
Detailed steps of western blotting were previously described [60]. Briefly, the primary apoptosis
antibodies (diluted 1:1000) including cleaved caspase-3 (c-Cas 3) rabbit mAb (Cell Signaling Technology,
Inc., Danvers, MA, USA) were used. The internal control primary antibody (diluted 1:5000) was
mAb-β-actin (Sigma-Aldrich, St. Louis, MO, USA). Following secondary antibody treatment, these
protein signals were detected using enhanced chemiluminescence (ECL) substrate (WesternBright™
ECL HRP, Advansta, Menlo Park, CA, USA).
For c-Cas 3-based flow cytometry, cells were fixed with 70% ethanol, washed, and incubated
with 1 μg/mL of c-Cas 3 (Asp175) rabbit mAb (Cell Signaling Technology) at 4 ◦C for overnight.
After washing, cells were incubated with a secondary polyclonal antibody conjugated with Alexa
Fluor 488 (ThermoFisher Scientific, San Jose, CA, USA) at room temperature for 1 h. Finally, the c-Cas
3 expression was analyzed by Accuri™ C6 flow cytometry. Cas 8 inhibitor Z-IETD-FMK (100 μM, 2 h)
or Cas 9 inhibitor Z-LEHD-FMK (100 μM, 2 h) were applied to examine the involvement of Cas 8 and
Cas 9 in apoptosis.
4.6. ROS Assay
DCFH-DA (Sigma-Aldrich; St. Louis, MO, USA) was used for ROS detecting dye [32].
Briefly, drugs-treated cells were incubated with DCFH-DA reagent (10 μM, 37 ◦C, 30 min).
Finally, the ROS level was analyzed by Accuri™ C6 flow cytometry.
4.7. MitoSOX Assay
MitoSOX™ Red (Molecular Probes, Invitrogen, Eugene, OR, USA) was used as mitochondrial
superoxide detecting dye [33]. Briefly, drugs-treated cells were incubated with MitoSOX reagent [48,49]
(5 μM, 37 ◦C, 30 min). Finally, the MitoSOX level was analyzed by Accuri™ C6 flow cytometry.
4.8. MitoMP Assay
JC-1 (Merckmillipore) was used to detect mitochondrial membrane potential (MitoMP).
JC-1 aggregate form generated red fluorescence indicating the normal function for MitoMP [35].
In contrast, JC-1 monomer form generated green fluorescence, indicating the dysfunction for MitoMP.
Therefore, green fluorescent signals were counted as the decrease of MitoMP. Briefly, drugs-treated cells
were treated with JC-1 (0.1 mM, 37 ◦C, 30 min). Finally, the MitoMP level was analyzed by Accuri™
C6 flow cytometry.
4.9. γH2AX Assay
DNA double strand break marker (γH2AX) was detected by antibody-based flow cytometry [40].
Briefly, drugs-treated cells were incubated with mouse primary antibody p-Histone H2A.X (Ser 139)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) (1:100 dilution, 4 ◦C, 1 h) and washed for incubation
with the secondary antibody-labeled with Alexa Fluor 488 (Cell Signaling Technology) (1:10000 dilution,
4 ◦C, 1 h). Finally, the γH2AX level was analyzed by Accuri™ C6 flow cytometry.
4.10. 8-oxodG Assay
8-oxodG was detected by antibody-based flow cytometry using a fluorometric OxyDNA assay kit
(#500095; EMD Millipore, Darmstadt, Germany) [65,66]. Briefly, drugs-treated cells were incubated
in antibody-labeled with FITC (10× dilution, 4 ◦C, 1 h). Finally, the 8-oxodG level was analyzed by
Accuri™ C6 flow cytometry.
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4.11. Statistical Analysis
Using JMP® 12 software, the significance of multiple comparisons between different treatments
were analyzed by one-way ANOVA with Tukey HSD Post Hoc Test. Data showing no overlapping
same small letters represent significant difference.
5. Conclusions
This study confirmed the hypothesis that manoalide may preferentially inhibit the proliferation of
oral cancer cells. We found several types of results supporting that oxidative stresses were induced by
manoalide. The oxidative stresses, such as intracellular ROS and MitoSOX/MitoMP, were also involved
in manoalide-induced apoptosis and DNA damages in oral cancer cells. Finally, these mechanisms
may contribute to preferentially inhibit the proliferation of oral cancer cells (Figure 9). Taken together,
this study firstly shows that manoalide preferentially kills oral cancer cells without cytotoxic side
effects to normal oral cells.
Figure 9. Expected mechanism of manoalide-induced preferential antiproliferation on oral cancer
cells. Manoalide may preferentially kill oral cancer cells by inducing oxidative stress, such as ROS
and MitoSOX productions, as well as MitoMP depolarization. These oxidative stresses may induce
DNA double strand break damage and oxidative DNA 8-oxodG DNA damage. DNA damage may
induce apoptosis and inhibit proliferation [67]. Finally, these oxidative stress and DNA damage
changes cooperate to induce apoptosis [50] and lead to preferential antiproliferation of oral cancer
cells. Additionally, apoptosis may also regulate DNA damage and oxidative stress. Solid lines (arrow
and T) indicate the activating and inhibiting results from this study, whereas dashed lines indicate the
mechanism is supported by literature.
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Abstract: Epidemiological studies suggest that chronic alcohol consumption is a lifestyle risk factor
strongly associated with colorectal cancer development and progression. The aim of the present
study was to examine the effect of ethanol (EtOH) on survival and progression of three different
colon cancer cell lines (HCT116, HT29, and Caco-2). Our data showed that EtOH induces oxidative
and endoplasmic reticulum (ER) stress, as demonstrated by reactive oxygen species (ROS) and ER
stress markers Grp78, ATF6, PERK and, CHOP increase. Moreover, EtOH triggers an autophagic
response which is accompanied by the upregulation of beclin, LC3-II, ATG7, and p62 proteins.
The addition of the antioxidant N-acetylcysteine significantly prevents autophagy, suggesting
that autophagy is triggered by oxidative stress as a prosurvival response. EtOH treatment also
upregulates the antioxidant enzymes SOD, catalase, and heme oxygenase (HO-1) and promotes
the nuclear translocation of both Nrf2 and HO-1. Interestingly, EtOH also upregulates the levels of
matrix metalloproteases (MMP2 and MMP9) and VEGF. Nrf2 silencing or preventing HO-1 nuclear
translocation by the protease inhibitor E64d abrogates the EtOH-induced increase in the antioxidant
enzyme levels as well as the migration markers. Taken together, our results suggest that EtOH
mediates both the activation of Nrf2 and HO-1 to sustain colon cancer cell survival, thus leading to
the acquisition of a more aggressive phenotype.
Keywords: colon cancer cells; ethanol; Nrf2; HO-1; ER stress; autophagy; MMPs
1. Introduction
Colorectal cancer (CRC) is one of the most widespread cancers in the world [1]. Epidemiological data
show the highest incidence of this tumor in countries characterized by high indices of development, such as
Cancers 2019, 11, 505; doi:10.3390/cancers11040505 www.mdpi.com/journal/cancers149
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Australia, Europe, and North America [2]. This geographic variability has been linked to differences in
environment and lifestyle [2]. Numerous risk factors have been correlated with the development of CRC,
including genetic factors, inflammation, intestinal microflora composition, as well as harmful lifestyle
habits, such as smoking, high consumption of red meats, and alcohol intake [3].
Chronic and heavy alcohol consumption, a common lifestyle habit of developed countries,
has been associated with an increased risk of developing gastrointestinal cancers, including CRC [4,5].
The association between alcohol drinking and CRC is dose-dependent. A recent meta-analysis of
literature from 1996 to 2013 shows that compared with non-occasional drinkers, the relative risk
was 0.97 for subjects who drink low doses of ethanol (≤12.5 g/day), 1.04 for moderate drinkers
(12.6–49.9 g/day), and 1.21 for heavy drinkers (≥50 g/day) [6]. Alcohol’s influence can also vary based
on individual differences in enzymes involved in alcohol metabolism. For example, the presence of
ADH1B [7] or ADH1C*1—two polymorphisms of alcohol dehydrogenase (ADH)—has been associated
with an increased risk of CRC [8]. In addition to act as a risk factor for carcinogenesis, many studies
indicate that chronic alcohol consumption also promotes colon tumor progression [6–9].
The mechanisms proposed to explain the role of alcohol in CRC promotion include acetaldehyde
mutagenic effects, oxidative stress increase, and folic acid deficiency [10,11]. Acetaldehyde, which is
produced by ADH, cytochrome P450 2E1 (CYP2E1), or catalase, is considered the most potent carcinogenic
metabolite of ethanol [12]. It is highly reactive and mutagenic by forming protein and DNA adducts,
which result in DNA mutations and reactive oxygen species (ROS) production [10]. In addition to
acetaldehyde, ROS have been also shown to contribute to colon carcinogenesis [13]. In alcoholics, ROS are
predominantly generated through CYP2E1, which is induced by chronic alcohol consumption in the mucosa
of the esophagus and colon [14]. CYP2E1-induced ROS production has been correlated with the generation
of lipid peroxidation products, such as 4-hydroxynonenal and malondialdehyde. These compounds can
bind to DNA forming etheno-DNA adducts which are highly carcinogenic [14,15].
It is well known that chronic inflammation also promotes colorectal cancer carcinogenesis.
To this regard, it has been reported that the persistent exposure of enterocytes to an inflammatory
environment induces molecular alterations favoring tumor development [16]. However, following
chronic inflammation epithelial cells can activate adaptive mechanisms to reduce the deleterious
action of oxidative stress and survival [17]. The major mechanism by which cancer cells increase their
antioxidant proteins is through the activation of nuclear factor erythroid 2-related factor 2 (Nrf2),
a transcription factor involved in the transcription of antioxidant and detoxifying factors in response
to oxidative stress [18,19]. Nrf2 is normally sequestered in the cytoplasm in an inactive complex
with kelch-like ECH-associated protein 1 (Keap1). ROS induce oxidation of critical cysteines of
Keap1 and its dissociation from Nrf2 [20]. This event allows Nrf2 to migrate into the nucleus and form
transcriptionally active complexes with other proteins, such as Mafs (musculoaponeurotic fibrosarcoma
proteins). Such molecular cascades lead to the increase in the transcription of cytoprotective and
antioxidant genes, such as superoxide dismutase (SOD), catalase, and heme oxygenase (HO-1),
thus favoring cancer cell survival [21]. In addition, previous reports showed that Nrf2, beyond
its antioxidant role, also exhibits a protumorigenic activity promoting proliferation and sustaining
migration and invasiveness of cancer cells [22]. To this regard, overexpression of Nrf2 has been
reported in colon cancer cells and has been related with tumor progression and poor prognosis [23].
Similarly, HO-1, the main target of Nrf2, can also exert a double role in cancer [24,25]. In fact,
HO-1 may counteract ROS-mediated carcinogenesis by favoring heme breakdown into biliverdin;
however, its overexpression has been shown to provide tumor cells with a more aggressive
survival phenotype [26]. Finally, under oxidative stress conditions HO-1 translocates into the
nucleus, where it interacts with Nrf2 preventing its GSK3β-mediated phosphorylation coupled with
ubiquitin–proteasomal degradation, thereby prolonging Nrf2 nuclear accumulation [27].
The aim of the present research was to evaluate the role of Nrf2/HO-1 axis in promoting colon
cancer survival and progression under ethanol stimulation. Our data suggest that ethanol induces both
Nrf2 and HO-1 nuclear translocation in response to oxidative and endoplasmic reticulum (ER) stress
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activation and that this event confers resistance to oxidative stress and contributes to the acquisition of
a more invasive phenotype.
2. Results
2.1. Effects of Ethanol in Colon Cancer Cell Viability
To evaluate the effect of ethanol (EtOH) on colon cancer cells, different colon cancer cell
lines (HCT116, HT29, and Caco-2 cells) were exposed to a range of EtOH concentrations (30–300
mM) for different durations. Then, the viability was assessed by 3-(4,5-dimethyl- thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay which evaluates the mitochondrial dehydrogenase activity,
as reported in methods. As shown in Figure 1A, compared with untreated cells, EtOH, also at high
doses, displayed a scarce effect on cell viability at 72 h of treatment, but slightly reduced cell viability
at 24 and 48 h, in particular in HT29 and Caco-2 cells. Our data also demonstrated that staining the
cells with propidium iodide (PI), a membrane impermeant dye that is generally excluded from viable
cells, evidenced that EtOH treatment did not induce cell death in this condition, in which we observed
a reduction of cell viability. Thus, the reduced viability assessed by MTT assay in EtOH-treated cells
for 24 or 48 h could be due to cell proliferation arrest or reduced metabolic activity of cells.
Figure 1. Ethanol effect on colon cancer cell viability and colony generation ability. (A) HCT116, HT29,
and Caco-2 cells (7 × 103) were incubated in the presence of various doses of EtOH (30–300 mM) for the
indicated times. Cell viability was assessed by 3-(4,5-dimethyl- thiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay and expressed as the percentage of the viable control cells in untreated cultures.
Values are the means of three independent experiments ± S.E. (*) p < 0.05 compared to the control.
(B) The clonogenic assay was performed seeding a single cell suspension (200 cells/well) in 6-well plate
and after 48 h treating it with different doses of EtOH. Clonogenic ability was evaluated after 14 days.
Photographic images of cells after staining with crystal violet were reported. Results are representative
of three independent experiments.
Morphological observations of cells confirmed the absence of cytotoxicity in all the conditions
tested also prolonging EtOH treatment (1 week), leading to the conclusion that colon cancer cells
survive even under treatment with high doses of ethanol.
To explore the ability of EtOH to counteract the production of colonies, HCT116 cells were plated
with or without the addition of different doses of EtOH, and maintained in culture for additional 14 days
to allow the formation of colonies. The results demonstrated no significant difference between control and
EtOH-treated cells (Figure 1B), thus suggesting that the compound does not affect colony formation.
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To evaluate the biochemical mechanisms linking high doses of alcohol consumption and
colon cancer progression, the next experiments were performed using100 mM and 300 mM EtOH,
two different high concentrations of alcohol.
2.2. Ethanol Treatment Induces Oxidative Stress in Colon Cancer Cells
EtOH metabolism produces acetaldehyde and reactive oxygen species (ROS), which have been
correlated with the toxic effects of the compound [28]. To ascertain ROS generation in our model
system, we performed fluorescence microscopy analysis by employing the fluorochrome H2DCFDA—a
general indicator of intracellular ROS levels. As shown in Figure 2A, EtOH treatment rapidly increases
the number of green fluorescent cells, which are indicative of intracellular ROS production. The effect
appears at 10 min of exposure to EtOH, then rapidly decreases with the time of treatment.
Figure 2. Ethanol induces oxidative and ER stress in colon cancer cells. (A) HCT116 cells (7 × 103)
were treated with 300 mM EtOH for the indicated times. Reactive oxygen species (ROS) production
was assayed by H2DCFDA staining. Images were taken by a Leica DC300F microscope (200× original
magnification) using a FITC filter. Results are representative of three independent experiments. (B,C)
Cells (1 × 105) were treated with 100 or 300 mMEtOH for the indicated times. Cell lysates (30 μg) were
analyzed by Western blotting for COX2, iNOS, Hsp90, and Hsp60 (B) or Grp78, CHOP, ATF6 and its
fragmented form (ATF6f) and PERK (C). Densitometric analysis of bands was carried out as reported
in Material and Methods and data were normalized to β-actin expression. Results are from three
independent experiments and statistical significance was determined using one-way ANOVA followed
by Bonferroni’s test. (*) p < 0.05 and (**) p < 0.01 compared to the untreated sample.
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Cyclooxygenase 2 (COX2) and inducible nitric oxide synthase (iNOS) are two important enzymes
expressed in response to a variety of stimuli that mediate inflammatory processes and tumor
progression [29]. Western blotting analysis shows that COX2 and iNOS proteins are significantly
up-regulated in EtOH-treated HCT116 cells. In particular, treatment for 3 h with 300 mM EtOH
increases the levels of the enzymes respect to untreated control by 2.7 and 2.2 fold, respectively
(Figure 2B, p < 0.05).
Moreover, we evaluated the effect of EtOH on the levels of Hsp90 and Hsp60, two heat shock
proteins induced by cellular stress [30,31]. As shown in Figure 2B, the exposure to 100 and 300 mM
EtOH for 3 h induces a significant increase of both Hsp90 and Hsp60 compared to the untreated
condition (p < 0.05).
2.3. Ethanol Treatment Induces ER Stress in Colon Cancer Cells
Oxidative stress can be responsible for accumulation of unfolded-proteins and induction of ER
stress [32]. To explore the ability of EtOH to activate ER stress in colon cancer cells, we analyzed
the levels of glucose-regulated protein of 78 kDa (GRP78), which is a chaperone interacting with
misfolded proteins and an indicator of ER stress, and CCAAT/enhancer-binding protein homologous
protein (CHOP), a transcriptional factor which promotes apoptosis under prolonged ER stress [32].
Data reported in Figure 2C show that, in HCT116 cells, EtOH significantly upregulates the levels of
Grp78 after 24 h (p < 0.05). In addition, EtOH upregulates CHOP level already after 3 h. After 24 h its
level remains higher (2.2-fold, p < 0.05) in 100 mM EtOH-treated cells than untreated ones, while it
lowers (0.8-fold) in cells exposed to 300 mM EtOH (Figure 2C). EtOH increases the levels of ER stress
markers also in HT29 and Caco-2 cells, although the effects were observed after a prolonged time of
treatment (24 h) (Figure S1).
We then evaluated the activation of ATF6 and PERK, two unfolding protein response (UPR)
sensors which promotes adaptive signal transduction under ER stress [32]. When unfolded proteins
increase, the full-length ATF6 is cleaved at Golgi into an active fragment (ATF6f), which migrates into
the nucleus upregulating the expression of chaperones, including GRP78 and CHOP [32]. Treatment of
HCT116 cells with EtOH decreases the ATF6 full-length protein at 3 h and concomitantly increases
that of ATF6f, suggesting the activation of the factor. These effects are not observed at 24 h of
EtOH treatment (Figure 2C). Moreover, EtOH treatment also promotes an early PERK increase that
significantly (p < 0.05) occurs already at 3 h of treatment (Figure 2C).
2.4. Ethanol Stimulates A Prosurvival Effect Sustained by An Autophagic Flux In Colon Cancer Cells
Under ER stress condition, autophagy can be activated to degrade unfolded/aggregated proteins
in order to maintain cell survival [33,34]. To assess whether this process occurs in our system model,
the presence of autophagic vacuoles was evaluated using fluorescence microscopy by staining the cells
with monodansylcadaverine (MDC). As Figure 3A shows, dot-likes structures appear in the cytoplasm
of EtOH-treated HCT116 cells. MDC-positive fluorescent cells are already observed after 24 h of
treatment with both 100 and 300 mM ethanol. The addition of the antioxidant N-acetylcysteine (NAC)
to EtOH-treated cells markedly reduces the presence of autophagic vacuoles (Figure 3A), suggesting
that autophagy is activated in response to oxidative stress as a prosurvival mechanism.
Then, we analyzed the levels of the autophagic markers by western blotting (Figure 3B).
Microtubule-associated protein light chain 3 (LC3) can be present in two different forms: a cytosolic
form (LC3-I) and an active lipidated form (LC3-II) [35], which is bound to the autophagosome
membrane [36]. As shown in Figure 3B, in HCT116 cells EtOH treatment favors the conversion
of LC3-I to LC3-II.
In addition to LC3, the level of beclin—a protein which plays an essential role in autophagosome
formation—was evaluated. Data reported in Figure 3B demonstrate that beclin protein level is
significantly higher after 3 h of treatment with 300 mMEtOH compared to untreated control (p < 0.05).
The level remains elevated after 24 h.
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Figure 3. Ethanol induces autophagy in HCT116 cells. (A) HCT116 cells (7 × 103) were treated with 100
or 300 mMEtOH for 24 h in the presence or absence of 2 mM NAC. Autophagic vacuoles production
was assayed by MDC staining under a Leica DC300F microscope (400× original magnification) using a
DAPI filter. Results are representative of three independent experiments. (B) Western blotting analysis
of LC3, beclin, ATG7, and p62 in HCT116 cells treated for the indicated times with 100 or 300 mM
EtOH. Quantitative estimations of the protein levels were determined by densitometry measurements
of Western blotting from three independent experiments after normalization with β-actin. (*) p < 0.05
compared to the untreated sample.
Moreover, EtOH treatment increases the level of ATG7, an essential regulator of autophagosome
assembly [37]. As shown in the same Figure 3B, ATG7 level significantly (p < 0.05) increased after 24 h
treatment with 100 mM EtOH with respect to the untreated sample (Figure 3B).
Finally, we also examined the level of p62, a multifunctional protein considered as a marker of
autophagic flux. p62 is localized to the autophagosome via LC3 interaction and is constantly degraded
by the autophagy–lysosome system [38]. The analysis of p62 shows that EtOH increases the content of
this protein at 3 h of treatment, while its level lowers after 24 h (Figure 3B), thereby suggesting that
HCT116 cells treated with ethanol undergo to a complete autophagic process.
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2.5. Ethanol Activates Nrf2-Dependent Antioxidant Pathway
Despite the activation of oxidative and ER stress by EtOH, MTT cell viability and clonogenic
assay, reported in Figure 1, show that colon cancer cells survive even after prolonged treatment with
high doses of EtOH, thus suggesting the activation of an antioxidant response.
Nrf2 is one of the major transcription factors that promotes cellular defense against oxidative
stress. Nrf2 is maintained in an inactive cytosolic complex with Keap1 [39]. Our data show that Nrf2
level is enhanced in HCT116 cells treated with EtOH. In fact, in comparison with control cells the
level of Nrf2 protein increases with 300 mM EtOH approximately by 1.5-fold (p < 0.05) after 3 h of
treatment (Figure 4). Data reported in the same Figure 4, also demonstrate that the increase of Nrf2 is
accompanied by a significant decrease of Keap1 in cells treated for 3 h with 300 mM EtOH compared
to untreated control (p < 0.05).
Figure 4. Effects of ethanol on Nrf2-dependent antioxidant pathway in HCT116 cells. Cells (1 × 105)
were incubated in the presence of various doses of EtOH for different periods. The levels of Nrf2,
Keap1, MnSOD, catalase, and HO-1 were assessed by Western blotting analysis. Immunoblot was
quantified by densitometry and normalized against β-actin expression. Results are from three
independent experiments and statistical significance was determined using one-way ANOVA followed
by Bonferroni’s test. (*) p < 0.05 and (**) p < 0.01 compared to the untreated sample.
It is known that Nrf2 controls the transcription of many antioxidant and detoxifying genes, such as
superoxide dismutase (MnSOD), catalase, and heme oxygenase (HO-1) [21]. We demonstrated that the
levels of these proteins transcriptionally regulated by Nrf-2 markedly increase after 24 h of treatment
with 300 mMEtOH (Figure 4). In particular, the increase in the presence of 300 mM EtOH is estimated
1.4-fold for catalase, 4-fold for MnSOD (p < 0.001), and 5.5-fold for HO-1 (p < 0.001) after 24 h of
treatment (Figure 4). An increase in the levels of Nrf-2 and HO-1 is also observed in both HT29 and
Caco-2 cells after EtOH treatment (Figure S2).
2.6. Ethanol Promotes Nrf2 and HO-1 Translocation
Then we analyzed if the Nrf2 increase is accompanied by its nuclear translocation. Western
blotting analysis showed that Nrf2 is present in both nuclear and cytosolic fraction in untreated HCT116
cells and that EtOH treatment increases the nuclear level of Nrf2, while, concomitantly, decreases its
cytosolic fraction (Figure 5A). The analyses by confocal microscopy confirmed that in control cells Nrf2
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is preferentially distributed in the cytoplasm, while in treated cells the immunoreactivity is mainly
nuclear (Figure 5B).
Figure 5. Ethanol induces the nuclear translocation of cytosolic Nrf2 and HO-1 in HCT116 cells.
(A) Cells were treated for 3 h and 24 h with 300 mM EtOH. Equal amounts of nuclear or cytosolic
proteins (30 μg) were analyzed by Western blotting and quantified by densitometry for Nrf2 and
HO-1 expression normalized against Lamin B and β-actin. Representative blots of three independent
experiments are shown. (*) p < 0.05 and (**) p < 0.01 compared to the untreated sample. (B) HCT116
cells (8 × 103) were grown on coverslips and treated for 24 h with 300 mM EtOH. EtOH-induced
nuclear translocation was observed under confocal microscope TCS SP8 employing Nrf2 or HO-1
specific antibodies followed by incubation with a fluorescein isothiocyanate (FITC) conjugated
IgG secondary antibody (green). The cells were also stained with Hoechst (blue fluorescence) to
visualize nuclear morphology. Original magnification: 400×. The results are representative of three
independent experiments.
It has been reported that HO-1 can undergo to intramembrane proteolysis and translocation
into the nucleus to sustain tumor survival and invasiveness without depending on its enzymatic
activity [40]. Interestingly, western blotting analyses showed that EtOH is able to increase nuclear
HO-1 levels (Figure 5A). This effect was already observed after 3h of treatment with 300 mM EtOH
(p < 0.01). Nuclear HO-1 translocation in EtOH-treated cells was also confirmed by confocal microscopy
experiments (Figure 5B, white arrows).
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2.7. Ethanol Increases MMPs and VEGF in Colon Cancer Cells
Given that metalloproteases (MMPs) are critical to cell invasion and metastasis [41], the expression
and activity of MMP2 and MMP9 in EtOH-treated HCT116 cells were examined by both Western
blotting analysis and gelatin zymography. Our results show that there is a significant increase in the
protein level of active MMP2 (7-fold, p < 0.001) in HCT116 cells treated with 300 mM EtOH already
after 24 h of treatment (Figure 6A). A minor increase (2.2-fold, p < 0.01) is observed for active MMP9
(Figure 6A). Moreover, gelatin zymography showed that 300 mM EtOH also increases the activity of
both metalloproteinases (Figure 6B).
Figure 6. Ethanol increases the levels of VEGF and activates MMPs in HCT116 cells. (A) Western
blotting analysis of MMP2, MMP9, and VEGF in HCT116 cells treated for different times with 100
or 300 mMEtOH. Quantitative estimations of the protein levels were determined by densitometry
measurements of western blotting from three independent experiments after normalization with
β-actin. (*) p < 0.05, (**) p < 0.01, (***) p < 0.001 compared to the untreated sample. (B) The activity
of MMP2 and MMP9 in HCT116 cells treated with 300 mM EtOH for 48 h was examined by gelatin
zymography assay. The results are representative of three independent experiments.
Finally, we also demonstrated that EtOH increases the level of vascular endothelial growth factor
(VEGF) in HCT116 cells. As shown in Figure 6A, in comparison with untreated cells, the level of
VEGF protein significantly increases after 24 h in EtOH-treated HCT116 cells approximately by 3.5-fold
(p < 0.01) with 100 mM and by 3.2 fold (p < 0.01) with 300 mM, respectively.
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2.8. Role of Nrf2/HO-1 Axis in Colon Cancer Survival and Aggressiveness
To further demonstrate the contribution of Nrf2 in protecting colon cancer cells by oxidative
damage induced by EtOH, Nrf2 was downregulated by transfecting HCT116 cells with a specific
siRNA pool directed against Nrf2. Western blotting analysis showed that the levels of Nrf2 protein in
siNrf2-transfected group are significantly decreased (p < 0.05) after 24 h compared with the siRNA
control group (Figure 7). Interestingly, the increases in HO-1 and MnSOD protein level caused by
300 mM EtOH treatment is suppressed by Nrf2 siRNA (Figure 7A), thus confirming that the expression
of such antioxidant proteins is under Nrf2 control. Moreover, cell viability assay showed that Nrf2
silencing reduces HCT116 cell viability (Figure 7B), thus suggesting a protective role of Nrf2 axis
against EtOH-mediated toxic effect.
Figure 7. Nrf2-silencing represses the increase in the levels of antioxidant enzymes, MMP2 and
VEGF induced by EtOH treatment. (A,B) HCT116 cells (1 × 105) were transiently transfected with a
nonspecific siRNA (siControl) or with Nrf2 specific siRNA pool (siNrf2) and, 24 h after transfection,
cells were treated with 300 mM EtOH for additional 24 h or 48 h. (A) The levels of HO-1, MnSOD,
MMP2, and VEGF were analyzed by Western blotting after 24 h of transfection. The successful of
Nrf2-silencing was verified by measuring the level of Nrf2 in transfected cells. Quantitative estimations
of the protein levels were determined by densitometry measurements of western blotting from three
independent experiments after normalization with β-actin (*) p < 0.05 and (**) p < 0.01 compared to the
untreated sample. (#) p < 0.05, (##) p < 0.01. (B) Effects of Nrf2-silencing on the viability of HCT116
cells evaluated after 48 h of EtOH treatment by MTT assay and expressed as the percentage of the
viable siControl cells in untreated cultures. Values are the means of three independent experiments
± S.E. (#) p < 0.05 between the two groups.
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Furthermore, to evaluate whether also nuclear HO-1 translocation favors the survival of
EtOH-treated colon cancer cells, HCT116 cells were incubated in the presence of E64d, an inhibitor
of the protease responsible for the proteolytic cleavage of HO-1, an event necessary for its nuclear
translocation [42]. Combination of E64d with 300 mM EtOHis accompanied by a significant reduction
in nuclear localization of HO-1 (p <0.05) (Figure 8A). In addition, the data showed that inhibition of
nuclear translocation of HO-1 by E64d significantly reduces the EtOH-induced increase of MnSOD
(Figure 8B), thus supporting the conclusion that nuclear HO-1 could regulate MnSOD expression.
Figure 8. E64d counteracts the increase in antioxidant enzymes, MMP2 and VEGF induced by EtOH
treatment in HCT116 cells. Cells were pretreated for 3 h with E64d, then 300 mM EtOH was added
and the treatment was protracted for another 24 h. Nuclear and cytosolic fractions were prepared
as reported in Materials and Methods section. Evaluation of the HO-1 level in nuclear fraction (A)
and those of HO-1, MnSOD, MMP2, and VEGF in total fraction (B) by Western blotting analysis.
Quantitative estimations of the protein levels were determined by densitometry measurements of
western blotting from three independent experiments after normalization with β-actin. (*) p < 0.05,
(**) p < 0.01 compared to the untreated sample; (#) p < 0.05; (##) p < 0.01 between the two groups.
It has been reported that both Nrf2 and HO-1 activation promote tumor progression by regulating
proinvasive and angiogenetic factors [22,43]. Thus, further analyses were performed to examine
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whether the Nrf2/HO-1 axis also plays a role in the acquisition of a tumor aggressive phenotype in
EtOH-treated colon cancer cells. As reported in Figures 7 and 8, in HCT116 cells the increase in MMP2
protein level induced by EtOH treatment at 300 mM is significantly (p < 0.05) suppressed by both
Nrf2 siRNA (Figure 7A) and E64d (Figure 8B). Moreover, the increase in VEGF level in EtOH-treated
cells is reduced by Nrf2 silencing (Figure 7A) and prevented by E64d (Figure 8B). These data indicate
that activation of Nrf2/HO-1 axis could enhance colon cancer progression by inducing MMP2 and
VEGF expression.
3. Discussion
Epidemiological studies highlighted that heavy alcohol drinking promotes colon cancer
progression [44], although the underlying molecular mechanisms are still not clear. Data reported
in this paper show that colon cancer cells survive even under treatment with high doses of ethanol
(100–300 mM), which have been shown to exert toxic effects in other tumor cell lines [45,46]. It is
interesting to note that concentrations ranging from 10 to 100 mM correspond to blood levels in
humans that could result from moderate-to-heavy alcohol drinking [47].
Supportive signs of evidence suggest that EtOH is able to increase ROS level in different cell
lines, including colon cancer cells, through both ADH and CYP2E1 activity [48]. Moreover, chronic
EtOH exposure causes inflammation in different organs, like pancreas and liver, as indicated by
the increase in proinflammatory cytokines and chemokines [49,50]. In line with these observations,
we demonstrated that EtOH stimulates oxidative stress and an inflammatory response in colon cancer
cells. This conclusion is supported by several pieces of evidence, such as rapid ROS production,
the increase in the levels of two enzymatic markers of inflammation iNOS and COX2, and the
upregulation of Hsp90 and Hsp60 induced by EtOH in colon cancer cells.
Our results also provided evidence that high doses of EtOH trigger ER stress as demonstrated by
upregulation of the ER stress markers Grp78, CHOP, and PERK, as well as the increase in the active
form of the transcription factor ATF6. These results are in line with the observation that ER stress
contributes to alcoholic damage of major organs such as liver, pancreas, and brain [51,52].
Accumulating evidence suggest that activation of autophagy, which degrades proteins in
organelles such as mitochondria and the ER, can play a protective role against the toxic effects
of ER stress [53]. On the other hand, ER stress can activate autophagy and there is a considerable
cross-talk between the ER and autophagy [54]. It has been reported that ER stress-activated PERK
promotes the phosphorylation of eIF2α to induce the activation of LC3, an autophagosome marker [55].
Moreover, Shimodaira et al. [33] demonstrated that in colon cancer cells activation of ER marker
CHOP promotes autophagy by activating inositol-requiring enzyme 1α (IRE1α). Our results provide
evidence that EtOH induced autophagy in colon cancer cells as demonstrated by the augmented
accumulation of acidic intracellular compartments. This effect is prevented by the addition of the
antioxidant N-acetylcysteine, thus suggesting that autophagy is activated as a survival mechanism in
response to oxidative stress. Our results are in line with the observation that EtOH activates autophagy
in neuronal cells to prevent the oxidative damage of ROS [56]. The activation of autophagy in our
system was also confirmed by the observation that EtOH promoted the cleavage of the cytosolic
form of LC3-I to LC3-II, as well increasing the level of beclin and ATG7, two factors involved in the
autophagosome formation [37]. Moreover, the observation that the level of p62 protein, a marker
of autophagic degradation, decreases after 24 h of EtOH treatment, which suggested to us that the
compound is able to trigger a complete autophagic flux.
In response to oxidative and ER stress production, we showed a significant activation of Nrf2,
a transcription factor which acts as a key regulator of antioxidant-responsive genes [57]. Under our
experimental conditions, EtOH promotes nuclear Nrf2 translocation, as suggested by the increase of
nuclear Nrf2 content already at 3 h following EtOH treatment. This event is a consequence of the
decrease of Keap1, a protein which in unstressed conditions sequesters Nrf2 in a cytoplasmic complex
leading to its ubiquitination and consequent proteasomal degradation [58]. Nuclear translocation of
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Nrf2 by EtOH could be promoted by oxidative events, in line with the observation that induction
of oxidative stress triggers Nrf2 nuclear import through the oxidation of redox-sensitive cysteines
within Keap1 [59]. Moreover, nuclear translocation could be also favored by ER stress activation.
In fact, it has been shown that phosphorylation of Nrf2 by PERK—a kinase activated following the
accumulation of unfolded proteins in ER—promotes dissolution of Nrf2/Keap1 complexes and Nrf2
nuclear import [60].
Activation of Nrf2 is responsible for transcription of a battery of genes encoding antioxidant
enzymes such as MnSOD, catalase, and HO-1 [61]. Our data indicated that the level of both MnSOD and
HO-1 is significantly upregulated after EtOH treatment in colon cancer cells, suggesting a protective
role of these enzymes against EtOH-induced oxidative stress. The observation that Nrf2 silencing
significantly reduces EtOH-induced HO-1 and MnSOD increase suggest to us that this effect is
mediated by the activation of Nrf2 transcriptional activity.
Interestingly, our data also provide evidence that EtOH promotes HO-1 nuclear translocation
already after 3 h of treatment. Nuclear expression of HO-1 has been detected in several tumors
and it has been correlated with tumor growth and invasion [43]. Our data showed that inhibition
of HO-1 nuclear translocation by the protease inhibitor E64d significantly reduces EtOH-induced
MnSOD increase, suggesting that HO-1 nuclear translocation could cooperate with Nrf2 to stimulate
antioxidant response and colon cancer cell survival. This suggestion is in accordance with some recent
evidence that demonstrates that nuclear HO-1 modulates the activation of Nrf2, leading to activation
of antioxidant genes [27].
Activation of the Nrf2/HO-1 axis represents a double-edged sword in cancer [61]. Increase in
antioxidant enzymes by Nrf2 prevents the development of tumors by counteracting the genotoxic
damage induced by ROS [62]. In line with this consideration, several dietary phytochemicals exert
a cancer preventive effect by activating the Nrf2/HO-1 axis [63,64]. Moreover, activation of Nrf2
reduces chronic inflammation which has been correlated with CRC induction [65]. On the other
hand, activation of the Nrf2/HO-1 antioxidant response in tumor cells can promote tumor survival by
creating an optimal environment for cell growth [61]. Overexpression of Nrf2 has been detected in
primary CRC and metastatic tissues relative to normal colon and contributes to chemoresistance in CRC
cell lines [66]. In addition, it has been reported that Nrf2 increases CRC risk by promoting angiogenesis
and uncontrolled proliferation [67]. Moreover, HO-1 overexpression has been associated with a more
aggressive behavior of tumors and poor prognosis in various cancers [68,69]. Western blotting and
zymography analyses demonstrated that EtOH increases both the levels and the activity of MMP-2 and
9—two enzymes involved in tumor progression—and upregulates VEGF, the main angiogenetic factor.
Interestingly, Nrf2 silencing prevented EtOH-induced MMP-2 increase and reduced that of VEGF.
Moreover, inhibition of HO-1 nuclear translocation by E64d counteracted the effect of EtOH on both
MMP-2 and VEGF, thus markedly suggesting a role of Nrf2/HO-1 axis in colon cancer progression.
Collectively, our findings demonstrate that high doses of EtOH enhance autophagy and activation
Nrf2/HO-1 axis in colon cancer cells. These events sustain the survival of cancer cells protecting
them from oxidative and ER stress induced by EtOH. Moreover, we show, for the first time, that the
activation of Nrf2/HO-1 axis could be also responsible for colon cancer progression through the
acquisition of a metastatic behavior, as demonstrated by the increase in the levels of MMP-2 and
VEGF. A schematic model of EtOH effects on colon cancer cells is shown in Figure 9. This study
provides a novel mechanistic link between ethanol-induced activation of Nrf2/HO-1 pathway and
increased survival and aggressiveness of colon cancer cells in in vitro models. However, to open to
this new scenario, further in vivo investigations are strongly required to sustain the role of Nrf2/HO-1
activation in CRC progression. Detection of Nrf2 and HO-1 overexpression in CRC biopsies of alcohol
drinkers could be, indeed, used as potential novel biomarkers to monitor CRC progression.
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Figure 9. Scheme of the mechanism activated by high doses of ethanol. High doses of ethanol induce
ROS generation and ER stress responsible for the induction of a prosurvival autophagic process and
the aggressive tumor phenotype. Such events are sustained by the nuclear translocation of Nrf2 and
HO-1, which activate antioxidant response systems and promote the upregulation of MMP2 and VEGF.
4. Materials and Methods
4.1. Cell Cultures and Chemicals
The human colon cancer lines HCT116, HT29, and Caco-2 (Interlab Cell Line Collection, ICLC,
Genova, Italy) were grown in monolayer in flasks of 75 cm2 in RPMI 1640 medium, supplemented
with 10% (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin,
and 50 μg/mL streptomycin in a humidified atmosphere of 5% CO2 in air at 37 ◦C. To study the
effects of ethanol (EtOH), cells were detached using trypsin-EDTA (0.5 mg/mL trypsin and 0.2 mg/mL
EDTA) and plated in accordance to the experimental conditions, as described in the paragraphs below.
Cells were allowed to adhere for 24 h and then treated with different concentrations of EtOH at
different times.
All the reagents used for cell cultures were purchased from Euroclone (Pero, Italy). EtOH,
E64d and all chemicals, except when stated otherwise, were supplied by Sigma-Aldrich (Milan, Italy).
4.2. Cell Viability
To evaluate the effect of EtOH on cell viability the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide) colorimetric assay was used as previously reported [70]. In brief, HCT116,
HT29, and Caco-2 cells (7 × 103/200 μL/well) were plated in 96-wells and treated with various
concentrations of EtOH (30–300 mM) for different times. Fresh ethanol-containing medium was added
to cells daily. Then, 20 μL MTT (11 mg/mL) was added and cells were incubated at 37 ◦C for 4 h.
Finally, the medium was removed and 100 μL of lysis buffer (20% sodium dodecyl sulfate in 50%
N,N-dimethylformamide) was added. At the end, the absorbance of the formazan was measured
directly at 490 nm with 630 nm as a reference wavelength using an automatic ELISA plate reader
(OPSYS MR, Dynex Technologies, Chantilly, VA, USA). Cell viability was expressed as the percentage of
the OD value of EtOH-treated cells compared with untreated samples used as control. Each experiment
was performed in triplicate. The viability of cells was also assessed through the use of propidium
iodide (PI) dye exclusion assay. The intact membrane of live cells excludes a variety of dyes that easily
penetrate the damaged, permeable membranes of dead cells. After incubation with ethanol, 2 μg/mL
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PI was added and the incubation was protracted for 15 min before the visualization of cell morphology
by a Leica DC 300F microscope (Leica microsystems, Wetzlar, Germany) equipped with a rhodamine
filter (excitation wavelength of 596 nm and emission wavelength of 620 nm). Also, cell morphology
was visualized using a Leica DC 300F microscope inverted.
4.3. Clonogenic Assay
For the colony formation assay, a single cell suspension (200 cells/well) was plated into each well
of a 6-well plate and incubated at 37 ◦C for 2 weeks. The colonies were fixed and stained with a dye
solution containing crystal violet as reported by Raffa et al. [71]. All assays were replicated three times.
4.4. Western Blotting Analysis
Cell lysates were prepared as reported [72] and protein concentration was determined by Bradford
Protein Assay (Bio-Rad Laboratories S.r.l., Segrate, Milan, Italy). Protein extracts (30 μg/sample) were
subjected to SDS-polyacrylamide gel electrophoresis. Then, proteins were blotted on nitrocellulose
membranes. Primary antibodies used for the identification of catalase, Lamin B, MnSOD, Nrf2, iNOS,
COX2, Grp78, Chop, MMP2, MMP9, and PERK (1:200) were purchased from Santa Cruz Biotechnology
(St. Cruz, CA, USA); β-actin (1:1000) from Sigma Aldrich; Hsp60, Hsp90, and HO-1 (1:1000) from
Enzo Life Sciences, (Milan, Italy), ATG7 (1:1000) from Cell Signaling Tecnology (Beverly, MA, USA);
and ATF6 (1:300) from Novus Biologicals (Milano, Italy). Membranes were then incubated with
HRP-conjugated secondary antibody (1:5000) (Pierce, Thermo Fisher Scientific, Loughborough, UK)
and the signals were detected using enhanced chemiluminescence (ECL) reagents (Cyanagen, Bologna,
Italy). The signal obtained was visualized and photographed with ChemiDoc XRS (Bio-Rad, Hercules,
CA, USA). After analysis, membranes were stripped (200 mM glycine, 0,1% SDS, 1% Tween 20,
pH 2.2) and reincubated. The intensity of the bands was performed using Quantity One software
(Bio-Rad). After checking that β-actin content was not modified by ethanol treatment vs untreated
sample, in accordance with Lamichhane et al. [73], β-actin was used as a loading control and for band
normalization. All the blots shown are representative of at least three separate experiments.
4.5. Extraction of Cytosolic and Nuclear Fraction
HCT116 cells were seeded in 100-mm tissue culture dishes (1 × 106 cells/5 mL culture medium)
and, after treatment with EtOH, were lysed as reported [74]. In particular, cells were washed in PBS
and scraped with lysis buffer (250 mM Sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, and protease inhibitors, pH 7.4). Next, cells were passed 10 times
through a needle of 25 g on ice for 20 min. The homogenates were centrifuged at 1000× g for 10 min at
4 ◦C. The pellets were resuspended in lysis buffer and passed 10 times through a needle of 25 g and
centrifuged at 1000× g for 10 min at 4 ◦C. The pellets of the second centrifugation (nuclear fraction)
were lysed with RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, inhibitors of proteases:
25 μg/mL aprotinin, 1 mM PMSF, 25 μg/mL leupeptin, and 0.2 mM sodium pyrophosphate) and
sonicated. The supernatants obtained from the first centrifugation were centrifuged at 10,000× g for
30 min at 4 ◦C. The supernatants obtained were considered as cytosolic fraction. Nuclear and cytosolic
fractions were used to evaluate Nrf2 and HO-1. β-actin and LaminB were used as cytoplasmic and
nuclear markers, respectively.
4.6. Monodansylcadaverine Test
To evaluate the formation of autophagic vacuoles monodansylcadaverine (MDC) test was
employed as reported [75]. HCT116 cells (7 × 103/200 μL culture medium) were plated in 96-wells
plates and treated with EtOH. After treatment, cells were incubated with 50 μM MDC for 10 min at
37 ◦C in the darkness. Then, cells were washed with PBS and analysed by fluorescence microscopy
using a Leica DMR (Leica Microsystems, Milan, Italy) microscope equipped with a DAPI filter system
(excitation wavelength of 372 nm and emission wavelength of 456 nm). Images were acquired by
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computer imaging system (Leica DC300F camera, Milan, Italy). Three different visual fields were
examined for each condition.
4.7. Nrf2 siRNA Transfection
RNA interference of Nrf2 was performed using FlexiTube siRNA (SI03246950, SI03246614 Qiagen,
Hilden, Germany) targeting Nrf2. A nonsilencing siRNA (SI03650318, Qiagen) was used as a negative
control. As previously reported [76] for transfection, HCT116 cells were seeded (2 × 105 cells/well)
in 6-well plates and cultured in antibiotic-free RPMI 1640 medium supplemented with 10% FBS for
24 h to reach approximately 60–80% confluence before transfection. Specific siRNAs (50 nM final
concentration) and negative siRNA control (50 nM) were transfected for 5 h into the cells in the
presence of 5 μL Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in a final volume of 1 mL
serum/antibiotic-free RPMI 1640 medium. The reaction was stopped by replacing the culture medium
with complete RPMI 1640 medium. After 24 h of transfection, cells were treated with EtOH for other
24 h or 48 h. Then, cells were employed for immunoblotting analysis or MTT.
4.8. Measurement of Intracellular ROS Content
Intracellular ROS production was detected using the cell-permeant 2′,7′-dichlorodihydrofluorescein
diacetate (H2DCFDCA Molecular Probes; Eugene, OR, USA) as described [77]. HCT116 cells
(7 × 103/200 μL) were seeded in 96-well plates and incubated with 300 mM EtOH for different times.
After treatment, cells were washed with PBS and incubated with a 10 μM H2DCFDA for 15 min at
37 ◦C in the dark. Finally, cells were resuspended in PBS and analyzed by fluorescence microscopy
using a Leica DMR (Leica Microsystems S.r.l., Wetzlar, Germany) inverted microscope equipped with
a FITC filter system (excitation wavelength of 485 nm and emission wavelength of 530 nm). Images
were acquired by computer imaging system (Leica DC300F camera). Three different visual fields were
examined for each condition.
4.9. Gelatin Zymography
HCT116 cells were seeded in 100-mm tissue culture dishes (5 × 105 cells/ 5 mL culture medium).
After 48 h of EtOH treatment, cells were washed in PBS and scraped with lysis buffer. The lysates were
centrifuged at 800× g for 10 min. The samples (50 μg of proteins prepared in sample buffer: 50 mM
Tris-HCl, 2% SDS, 0.1% Bromophenol Blue, 40% Glycerol, pH 6.8) were loaded on polyacrylamide
gels (10%) with 10× gelatin and subjected to electrophoresis. After, the gel was washed for 1 h with
enzyme renaturing buffer (200 mM NaCl, 5 mM CaCl2, 5 μM ZnCl2, 2,5% (v/v) Triton X-100 and
50 mM Tris-HCl, pH 7.5) and incubated overnight at 37 ◦C with developing buffer (50 mM Tris base,
200 mM NaCl, 5 mM CaCl2, pH 7.5). Then, the gel was incubated for 30 min at room temperature
with staining solution (0.125% Coomassie brilliant blue R-250, 50% methanol, 20% acetic acid) and
washed with destaining solution (30% methanol, 0,01% formic acid) until clear bands of MMP activity
are visible in the blue background.
4.10. Immunofluorescence
HCT116 cells (8 × 103) were plated on coverslips and treated with 300 mM EtOH for different
times. Immunofluorescence was performed as previously described [78,79]. Briefly, after washing
twice in PBS, cells were fixed in methanol for 30 min at room temperature. After fixation, cells were
washed three times in PBS for 5 min and treated with a blocking solution (3% BSA in PBS) for 30 min.
Subsequently, the cells were washed twice in PBS and incubated with the primary antibody directed
against HO-1 (anti-rabbit, Enzo Life Sciences) or against Nrf2 (anti-rabbit, Santa Cruz Biotecnology,
St Cruz, CA, USA) at a dilution 1:100, overnight at 4 ◦C. Then, cells were washed three times in PBS
for 5 min and incubated for 1h with a conjugated secondary antibody: anti-rabbit IgG–FITC produced
in goat (Sigma-Aldrich) at dilution 1:200. Nuclei were stained with Hoechst Stain Solution (1:1000,
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Hoechst 33258, Sigma-Aldrich). The images were captured using a Leica Confocal Microscope TCS
SP8 (Leica Microsystems). Ten random visual fields were examined for each condition.
4.11. Statistical Analysis
Data were represented as mean ± S.E. and analysis was performed using the Student’s t-test
and one-way analysis of variance. Comparisons between the control (untreated) vs. all treated
samples were made. If a significant difference was detected by ANOVA analyses, this was re-evaluated
by post-hoc Bonferroni’s test. GraphPadPrismTM 4.0 software (Graph PadPrismTM Software Inc.,
San Diego, CA, USA) was used for statistical calculations. The statistical significance threshold was
fixed at p < 0.05.
5. Conclusions
In summary, cell culture experiments performed in three different colon cancer cell lines
demonstrate that nuclear translocation and consequent activation of both Nrf2 and HO-1 in response to
high doses of ethanol exert a protective effect against the toxic effects of alcohol-induced oxidative and
ER stress. Moreover, Nrf2/HO-1 activation also favors the acquisition of a more aggressive phenotype
through the upregulation of proinvasive and angiogenetic factors like MMPs and VEGF. This might
represent a causative link between alcohol consumption and an increased risk of CRC progression.
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Abstract: Antimitotics are important anticancer agents and include the natural alkaloid prodrug
colchicine (COL). However, a major challenge of using COL as an anticancer drug is its cytotoxicity.
We developed a novel drug delivery system (DDS) for COL using mesoporous silica nanoparticles
(MSNs). The MSNs were functionalized with phosphonate groups, loaded with COL, and coated
with folic acid chitosan-glycine complex. The resulting nanoformulation, called MSNsPCOL/CG-FA,
was tested for action against cancer and normal cell lines. The anticancer effect was highly enhanced
for MSNsPCOL/CG-FA compared to COL. In the case of HCT116 cells, 100% inhibition was achieved.
The efficiency of MSNsPCOL/CG-FA ranked in this order: HCT116 (colon cancer) > HepG2 (liver
cancer) > PC3 (prostate cancer). MSNsPCOL/CG-FA exhibited low cytotoxicity (4%) compared to
COL (~60%) in BJ1 normal cells. The mechanism of action was studied in detail for HCT116 cells
and found to be primarily intrinsic apoptosis caused by an enhanced antimitotic effect. Furthermore,
a contribution of genetic regulation (metastasis-associated lung adenocarcinoma transcript 1 (MALAT
1), and microRNA (mir-205)) and immunotherapy effects (angiopoietin-2 (Ang-2 protein) and
programmed cell death protein 1 (PD-1) was found. Therefore, this study shows enhanced anticancer
effects and reduced cytotoxicity of COL with targeted delivery compared to free COL and is a novel
method of developing cancer immunotherapy using a low-cost small-molecule natural prodrug.
Keywords: colchicine alkaloid; colon cancer cells; mesoporous silica nanoparticles; targeted delivery
system; apoptosis; PD-1 immune checkpoint inhibitor and cancer immunotherapy
1. Introduction
Colchicine (COL) is a natural alkaloid compound derived mainly from the medicinal plant
Colchicum automnale and has been used in the clinic for treating gout and familial Mediterranean fever.
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COL has also shown some benefit in primary biliary cirrhosis [1], amyloidosis [2], and condyloma
acuminate treatments [3]. COL is an antimitotic drug, which interferes strongly with cell division by
affecting microtubule assembly and disassembly during mitosis. Most of the antimitotic drugs are toxic
anticancer agents, which preferentially kill cancer cells, as they divide much faster than normal cells.
However, the major challenge for COL is its toxicity, which causes severe side effects to patients [4].
Despite COL not yet being used clinically for cancer therapy because of its toxicity to normal cells,
it is used as a lead compound in generating potent anticancer agents [5–9]. To reduce the side effects of
COL on normal cells, many types of research have included analogs of COL [10,11] and combination
treatments with other drugs [12]. Regarding the mechanism underlying the antimitotic effects of COL,
several actions are associated with antimitotic and post-antimitotic responses. Gupta and Dudani [13]
proposed that the mechanism of action for antimitotic drugs, such as COL, includes blockade of cell
growth at metaphase upon the binding of antimitotic drugs to tubulin (for COL through the colchicine
binding site) due to cell-cycle arrest (e.g., at G2/M). Following this action, the microtubules cannot
exert any cellular functions [13]. In the presence of antimitotic drugs, cells either die during mitosis
or exit mitosis. When they exit mitosis, several post-mitotic responses occur that can lead to cell
death, including cell-cycle arrest and apoptosis [14]. In a report on the mitotic cell death that occurs
during mitosis, Castedo et al. [15] proposed that the mitotic cell death catastrophe results from a
combination of deficient cell-cycle checkpoints and cellular damage. Cell death occurring during
mitosis is characterized by activation of caspase-2 in response to DNA damage, or caspase-9, caspase-3,
and cytochrome c in response to mitochondrial membrane permeabilization. These effectors make up
the molecular hallmarks of apoptosis. Thus, mitotic catastrophe is controlled by molecular players,
including cell cycle-specific kinases, cell-cycle checkpoint proteins, caspases, and some proteins of
the Bcl-2 family (e.g., Bax, Bcl-2), among others. Qi et al. provided evidence that, by arresting cell
cycle progression in the presence of antimitotic drugs, mitotic spindles are disrupted, and cancer cells
directly undergo apoptosis via the mitotic catastrophe [16].
Recently, antimitotic agents such as COL were reported to have a regulatory effect on most
immune cell types, leading to the development of effective cancer immunotherapies [17]. With respect
to cancer immunotherapy, targeting programmed cell death protein 1 (PD-1) and programmed cell
death-ligand 1 (PD-L1), among other immune checkpoints, is important. PD-1 is an inducible immune
modulatory receptor expressed on surface-activated T cells, and its ligand PD-L1 is expressed on
cancer cells [18]. Binding PD-1 to PD-L1 leads to prevent from the immune antitumor effects by T cells
against cancer cells [19]. However, recent studies have revealed the intrinsic expression of PD-1 in
many cancers, along with immune T cells [20,21]. Therefore, it is considered a new potential target
for cancer immunotherapy [19,21]. Thus, checkpoint blockade immunotherapy has revolutionized
treatment for many tumors. In the next few years, scientists will be able to focus on immunotherapy
research and broaden target cancers with different strategies [22]. Recently, the regulatory action by
which antimitotic drugs inhibit PD-1 over-expression on the surface of T-cells was highlighted, and
that PD-1 is strongly inhibited in the presence of the COL-binding site (CBS) of tubulin [23].
Traditional treatments for cancer, including surgery, radiation, cryosurgery, and chemotherapy,
can be used alone or in combination. These methods have several limitations, such as toxicity, side
effects, and expense. When chemotherapy is considered, normal treatment protocols include anticancer
drugs alone or in combination to inhibit/kill cancer cells by affecting cell division and proliferation
through different mechanisms. Drugs can produce various side effects for patients (e.g., neutropenia,
liver and gastrointestinal toxicity, anemia, mucositis, and others) [24]. Therefore, cancer-targeting
delivery systems with different nano-platforms have gained attention [25–27].
Despite the promising anticancer effects of COL, a few COL drug delivery systems (DDSs)
have been tested to improve its therapeutic efficiency through cancer-targeting [28,29]. We focused
on developing a novel DDS for COL by facilitating the active targeting of cancer cells. In the
current study, we constructed a DDS for COL using three-dimensional fibrous dendritic mesoporous
silica nanoparticles with a spherical shape (MSNs) known as KCC-1 type [26,30]. MSNs have been
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investigated as a drug delivery carrier for several drugs and biomolecules [27,31,32]. The tailored DDS
comprises MSNs functionalized with phosphonate functional groups (MSNsP), and then loaded with
COL MSNsPCOL, with the latter product subsequently coated with chitosan-glycine conjugated to
folic acid (FA) to obtain a nanoformulation called MSNsPCOL/CG-FA. Glycine was employed as a
source of amino groups that require for cancer growth [33]. FA was employed as the main targeting
ligand, which is known for its binding potential to folate receptors, which are over-expressed on many
cancers and facilitate the endocytosis pathway [26,34–36].
2. Results and Discussion
2.1. Synthesis and Characterization of the Targeted Delivery System
The targeted drug delivery system for COL, MSNsPCOL/CG-FA, comprised COL-loaded MSNsP
subsequently coated with chitosan-glycine conjugated to folic acid. The schematic representation of
the process is shown in Figure 1.
Figure 1. Schematic representation of the steps to obtain the proposed drug delivery system with the
final product (MSNsPCOL/CG-FA) and various biological evaluations in vitro.
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2.2. Electron Microscopy of Materials
To observe the structural changes between the prepared materials, we used TEM STEM and
FE-SEM techniques. The FE-SEM images (Figure 2A) show the 3D dendritic mesoporous structure
of MSNs with a spherical shape that is uniform in size. No aggregation was seen. In TEM images
(Figure 2B), there were no detectable differences between MSNs, MSNsP, and MSNsPCOL. However,
in MSNsPCOL/CG-FA, the central part appeared gray-white in color due to the coating complex
(chitosan-glycine). This observation is similar to that seen in STEM images, where MSNsPCOL/CG-FA
was white in color (Figure 2C). Thus, the coating was confirmed by STEM and TEM observations.
 
Figure 2. Morphological structures of the materials. (A) Field emission scanning electron
microscopy (FE-SEM) of prepared mesoporous silica nanoparticles (MSNs) at different magnifications.
(B) High-resolution transmission electron microscopy (HR-TEM) of prepared materials at different stages:
Before and after of modification, colchicine (COL) loading, and coating. (C) Scanning transmission
electron microscopy (STEM) of prepared materials at different stages: before and after of modification,
COL loading, and coating.
2.3. Surface Area Characteristics
The specific surface area and pore volume characteristics were measured (Table 1). Via modification
with phosphonates, COL loading, and coating with CG-FA, both surface area and total pore volume
were decreased compared to MSNs (380.1 m2/g and 0.772 cm3/g of specific surface area and total pore
volume, respectively). This observation indicates successful preparation, in agreement with previous
results [26,27,37,38].
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Total Pore Volume a
(cm3/g)
P, COL, CG-FA Content Calculation from
Weight Loss (wt%) b
MSNs 380.1 0.772 3.3
MSNsP 202.1 0.489 6.98 as P
MSNsPCOL 181.8 0.467 3.60 as COL
MSNsPCOL/CG-FA 89.5 0.352 33.48 as CG-FA
a Pore volume from nitrogen adsorption-desorption measurements at 0.999 P/P◦. b Calculated from the
thermogravimetric analysis. MSNs: mesoporous silica nanoparticles; P: phosphate groups; COL: colchicine;
CG-FA: chitosan-glycine-folic acid.
2.4. Elemental Content Analysis
Energy-dispersive X-ray spectroscopy allowed us to determine the changes in the elemental
content of prepared materials (Figure S1A, Supporting Information). Prior to modification, MSNs
were composed of 53.18 wt% Si and 46.82 wt% O. Additional modification with organic phosphonate
groups changed the elemental content, resulting in the presence of new elements, including 0.24 wt% P,
7.40 wt% C, and 0.95 wt% Na, as seen for MSNsP, confirming the modification. With further loading
of COL on MSNsP, the C content increased and P content decreased in MSNsPCOL as a result of
COL loading because it is an organic compound. Further polymer coating of MSNsPCOL relatively
increased the C amount to 9.92 wt% and N amount to 2.77 wt% in MSNsPCOL/CG-FA. This observation
is expected because both chitosan and glycine are composed of amino groups, which is important for
confirmation of the coating process.
2.5. Particle Size Measurement
The particle size distribution was measured by nanoparticle tracking analysis (NTA) in aqueous
solution (Figure S1B, Supporting Information). The mean size distribution for MSNs was 324 ± 33.2 nm.
For MSNsP, the size increased to 407 ± 13.9 nm. For MSNsPCOL, the size slightly decreased to
391 ± 3.9 nm but was an insignificant difference. Unexpectedly, MSNsPCOL/CG-FA size decreased
to 330 ± 22.2 nm compared to MSNsPCOL. An explanation may be the coating used for most of
the particles with a smaller size compared to particles with a larger size, leading to an increase in
their average size in the sample. This observation is in agreement with the two peaks appearing at
10–200 nm, which has not been observed previously.
2.6. Functional Group Determination
FTIR was used to identify surface functional groups (Figure 3). MSNs had several peaks at
450, 800, and 1056 cm−1 because of the siliceous mesostructured framework. As their surface was
functionalized with phosphonate groups in MSNsP, we observed a new band at 953 cm−1 and a broad
peak from 3000 to 3600 cm−1, reflecting phosphonate groups [39]. Two new peaks at 1639 cm−1, and
an intensive peak centered at 3355 cm−1 were presented in MSNsPCOL, corresponding to shifted
peaks at 1542 and 3629 cm−1 for COL. Additional coating resulted in several new peaks, with bands at
698 and 946 cm−1 attributed to chitosan, glycine, or folic acid. A band at 1315 cm−1 could correspond to
chitosan, a band at 1436 cm−1 could correspond to either chitosan or folic acid, but a band at 2900 cm−1
could correspond to folic acid. A peak centered at 1034 cm−1 became broader, which ascribes all
components for coating.
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Figure 3. Fourier transform infrared spectroscopy (FTIR) spectra of MSNs before and after modification
and COL loading, as well as chitosan (C), and glycine (G), folic acid (FA), and COL.
2.7. Simultaneous Thermal Analysis (STA-DSC) and XRD Characterization
To identify the mass fraction of phosphonate groups, COL, and polymer, thermal analysis was
performed by calculating the weight loss values over their thermal decomposition (Figure 4A and
Table 1). MSNs lost ~3.32 wt% because of moisture content. The weight loss further increased with
MSNsP resulting from the decomposition of phosphonate groups. The heating of MSNsPCOL resulted
in increased loss compared to MSNsP, which was calculated as COL loaded on MSNsP (3.60 wt%).
The highest weight loss was recorded for MSNsPCOL/CG-FA, which was the result of decomposition
of the coating complex (calculated to be 33.4 wt%), which confirms successful fabrication of the coating.
The results of the DTG thermograms in Figure 4B are consistent with STA, providing clear data
that confirm the degradation. In MSNsP, a peak at 63 ◦C showed moisture, and another at 500 ◦C was
attributed to organic decomposition. The degradation of COL was confirmed with the peak in the
range of 340 to 525 ◦C in MSNsPCOL based on the two maximum peaks at 342 ◦C and 550 ◦C for
free COL. A peak recorded at 106 ◦C in MSNsPCOL/CG-FA corresponded to decomposition of the
coating material.
To further understand whether COL loaded on the surface of or inside particles, differential
scanning calorimetry (DSC) analysis was conducted. Figure 4C shows no peaks in the MSNsPCOL
and MSNsPCOL/CG-FA spectrum corresponding to free COL melting (409 to 537 ◦C). This observation
shows that COL was enclosed in the particles.
To further verify the DSC results, we used XRD analysis. Figure 4D illustrates that no peaks
appeared in the MSNsPCOL pattern corresponding to COL. We propose two reasons for this finding:
Low loading and entrapment in pores. To confirm that we created a physical mixture of MSNsP
and COL, no peaks were observed corresponding to COL. The MSNsPCOL/CG-FA pattern did
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not represent any peaks corresponding to chitosan, glycine, or folic acid, confirming the DSC data.
These two complementary techniques show the characteristics of the meso-porosity of MSNs allowing
the accommodation of various molecules, including functional groups, polymers, and drugs.
Figure 4. Thermal analysis of materials. (A) Simultaneous thermal analysis (STA) before and after
surface modification, COL loading, and coating. (B) DTG analysis before and after surface modification,
COL loading, and coating. (C) Differential scanning calorimetry (DSC) analysis before and after surface
modification, COL loading, and coating. (D) X-ray diffraction (XRD) analysis before and after surface
modification, COL loading, and coating. (E) Zeta potential measurements in aqueous solution before
and after surface modification, COL loading, and coating.
2.8. Zeta Potential Measurements
Figure 4E shows the differences in zeta potential for the materials and pH conditions. MSNs had
a very low positive value (<+2 mV) in acidic media and very negative in alkaline medium (−55 mV).
As expected, MSNsP had negative zeta values compared to MSNs associated with phosphonate groups.
MSNsPCOL exhibited negative values at various pH values, probably due to the low COL content in
particles. MSNsPCOL/CG-FA exhibited high positive values (>+40 mV) when medium was acidic
(pH 2, 2.5 and 5.1). This observation is important for the cellular uptake of these particles by cancer
cells to reach tumor sites. Negative values were found for MSNsPCOL/CG-FA particles in neutral or
alkaline medium (pH 7.2, 9.9 and 12). The high positive zeta values for MSNsPCOL/CG-FA particles
suggest that they can enter cells via endocytosis. The surface charge of particles (neutral, anionic, and
cationic charges) determines their internalization into cells. Anionic nanoparticles are less efficiently
internalized than cationic and neutral particles [40–43]. These results suggest that the developed DDS
leads to higher cellular uptake in cancer cells.
2.9. MSN Cytotoxicity Evaluation
Figure 5 presents the dependence of cell inhibition on concentration, time, cell line, and MSNs,
with significant differences at p < 0.5. A gradual cell inhibition effect was found only when cells were
treated with either MSNs or MSNsP at an increased concentration of 1000 μg/mL and incubation for 72 h.
Higher cytotoxicity was recorded for HCT116 cells than PC3 and HepG2 cells, with 1000 μg/mL MSN
and MSNsP treatment of HCT116 cells resulting in 85.9 ± 6.0% and 77.4 ± 4.7% inhibition, respectively.
In contrast, normal BJ1 cells were less inhibited than cancer cells under the same treatment conditions.
177
Cancers 2020, 12, 144
Figure 5. In vitro cytotoxicity (as percent inhibition) of MSNs and MSNs functionalized with
phosphonate functional groups (MSNsP) for biocompatibility evaluations in cancer and normal
cell lines after 24, 48, and 72 h of incubation with cancer cells (liver, HepG2; prostate, PC3; and colon,
HCT116) and normal fibroblasts (BJ1). (A) Cytotoxicity of MSNs towards cell lines. (B) Cytotoxicity of
MSNsP towards cell lines. Note: A blue asterisk (*) indicates significant (p < 0.05) differences between
tested concentrations, whereas an orange asterisk (*) indicates significant differences between cell lines.
NS, not significant. All data are expressed as mean ± SD.
The toxicity differences between MSNs and MSNsP varied according to cell line in response to
concentration and time (Table S1 in Supplementary Information). With the IC50 value, it is possible
to identify the differences in cytotoxicity; MSNs had a more toxic effect on HepG2 and HCT116 cells
after 48 h compared to other incubations. In contrast, MSNsP had a more toxic effect on HCT116
cells after 24 and 72 h compared to 48 h. In addition, HCT116 cells were more sensitive than other
cancer cell lines. Both types of nanoparticles had nearly equal IC50 values in PC3 cells after 24 and
48 h. Negligible cytotoxicity (IC50 > 1000 μg/mL) was observed for normal BJ1 cells in response to
both types of nanoparticles. The negligible cytotoxicity on BJ1 normal cells can be related to the low
internalization of nanoparticles in BJ1 normal cells. There is evidence in literature that cancer cells
allow higher nanoparticles internalization compared normal cells due to the enhanced permeation and
retention effect [44]. This, because of the vasculature of tumors, is often leaky, leading to accumulating
nanoparticles in the bloodstream compared to normal tissue [45]. This finding agrees with previously
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published data for MCF-7 cells and BJ cells treated with MSNs and phosphonate-functionalized
MSNs [39]. They mentioned that cancer cells uptake more MSNs than normal cells, and MSNs are more
cytotoxic for cancer cells compared normal cells. Therefore, either MSNs or MSNsP is a promising
nanocarrier for COL delivery.
2.10. In Vitro Anticancer Effects against Cancer Cells
We studied the anticancer activity in terms of cell inhibition and found that it was significantly
dependent on the cell line, concentration, incubation time, and delivery method. For HepG2 cells
(Figure 6A), high inhibition was observed after 72 h and 200 μg/mL of all treatments. Regarding the
role of the delivery route, MSNsPCOL/CG-FA exhibited high inhibition (80–82%), especially at 100 and
200 μg/mL, compared to MSNsPCOL and COL. This finding was also confirmed by IC50 values, with
lower values detected for three incubation times with MSNsPCOL/CG-FA (Table S1 in Supplementary
Information). Obviously, these results indicate that the anticancer activity against HepG2 cells was
ranked in the following order: MSNsPCOL/CG-FA > COL >MSNsPCOL/CG-FA.
As shown in Figure 6B, PC3 cells were significantly inhibited by increasing dose and incubation
time. Notably, MSNsPCOL/CG-FA had a gradual inhibitory effect compared to carriers; it had lower
inhibition at 24 h and increased after 72 h, with a maximum inhibition of 80% when treated at 200 μg/mL.
The anticancer effect in PC3 cells was ranked in this order: MSNsPCOL/CG-FA > COL >MSNsPCOL.
This effect was also confirmed by IC50 values (Table S1 in Supplementary Information), with lower
values obtained for MSNsPCOL/CG-FA compared to other treatments.
Interestingly, HCT116 cancer cells were highly inhibited compared to HepG2 and PC3 (Figure 6C).
We observed that at a high concentration of 200 μg/mL MSNsPCOL, MSNsPCOL/CG-FA, and COL
inhibited 100% at 24, 48, and 72 h. However, differences were seen among the three treatments
when the concentration was decreased. MSNsPCOL/CG-FA potentially inhibited HCT116 growth
>90% after 72 h compared to other carriers. Clear differences were confirmed by IC50 calculations,
as MSNsPCOL/CG-FA had lower values than MSNsPCOL and COL and reached 19.7 μg/mL after
24 h, 17.4 μg/mL after 48 h, and 17.0 μg/mL after 72 h. The anticancer activity pattern against HCT116
was ranked in this order: MSNsPCOL/CG-FA > COL >MSNsPCOL. Thus, the findings concerning
anticancer effects in three cancer cell lines show that HCT116 cells were more sensitive than HepG2
and PC3 cancer cells. Therefore, we selected HCT116 cancer cells for further investigation in our study.
For normal BJ1 cells, we observed that the inhibitory effect depended on the concentration and
delivery route (Figure 6D). MSNsPCOL/CG-FA inhibited 4% after 72 h, compared to 60% for COL, which
indicates negligible effects. As seen in the IC50 values (Table S1 in Supplementary Information), the
delivery COL in the nano or free form had IC50 values > 100 μg/mL. MSNsPCOL/CG-FA significantly
inhibited all tested cancer cells lines than COL ranking in this order: HCT116 >HepG2 > PC3. Also,
MSNsPCOL/CG-FA had less or negligible toxic effects on normal BJ1 cells versus cancer cells than
COL. Thus, this effect is the most likely to be developed as a DDS for cancer therapy.
From the observations, the proposed delivery route has an enhanced anticancer effect with a
longer duration to 72 h. The reason for this is that the anticancer effect is in response to COL release
from nanoformulations because it is controlled by a coating that needs some time for degradation.
The polymeric coating controls the release of guest molecules from MSNs depending on time, pH,
and other factors [27,31,46]. The enhanced anticancer effects with MSNsPCOL/CG-FA compared to
free COL supports a cancer-targeting effect. This is possible through the interaction of folate receptors
in cells and folic acid in nanoparticles. The sensitivity of HCT116 cancer cells to MSNsPCOL/CG-FA
compared to HepG2 and PC3 is because folate receptors are overexpressed among cancer cell types [36].
It was shown that expression levels of folate receptors vary depending on type of cancer and the
colorectal cancers show higher level than liver and prostate cancers [47]. However, the anticancer effect
of free COL or enhanced delivery route is in response to inherited antimitotic effects from COL.
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Figure 6. In vitro cytotoxicity (as percent inhibition) of the proposed delivery system in cancer and
normal cells after 24, 48, and 72 h of incubation with cells. (A) Anticancer effects on HepG2 cancer cells.
(B) Anticancer effects on PC3 cancer cells. (C) Anticancer effects on HCT116 cancer cells. (D) Anticancer
effects on BJ1 normal cells. Note: A blue asterisk (*) indicates significant (p < 0.05) differences between
tested concentrations, whereas an orange asterisk (*) indicates significant differences between tested
samples (nanoformulations and COL). NS, not significant. All data are expressed as mean ± SD.
2.11. Inhibition of Tubulin Activity in HCT116 Cancer Cells
As shown in Figure 7A, MSNs and MSNsP significantly inhibited tubulin in response to increasing
the concentration used to treat cells. In this context, MSNsP inhibited ~12% compared to MSNs ~7% at
1000 μg/mL. Figure 7B shows that MSNsPCOL/CG-FA inhibited 90% more than COL at 50 μg/mL. Thus,
the developed DDS is the most likely reason for enhanced tubulin inhibition because of the COL tubulin
inhibitor agent [5,48,49]. We propose that the action for MSNsPCOL/CG-FA is the release of COL
molecules into cells after folate receptor–folic acid interaction; the COL binds to tubulin in cells through
colchicine binding sites, destabilizing tubulin [50], and further interferes with microtubule dynamics.
180
Cancers 2020, 12, 144
The later response causes effective mitotic action against HCT116 cells. Further post-antimitotic
response can arrest the cell cycle at the G2/M phase [51] and cause apoptotic cell death [52].
Figure 7. (A) Tubulin inhibition activity of HCT116 cells treated with MSNs and MSNsP as a function of
concentration. (B) Tubulin inhibition activity HCT116 cells treated with the proposed delivery system
as a function of concentration. (C) Caspase-3 activity of HCT116 cells treated with MSNs and MSNsP as
a function of concentration. (D) Caspase-3 activity of HCT116 cells treated with the proposed delivery
system and compared to the model anticancer drug (5-FU) as a function of concentration. Note: A blue
asterisk (*) indicates significant (p < 0.05) differences between tested concentrations, whereas an orange
asterisk (*) indicates significant differences between tested samples. NS, not significant. All data are
expressed as mean ± SD.
2.12. Cell Cycle Arrest at the G2/M Phase in HCT116 Cancer Cells
The G2/M checkpoint inhibitor class of drugs leads to DNA damage, preventing cells from passing
mitosis and stopping their proliferation. As a result, cells cannot enter mitosis prior to repairing their
DNA damage, resulting in apoptosis or death after their division [53] through various molecular
signaling pathways [54,55]. Several reports have demonstrated that COL can arrest at G2/M in different
cancer cells [7,56].
The cell cycle analysis was dependent on incubation time (Figure S2A,B in Supplementary
Information). After 24 h, MSNsPCOL/CG-FA resulted in the maximum accumulation of cells at G2/M
(14.8%), followed by 5-FU (12.4%), MSNsPCOL (11.2%), and COL (8.7%), with the lowest accumulation
for MSNs (4.9%), MSNsP (4.8%), and untreated control (4.76%). In contrast, accumulation of cells
at S phase was inhibited by MSNsPCOL/CG-FA (18.8%), MSNsPCOL (21.1%), 5-FU (21.2%), COL
(23.3%), MSNsP (27.4%), and MSNs (27.6%) compared to control (27.7%). After 72 h, the number of
cells increased at G2/M and deceased at S phase compared to 24 h. This cycle analysis pattern shows
the endorsement of HCT116 cancer cell arrest at G2/M phase together with evidence that cells could
not enter the S phase.
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2.13. Enhancement of Apoptosis Induction in HCT116 Cancer Cells
Apoptosis is a distinct or intrinsic occurrence relating to different physiological and pathological
responses [55] and usually contributes to efficient antitumor action for most anticancer drugs [54,57].
To investigate whether the treatments induce apoptosis, HCT116 cells were stained with Annexin
V-FITC and propidium iodide (PI), and then analyzed by flow cytometry. The parameters of late
apoptosis, early apoptosis, and necrosis were quantified. Total apoptosis induction (early plus late)
increased with treatment compared to untreated control cells after 72 h compared to 24 h (Figure S3A,B
in Supplementary Information). The effects on total apoptosis were in this order: MSNsPCOL/CG-FA
(15.0%)>MSNsPCOL (14.2%)> 5-FU (13.2%)>COL (10.6%)>MSNsP (0.5%)>MSNs (0.43). Compared
to untreated control (0.5%), MSNs and MSNsP had no effects on apoptosis, reflecting the importance of
DDS other than COL and 5-FU drugs. In addition to the induction of apoptosis, MSNsPCOL/CG-FA
had a 1.4% necrosis effect. As MSNsPCOL/CG-FA promoted apoptosis (early and late apoptosis)
(Figure 8B), the G2/M arrest triggers apoptosis in HCT116 cancer cells [58,59].
Figure 8. (A) Bax activity of HCT116 cells treated with MSNs and MSNsP as a function of concentration.
(B) Bax activity of HCT116 cells treated with the proposed delivery system and compared to the model
anticancer drug (5-FU) as a function of concentration. (C) Bcl-2 inhibition activity of HCT116 cells
treated with MSNs and MSNsP as a function of concentration. (D) Bcl-2 inhibition activity of HCT116
cells treated with the proposed delivery system and compared to the model anticancer drug (5-FU) as a
function of concentration. Note: A blue asterisk (*) indicates significant (p < 0.05) differences between
tested concentrations, whereas an orange asterisk (*) indicates significant differences between tested
samples. NS, not significant. All data are expressed as mean ± SD.
2.14. Activation of Caspase-3 in HCT116 Cancer Cells
The activation of intracellular caspase is one of the main characteristics of the apoptosis cell
death pathway leading to the cleavage and inactivation of many cellular proteins, leading to the
occurrence of apoptotic cell death in most cancer cell types [60]. As shown in Figure 7C, a significant
effect was detected among MSNs and MSNsP. Treatment of cells with 500 μg/mL MSNs significantly
increased activity compared to 10 μg/mL. In contrast, no significant differences were detected in either
concentrations of MSNsP. Maximal activation of both treatments did not reach >55 pg/mL, which
is a low enhancement effect. The caspase-3 activity was dependent on concentration and delivery
method (Figure 7D), with high activity resulting from increased concentration to 60 μg/mL compared to
10 μg/mL. Maximal caspase-3 activity (>1000 pg/mL) was recorded for MSNsPCOL/CG-FA. Caspase-3
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activation was enhanced in this order: MSNsPCOL/CG-FA >MSNsPCOL > 5-FU > COL. These results
agree with our previous results using MSNs [26,27].
2.15. Modulation of Proapoptotic Bax/Bcl-2 in HCT116 Cancer Cells
Figure 8A shows no significant effect of MSNs and MSNsP on Bax, but these nanoparticles enhanced
it to a little over 1 FLD. Figure 8B shows the significant difference for Bax at 60 μg/mL compared
to 10 μg/mL. In addition, MSNsPCOL/CG-FA enhanced Bax to ~14 FLD, and the enhancement
ranked in the following order: MSNsPCOL/CG-FA > 5-FU > COL > MSNsPCOL. In particular,
MSNsPCOL/CG-FA strongly enhanced Bax compared to the clinically used 5-FU drug.
Though MSNs and MSNsP had not significant effect, they slightly inhibited BCL-2 ~1.2 FLD
(Figure 8C). As shown in Figure 8D, the inhibition of BCL-2 was affected by concentration. Treatment
of cells at 10 μg/mL resulted in low inhibition and ranked in effect as follows: MSNsPCOL and 5-FU
(>0.2 FLD) >MSNsPCOL/CG-FA and COL (~0.35 FLD). Upon further increasing the concentration to
60 μg/mL, BCL-2 highly inhibited to ~0.1 FLD (for MSNsPCOL/CG-FA and MSNsPCOL), <0.2 FLD (for
COL), and ~0.2 FLD. These findings show significantly better molecular targeting of nanoformulations
in HCT116 cells via Bax enhancement and BCL-2 inhibition than free COL and 5-FU. Furthermore,
this effect strongly requires efficient upregulation of Bax and down-regulation of BCL-2, allowing
progression of the apoptotic pathway in HCT116 cancer cells. Inhibition of BCL-2 is important
because it is considered a potent death suppressor protein; it promotes cell survival by blocking
apoptosis and is upregulated in several cancers. BCL-2 is classified as an anti-apoptotic protein in many
cancers, including colorectal cancer [61,62], inducing cancer resistance to drugs. Bax is a pro-apoptotic
protein that promotes apoptosis in cells but is always present in inactivated states in many cancers,
including colon cancer [57,63]. Therefore, these results confirm that the enhancement of apoptosis by
MSNsPCOL/CG-FA interconnects with reduced Bcl-2 and increased Bax.
2.16. Inhibition of BRAF Expression in HCT116 Cancer Cells
Colon cancer is associated with multiple processes through various genetic alterations [64],
including RAF genes, which mediate several cellular responses [65]. They contribute to carcinogenesis
by upregulating the anti-apoptotic RAS/RAF/MEK/ERK pathway [66]. High expression of BRAF
(anti-apoptotic protein) inhibits apoptosis by activating the BRAF/MEK/ERK route, which interferes
with apoptosis through reduction of caspase and cytochrome c [67].
BRAF inhibition was concentration- and time-dependent. MSNs and MSNsP (at 1000 μg/mL)
reduced BRAF ~3% to 3.5% for cells incubated for 24 and 48 h, respectively (Figure 9A,B). Significant
inhibition of BRAF was dependent on concentration, time, and delivery route (Figure 9C,D).
It was decreased in cells incubated for a longer time. For example, at 50 μg/mL treatment, the
inhibition was ~90%, ~87%, ~82%, and ~80% with MSNsPCOL/CG-FA, MSNsPCOL, COL, and 5-FU,
respectively. This pattern shows that MSNsPCOL/CG-FA is efficient in inhibiting BRAF in HCT116
cells. Our findings on MSNsPCOL/CG-FA confirm the killing of HCT116 cancer cells was enhanced
through apoptosis mechanisms.
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Figure 9. (A) BRAF activity of HCT116 cells treated with MSNs and MSNsP as a function of concentration.
(B) BRAF activity of HCT116 cells treated with the proposed delivery system and compared to the
model anticancer drug (5-FU) as a function of concentration. (C) BRAF inhibition activity of HCT116
cells treated with MSNs and MSNsP as a function of concentration. (D) BRAF inhibition activity of
HCT116 cells treated with the proposed delivery system and compared to the model anticancer drug
(5-FU) as a function of concentration. Note: A blue asterisk (*) indicates significant (p < 0.05) differences
between tested concentrations, whereas an orange asterisk (*) indicates significant differences between
tested samples. All data are expressed as mean ± SD.
2.17. Enhancement of Cytochrome c Triggers in HCT116 Cancer Cells
As shown in Figure 10A, no significant effect was detected for MSNs and MSNsP treated at
500 μg/mL for 72 h. Significant effect was detected in HCT116 cells treated with the nanoformulations
compared to COL (Figure 10B). Triggering of cytochrome c was found in this order: MSNsPCOL/CG-FA
> MSNsPCOL > COL > 5-FU. Our results agree with the results by Zhang et al. that COL
triggers cytochrome c from the mitochondria to the cytoplasm in human gastric cancer cells [68].
These results confirm that the delivery system for COL activates apoptosis via the intrinsic apoptotic
signaling pathway.
2.18. Reduction of Mitochondrial Membrane Potential in HCT116 Cancer Cells
No significant effect was observed among MSNs and MSNsP treated at 500 μg/mL for 72 h
(Figure 10C). Importantly, treatment of HCT116 cells with MSNsPCOL/CG-FA significantly decreased
mitochondrial membrane potential compared to MSNsPCOL, COL, 5-FU, and control (Figure 10D).
Minimal mitochondrial membrane potential was found in this order: MSNsPCOL/CG-FA < 5-FU <
COL <MSNsPCOL. It was reported that free COL decreased mitochondrial membrane potential in
HT-29 colon cells, which led to intrinsic apoptotic cell death [6].
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Figure 10. (A) Cytochrome c triggering of HCT116 cells treated with MSNs and MSNsP at 500 μg/mL.
(B) Cytochrome c triggering of HCT116 cells treated at 60 μg/mL with the proposed delivery system
for 72 h and compared to the model anticancer drug (5-FU) and control (without any treatment).
(C) Mitochondrial membrane potential (Δψm) of HCT116 cells treated with MSNs and MSNsP at
500 μg/mL. (D) Mitochondrial membrane potential of HCT116 cells treated at 60 μg/mL with the
proposed delivery system for 72 h and compared to the model anticancer drug (5-FU) and control.
Note: An orange asterisk (*) indicates significant (p < 0.05) differences between tested samples. NS, not
significant. All data are expressed as mean ± SD.
2.19. Inhibition of CD44 Expression in HCT116 Cancer Cells
As CD44 is a transmembrane glycoprotein, it can take part in different cellular processes, including
growth, survival, cell differentiation, resistance to apoptosis [69–71], and tumorigenesis of colon cancer,
such as HCT-116 cells [72]. CD44 is well-recognized as a robust marker (via overexpression) of colon
cancer initiation because it promotes cell adhesion, maintains cell–matrix interactions [73], and induces
anti-apoptotic properties [71,74]. Therefore, CD44 is a potential therapeutic target in colon cancer.
MSNsPCOL/CG-FA, MSNsPCOL, and COL highly attenuated the CD44 concentration in HCT116
compared to positive control cells (185.5 ± 15.4 ng/mL; Figure 11A). We found no significant
differences between MSNsPCOL/CG-FA (33.3 ± 3.5 ng/mL), MSNsPCOL (34.1 ± 3.3 ng/mL), and COL
(37.3 ± 3.2 ng/mL). However, they significantly inhibited CD44 compared to 5-FU (63.7 ± 8.5 ng/mL).
Concerning the anti-apoptotic effect of CD44 expression in colon cancer, Lakshman et al. previously
reported that it prevents the apoptosis killing pathway because it promotes cell transformation into a
malignant phenotype with the help of other anti-apoptotic factors in the tumor microenvironment [75].
We recorded the maximum inhibition for MSNsPCOL/CG-FA, supporting the results obtained for
apoptosis induction. In a previous study of colon cancer cells, Park et al. reported that knockdown of
CD44 leads to inhibition of cell proliferation and induction of apoptosis [71].
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Figure 11. (A) MALAT-1 protein expression in normal WI-38 cells, HCT116 cells, and HCT116 cells
treated with proposed delivery and 5-FU. (B) mir-205 expression in normal WI-38 cells, HCT116 cells,
and HCT116 cells treated with proposed delivery and 5-FU. (C) Ang-2 protein expression in normal
WI-38 cells, HCT116 cells, and HCT116 cells treated with proposed delivery and 5-FU. (D) CD44 protein
expression in normal WI-38 cells, HCT116 cells, and HCT116 cells treated with proposed delivery and
5-FU. (E) PD-1 protein expression in normal WI-38 cells, HCT116 cells, and HCT116 cells treated with
proposed delivery and 5-FU. Note: An orange asterisk (*) indicates significant (p < 0.05) differences
between tested samples, whereas a blue asterisk (*) indicates significant differences between specific
samples. NS, not significant. All data are expressed as mean ± SD.
2.20. Inhibition of MALAT-1 Expression in HCT116 Cancer Cells
In recent years, emerging indications are that lncRNAs, non-protein coding transcripts longer
than 200 nucleotides, are responsible for a broad spectrum of biological impacts with gene regulation
and other functions in many diseases [76,77]. Among others, MALAT1 increases tumor formation in
many cancers, including gastric, gallbladder, and lung cancer in vivo [77–80]. Importantly, MALAT1
has been shown in several studies to promote colorectal cancer cell development via proliferation,
migration, and invasion [81,82], and is considered a potential therapeutic target for colon cancer.
MALAT-1 was significantly inhibited by all delivery methods and free drugs (Figure 11B) compared
to positive control cells. MSNsPCOL/CG-FA had a maximum inhibition effect with 0.3 ± 0.05-fold
change, followed by COL (0.46 ± 0.05-fold change), MSNsPCOL (1.5 ± 0.15-fold change), and 5-FU
(10.06 ± 0.57-fold change) compared to positive control cells (~160-fold change). Importantly, when
HCT116 cells were treated with MSNsPCOL/CG-FA, the inhibition level was close to the level of
normal cells. These results point out that COL and its nanoformulations are more efficient than 5-FU in
hindering the expression of MALAT-1 in HCT116 cells, which is necessary for therapeutic targeting of
colon cancer. To the best of our knowledge, no data are available yet on the effects of COL on MALAT1
inhibition or promotion.
2.21. Attenuation of mir-205 Expression in HCT116 Cancer Cells
Micro-RNAs are small non-coding RNAs discovered in 1993 that play crucial roles in cancer,
including in cell viability, proliferation, invasion, metastasis, tumor suppressors, and oncogenes [83,84],
allowing them to be used in cancer diagnosis and treatment [85,86]. Jing et al. showed that the
expression of mir-205 is upregulated in plasma from colon cancer patients, permitting the occurrence
and development of the cancer. Thus, mir-205 may be a potential tumor marker and therapeutic
target [87]. However, mir-205 has also been reported to be downregulated in colon cancer [88].
Treating HCT116 cells with MSNsPCOL/CG-FA, MSNsPCOL, 5-FU, and COL decreased mir-205
expression. The inhibition values were 0.53 ± 0.05, 0.97 ± 0.05, 10 ± 0.3, and 3.4 ± 0.7-fold change,
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respectively, compared to the 14-fold change in positive control cells. This provides of evidence of
possible mir-205 targeting in colon cancer (Figure 11C). To the best of our knowledge, there are no
data available yet on the effects of COL in either downregulating or upregulating mir-205 in cancer.
Our results may pave the way for further deep investigations.
2.22. Inhibition of Ang-2 Expression in HCT116 Cancer Cells
One characteristic of cancer is pathological angiogenesis, which plays a crucial role in selecting a
therapy. Ang-2 is a pro-angiogenic cytokine that maintains angiogenesis and restricts the antitumor
immune response from attacking cancer cells. In a study by Schmittnaegel et al., inhibition of Ang-2
together with vascular endothelial growth factor A (VEGFA) enhanced the antitumor immunity,
allowing PD-1 checkpoint inhibition [89]. In addition, Kim et al. indicated that Ang-2 maybe play a
crucial role as an oncogene in colorectal carcinogenesis, supporting tumor progression as a prognostic
marker [90]. Therefore, we sought to explore the proposed DDS for the possibility of inhibiting Ang-2
and further explain the PD-1 checkpoint inhibitor.
A significant difference was detected between all treatments and positive control cells (HCT116
cells with no treatment; Figure 11D). Notably, treated HCT116 cells had strongly inhibited expression of
Ang-2, which was slightly like its expression level in normal cells (172.1± 2.5). A maximum inhibition of
Ang-2 recorded for MSNsPCOL/CG-FA (174.0 ± 0.75 ng/mL) >MSNsPCOL (175.7 ± 1.0 ng/mL) > 5-FU
(182.3 ± 1.15 ng/mL) > COL (188.6 ± 1 ng/mL) compared to positive control cells (213.3 ± 3.0 ng/mL).
These results suggest that the anticancer activity of the proposed DDS could promise to target Ang-2
supporting the immune checkpoints inhibition [89,91].
2.23. Inhibition of PD-1 Expression in HCT116 Cancer Cells
Figure 11E shows the suppression of PD-1 checkpoint with significant changes compared
control cells; the maximum inhibition level was reached at 9.8 ± 0.3 ng/mL and 10 ± 0.3 ng/mL for
MSNsPCOL/CG-FA and MSNsPCOL, respectively, compared to 14 ± 0.5 ng/mL with positive control
cells. This was similar to the PD-1 concentration in normal BJ1 cells (9.6 ± 0.5), which is significant.
PD-1 reached 10.3 ± 0.2 and 11.2 ± 0.5 with free COL and 5-FU, respectively.
Recent studies have revealed the intrinsic expression of PD-1 in many cancers, along with T
immune cells [20,21]. Therefore, it is considered as a new potential for cancer therapy [19] and efficient
treatments [92]. Checkpoint blockade immunotherapy has revolutionized treatment for tumors and, in
the next years, scientists are expected to focus on immunotherapy research and broaden its scope to
target cancers by different strategies [22]. PD-1 immune checkpoint inhibitors act by blocking the PD-1
protein and activate the immune system to treat many tumors [22,93]. MSNsPCOL/CG-FA inhibited
PD-1 in HCT116 cells to the range close to normal BJ1 cells, which is important. These are the first
results for COL or a DDS as a small drug molecule. PD-1 inhibitors are usually large molecules, such
as antibodies, antigens, peptides, and therapeutic proteins. Although many approved therapies are
efficient in cancer (e.g., nivolumab and pembrolizumab), they have many limitations, including side
effects, toxicity, internal response changes in the immune system, and expense [94,95]. The results
create an opportunity to develop a new approach of PD-1 inhibitors through further ongoing research.
In summary, the main findings in the current study were enhancement of the antimitotic effects of
COL by means of a targeted delivery system (MSNsPCOL/CG-FA). The enhanced antimitotic effects
block cancer cell growth due to the binding of COL to tubulin in cells, leading to cell death. The main
mechanism of action is an apoptosis cell death mechanism through different molecular pathways
known for COL action on cancer cells. In addition, genetic regulation and immunotherapeutic effects
have a role. A schematic representation of the nanoformulation mechanism of action is shown in
Figure 12, and Table 2 outlines the results of the current study. The following factors explain the
feasibility of cancer-targeting via folate receptors using folic acid ligands as developed here:
(1) The developed nano-delivery system efficiently targets the interaction of folic acid (on the
surface of MSNsPCOL/CG-FA) with folate receptors over-expressed on cancer cells. In a next step, it
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releases COL into cancer cells, which can bind to the tubulin forming the microtubules in the cellular
skeleton, resulting in tubulin inhibition. This effect is important because microtubules enable cells to
undergo mitosis or subsequent intracellular post-antimitotic responses. Maximum tubulin inhibition
(~90%) was achieved when HCT116 cancer cells were treated with MSNsPCOL/CG-FA.
(2) By producing the antimitotic effect via tubulin inhibition, the cells died. The cell-killing was
cell line-, concentration-, time-, and delivery method-dependent. We observed that HCT116 cells
were more sensitive to treatments than HepG2 and PC3 cells. In the case of HepG2 and PC3 cells,
MSNsPCOL/CG-FA efficiently inhibited the cells compared to COL at all concentrations used. In the case
of HCT116 colon cells, a strong effect was observed when incubating cells for 72 h. MSNsPCOL/CG-FA
and COL had equal inhibition (100%) at 200 μg/mL. At lower concentrations, MSNsPCOL/CG-FA
significantly inhibited HCT116 cells compared to COL. Thus, at all concentrations, MSNsPCOL/CG-FA
was more efficient than COL in HCT116 cells. Concerning IC50, MSNsPCOL/CG-FA had a lower
value (17.0 μg/mL) than free COL after 72 h. In addition, MSNsPCOL/CG-FA had less toxicity towards
normal cells (10%) than COL (60%).
(3) Because COL inhibits tubulin, the post-antimitotic response resulted in various molecular
pathways, including cell-cycle arrest, apoptosis, and genetic regulation [14]. We investigated several
molecular, genetic, and immunology pathways to explore the mechanism of action. The results confirm
that tubulin was markedly inhibited, especially with MSNsPCOL/CG-FA compared to COL. Because
of the inhibition of tubulin and the resulting cell cycle arrest, we investigated cell cycle analysis by
flow cytometry. MSNsPCOL/CG-FA enhanced the cell-cycle arrest at G2/M phase compared to COL.
This observation confirms the tubulin inhibition effect. Arresting cells at the G2/M phase results in
apoptosis. The maximum induction of apoptosis was detected for MSNsPCOL/CG-FA. Therefore, this
observation confirms that the apoptosis cell death mechanism occurs in HCT116 cancer cells. To further
confirm whether apoptosis is the main mechanism of action, we tested many molecular pathways. We
observed that caspase-3 was enhanced when cells were treated with MSNsPCOL/CG-FA compared to
other formulation, and this is one of the main routes for apoptosis. The modulation of pro-apoptotic
proteins is shared with apoptosis; treating cells with MSNsPCOL/CG-FA promoted Bax and inhibited
Bcl-2 protein. The anti-apoptotic BRAF protein and CD44 cellar protein levels were highly inhibited
after cells were treated with MSNsPCOL/CG-FA. The observations provide strong evidence of the
intrinsic apoptosis mechanism due to enhanced cytochrome c triggering and reduce the mitochondrial
membrane potential, in agreement with the literature.
(4) New effects were obtained in our study. The antimitotic drugs act by inducing various genetic
regulations that may or may not be related to the apoptosis mechanism. Our results show that
MSNsPCOL/CG-FA inhibited MALAT 1 and mir-205 in treated cells. Regarding the importance of
cancer immunotherapy because of the post-antimitotic effects, MSNsPCOL/CG-FA markedly inhibited
Ang-2 protein and PD-1 in HCT116 cancer cells compared to normal WI-38 cells. To the best of
our knowledge, the results for MALAT1, mir-205, and PD-1 with COL and its delivery in HCT116
cancer cells were obtained for the first time. The findings suggest that the killing of cancer cells is in
response to the effects of the post-antimitotic response of the COL delivery route. We propose that the
anticancer mechanism is mainly apoptosis cell death, with the contribution of genetic regulation and
immunotherapy effects.
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Figure 12. Schematic representation of cancer cell killing and possible anticancer mechanisms by which
the proposed drug delivery system for colchicine (MSNsPCOL/CG-FA nanoformulation) acts in vitro
against HCT116 colon cancer cells.
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3. Materials and Methods
3.1. Materials
COL, 5-fluorouracil (5-FU), tetraethyl orthosilicate (TEOS), cetylpyridinium bromide (CPB),
cyclohexane, isopropanol, urea, glycine, folic acid, insulin, penicillin G, streptomycin, and MTT assay
kits were purchased from Sigma-Aldrich (St. Louis, MO, USA), and the Caspase-3 (active) Human ELISA
kit from Invitrogen (Camarillo, CA, USA). 3-(Trihydroxysilyl)propyl methylphosphonate monosodium
salt solution was purchased from Santa Cruz Biotechnology, Texas, USA. Methanol, ethanol, and
acetic acid were obtained from Fisher Scientific UK (Loughborough, UK). Dimethyl sulfoxide (DMSO)
was obtained from Tedia (Fairfield, OH, USA). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS), and chitosan (100,000-300,000 Da) were obtained
from Acros Organics (Geel, Belgium). Phosphate-buffered saline (PBS), Dulbecco’s modified Eagle
medium (DMEM), Roswell Park Memorial Institute medium (RPMI 1640), and fetal bovine serum
(FBS) were obtained from Gibco/Life Technologies (Thermo Fisher Scientific, Langenselbold, Germany).
Insulin (Novo Nordisk, Bagsvaerd, Denmark) and trypsin versene (Vacsera, Giza, Egypt) were also used.
The well plates were obtained from Greiner Bio-One GmbH (Frickenhausen, Germany). The Annexin
V-FITC Apoptosis Detection Kit was from BioVision (Mountain View, CA, USA), the flow cytometry
kit for cell cycle analysis (ab139418) from Abcam® (Cambridge, UK), Script One-Step RT-PCR Kit with
SYBR® Green from BIO-RAD (Hercules, CA, USA), Human Angiopoietin 2 ELISA Kit and Human
Programmed Cell Death Protein 1 ELISA Kit from Bioassay Technology Laboratory Systems (Shanghai,
China), Human CD44 ELISA kit from Gen-Probe Diaclone SAS (Besançon, France), and the miRNeasy
extraction kit from Qiagen (Valencia, CA, USA). Enzyme-linked immunosorbent assays (ELISAs) used
a kit for tubulin β (TUBb; SEB870Hu, Cloud-Clone Corp., Houston, TX, USA) and human B-RAF/B-Raf
sandwich ELISA (LifeSpan BioSciences, Seattle, WA, USA). TMRE Mitochondrial Membrane Potential
Assay Kit (Cymans Chemical, Ann Arbor, MI, USA). Cytochrome c Human ELISA Kit (abcam, Austria).
Ultrapure water (18.2 MΩ; Milli-Q® system, Millipore, Darmstadt, Germany) was used in all prepared
solutions. All other reagents were of analytical grade.
3.2. Methods
3.2.1. Synthesis and Modification of Mesoporous Silica Nanoparticles
We prepared MSNs of KCC-1 type nanospheres with a 3D fibrous dendritic structure using the
detailed synthesis methods according to Polshettiwar et al. [30] and AbouAitah et al. [26]. For further
surface modification through the post-synthesis route, to graft phosphonate groups, the MSNs were
dried at 50 ◦C for 5 h to remove the physically adsorbed water. Next, 1 g of dried MSNs was suspended
in 100 mL of ultra-pure water with the aid of sonication (Elma GmbH, Singen, Germany) for 30 min, and
then 1.5 mL of 3-(trihydroxysilyl)propyl methylphosphonate monosodium salt was added drop-wise
over with stirring. The mixture solution was left at room temperature under reflux conditions for 24 h.
The material was collected by centrifugation (Cooling Sigma 16K, Laborzentrifugen GmbH, Osterode
am Harz, Germany) at 10,000 rpm for 10 min, and then washed three times with methanol. Finally,
the material was dried in an oven at 50 ◦C for 6 h to obtain MSNsP.
3.2.2. Colchicine Loading
To load COL into MSNsP, we followed our previous method with some modification [38]: 100 mg
COL was dissolved in 10 mL deionized water (pH 7), and then 300 mg of MSNsP was added and
stirred (DAIHAN Scientific, Seoul, Korea) for 24 h at room temperature. The solution was centrifuged
(Cooling Sigma 16K, Laborzentrifugen GmbH, Osterode am Harz, Germany) for 10 min and washed
with deionized water once. Finally, the collected material was heated in an oven at 50 ◦C for 12 h and
labeled as MSNsPCOL.
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3.2.3. Coating and Conjugation with Chitosan-Glycine and Folic Acid
Coating with chitosan-glycine and conjugating with folic acid was achieved via the following steps.
First, the chitosan-glycine was prepared based on a coacervate and EDC/NHS coupling reaction [27]
by dissolving 250 mg of chitosan in 20 mL (2%) acetic acid and stirred for 2 h at 60 ◦C (solution A).
In another beaker, 100 mg of glycine was dissolved in 10 deionized water, followed by the addition
of 60 mg EDC and 50 mg NHS and stirring for 2 h at room temperature (solution B). Solution B was
introduced to solution A drop-wise and left to stir for 4 h at 50 ◦C. Hereafter, the mixture solution is
referred to as the CG complex solution. Second, the activation of folic acid was carried out by dissolving
85 mg of folic acid, 70 mg of EDC, and 50 mg of NHS in 20 mL DMSO, stirring the mixture for 20 h at
room temperature. Third, the activated folic acid solution was added drop-wise into the CG complex
solution and stirred for 4 h at 50 ◦C to obtain CG-FA complex solution. The solution was kept at −20 ◦C
until further use. Fourth, COL-loaded nanoparticles were coated with chitosan-glycine and conjugated
to folic acid by dispersing 600 mg of MSNsPCOL into 15 mL of CG-FA complex solution and stirring
at room temperature for 24 h. The MSNsPCOL-CG-FA product was collected by centrifugation and
washed with ethanol and ultra-pure water, then dried in an oven at 50 ◦C for 12 h.
3.2.4. Characterization Techniques
The following techniques were used to characterize the obtained materials: Field emission
scanning electron microscopy (FE-SEM; Ultra Plus, Zeiss, Germany) equipped with QUANTAX
EDS (Bruker); scanning transmission electron microscopy (STEM; FEI TECNAI G2 F20 S-TWIN,
Thermo Fisher Scientific, Waltham, MA, USA); powder X-ray diffraction (XRD; X’PertPRO System,
PANalytical) using CuKα radiation in the 2θ range of 10–100; and Brunauer, Emmett, and Teller
(BET) specific surface area analysis using a Gemini 2360 instrument (Micromeritics) according to
ISO 9277:2010. Before the density and SSA measurements were carried out, the powders were
dried at 150 ◦C (without drug) or 50 ◦C (with drug and polymer) for 24 h under a constant flow
of helium (FlowPrep 060 desorption station by Micromeritics). Fourier transformed infrared (FTIR)
spectroscopy (Bruker Optics Tensor 27, Bruker Corporation, Billerica, MA, USA) was performed with
attenuated total reflectance (ATR, model Platinum ATR-Einheit A 255). Simultaneous thermal analysis
(STA)-coupled differential scanning calorimetry (DSC) (STA-DSC) analysis was performed using the
STA 499 F1Jupiter (NETZSCH-Feinmahltechnik GmbH, Germany). Samples weighing 10–20 mg were
inserted into the alumina pan of the STA unit, and before measurements, helium was flowed through
the STA furnace chamber for 30 min. The experimental parameters were programmed to reach 850 ◦C
with a heating rate of 10 ◦C/min under a helium/air mixture. Zeta potential measurements using a
Malvern ZetaSizer (NanoZS, UK) were performed based on the water suspension of nanoparticles
at 24 ◦C. Water suspensions were used for nanoparticle tracking analysis (NTA) using NanoSight
NS500 instrument (Malvern Instruments Ltd., Malvern, UK) and data analyzed by NanoSight software
(Malvern Instruments Ltd., Malvern, UK).
3.2.5. In Vitro Cytotoxicity Assessment
For the estimation of in vitro cytotoxic potency, the 3-4,5-dimethylthiazol-Z-yl-2,5-diphenyltetrazolium
bromide (MTT) assay was conducted according to Mosmann [96]. Human prostate adenocarcinoma
PC3 cells (ATCC®CRL-1435 TM), human colon colorectal carcinoma HCT116 cells (ATCC®CCL-247TM),
human hepatic carcinoma HepG2 cells (ATCC® HB-8065TM), and human fibroblast BJ1 cells
(ATCC®CRL-2522™) were grown in RPMI supplemented with 10% fetal bovine serum (Cologne,
Germany) and 1% penicillin-streptomycin solution (penicillin 10,000 IU/mL; streptomycin 10,000μg/mL.
The cell lines were cultured at 37 ◦C in 95% humidity and 5% CO2, and subcultured twice weekly using
trypsin versene 0.15%. The cells were seeded in flat-bottom 96-well plates at a density of 10,000 cells
per well for 24 h. The serum enriched medium was used during the bioassay to keep the cells alive
through the long duration of the bioassay and to better simulate in vivo conditions. Cells were
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treated with the different samples diluted in medium at 125, 250, 500, and 1000 μg/mL (for MSNs and
MSNsP) to test the biocompatibility of nanoparticles. For anticancer activity, cells were treated (as
equivalent amount to COL in nanoformulations, the equivalent amount used throughout all studies
for investigated nanoformulations) at 25, 50, 100, 200 μg/mL (for MSNsPCOL, MSNsPCOL/CG-FA,
COL, 5-FU). After treatment for 24, 48, or 72 h, 10 μL of MTT was added, and after 5 h of incubation
the color was measured at 495 nm against the 690 nm reference. Finally, the percent cytotoxicity was
calculated according to [1-(av(S)/(av(NC))] × 100, where av(NC) is the average absorbance of the three
negative control wells measured at 495 nm (reference 690 nm) and av(S) is the average absorbance of
the three sample wells measured at 495 nm (reference 690 nm). IC50 and IC90 values were calculated
using Probit analysis and SPSS for Windows statistical analysis software package, version 9 (1989,
SPSS Inc., Chicago, IL, USA).
3.2.6. Apoptosis Detection and Cell Cycle Analysis with Flow Cytometry
To analyze apoptosis and the cell cycle, we followed manufacture protocols and our pervious
study [27]; HCT116 cells were seeded on a six-well plate at a density of 2 × 105 cells/per well in
RPMI 1640 supplemented with 10% FBS, 1% penicillin/streptomycin and incubated at 37 ◦C in a 5%
CO2 atmosphere. After 24 h, the medium was replaced with fresh, treated with different samples
at 40 μg/mL (100 μL), and incubated for 24 h or 72 h. Control cells received no treatments. For cell
cycle analysis, cells were trypsinized, washed with cold PBS, and fixed with 70% ethanol. The fixed
cells were rinsed with PBS, and then labeled with propidium iodide (PI) following the manufacturer’s
instructions (Abcam®, Cambridge, UK). Finally, cells were analyzed by flow cytometry (FACSCalibur,
Becton Dickinson, NJ, USA). Cell cycle analysis was performed with an FL2-A histogram of single
cells. The Annexin V-FITC Apoptosis Detection Kit (BioVision, CA, USA) was used to detect apoptosis
according to the manufacturer’s instructions. After treating the cells as mentioned, the cells were
trypsinized, fixed in 70% ethanol, washed with cold PBS, and suspended in binding buffer (500 μL).
Next, 5 μL of Annexin V-FITC and 5 μL of PI were added and incubated for 10 min in the dark, and
then immediately analyzed by flow cytometry (FACSCalibur, Becton Dickinson, NJ, USA).
3.2.7. Caspase-3 Activity Assay
The caspase-3 activity was determined according to the manufacturer’s instructions using
the human active caspase-3 content assay kit. HCT116 cells were cultured on 96-well plates
(1.2–1.8 × 10,000 cells/well) in 100 μL of RPMI 1640 containing 10% FBS, 1% penicillin/streptomycin at
37 ◦C. The cells were treated at 10 and 500 μg/mL (for MSNs and MSNsP) or 10 and 60 μg/mL (for
MSNsPCOL, MSNsPCOL/CG-FA, COL, 5-FU) with 100 μL sample volume per well and incubated for
72 h prior to the assay. The procedures are reported in detail in our previous study [27]. The absorbance
was measured at 450 nm using the Robonik P2000 ELISA reader. The assay was performed in triplicate,
and data are expressed as mean ± SD.
3.2.8. Tubulin Assay
To assess tubulin polymerization, the ELISA kit for TUBb (SEB870Hu, Cloud-Clone Corp., Houston,
TX, USA) was used following the manufacturer’s instructions. HCT116 cells were seeded in 96-well
plates at a cell density of 1.2–1.8 × 10,000 cells/well in 100 μL growth medium (DMEM); 100 μL of
each sample was added per well. MSNs and MSNsP were tested at 125, 250, 500, and 1000 μg/mL,
whereas MSNsPCOL, MSNsPCOL/CG-FA, and COL were used at 0.4, 2, 10, and 50 μg/mL. After 48 h
of incubation, the solution was removed, cells were detached by trypsinization, washed with cold PBS
buffer, suspended in PBS, and followed by three freeze/thaw cycles to lyse the cells. Cell lysates were
centrifuged in a cooling centrifuge for 10 min, which permits the removal of cellular debris to detect
β-tubulin in the supernatant. The assay was performed as instructed in the kit. Finally, ELISA reader
ROBONIK P2000 (Robonik India PVT LTD, Thane, India) was used to measure the color at 450 nm in
triplicate. Data were calculated as percent inhibition.
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3.2.9. Expression of Bax and Bcl-2
Cell Culture Treatment and RNA Extraction
HCT116 cells were cultured at a density at 1 x 106 and incubated for 48 h at 10 and 500 μL (for MSNs
and MSNsP) or 10 and 60 μg/mL (for MSNsPCOL, MSNsPCOL/CG-FA, COL, and 5-FU). Cells were then
collected for RNA extraction using the RNeasy extraction kit according to the manufacturer’s protocol
(Qiagen, Hilden, Germany). Cells were disrupted in buffer RLT, homogenized, and disrupted before
adding ethanol to the lysates to create conditions that subsequently promoted the selective binding of
RNA to the RNeasy membrane. A total of 100 μl of sample lysate was added to a RNeasy Mini spin
column, with total RNA binding to the membrane. High-quality RNA was eluted using RNase-free
water. Centrifugation in a micro-centrifuge was used during all steps (binding, washing, elution).
Quantitative Determination by RT-PCR
Bax and Bcl-2 expression was investigated by real-time polymerase chain reaction (RT-PCR)
using the BIORAD iScriptTM One-Step RT-PCR Kit with SYBR® Green (Bio-Rad, Hercules, CA)
according to the manufacturer’s instructions and as described by Labib et al. [97]. The RT-PCR
reactions were performed using the following primers for the BAX, BCL-2, and β-actin genes: Bax
F, 5′-GTTTCA TCC AGG ATC GAG CAG-3′; Bax R, 5′-CATCTT CTT CCA GAT GGT GA-3′; Bcl-2
F, 5′-CCTGTG GAT GAC TGA GTA CC-3′; Bcl-2 R, 5′-GAGACA GCC AGG AGA AAT CA-3′;
β-actin F, 5′-GTGACATCCACACCCAGAGG-3′; and β-actin R, 5′-ACAGGATGTCAAAACTGCCC-3′.
The reaction and amplifications protocol done according to Labib et al. [97]. A reaction mix (50 μL) was
used, prepared as following: 2X Sybr Green RT-PCR Master (25 μl), forward primer—10 μM (1.5 10 μL),
Reverse primer—10 μM (1.5 μL), nuclease-free H2O (11 μl), RNA template (1 pg to 100 ng total RNA)
(10 μL), and iScript Reverse Transcriptase for One-Step RT-PCR (1 μL). The amplification protocol
was performed as follows: cDNA synthesis: 50 ◦C (10 min), iScript Reverse transcriptase inactivation
(95 ◦C, 5 min), PCR cycling and detection (40 cycle) (95 ◦C, 10 s), data collection step (60 ◦C, 30 s),
melt curve analysis (95 ◦C, 1 min, 55 ◦C (1 min) and 55 ◦C (10 s) (80 cycles, increased 0.5 ◦C for each
cycle). The reactions were performed in triplicate on a Rotor-Gene 3000 RT-PCR system. The data were
analyzed by Rotor-Gene Series Software 1.7 (Build 87).
3.2.10. BRAF Assay
The BRAF ELISA kit was used with cell lysates according to the manufacturer’s protocol (LifeSpan
BioSciences “LSBio”, Seattle, WA, USA). HCT116 cells were cultured at density of 1 × 106 and incubated
for 48 h at 125, 250, 500, and 1000 μl (for MSNs and MSNsP) or 0.4, 2, 10, and 50 μg/mL (for MSNsPCOL,
MSNsPCOL/CG-FA, COL, and 5-FU). The cells were then collected and pelleted by centrifugation to
remove the supernatant before washing three times with PBS. Next, the cells were resuspended in
PBS, lysed, and centrifuged at 1500× g for 10 min with cooling centrifugation to remove cellular debris.
The supernatant was collected for assay, 100 μL added to the plate reader and incubated for 90 min
at 37 ◦C, and the liquid removed. Subsequently, 100 μL of 1× Biotinylated Detection Antibody was
added to each well and incubated for 1 h at 37 ◦C, followed by removal of the liquid and washing three
times with wash buffer. Next, 100 μL of 1×HRP conjugate working solution was added to each well
and incubated for 30 min at 37 ◦C, then replaced with 90 μL of TMB substrate solution and incubated
for 15 min at 37 ◦C. Finally, 50 μL of stop solution was added and the absorbance measured at 450 nm
using the microplate reader ROBONIK P2000 (Robonik India PVT LTD, Thane, India). Measurements
were made in triplicate.
3.2.11. Cytochrome c Assay
The cytochrome c was measured using the human cytochrome c ELISA kit in cell lysates according
to the manufacturer’s protocol (Abcam, Austria). HCT116 cells were cultured at density of 1.2–1.8 ×
10,000 cells/well and incubated for 72 h at 500 μL (for MSNs and MSNsP) or 60 μg/mL (for MSNsPCOL,
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MSNsPCOL/CG-FA, COL, and 5-FU). The cells were then collected and pelleted by centrifugation to
remove the supernatant before washing with PBS. Next, several steps were procced as the kit protocol.
Finally, absorbance was measured at 450 nm using the microplate reader (Robonik India PVT LTD,
Thane, India). Measurements were made in triplicate.
3.2.12. Measurement of Mitochondrial Membrane Potential
The mitochondrial membrane potential was done by means of flow cytometry with cell lysates
according to the manufacturer’s protocol TMRE mitochondrial potential assay (Cyman chemical,
Ann Arbor, MI, USA). HCT116 cells were cultured at density of 1.2–1.8× 10,000 cells/well and incubated
for 72 h at 500 μL (for MSNs and MSNsP) or 60 μg/mL (for MSNsPCOL, MSNsPCOL/CG-FA, COL,
and 5-FU) with volume of 100 μg/mL. The cells were then collected and pelleted by centrifugation to
remove the supernatant before washing with PBS. Next, we resuspended it in 100 μL of assay buffer
assay, followed by adding 100 μL of TMRE buffer, and incubated for 30 min. Then, it was centrifuged,
and resuspended in assay buffer, and the data collected by flow cytometry (FACSCalibur, Becton
Dickinson, Franklin Lakes, NJ, USA). Finally, measurements were made in triplicate.
3.2.13. Assays for MALAT-1, mir-205, Ang-2-CD44, and PD-1
Cell Culture and Treatment
HCT116 colon cancer cells were obtained from American Type Culture Collection (ATCC®
CCL-247), cultured in 96-well plates (cells density 1.2–1.8 × 10,000 cells/well) in RPMI 1640 medium
supplemented with 10% FBS, 10 μg/mL of insulin, and 1% penicillin-streptomycin, and allowed to
attach and grow for 24 h. The cell culture was treated with different samples, and control cells were left
untreated. To prepare cell culture supernatants, after incubation, cells were harvested after detaching
with trypsin and lysates collected by centrifugation. The cells were lysed with cell lysis buffer and
centrifuged at 1500g for 10 min at 2–8 ◦C to exclude cell debris. The expression levels of angiopoietin-2
(Ang-2), PD-1, CD44, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1, and miR-205
were measured in the prepared cell culture supernatants by RT-PCR or ELISA.
The supernatant was used to measure Ang-2 and PD-1 by ELISA using an ELISA plate reader
(Model stat fax 2100, Awareness, Ramsey, MN, USA) according to the manufacturer’s instructions.
For quantitative detection of total soluble human CD44, normal and variant isoforms were measured
by ELISA. For measurement of long non-coding RNAs (lncRNAs) for MALAT1 and mir-205, cells were
collected, and RNA extracted using the miRNeasy extraction kit. Total RNA including non-coding
RNAs was extracted from supernatants using the miRNeasy extraction kit (Qiagen, Valencia CA,
USA) and QIAzollysis reagent according to the manufacturer’s instructions. The concentration of
RNA was determined using NanoDrop2000, which is very accurate for measuring even the smallest
quantities of RNA (NanoDrop2000, Thermo Scientific, Wilmington, NC, USA). Reverse transcription
was carried out on extracted RNA in a final volume of 20 μL using the RT2 First Strand kit (Qiagen)
according to the manufacturer’s instructions. The expression levels of the studied lncRNAs were
evaluated using GAPDH, which is widely used as an internal control for serum lncRNAs in numerous
studies [98,99] according to the manufacturer’s protocol. The MALAT1 Ref Seq no. was NR
002819.2. The primer sequences for GAPDH were 5’-CCCTTCATTGACCTCAACTA-3’ (forward) and
5’-TGGAAGATGGTGAT GGGATT-3’ (reverse). RT-PCR was done in a 20 Ml reaction mixture using
the Rotor gene Q System (ROTOR-Gene Q, SN R1211164, Qiagen, Hilden, Germany) with the following
conditions: 95 ◦C for 10 min, followed by 45 cycles at 9 ◦C for 15 s and 60 ◦C for 60 s. The cycle
threshold (Ct) method was used to quantify target genes relative to their endogenous control. The ΔCt
of microRNAs was calculated by subtracting the Ct values of SNORD 68 from miR-205. The ΔCt of
lncRNAs was calculated by subtracting the Ct value of GAPDH from that of MALAT1. The fold change
in miR-205 and MALAT1 expression levels were calculated using the equation 2−ΔΔCt. Gene expression
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was calculated relative to the internal control (2−Ct). The fold change was calculated using 2−Ct for
relative quantitation [100].
3.3. Statistical Analysis
Data for biological evaluations are expressed as mean± SD. Significance differences were calculated
using the Student t-test, Mann Whitney U test, and analysis of variance (ANOVA) analysis at p < 0.05.
All statistical calculations were performed in triplicate using computer program IBM SPSS (Statistical
Package for the Social Science; IBM Corp, Armonk, NY, USA) release 22 for Microsoft Windows.
4. Conclusions
We successfully designed a novel DDS for COL prodrug that efficiently targets cancer cells.
The DDS was fabricated by loading COL into spherical mesoporous silica nanoparticles and
their subsequent modification with phosphonate groups. They were subsequently coated with
chitosan-glycine complex conjugated to folic acid, which acted as a targeting ligand for cancers.
Full inhibition of HCT116 colon cancer cells was observed. A weaker effect was observed in
HepG2 liver and PC3 prostate cancer cells. The most important characteristic of the DDS was its
negligible cytotoxicity in normal cells. We observed, after 72 h of incubation with MSNsPCOL/CG-FA,
low inhibition in normal BJ1 cells (4%) compared to free COL (~60%). Apoptosis (intrinsic) was
found to be the main mechanism of action occurring as a consequence of the strong antimitotic
effects. MSNsPCOL/CG-FA more strongly inhibited tubulin than free COL. It also increased the
cell cycle at G2/M, caspase-3 activation, and Bax expression compared to COL. On the other hand,
MSNsPCOL/CG-FA inhibited anti-apoptotic proteins (Bcl-2, BRAF, and CD44) more strongly than
clinically used COL and 5-FU anticancer drugs. New effects of the DDS on genetic regulation and
cancer related immuno-effects were found. MSNsPCOL/CG-FA significantly inhibited MALAT1,
mir-205 expression, Ang-2 protein, and PD-1 compared to COL and 5-FU. We expect that the tailored
DDS for COL has the potential to become a nanomedical platform for cancer treatment.
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Abstract: β-glucans represent a heterogeneous group of naturally occurring and biologically active
polysaccharides found in many kinds of edible mushrooms, baker’s yeast, cereals and seaweeds,
whose health-promoting effects have been known since ancient times. These compounds can be taken
orally as food supplements or as part of daily diets, and are safe to use, nonimmunogenic and well
tolerated. A main feature of β-glucans is their capacity to function as biological response modifiers,
exerting regulatory effects on inflammation and shaping the effector functions of different innate
and adaptive immunity cell populations. The potential to interfere with processes involved in the
development or control of cancer makes β-glucans interesting candidates as adjuvants in antitumor
therapies as well as in cancer prevention strategies. Here, the regulatory effects of dietary β-glucans
on human innate immunity cells are reviewed and their potential role in cancer control is discussed.
Keywords: innate immunity; β-glucans; nutrition; immunotherapy; cancer
1. Introduction
The immune system has an active role in all phases of carcinogenesis, exerting multifaceted
functions that range from antitumoral to protumoral activities. Tumors are populated by a vast
and diverse array of immune components: innate sentinels including phagocytes [macrophages,
neutrophils and dendritic cells (DC)], natural killer (NK), natural killer T (NKT) and γδ T cells, as well
as adaptive leukocytes, including naive, memory, and effector B- and T-lymphocytes [1]. The degree
of immune infiltration and the composition of the infiltrate, as well as of the circulating immune cell
pool can vary markedly across tumor types and stages [1,2], and can represent important correlates
of cancer prognosis and treatment responsiveness [1–3]. Although the immune system can elicit an
antitumor response that leads to tumor destruction in some cases, the successful development of
such a response is often hampered by a plethora of factors. Indeed, immune cell populations are
conditioned by soluble factors, enzymes and metabolites produced by nearby tumor and stromal
cells within the tumor microenvironment (TME) that contribute to dampen the antitumor immune
response [4]. Moreover, the immunosuppressive TME can even shape immune cell functions toward a
tumor-promoting response [5].
Cancer is frequently associated with chronic inflammation, which is considered a requirement
for maintaining an immunosuppressive network. Innate immune cells are the main actors in
the inflammatory response by virtue of their expression of pathogen recognition receptors (PRR).
The engagement of these receptors not only induces the secretion of proinflammatory cytokines, thereby
further supporting inflammation, but also activates antigen presenting cell functions, thus favoring the
recognition and killing of tumor cells and the orchestration of a specific adaptive response.
Shifting the balance towards a protective response has been the goal of many anticancer strategies.
An adequate response has been achieved in several human cancers with the use of nonspecific
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immunotherapies, vaccines, adoptive cell therapy and, more recently, through the blockade of immune
checkpoints. Nevertheless, the high antigen-specific T-cell-mediated response measured in some tumor
cases does not correlate with clinical benefit [6], suggesting that resistance mechanisms within the TME
might orchestrate tumor escape, and that an appropriate activation of innate immunity cells may be
the most critical determinant of therapeutic success.
In recent years, a clear-cut association between nutrition and cancer has been highlighted by several
epidemiological and research studies [7]. Dietary patterns and bioactive food-derived compounds
have been associated with either increased or decreased risk of several human noncommunicable
diseases, including cancer, and their capacity to influence the immune response under physiological
and pathological conditions has been widely described (World Cancer Research Fund. Continuous
Update Project Expert Report 2018. Diet, Nutrition, Physical Activity and Colorectal Cancer. Available
at: dietandcancerreport.org. 2018). There is currently a growing interest in studying the mechanisms
underlying the capacity of bioactive food compounds to modulate processes implicated in either the
promotion of or in the protection against carcinogenesis. In this regard, the ability of natural food
compounds to regulate innate cell functions and to promote or attenuate inflammation is receiving
great attention. Among a vast array of compounds naturally occurring polysaccharides, including
β-glucans, have been widely studied for their effects on human health and disease in both western
and eastern medicine [8,9]. Indeed, despite their structural function, some β-glucans exert important
biological activities.
In this review, we will overview the immunomodulatory effects of β-glucans derived from
edible mushrooms, baker’s yeast and cereals, assumed as dietary supplements in the form of purified
compounds or as extracts. We will focus on human studies and describe the in vitro and in vivo
effects of these compounds on innate immunity cells involved in cancer surveillance. The mechanisms
underlying the capacity of β-glucans to modulate immune response and how this may impact on
tumor development/progression will be discussed.
2. Dietary β-glucans: Main Features and Sources
Dietary fibers have been consumed for a long time, due to their beneficial effects on health, as part
of the carbohydrate fraction within food [10]. All existing definitions recognize fibers as a group of
carbohydrate polymers and oligomers (and lignin) that are resistant to digestion and absorption in
the human small intestine where they are, partially or completely, fermented by the gut microbiota.
They are present in two main forms depending on their solubility in water (i.e., soluble and insoluble
fibers) [8]. Among soluble fibers, β-glucans are homopolysaccharides composed of D-glucopyranosyl
residues linked through β-glycosidic bonds comprising a heterogeneous group of naturally occurring
biologically active compounds found in the bran of some cereal grains (oat, barley), in the cell wall
of baker’s yeast, in many kinds of edible mushrooms (fruit bodies and cultured mycelium) and
seaweeds [11,12]. β-glucans of different origins differ in their macromolecular structure and β-linkage,
with mushroom- and yeast-derivedβ-glucans exhibiting primarilyβ-(1,3/1,6) linkages, while those from
cereals have β-(1,3/1,4) linkages [9]. They have the peculiarity of being encountered by humans either
as part of their diet or as pathogen associated molecular patterns (PAMP), since they also constitute the
cell wall of some pathogenic yeasts and bacteria, and strongly contribute to microorganism recognition
and clearance [13]. β-glucans greatly vary in their macromolecular structure, solubility, molecular
weight, degree of branching and charge of polymers, as well as in receptor recognition/binding affinity,
and their biological activity strongly depends on these features [14,15]. β-glucans derived from
different sources appear to show diverse activities. While β-glucans originated from mushrooms are
effective as antitumor defense and immunity boost, those found in cereals are more active in lowering
cholesterol and blood sugars [15,16].
Upon oral ingestion as dietary components, they reach, in an undigested form, the small intestine
where intestinal epithelial and/or M cells internalize and present them to the immune cell populations
within the Peyer’s patches [17]. β-glucan particles can also reach distant lymphoid organs via blood
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or lymph [18–20]. The recognition by innate immunity cells occurs via ligation of specific PRR,
such as Toll-like (TLR) and C-type lectin-like receptors [15,21]. Among the latter, Dectin-1 is the best
characterized receptor, reported to bind β-glucan from different sources, and is expressed on the
surface of monocytes, macrophages, neutrophils, DC and T lymphocytes [22]. Other PRR, including
lactosylceramide receptor, mannose receptor, complement and scavenger receptors were reported to
directly bind β-glucan or to cooperate with Dectin-1 for its recognition [15,21,23]. Recently, β-glucan
was shown to stimulate NK cell cytotoxic activity through direct binding to the NKp30 activating
receptor [24]. Receptor binding on innate immunity cells elicits a number of cellular responses through
the modulation of inflammasome and transcription factor activation, and the production of immune
response modifiers [cytokines, chemokines, reactive oxygen species (ROS)], finally shaping adaptive
immune response.
3. Immunomodulatory Effects of β-glucans
β-glucans from different sources have been extensively studied for their anti-inflammatory,
anti-allergic, anti-obesity and anti-osteoporotic activities [9]. The regulatory effects of β-glucans
on immune response have been identified as one of the main biological functions that make these
compounds attractive targets for therapeutic interventions. Strong evidence on the immunomodulatory
activities of β-glucans has been proved by in vitro, as well as by animal- and human-based clinical
studies, highlighting their ability to protect against infections and to improve the immunogenicity of
vaccines, their antitumor activity and, more recently, their therapeutic potential when combined with
other cancer therapies [25–28]. Indeed some β-glucan preparations have been approved as adjunctive
therapeutic drugs for cancer treatment. The safety and lack of toxicity of their oral or intravenous
administration have been assayed in phase I–II clinical trials carried out in healthy volunteers, as well
as virus-infected or cancer patients [29–34]. The size and biochemical composition of β-glucans isolated
from different sources have been reported to affect their immunomodulatory properties with the
molecular pathways activated and the features of the immune response generated depending on
the cell type and receptor triggered [15,35]. Furthermore, β-glucans derived from different sources
differ in their capacity to function as PAMP and, as a consequence, in their immunoregulatory
efficacy. In this regard, β-glucans derived from baker’s yeast and mushrooms are by far the
best-documented immunostimulators, while those from cereals fall short as immune regulators,
as they are structurally different and not recognized as PAMP [36,37]. The ensemble of these variables
can result in different pharmacologic activities and bioavailability, thus explaining the discrepancies
observed when comparing different studies.
The main evidence on the in vitro effects of β-glucans on human innate immunity cells, as well as
the clinical studies assessing their in vivo effects on the same cell populations in either healthy subjects
or cancer patients, are reviewed in the next sections and summarized in Tables 1–3.
3.1. In Vitro Effects on Innate Immunity Cells
In vitro studies have shown that β-glucans from yeasts, mushrooms or cereals are able to enhance
the responsiveness or function of human primary immune cells, eliciting potent immune responses
through their recognition by a variety of PRR, particularly Dectin-1 and complement receptor 3
(CR3). Within the innate immune system, the targeted cells of β-glucans include macrophages,
neutrophils, monocytes, NK cells and DC. Specifically, β-glucans can enhance the functional activity
of monocytes/macrophages and DC and activate antimicrobial activity of mononuclear cells and
neutrophils in vitro. This enhanced immune response is accomplished by an increased proinflammatory
cytokine and chemokine production and an enhanced oxidative burst, as mainly demonstrated in
mouse models [38].
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Abbreviations: anti-β glucan antibodies, ABA; antibody-dependent cellular phagocytosis, ADCP; β-glucan receptor,
βGR; cytotoxic T lymphocyte, CTL; dendritic cells, DC; Killer immunoglobulin receptor, KIR; Lymphotoxin a,
LTA; leukotriene B4, LTB4; monocyte-derived dendritic cells, MDDC; mannose receptor, MR; natural killer, NK;
nitric oxide, NO; platelet-activating factor, PAF; prostaglandin E2, PGE2; reactive oxygen species, ROS. 1 β-glucan
concentrations are shown when available.
As shown in Table 1, biologically active fungalβ-glucans found in edible mushrooms (e.g., Agaricus
brasiliensis, Pleurotus citrinopileatus, Agaricus blazei, Flammulina velutipes) can enhance inflammatory
cytokine production in monocytes [39–41,43,44] as well as in monocyte-derived macrophages
(MDM) [40]. Furthermore, Minato and colleagues have recently explored the functional effect
of Pleurotus citrinopileatus polysaccharide (PCPS) on monocyte-to-macrophage differentiation, finding
that PCPS can direct Dectin-1 and TLR2-mediated differentiation of monocytes toward a macrophage
cell population with reduced proinflammatory capacity [43]. Similarly, the function of DC can
be influenced by β-glucans from mushroom extracts in terms of secretion of proinflammatory
cytokines/chemokines [45,48], through Dectin-1 signaling and Syk/Raf-1-dependent pathways [45].
In addition, it has been reported that β-glucans derived from Armillariella mellea, Hericium erinaceum
and Piptoporus betulinus, enhance phenotypic and functional maturation of monocyte derived dendritic
cells (MDDC), with significant interleukin (IL)-12 and IL-10 production, and upregulation of surface
maturation markers [44–48]. In general, β-glucans of a larger size and more branching complexity
have higher immunomodulating potency [59], while the effect of fruit body extracts of various higher
Basidiomycetes are slightly higher than those observed for mycelium extracts of the same species [49].
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Additional studies indicated that also β-glucans isolated from yeasts overall enhance the immune
response by modulating proinflammatory cytokine production in macrophages via Dectin-1/Syk
signaling pathway and NLPR3 inflammasome activation, as well as in MDDC via PI3K/AKT signaling
pathway [52–54]. Moreover, yeast-derived β-glucans induce DC maturation, significantly increase
tumor-specific cytotoxic T lymphocyte (CTL) responses [53] and program DC to express cell adhesion
and migration mediators, antimicrobial molecules, and Th17-polarizing factors [54]. Furthermore,
the role of secondary mediators, which include lipids, in the induction of the cytokine signature
was demonstrated in DC stimulated with zymosan, a cell-wall extract from Saccharomyces cerevisiae
that contains a β-glucan component, providing mechanistic clues that β-glucans can modulate the
immune response by acting on the lipid mediator cascade and by activating STAT3 signaling [55,56].
The regulation of additional cellular responses by mushroom-derived β-glucans in monocytes and
DC has been also described. Specifically, β-glucans from Agaricus brasiliensis, Agaricus blazei or
Flammulina velutipes extracts with immunomodulatory and antitumor activities, significantly increase
the adherence and phagocytosis by monocytes [39–41] and enhance ROS production in monocytes
and macrophages [40], while water-soluble components from Armillariella mellea or Hericium erinaceum
decrease the MDDC endocytic capacity [46,47]. Besides β-glucans from yeasts and mushrooms,
also those derived from cereals influence MDDC functions. The interaction of barley β-glucan with DC
enhances maturation and cytokine production, leading to changes in the balance of Th1/Th2 cytokines
in autologous T cells [60]. However, the effects of this compound on DC maturation/activation are
rather weak as compared to those of β-glucans derived from mushrooms [59].
Large β-glucans can be degraded by macrophages into smaller fractions that, when released,
prime CR3 on neutrophils and NK cells, triggering antimicrobial activity. Indeed, poly-[1–6]-d-
glucopyranosyl-[1–3]-d-glucopyranose (PGG) glucan from yeast Saccharomyces cerevisiae (Imprime
PGG) as well as aqueous extracts from fruit bodies and mycelia of various higher Basidiomycetes,
enhance ROS production and antibody-dependent cellular phagocytosis by neutrophils [49,57,61]
and monocytes [57], respectively. Mechanistically, Imprime binding and functional activation of
these innate effector cells require first the formation of an immune complex with naturally occurring
anti-β-glucan antibodies and subsequent opsonization by complement proteins [57,62], the activation of
NF-kB [61], which results in enhanced cell migration toward the chemoattractant C5a [58]. Conversely,
studies investigating the biological effects of β-glucans on NK cells have been rarely performed.
Nevertheless, the effects of fungal- or yeast-derived β-glucans on primary NK cells demonstrate that
these polysaccharides markedly enhance NK cell cytotoxicity by stimulating interferon (IFN)γ and
perforin secretion and increasing the expression of the activating receptor NKp30, with CR3 as a critical
receptor [51]. Moreover, β-glucans present in Pleurotus ostreatus extracts have the ability to induce
NK-cell mediated cytotoxicity against cancer cells and to enhance cytokine production. The cytotoxic
effects are mediated by NKG2D and IFNγ upregulation and are enhanced in the presence of IL-2,
while the activation for cytokine secretion is associated with upregulation of KIR2DL genes [50].
In summary, these studies suggest that β-glucans, derived from edible mushrooms, yeasts or
cereals, have the potential to regulate a plethora of immune functions. β-glucans binding to specific
receptors on DC and macrophages trigger their activation and maturation, enhance the production
of proinflammatory cytokines that in turn stimulate the polarization toward Th1 or Th17 responses,
and induce the activation of antigen-specific CD8+ CTL. Furthermore, β-glucans can enhance the
antimicrobial activity of neutrophils and promote NK cell cytotoxicity.
3.2. In Vivo Effects in Healthy Subjects
A number of human studies involving healthy volunteers have examined the effects of dietary
supplementation with β-glucans of different origins on innate immune responses (Table 2).
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Abbreviations: Natural Killer, NK; Physical activity, PA; Polymorphonuclear leukocyte, PMN; Reactive oxygen
species, ROS; Respiratory burst activity, RBA; Subjects’ number, N; T helper, Th; Upper respiratory tract infection,
URTI. 1 β-glucan concentrations are shown when available.
In keeping with the in vitro studies, these compounds were reported to affect either the
abundance/frequency or the effector functions of different innate cell populations. In a study performed
on regularly training athletes (from different sport disciplines) receiving a three months supplementation
with insoluble, particulate β-glucan (Pleuran, Imunoglukan) extracted from the fruit bodies of Pleurotus
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ostreatus, the number of circulating NK cells significantly increased in the treated as compared to the
placebo group [63]. In agreement with data from in vitro studies [49], a concomitant enhancement of
polymorphonuclear leukocyte (PMN)-mediated phagocytosis was observed in treated subjects, together
with a decreased incidence of upper respiratory tract infection (URTI) symptoms [63]. Moreover,
a two-month oral supplementation with the same compound (Pleuran) was found to counteract the
decrease of blood NK cell number and activity (NKCA), but not that of granulocytes and monocytes,
induced by short-term high-intensity exercise in elite athletes [64]. This evidence points to a role of
Pleurotus ostreatus insoluble β-glucan not only as immune modifier and adjuvant of regular physical
activity but also in the prevention of immunosuppression induced by acute exhausting physical load.
Moreover, these studies, together with in vitro evidence on the enhancement of NK cell cytotoxicity
against tumor cells [50], highlight the peculiar feature of this compound to boost innate immunity
mainly by acting on NK cells. β-glucan-mediated increase of NKCA and Th1-type immune responses,
although not statistically significant, was also observed in a Japanese clinical trial in which the subjects
ingested water extracts (β-glucan content 24 mg/meal) from Oyster mushroom Pleurotus Cornucopiae
(Tomogitake) for 8 weeks [65]. In contrast, a beverage supplement containing soluble β-glucan
extracted from oat did rescue neither NKCA and PMN respiratory burst activity, nor the incidence of
URTI symptoms, with respect to a placebo over an 18-day intake in trained male cyclists [68,71].
Regulatory effects on blood granulocytes and monocytes (i.e., increased frequency or reduction of
proinflammatory cytokine and ROS production) have been described after oral administration of extracts
from the higher Basidiomycetes Grifola frondosa and Agaricus blazei Murill (AbM, AndoSan) [66,67].
However, although these extracts are characterized by a high content of β-glucan, the specific
contribution of the glucan fraction to the immunomodulatory activity has not been demonstrated in
these studies [66,67]. Finally, β-glucan purified from the cell wall of Saccharomyces cerevisiae (Imuneks)
was reported to reduce some immunopathogenic processes characterizing subjects with allergic
rhinitis [69]. In particular, a 12-week oral supplementation with β-glucan in allergen-sensitized subjects
resulted in a significant decrease in the frequency of eosinophils, crucial effectors in allergic reactions,
in the nasal lavage fluid [69]. Conversely, in a pilot intervention study on healthy volunteers, dietary
supplementation with Saccharomyces cerevisiae insoluble β-glucan for 7 days did not affect cytokine
production and microbicide activity of peripheral blood phagocytes [70].
With the exception of some studies on animal models, the impact of dietary whole mushroom
consumption on immunity has been only poorly investigated in humans. In a study by Dai
and colleagues, a regular consumption of dried Lentinula edodes mushrooms (5 or 10 g/day) for
four weeks was found to significantly increase the activation and proliferative potential of innate
lymphocytes, particularly γδ T and NKT cells, concomitantly with a decrease of systemic inflammatory
markers [72]. Regardless of the mechanism(s) and bioactive fraction(s) responsible for this activity,
these results suggest that regular dietary intake of mushrooms could improve innate immunity and
dampen inflammation.
3.3. In Vivo Effects in Cancer Patients
The effects of dietary supplementation with β-glucans of different origins have been investigated
in a number of clinical trials carried out in cancer patients either undergoing conventional anticancer
therapy, or in the absence of any other concomitant therapeutic option (Table 3).
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Abbreviations: Patients’ number, N; Immunoglobulin, Ig; Immunosuppressive acidic protein, IAP; Killer
immunoglobulin receptor, KIR; Lymphokine-activated killer, LAK; Myeloid-derived suppressor cell, MDSC;
Natural killer, NK; Non-small cell lung carcinoma, NSCLC; Plasmacytoid DC, pDC; Quality of life, QOL; Regulatory
T, Treg. 1 β-glucan concentrations are shown when available.
The majority of these studies investigated changes in patients’ immune system by monitoring
surrogate markers such as leukocyte counts or cytokine profiles as well as by measuring
chemotherapy-associated side effects and indexes of quality of life (QOL). One of the most prominent
effect described for the oral administration of β-glucans is the attenuation of chemotherapy-induced
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fall of leukocyte counts paralleling numerical or functional changes of some specific immune cell
populations. As shown in Table 3, Lentinula edodes extracts and yeast-derived β-glucan (Imuneks)
counteract the chemotherapy induced decrease in NK and lymphokine-activated killer (LAK) cell
activity when administered to advanced breast cancer patients [75,80]. Likewise, NK, NKT and
LAK cell cytotoxic activity was reported to be higher in cancer patients administered with Agaricus
blazei or Lentinula edodes extracts [73,75,76]. Conversely, the administration of Agaricus blazei Murill
extracts (AndoSan) to multiple myeloma patients undergoing high dose chemotherapy resulted in the
expansion of different immune cell populations such as regulatory T (Treg) cells and plasmacytoid DC,
and in enhanced serum levels of IL-Ra, IL-5 and IL-7. Furthermore, the expression of immunoglobulin
and NK cell-related genes was also observed [74]. The capacity of β-glucans to numerically/functionally
influence specific subsets of immune cells has been also documented by studies assessing the effects
of yeast-derived β-glucan (Imuneks) in patients affected by advanced breast cancer. These studies
reported that β-glucan stimulates the proliferation and activation of CD14+ monocytes expressing
high levels of CD95 and CD45RA surface antigens [82].
The ability of β-glucan to counteract, at least in part, the negative effect of chemotherapy on blood
cell counts mainly relies on its hematopoiesis-enhancing capacity. In this regard, administration of
carboxymethyl-glucan (CM-G), a water-soluble derivative of Saccharomyces cerevisiae, to advanced
prostate cancer patients, has been reported to enhance hematopoietic regeneration. After CM-G
administration, the total leukocyte, red blood cell and platelet counts, as well as hematocrit and
hemoglobin increased significantly independently of changes in the lifestyle habits of patients [87].
Numerical and functional changes of immune cell populations have been also observed following
β-glucan supplementation to cancer patients in the absence of any other therapeutic option, either in
newly diagnosed patients or in those who have already completed their therapeutic pathway. In this
regard, in non small cell lung carcinoma patients, the administration of yeast-derived particulate
β-glucan soon after diagnosis decreases the frequency of circulating CD33+HLA-DR− myeloid-derived
suppressor cells (MDSC) with improved effector function [86]. A similar decrease in the percentage of
CD33+HLA-DR− MDSC was also observed in a phase I trial involving patients with biochemically
recurrent prostate cancer following supplementation with Agaricus bisporus powder [83]. Other clinical
studies highlighted the effects of the administration of β-glucan enriched D-Fraction, extracted from
the fruit body of the Maitake mushroom Grifola frondosa, to either advanced lung or breast cancer
patients [84] as well as to breast cancer patients free of disease after initial treatments [85]. While in
patients at advanced stages of disease the administration of D-fraction promoted NK cell activation [84],
in those free of disease the main changes were observed at the level of CD3+ CD56+ NKT and CD4+
CD25+ Treg cells, whose frequency was increased in the β-glucan treated group [85].
Some studies also reported modulations of cytokine serum levels as well as functional changes of
ex-vivo immune cell populations upon in vitro stimulation. In particular, increased secretion of IL-12
paralleling a decrease in IL-4 content was observed in advanced breast cancer patients administered
with Imuneks [80] as well as in esophageal cancer patients supplemented with Lentinan, a purified
β-glucan from Lentinula edodes [77]. Interestingly, a significant increase in the serum content of IL-15,
a cytokine promoting NK cell differentiation and optimizing NK cell function, was detected upon
supplementation with Agaricus bisporus [83]. Likewise, functional changes were observed in ex-vivo
immune cells from breast cancer patients free of disease including granulocyte response to phorbol
myristate acetate (PMA) stimulation, IL-10 production by PMA stimulated CD14+ cells, and constitutive
IL-2 secretion by CD3+ CD56+ NKT cells [85].
The most promising evidence to date in clinical trials has come from studies investigating the
benefits of β-glucan, in combination with conventional cancer treatment, on therapy side effects,
QOL and survival of cancer patients. Indeed, a significant reduction of chemotherapy-associated side
effects such as loss of appetite, alopecia, emotional instability, and general weakness was reported in
β-glucan supplemented patients, leading to a general improvement of QOL [73,75–78,81]. In this regard,
a recent systematic review of clinical applications of Lentinan in treating lung cancer during the past 12
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years in China reported a solid effect of Lentinan on improving QOL and on promoting the efficacy of
chemotherapy and radiation therapy [88]. In contrast with these results, Yoshino and colleagues failed
to detect any change in leukocyte/neutrophil counts or any improvement in chemotherapy-induced side
effects and QOL in unresectable or recurrent gastric cancer patients upon administration of Lentinan.
These discrepancies likely rely not only on differences in the compound administered but also in the
type of cancer and related chemotherapeutic options. However, it is of interest that a subpopulation of
patients with Lentinan-binding monocytes ≥ 2% in the peripheral blood showed a longer survival time
when this compound was administered together with chemotherapy, suggesting that Lentinan-binding
monocytes could represent a potential biomarker predicting chemotherapy response [79].
Taken together, these observations suggest that β-glucan provides an additional alternative
therapeutic modality to maintain innate immunity cell activity and, in particular, to reduce many severe
side effects caused by chemotherapy in cancer patients by stimulating hematopoiesis and assisting
with an overall improvement in quality of life.
4. Conclusions
Nowadays, dietary β-glucans consumed in a daily diet or as a food supplement are well studied for
their multifaceted activities with important implications for human health. Multiple effects have been
reported for these compounds, including metabolic and anti-obesity activities, anti-osteoporotic,
anti-allergic and anti-inflammatory effects, promotion of hematopoiesis, and regulation of gut
commensal flora (Figure 1). The anticarcinogenic effects of β-glucans are clearly evidenced in
the scientific literature and include: (i) the direct control of cancer cell growth, (ii) the modulation of
TME, both by bridging the innate and adaptive arms of the immune system and by orienting
immunosuppressive cells toward an immunostimulatory phenotype, (iii) their synergism with
conventional anticancer therapy. In this regard, preclinical studies have demonstrated that the
administration of certain β-glucans can effectively manipulate TME, for example by inducing the
phenotypic conversion of tumor associated macrophages, leading to a significant reduction of primary
tumor and distant metastases [89,90].
 
Figure 1. A schematic representation of the potential role of β-glucan in the control of cancer.
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In this review, we focused on the immunomodulatory effects of β-glucans indirectly affecting
tumor development/progression that may be relevant for their potential application in the fight against
cancer in combination therapies. As schematically represented in Figure 1, multiple innate immunity
cell subsets and biological processes are modulated by β-glucans, ranging from secretion of immune
mediators to induction of phagocytosis and cytotoxic functions. Furthermore, the capacity of these
compounds to attenuate chemotherapy-induced side effects, to promote hematopoiesis and to improve
QOL has been reported in cancer patients. The ensemble of effects on innate immunity cells, key players
in cancer surveillance, observed in vitro as well as in preclinical and clinical studies, clearly highlights
the potential of β-glucans to modulate key processes involved in carcinogenesis and immune-mediated
control of cancer, and make these compounds attractive as adjuvants in cancer therapies.
Nevertheless, the emerging success of combinatorial approaches to cancer treatment involving
Imprime, a yeast-derived soluble β-glucan in clinical development for cancer, as an intravenously
administered immunotherapy, in combination with immune checkpoint inhibitors (CPI), expanded the
clinical benefit of CPI therapy by enhancing the anticancer immune response. The combinatorial use of
β-glucan with immunotherapy or conventional cancer therapy is beginning to show great promise in
improving patient morbidity and mortality, strongly suggesting that β-glucans may play an essential
role in future strategies to inhibit tumor growth and to improve the clinical responses to current
therapies. To this aim, studies that deeply characterize how β-glucans with different structures and
size interact with specific receptors and regulated molecular pathways—as well as the use of β-glucan
molecules with precisely defined biochemical properties—are necessary for the full exploitation of
these food-derived biological response modifiers in the fight against cancer.
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Abstract: Epithelial mesenchymal transition (EMT) is a key process in the progression of malignant
cancer. Therefore, blocking the EMT can be a critical fast track for the development of anticancer
drugs. In this paper, we update recent research output of EMT and we explore suppression of EMT
by natural anti-inflammatory compounds and pro-resolving lipids.
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1. Introduction
The epithelial–mesenchymal transition (EMT) is defined as a phenomenon that epithelial cells
transform into mesenchymal cells [1]. EMT plays a key role in cancer progression and fibrosis.
Many researchers and pharmaceutical companies have tried to develop novel EMT blockers due to its
importance in such diseases [2–4].
Inflammation is one of ten in cancer hallmark [5]. It is a critical factor of tumor microenvironment
affecting EMT. Several reviews have emphasized role of inflammation in EMT [6]. However, there
are a few reviews that deal with the blocking of EMT by natural anti-inflammatory compounds and
pro-resolving lipids.
In this review, I have dealt with ingredients derived from natural products that were not covered in
the 2018 review on EMT [6]. I have also added the story of inflammasomes, which play an essential role
in the early steps of inflammation, and how they are involved in EMT. Naturally derived compounds
that control these inflammasome-related molecules in the EMT have been discussed. About the
resolution of inflammation, the newly discovered pro-resolving lipids including RvTs are added and
the receptors specifically acting on pro-resolving lipids have also been discussed. Understanding the
action of natural anti-inflammatory compounds and pro-resolving lipids with anti-EMT activities
might provide a new armory to suppress the progression of cancer.
2. EMT in Cancers
EMT shows the reduced expression of epithelial markers including E-cadherin and keratins and
the increased expression of mesenchymal marker proteins such as vimentin and N-cadherin via actions
of transcription factors including as SNAIL1 and ZEB1 (Figure 1) [6]. The molecular mechanism of
EMT process has been well explained in the report (references in it) [1]. In this part, we will briefly
update the concept that reflects recent achievements for EMT.
EMT occurs by a various mediators from tumor microenvironments via receptor through signal
transduction. EMT-related transcription factors blocks the expression of epithelial cell-marker genes
and evoke mesenchymal-marker genes. E-cadherin, keratin, ZO-1, miR-34, and miR-200 belong to the
epithelial markers, and N-cadherin, vimentin, fibronectin, SNAIL, ZEB1, TWIST, Brachyury, Foxq1,
Runx2, GATA, and SOX belong to the mesenchymal markers. P-cadherin is the marker of partial EMT.
The dot triangle indicates the relative ratio of p-cadherin expression. Modified from Lee’s report [6].
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Figure 1. Epithelial–mesenchymal transition (EMT).E-cadherin: Epithelial cadherin; EGF: Epidermal
Growth Factor; FGF: Fibroblast Growth Factor; GATA: GATA Binding Protein; HGF: Hepatocyte
Growth Factor; IGF: Insulin Like Growth Factor; ILK: Integrin Linked Kinase; JAK: Janus Kinase;
LATS: Large Tumor Suppressor Kinase; miR34: microRNA 34; miR200: microRNA 200; N-cadherin:
Neural cadherin; P-cadherin: Placental cadherin; PDGF: Platelet Derived Growth Factor; Runx2: RUNX
Family Transcription Factor 2; SMAD: Sma- And Mad-Related Protein; SMO: Smoothened, Frizzled
Class Receptor; SOX: SRY-Box Transcription Factor; TGF-β: Transforming Growth Factor Beta; Wnt:
Wingless-Type MMTV Integration Site Family; ZEB1: Zinc Finger E-Box Binding Homeobox 1; ZO-1:
Zona Occludens 1.
2.1. Adaptation to New Concepts of EMT
2.1.1. Signaling Pathways in the EMT Process
A typical signaling pathway of EMT is the transforming growth factor-β1 (TGF-β1) pathway.
TGF-β1 induces EMT via SMAD-dependent or non-SMAD signaling pathway [7]. Growth factors
including FGF, HGF, IGF1, EGF, and PDGF via receptor tyrosine kinase can induce EMT via signaling
pathway of PI3K-AKT and ERK MAPK [8–11]. Wnt signaling, hedgehog signaling, Notch signaling,
hypoxia, and inflammatory tumor microenvironment also involves in EMT [5]. Recently, it has been
shown that hippo signaling is also involved in EMT [12]. YAP and TAZ can enhance EMT through
upregulation of EMT transcription factors such as forkhead box C2 (FOXC2), snail family zinc finger
1/2 (SNAIL1, SLUG), twist-related protein 1 (TWIST1), and ZEB1 [12–15].
2.1.2. Transcription Factors Involved in EMT
Novel players are newly recognized as regulatory transcription factor in the EMT. Brachyury, the
T-box transcription factor, is a novel transcription factor implicated in the EMT of cancer cells [16].
Brachyury is known as the target gene of WNT, one of the major signaling pathways of EMT [17].
Foxq1, one of forkhead transcription factor, has also regarded as a novel transcription factor mediating
the EMT of gastric cancer [6,18]. Runt-related transcription factor 2 (Runx2) belongs to the runt-related
transcription factor family [19]. Runx2 plays a key role in EMT of hepatocellular carcinoma (HCC) [20].
GATA transcription factors are also implicated in the EMT of cancer cells [21]. Serine 161 and serine
187 phosphorylated GATA1 by PAK5 can promote EMT of breast cancer cells by recruiting histone
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deacetylase 3/4 to E-cadherin promoter [22]. Other players of EMT include SRY-box (SOX) transcription
factors [23]. Sox4 acts as a master regulator in EMT of cancerous breast epithelial cells [24].
2.1.3. Partial EMT
EMT could be not defined as a dichotomous transition from epithelial status to mesenchymal one
of cells [6,25].
Partial EMT with both epithelial and mesenchymal cell markers was proposed (Figure 1) [25].
Cells that have undergone with partial EMT have the capability showing collective sheet or cluster
migration [26]. Partial EMTed cells have the competitiveness in that not all cells need to respond to
EMT signals. Thus, they can far more efficiently execute plasticity in converting to a colonization state
of metastasis via MET [25].
2.1.4. Parallelism between Cancer Stem Cell and EMT
A cancer stem cell (CSC) is a cancer cell having the ability of self-renewal and differentiation.
It divides to progenitor cancer cells. It is a culprit of cancer recurrence and metastasis [27]. Several
EMT transcription factors and inducers can evoke the expression of cancer stem cells markers, thereby
enhancing the capability to initiate cancer, a typical characteristic of cancer stem cells [28]. TGF-β
promotes the de-differentiation of human basal breast non-CSCs into CSCs via ZEB1, suggesting that
the activation of EMT in cancer cells by TGF-β/ZEB1 is closely linked to the de-differentiation of cancer
cells into the CSC state [29].
2.2. Focus on Chemoresistance and Immune Evasion of EMT in Cancers
In the course of EMT, epithelial cancer cells can lose contacts between cells and apicobasal
polarity but gain enhanced migration and invasion [1,6]. EMT has also strong influences on several
hallmarks of cancer including cancer initiation, immune evasion, proliferation, survival, and resistance
to therapeutics [6,30]. We will briefly update EMT’s roles in cancer such as chemoresistance and
immune evasion.
2.2.1. Chemoresistance
Chemoresistance to anticancer chemotherapeutics implies that cancer cells can survive despite
the administration of an anticancer drug in a dose that can usually kill cancer cells. A significant
correlation has been found between EMT-related gene expression and chemo-resistance to anticancer
therapy [6,30,31]. Although the role of EMT in metastasis is disputable by some group, EMT is crucial for
anticancer drug resistance [32,33]. For example, TWIST-mediated EMT is related to sorafenib resistance
to advanced HCC [34]. Therefore, EMT should be understood as a predictor of chemoresistance for
anticancer drugs.
2.2.2. Immune Evasion
EMT has been understood as a key mechanism of immune escape of cancer cells. When snail1,
an EMT transcription factor, is ectopically expressed in MCF7 breast cancer cells, cancer cell lysis
executed by TNF-α-induced CTL is curtailed [35]. When snail1 is overexpressed in B16 melanoma cells,
CTL-induced lysis is reduced and maturation of dendritic cells is inhibited while inhibitory Treg-like
CD4+ Foxp3+ cells are expanded [36].
Enhanced EMT properties in cancer cells (A549, MCF7, and HepG2) by the TGF-β, IFN-γ, and
TNF-α may affect differentiation and death of natural killer (NK), T, and B cells [37]. Reduced miR-200
and enhanced ZEB1 expression in lung cancer cells not only can evoke EMT, but also can lead to
enhanced expression of PD-L1, which is related to the exhaustion of CD8+ T lymphocytes in lung
cancer tissues [38]. In contrast, activated CD8+ T cells provoke mammary epithelial tumor cells to
experience EMT, thus obtaining cancer-initiating power of breast cancer stem cells [6,39].
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3. Induction of EMT by Mediators from the Chronic Inflammatory Tumor Microenvironment
3.1. Upgrade of Inflammation Concept: From Initiation (alpha) to Resolution (omega)
Inflammation is intrinsically a protective process via microcirculation. Local or systemic
inflammatory reactions delete the causing stimuli and reboot repair and healing processes of tissue [40].
Acute inflammation has two phases: initiation (alpha) and resolution (omega). Inflammation
starts by the soluble inflammatory mediators such as complement, cytokines including chemokines,
free radicals, vasoactive amines, and eicosanoids (including prostaglandins) by adjacent cells of the
infected or injured part in the body [6,40,41].
Inflammasome is a multiprotein oligomer responsible for the activation of inflammatory responses
and consists of NLRP protein such as NLRP3, ASC, and procaspase-1 [42,43]. The inflammasome can
promote the maturation and secretion of interleukin 1β (IL-1β) and IL-18 [44].
Inflammasomes are involved in the EMT of cancer or other epithelial cells. For example, knockdown
of NLRP3 alleviates high glucose or TGF-β1-induced EMT in human renal tubular cells [45]. NLRP3
regulates cellular proliferation and metastasis via EMT and the PTEN/AKT signaling pathway [46].
NLRP3 inhibition can attenuate silica-induced EMT in human bronchial epithelial cells [47]. NLRP3 also
participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis [48]. Uric acid can activate
NLRP3 inflammasome in the EMT in the kidney of rats [49]. NLRP3 appears to be important for EMT
since inflammasome-independent NLRP3 is enough to EMT in colon cancer cells [50].
The resolution (omega) phase of inflammation releases specialized lipid mediators that can
actively prevent further progress of inflammation and enhance resolution of inflammation [51]. A new
specialized group of lipids that can actively terminate inflammation has been found by Serhan et al. [52].
These kinds of lipids include lipoxins (Lx), resolvins (Rvs), protectins (PDs), and maresins (MaRs;
Figure 2). They exhibit inflammation-suppressing action with pro-resolving effect that can promote
efferocytosis [41,52].
Figure 2. Inflammatory contribution to EMT. PGE2 and LTB4 produced from arachidonic acid can
induce EMT in epithelial cancer cells. In contrast, LxA4 and AT-LxA4 from arachidonic acid can
repress EMT in cancer cells. RvD1, RvD2, PDX, and MaR1 from DHA can suppress EMT in cancer cells
or immortalized cells. AT-LxA4 (15(R)-lipoxin A4) is produced from 15(R)-HETE from arachidonic
acid by aspirin trigger. Modified from Lee’s report [6]. 14-HDHA: 14-hydroxy Docosahexaenoic
Acid; AA: arachidonic acid; AT-LxA4: Aspirin-triggered lipoxin A4; EPA: Eicosapentaenoic acid;
DHA: Docosahexaenoic acid; DPA: Docosapentaenoic acid; MaR1: Maresin 1; MaR2: Maresin 2; PD1:
Protectin 1; PDX: Protectin X; PGD2: Prostaglandin D2; PGF2a: ProstaglandinF2a; PGI2: Prostaglandin
I2; PLA2:Phospholipase A2; LTB4: Leukotriene B4; LTC4: Leukotriene C4; LxA4: LIpoxin A4; RvD1-2:
Resolvin D1-2; RvD3-6: Resolvin D3-6; RvE1-2: Resolvin E1-E2; RvE3: Resolvin E3; RvT1-4: 13-series
resolvins; TXs: Thromboxane.
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13-series resolvins (RvT1-4) derived from docosapentaenoic acid (DPA) have been newly
discovered [53]. Briefly describing their production, human platelets pre-treated with aspirin or
atorvastatin convert omega-3 DPA (DPAn-3) to a 13S-hydroperoxy intermediate via aspirin-treated
or atorvastatin-treated COX-2. This intermediate is converted into four RvTs via ALOX5
enzyme activity exerted on the nearby neutrophils [53]: RvT1 (7,13R,20-trihydroxy-DPAn-3); RvT2
(7,8,13R-trihydroxy-DPAn-3); RvT3 (7,12,13R-trihydroxy-8Z,10E,14E,16Z,19Z-DPAn-3); and RvT4
(7,13R-dihydroxy-DPAn-3). Four RvTs are also formed by a mixture of human neutrophils and vascular
endothelium cells, which are found in infected rodent and human tissues. [52].
3.2. EMT Inducers from Chronic Inflammatory Tumor Microenvironments
The tumor microenvironment mainly influences the progression of cancers via secretion of various
factors that cause EMT [54,55]. Cancer-related chronic inflammation is described as a chaotic state
where both pro-inflammatory and anti-inflammatory signals are present to permit tumor growth and
immune evasion [6]. Besides, the tumor microenvironment contributes to the cancer heterogeneity.
Therefore, the tumor microenvironment has been regarded as a promising target for the cure of cancer.
Thus, Vanneman and Dranoff have demonstrated a novel way of curing cancer by re-educating the
tumor microenvironment [56].
Here, we will briefly introduce EMT inducers from chronic inflammatory tumor microenvironment
(Figure 3).
TNF-α is a critical determiner of inflammatory responses [57]. Serum concentration of TNF-α
was determined as 1.47 pg/mL in invasive breast cancer patients and 0.98 ± 0.37 pg/mL in the control
cohort [6,58]. TNF-α produced by macrophages can accelerate TGF- 1-induced EMT [59].
IL-6 serves as either a pro-inflammatory or anti-inflammatory cytokine [6]. The mean serum
concentration of IL-6 was observed as 31.7 pg/mL in patients with breast cancer and 3.3 pg/mL in
the normal cohort [6,60]. IL-6 induces EMT of human breast cancer cells [61]. IL-6/STAT3-induced
expression of lncTCF7 can promote EMT of liver cancer cells [62]. The IL-6 pathway induces EMT in
biliary tract cancer via cross-talking to the SMAD4 in the TGF- 1 pathway [63].
IL-8 is a chemokine mainly secreted by macrophages [64]. The mean serum concentration of
IL-8 was found as 40.1 pg/mL in patients with breast cancer and 5.3 pg/mL in the normal group [60].
IL-8 expression is highly increased in TGF- 1-induced EMT in colon carcinoma and nasopharyngeal
carcinoma [65]. IL-8 is also involved in mast cell-induced EMT of human lung and thyroid cancer
cells [66,67]. JAK2/STAT3/Snail pathway is involved in the IL-8-induced EMT of HCC cells [68].
Brachyury-induced EMT of the tumor is mediated by IL-8/IL-8R signaling pathway [69].
IL-17 is a pro-inflammatory cytokine and mainly released from Th17 cells and macrophages [70].
IL-17 induces EMT of prostate cancers via MMP7 [71]. IL-17 induces EMT through STAT3 in the lung
adenocarcinoma [72]. IL-17 can evoke self-renewal of CD133+ cancer cells in ovarian cancer [73].
High-mobility group box 1 (HMGB1) is a nuclear DNA-binding protein and released to the
outside from macrophages, NK cells, dendritic cells, necrotic cells, and apoptotic cells according to
infection, injury, and inflammation [74]. The mean serum HMGB1 level was 4.64 ng/mL in patients
with malignant breast cancer, which was remarkably higher than in patients with benign breast cancer
(1.32 ng/mL) or in healthy subjects (1.36 ng/mL) [75]. HMGB1 (2 μg/mL) induces EMT of colorectal
and prostate cancer cells via the RAGE/NF-κB pathway [76,77].
IL-10 is a potent anti-inflammatory cytokine that suppresses T cell/macrophage cytokine synthesis
and blocks their antigen-presenting capacity [78]. In vitro generated M1- and M2-macrophages both
can induce EMT of pancreatic cancer cells via the IL-10 signaling pathway [79].
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TGF- 1 is a potent anti-inflammatory cytokines [80]. Plasma TGF- 1 levels were significantly higher
in stage IIIB/IV breast cancer patients (2.40 ng/mL) than those in healthy controls (1.30 ng/mL) [81].
It is a typical EMT inducer involved in cancer progression [6]. Please read other review for a detailed
information about TGF- 1-induced EMT [6,82]. TGF- 1 promotes the production of IL-10 in macrophages
from mouse cancer [83]. HMGB1 promotes expression of TGF- 1 via RAGE pathway to mediate
TGF-1-induced EMT [84].
PGE2 is biosynthesized from arachidonic acids (Figure 2). The mean serum level of PGE2 was
6.324 pg/mL in patients with brain cancer and 1.677 pg/mL in the compared normal cohort [85]. PGE2
acts through G protein-coupled receptors such as EP1-EP4 [86]. PGE2 (2–10 μg/mL) works in an
autocrine or paracrine manner, leading to stimulation of EMT through the expression of SNAIL and
ZEB1 [87]. In turn, SNAIL induces blocking of degradation of PGE2 by repressing prostaglandin
dehydrogenase, generating a positive loop that promotes cancer progression [88]. PGE2 (5 μM)
enhances invasion of HCC cells via EP1-mediated expression of YB-1, which induces TGF- 1-induced
EMT by AKT activation [89]. PGE2 (0.01–1μM) inhibits fibroblast chemotaxis but stimulates chemotaxis
of epithelial cells in the airway [90]. PGE2′s inhibitory action against TGF-1-induced EMT seems to be
via the EP2 pathway since EP2 agonist can block TGF- 1-induced EMT [91]. As such, the effect of PGE2
on EMT varies depending on concentration and in cell types.
Leukotriene B4 (LTB4) can be produced via the 5-lipoxygenase pathway. Significantly higher
levels of LTB4 have been found in the whole blood of lung cancer patients than those in the control
group (44.1 vs. 17.9 pg/mL) [92]. LTB4 acts via two distinct GPCR called BLT1 and BLT2. BLT2 is
involved in keratin phosphorylation and perinuclear reorganization, which is a prelude of EMT [93].
Accordingly, BLT2 is involved in the ras-promoted TGF-1-induced EMT [94]. As expected, LTB4
(100 nM) can induce EMT leading to vimentin expression through the BLT2/ERK2 activation [95].
Cysteinyl leukotrienes (CysLTs) include LTC4, LTD4, and LTE4 [96]. Mean serum levels of LTD4
found in HCC patients and healthy groups were 174.95 and 10.75 pg/mL, respectively [97]. Actions
of CysLTs are mediated via GPCRs such as CysLT1 and CysLT2 [98]. LTD4 (100 nM) can suppress
E-cadherin expression in cancer cells through enhanced translocation of -catenin to the nucleus while
montelukast (0.1 mM) suppresses eosinophil-induced EMT in bronchial epithelial cells [99]. Recently,
exosomes and cells from ascites in lung cancer patients can convert LTC4 to LTD4 to promote cancer
cell migration and invasion via CysLT1 [100].
4. Reversal of EMT by Anti-inflammatory and Pro-Resolving Natural Compounds
The 2018 review by us did not cover the regulation of EMT by natural products [6]. In this part,
we describe anti-inflammatory natural compounds and pro-resolving lipids that can prohibit EMT
stimulated by mediators released in the tumor microenvironment.
4.1. Reversal of EMT by Anti-Inflammatory Natural Compounds
Diverse natural products can inhibit EMT of cancer cells or epithelial cells. We focused on EMT
inhibitors found from natural compounds that can inhibit the EMT of cancer cells caused by EMT
inducers from the chronic inflammatory tumor microenvironment due to limited space (Figure 4,
Table 1).
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Table 1. Lists of EMT inhibitors from natural sources.
Name Source Name Source




Berberine Berberis Hypaconitine Aconitum
Betanin beets Jatrophone Jatropha isabellei
Brusatol Brucea sumatrana Ligustrazine Nattō, fermented cocoa
beans






Nitidine chloride Zanthoxylum nitidium
Codonolactone Atractylodes lancea Osthole Cnidium monnieri
Cordycepin Cordyceps militaris Oxymatrine Sophorae flavescentis
Cryptotanshinone Salvia miltiorrhiza Paeoniflorin Paeonia lactiflora
Curcumin Zingiberaceae Paeonol Paeonia suffruticosa
Dioscin Dioscorea villosa Parthenolide Tanacetum parthenium
Delphinidin Viola, Delphinium Plectranthoic acid Ficus microcarpa
Epigallocatechin-3-gallate Green tea Piperlongumine Piper longum
Eupatolide Inula britannica Plumbargin Plumbago
Galic acid gallnuts, sumac, witch
hazel, tea leaves
Polyphyllin I Rhizoma of Paris
Gambogic acid Garcinia hanburyi Pterostilbene blueberries
Gedunin Azadirachta indica Resveratrol grapes
Genistein Genista tinctoria Salvianolic acid Salvia miltiorrhiza
Geraniin Geraniums α−Solanine Solanum
Gigantol Cymbidium goeringii Sulforaphane cruciferous vegetables
Ginkgolic acid Ginkgo biloba Tannic acid Caesalpinia spinosa
Ginsenosides Ginseng Withaferin A Solanaceae
Arctigenin from Asteraceae has anti-inflammatory effects [101]. Arctigenin (12–50 μM) can
suppress TGF–induced EMT of human lung cancer cells, thus blocking invasion [102]. Arctigenin
(0.25–1 μM) can inhibit the expression of MCP-1 and subsequent EMT induced by ROS-dependent
ERK/NF-κB pathway of renal tubular epithelial cells [103].
Baicalin found in Scutellaria baicalensis and Scutellaria lateriflora has well-known anti-inflammatory
effects [104]. Baicalin (2 μM) can suppress TGF-1-mediated EMT in MCF10A cells by reducing the
expression of slug [105]. Baicalin (12.5–25 μM) can inhibit the expression of TGF-1-induced EMT-related
transcription factors in osteosarcoma cells and inhibit the aggressive metastasis of breast cancer by
blocking EMT via inhibiting the activation of -catenin [106,107]
Berberine found in Berberis can reduce the secretion of IL-1 and TNF-α [108,109]. Berberine
(5–20 μM) can reverse EMT in uterine cancer, leading to suppression of cancer metastasis [110].
Berberine can inhibit the metastatic ability of prostate cancer cells by suppressing EMT-associated
genes [111]. Berberine (50 μM) can make nasopharyngeal carcinoma cells sensitive to radiation through
EMT inhibition [112].
Betanin from beets can decrease the production of superoxide anion and cytokines TNF-α and
IL-1 [113,114].
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Betanin (25–50 μM) can inhibit high glucose-induced EMT of renal proximal tubular cells [115].
However, activity of betanin for EMT of cancer cells has not been reported yet.
Brusatol from the seeds of Brucea sumatrana can inhibit the response of cultured beta-cells to
pro-inflammatory cytokines in vitro [116]. Brusatol (2 μM) can inhibit the EMT of pancreatic cancer
cells [117].
Cardamonin, one of major component of Alpinia katsumadai has anti-tumor, anti-inflammatory,
anti-nociceptive, and anti-itching activities [118–120]. Cardamonin (1–10 μM) can suppress
TGF-1-stimulated EMT of A549 cells by restoring protein phosphatase 2A expression [120]. Cardamonin
(5–20 μM) can block the invasiveness of human triple negative breast cancer cell by downregulation of
Wnt/-catenin signaling pathway and induce the reversal of EMT [121]. Cardamonin (5–25 μM) also
inhibits transglutaminase-2, one players in EMT, leading to JNK activation and NF-κB pathway [122].
Carnosol, found in Rosmarinus officinalis and Salvia pachyphylla, can block UV-induced inflammation
through inhibition of STAT3 [123–125]. For a more in-depth look at various anti-inflammatory effects of
carnosol, please refer to the 2017 review [126]. Carnosol (0.1–10 μM) controls the human glioblastoma
stemness features by modulating EMT and inducing cancer stem cell apoptosis [127]. Carnosol
(5–10 μM)-mediated SIRT1 activation inhibits the enhancer of zeste homolog 2 to attenuate liver
fibrosis [128].
Celastrol (0.1–1 μM), from the root extracts of Tripterygium wilfordii and Celastrus regelii, can
suppress experimental autoimmune encephalomyelitis [129]. Celastrol can inhibit the expression of
snail and increased the expression of E-cadherin in the lung cancer cells [130]. Many studies have
reported the effect of celastrol on EMT of diseases other than cancer (please refer the ref 128 by
Kashyap et al.) [131].
Codonolactone, a major component of Atractylodes lancea, exhibits anti-allergic activity,
anti-inflammatory, anticancer, gastroprotective, and neuroprotective activities [132,133]. Codonolactone
(10–40 μM) can inhibit EMT in breast cancer cells by downregulating the transcriptional activity of
Runx2 [134].
Cordycepin from the fungus Cordyceps militaris can suppress LPS-induced cytokine production
by increasing heme oxygenase-1 expression [135,136]. Cordycepin (25–100 μM) can inhibit cancer
stemness of TGF- induced chemo-resistant ovarian cancer cells [137]. Metronomic cordycepin therapy
(25 mg/kg and 50 mg/kg) can prolong the survival of oral cancer-bearing mice and it (50 μM) inhibit
EMT [138]. Cordycepin (100–200 μM) suppresses integrin/FAK signaling and EMT in HCC [139].
Cryptotanshinone, obtained from the root of Salvia miltiorrhiza, can protect against IL-1-induced
inflammation in human osteoarthritis chondrocytes [140]. Cryptotanshinone (5–10 μM) targets
tumor-initiating cells through down-regulation of stemness genes expression [141].
Curcumin, a phenolic compound found in Zingiberaceae turmeric, has strong anti-inflammatory,
antioxidant, and antitumor properties [142]. A more extensive and detailed review of curcumin’s EMT
has been reported recently [143]. Curcumin (25–50 μM) can inhibit metastasis in human papillary
thyroid carcinoma cells by negatively regulating TGF-1-mediated Smad2/3 signaling pathway [142].
Curcumin (15 μM) can inhibit TNF-α-induced EMT in melanoma [144]. It can decrease EMT in
cervical cancer cells by a pirin-dependent mechanism [145]. Pirin is a coregulatory of NF-κB involved
in EMT [146]. Curcumin (30 μM) can suppress paraquat-induced EMT by blocking TGF- in A549
cells [147]. It (8 μM) can reverse oxaliplatin resistance caused by EMT in colorectal cancer through
inhibition of the TGF-/Smad2/3 pathway [148].
Dioscin from roots of wild yam (Dioscorea villosa) shows potent anti-inflammatory effects via
suppression of TNF-α-induced NF-κB-mediated VCAM-1, and ICAM-1 expression [149,150]. Dioscin
(3 μM) can suppress TGF-1-induced EMT in A549 and HepG2 cells [149,151]. Dioscin (1–10 μM) also
reverses HMT-induced EMT by down-regulating mdm2 and vimentin [152]. Diosgenin (400 μM), an
aglycone of dioscin inhibits breast cancer cells with stem cell like properties by attenuation of the
Wnt-catenin signaling [153].
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Delphinidin, an anthocyanin, can reduce levels of inflammatory mediators including IL-6 and
TNF-α induced by LPS [154]. Delphinidin (10–50 μM) inhibits TGF-1-induced EMT through a TGF-
1/Smad2 signaling pathway in glioblastoma cells and EGF-induced EMT in HCC cells [155,156].
Epigallocatechin-3-gallate found in green tea can regulates anti-inflammatory action through
laminin receptor-mediated tollip signaling induction in LPS-stimulated human intestinal epithelial
cells [157]. Epigallocatechin-3-gallate (25–50 μM) can also suppress nicotine-induced migration and
invasion by blocking angiogenesis and EMT of non-small cell lung carcinoma (NSCLC) cells [158].
It (10–60 μM) also suppresses EMT and invasion in anaplastic thyroid carcinoma cells by blocking
TGF-1/Smad pathways [159].
Eupatolide from the Inula britannica is used to treat bronchitis, disorders of the digestive system
and inflammation [160]. Eupatolide can prohibit LPS-stimulated COX-2 and iNOS expression of
RAW264.7 cells by evoking proteasomal degradation of TRAF6 [161]. Eupatolide (3–10 μM) can inhibit
TGF-1-induced migration of breast cancer cells via down-regulation of SMAD3 phosphorylation and
transcriptional repression of ALK5 [160].
Gallic acid is a trihydroxybenzoic acid found in gallnuts, sumac, witch hazel, and tea leaves [162].
For various anti-inflammatory effects of gallic acid, please refer to the 2017 review [163]. Gallic
acid-coated sliver nanoparticle (50 μg/mL) can alter the expression of radiation-induced EMT in
NSCLC [164]. Black tea polyphenols (10–40 μM) can also reverse EMT and inhibit invasion of human
oral cancer cells [165].
Gambogic acid from the brownish or orange resin of Garcinia hanburyi can enhance the expression
of heme oxygenase-1 through Nrf2 pathway and inhibit NF-κB and MAPK activation to mitigate
inflammation in LPS-activated RAW264.7 cells [166]. Gambogic acid (0.5–1 μM) can suppress cancer
invasion and migration by inhibiting TGF-1-induced EMT [167]. It (2 μM) can induce cleavage of
vimentin in HeLa cells [168].
Gedunin, one of the main chemical compounds in the neem tree, can protect TLR-mediated
inflammation by suppression of inflammasome activation and cytokine production [169,170]. Gedunin
(15 μM) suppresses EMT of pancreatic cancer by inhibiting sonic hedgehog signaling pathway [171].
Genistein first isolated from Genista tinctoria can suppress psoriasis-related inflammation through
a STAT3/NF-κB-dependent mechanism in keratinocytes [172,173]. For more detailed information about
genistein’s anti-inflammatory action or anti-EMT, please refer to a previous review by Spagnulo et al.
and Lee et al. [174,175]. Genistein (200 μM) can induce apoptosis of colon cancer cells by reversal of
EMT via a notch1/NF-κB/slug/E-cadherin pathway [176]. miR-223 inhibitor and genistein (20 μM) can
synergistically reverse in EMT of gemcitabine-resistant pancreatic cancer cells [177].
Geraniin found in geraniums can ameliorate experimental acute reflux esophagitis via NF-κB-regulated
anti-inflammatory activities in rats [178,179]. It (15–20 μM) can also suppress TGF-1-induced EMT,
migration, invasion and anoikis resistance in A549 lung cancer cells [180].
Gigantol from the Cymbidium goeringii can suppress LPS-stimulated iNOS and COX-2 expression
through NF-κB inactivation in RAW 264.7 cells [181]. It (5–20 μM) can attenuate cancer stem cell-like
phenotypes and induce anoikis in human lung cancer H460 cells [182,183].
Ginkgolic acid from Ginkgo biloba can significantly inhibit the production of NO, PGE2, and
pro-inflammatory cytokines in ox-LDL-stimulated HUVECs cells [184]
Ginkgolic acid (100 μM) can inhibit TGF-1-induced EMT of lung cancer cells through
PI3K/AKT/mTOR inactivation [185]. PPAR-γ might be involved in the suppression of EMT since
ginkgolic acid is a PPAR-γ modulator.
Ginsenosides Rh1, Rg3, Rb1, Rg5, and Rg1 from ginseng can block inflammatory responses by
inhibiting the activation of NLRP3, NLRP1, and AIM [186]. Rg3 (25–100 μM) can suppress EMT and
invasion in lung cancer cells by reducing expression of FUT4 [187]. It (75 μg/mL) can also sensitize
hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated EMT [188]. Rb1 (160 μg/mL) can
inhibit hypoxia-induced EMT in ovarian cancer cells by regulating miR-25 [189]. Downregulation of
HDAC3 by Rg3 (25 and 50 μg/mL) can inhibit EMT of cutaneous squamous cell carcinoma through c-Jun
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acetylation [190]. Rg3 (75 μg/mL) can inhibit growth and EMT of human oral squamous carcinoma
cells by down-regulating miR-221 [191].
Glycyrrhizin (50–200 μM) from the roots of Glycyrrhiza glabra (Licorice) has anti-inflammatory
and antiviral activities. It is also a novel pharmacological inhibitor of HMGB1 [192]. Glycyrrhizin can
attenuate the EMT of prostate cancer cells by suppressing HMGB1-involved signaling pathway [192].
Honokiol from the Magnolia possesses anti-inflammatory activity by blocking downstream
signaling of MEKK-1 in NF-κB activation pathway [193,194]. It (30 μM) can also inhibit EMT-mediated
migration of human NSCLC cells in vitro by targeting c-FLIP and EMT of breast cancer cells by
targeting STAT3/Zeb1/E-cadherin axis [195,196]. Honokiol (20 μM) can inhibit the metastasis of renal
cancer cells by blocking EMT through regulating miR-141/ZEB2 pathway [197]. It (5–20 μM) can also
inhibit the invasion of U87MG human glioblastoma cell via regulation of EMT [198].
Hypaconitine from the root of Aconitum species can suppress 0.1% histamine-induced acute
inflammation without showing an ulcerogenic effect [199]. Hypaconitine (8 μM) can inhibit
TGF-1-evoked EMT of A549 lung cancer cells possibly by blocking NF-κB activation [200].
Jatrophone from Jatropha isabellei has anti-nociceptive and anti-inflammatory activities [201].
Jatrophone (2 μM) can interfere with Wnt/-catenin signaling and reverses EMT of human triple-negative
breast cancer [202].
Ligustrazine found in nattō and in fermented cocoa beans can significantly decrease CCL3, CCL19,
CCl21, IL-4, IL-5, and IL-17A in bronchoalveolar lavage fluid of ovalalbumin-induced mice [203,204].
There are many reports of anti-inflammatory effects of ligustrazine [205]. Ligustrazine (100 μM) can
suppress EMT of renal cell carcinoma cells by blocking MMP9 and TGF-1 [206].
Luteolin is a natural flavonoid that possesses anti-inflammatory and anti-cancer activities [207].
Luteolin (40 μM) inhibits TGF-1-induced EMT of A549 lung cancer cells through interfering with
PI3K/AKT/NF-κB/Snail pathway [207]. Luteolin (10 μM) can suppress EMT and negatively regulating
-catenin expression in breast cancer cells [208,209]. It (5–20 μM) can inhibit metastasis of melanoma
cells by decreasing HIF-1α/VEGF signaling-mediated EMT [210]. It (5 μM) can also inhibit EMT of
colorectal cancer cell by suppressing CREB1 expression [211]. Luteolin (20 μM) can inhibit the invasion
of cervical cancer by blocking EMT signaling [212]. It (30 μM) can block gastric cancer progression by
reversing EMT through inhibition of the notch signaling [213]. It (15.6–31.3 μM) can also inhibit EMT
in paclitaxel-resistant ovarian cancer cells [214]. Luteolin (20–160 μM) can also block IL-6-induced
EMT in pancreatic cancer cells by inhibiting STAT3 signaling [215].
Nimbolide, from the neem tree (Azadirachta indica), can inhibit NF-κB pathway in intestinal
epithelial cells and macrophages, resulting in alleviation of experimental colitis in mice [216]. Nimbolide
(5 μM) can suppress pancreatic cancer growth and metastasis through inhibition of EMT [217].
It (1–6 μM) can also suppress NSCLC cell invasion and migration via manipulation of DUSP4
expression and ERK1/2 signaling [218].
Nitidine chloride, a pentacyclic alkaloid isolated from the root of Zanthoxylum nitidium, can
suppress LPS-induced interleukin production via MAPK and NF-κB in RAW 264.7 cells [219]. Hedgehog
pathway is implicated in nitidine chloride (2.5 μM)-induced blocking of EMT of breast cancer cells [220].
Nitidine chloride (5 μM) can also inhibit EMT of osteosarcoma cell via Akt/GSK-3/snail signaling
pathway [221].
Osthole, the major natural coumarin from Cnidium monnieri (L.) Cuss, exerts anti-inflammatory
effects by blocking of the activation of the NF-κB and MAPK/p38 pathways [222]. Osthole (20 μM) can
suppress HGF-induced EMT via repression of the c-Met/Akt/mTOR pathway in human breast cancer
cells [223]. Osthole (20–40 μM) can also inhibit IGF-1-induced EMT by inhibiting PI3K/Akt signaling
pathway in human brain cancer cells [224]. By inhibiting snail signaling and miR-23a-3p, osthole
(20–80 μM) can suppress EMT-mediated metastatic ability in prostate cancer [225]. Osthole (5–20 μM)
an also inhibit TGF -induced EMT by suppressing NF-κB mediated snail activation in A549 cells [226].
Oxymatrine, the active component from Radix Sophorae flavescentis, is well known for its
anti-inflammatory activity [227]. Oxymatrine (1.5–6 μM) can reverse EMT of breast cancer cells
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by depressing αV3 integrin/FAK/PI3K/Akt signaling activation [228]. It (0.25–0.75 μM) can inhibit EMT
of colorectal cancer cells by suppressing NF-κB signaling [229]. Chronic oxymatrine treatment can
induce resistance and EMT of colorectal cancer cells [230].
Paeoniflorin from Paeonia lactiflora has anti-inflammatory effects [231,232]. Paeoniflorin (5–10 μM)
can suppress EMT of human colorectal cancer cells and glioblastoma cells and prevent hypoxia-induced
EMT of human breast cancer cells [233,234].
Paeonol found in Paeonia suffruticosa (moutan cortex) can suppress LPS-induced HMGB1
translocation from the nucleus to the cytoplasm in RAW264.7 cells [235,236]. It (60–120 μM) can
attenuate aging of MRC-5 cells and inhibit EMT of HaCaT cells induced by aging MRC-5 cell-conditioned
medium [237].
Parthenolide from Tanacetum parthenium has well-known anti-inflammatory activities [238].
Parthenolide (5 μM) can inhibit TGF-1-induced EMT of colorectal cancer cells [239]. Parthenolide
(10–20 μM) can suppress HIF-1α signaling and hypoxia-induced EMT in colorectal cancer [240].
Parthenolide binds Gly-Leu-Ser/Lys- “co-adaptation pocket” to inhibit EMT of lung cancer cell [241].
Plectranthoic acid isolated from Ficus microcarpa, can alleviate the symptoms of type 2 diabetes
mellitus by inhibiting dipeptidyl peptidase 4 [242]. Plectranthoic acid is a novel activator of AMPK
can induce apoptotic death in prostate cancer cells [243]. Plectranthoic acid (20–40 μM) can suppress
EMT of prostate cancer [244].
Piperlongumine, a constituent of the fruit of the long pepper (Piper longum) can inhibit
neuroinflammation via regulating NF-κB signaling pathways in LPS-stimulated BV2 microglia
cells [245,246]. Piperlongumine (1–5 μM) inhibits TGF–induced EMT by modulating the expression of
E-cadherin, Snail1, and Twist1 [247].
Plumbargin from Plumbago genus can attenuate the expression of inflammatory cytokine in
LPS-activated BV-2 cells [248]. Plumbagin (0.5–1 μM) can inhibit EMT of human cervical carcinoma
cells and inhibit tumor invasion of endocrine-resistant breast cancer through EMT [249]. It (0.1–0.5 μM)
suppresses EMT via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell
carcinoma cells [250]. Plumbagin (1–5 μM) can inhibit PI3K/Akt/mTOR-mediated EMT in human
pancreatic cancer cells [251]. Plumbagin (1–5 μM) shows differential proteomic responses to EMT of
PC-3 and DU145 prostate cancer cells [252].
Polyphyllin I, a component in the Rhizoma of Paris, can improve collagen-induced arthritis by
blocking the inflammation response in macrophages through the NF-κB Pathway [253]. Polyphyllin
I (0.3 μM) can overcome EMT-associated resistance to erlotinib in lung cancer cells via IL-6/STAT3
pathway inhibition [254].
Pterostilbene (5–10 μM) from blueberries can effectively suppress the generation of cancer stem
cells and metastatic potential under the influence of M2 TAMs by modulating EMT associated
signaling pathways, specifically the NF-κB/miR488 circuit [255]. Pterostilbene (10 μM) can also inhibit
triple-negative breast cancer metastasis by inducing miR205 expression and negatively modulates
EMT [256]. Long non-coding RNAs such as MEG3, TUG1, H19, and DICER1-AS1 contribute to the
inhibitory effect of pterostilbene (1–50 μM) on proliferation and EMT of human breast cancer cells [257].
Resveratrol, a constituent of grapes and various other plants, is an activator of PPAR and
SIRT1 [258]. Resveratrol (12 μM) can suppress TGF-1-induced EMT in colorectal cancer through
the TGF-1/SMADs signaling pathway [259]. Resveratrol (20 μM) can inhibit TGF-1-induced EMT
and suppress lung cancer invasion and metastasis [260]. Resveratrol (50 μM) can inhibit the EMT of
pancreatic cancer cells through suppression of the PI3K/Akt/NF-κB pathway [261]. Resveratrol might
inhibit EMT via downregulation of COX and SIRT1 activation, although roles of SIRT1 in EMT of
cancer cells show conflicting results [262,263].
Salvianolic acid, an active compound present in Salvia miltiorrhiza, can suppress CCL-20 expression
in TNF-α-treated macrophages [264]. Salvianolic acid B (1–100 μM)-induced expression of miR-106b-25
can suppress EMT of HK-2 cells [265]. Salvianolic acid B (1–10 μM) can prevent EMT through the
TGF-1 signal transduction pathway [266].
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α−Solanine is a glycoalkaloid poison found in species of the nightshade family within the genus
Solanum, such as the potato and the eggplant [267]. A chloroform fraction of Solanum nigrum can
suppresses nitric oxide and TNF-α in LPS-stimulated mouse peritoneal macrophages through inhibition
of p38, JNK and ERK1/2 [268]. α-Solanine (4–12 μM) can suppress the invasion of human prostate
cancer cell by inhibiting EMT and MMPs expression [269].
Sulforaphane from cruciferous vegetables may directly impair the formation of NLRP3
inflammasome by inhibiting ASC or caspase-1 [270]. Sulforaphane (1–5 μM) can also inhibit the EMT
and metastasis of human lung cancer through miR616-5p-involved GSK3/-catenin pathways [271].
Sulforaphane (20–40 μM) can suppress TGF-1-induced EMT of HCC cells via the ROS-dependent
pathway [272]. It (5–20μM) can block the EMT of human bladder cancer cells via COX-2/MMP2,9/SNAIL,
ZEB1, and miR200c/ZEB1 pathways [273].
Tannic acid is a type of polyphenol inhibits NLRP3 inflammasome-mediated IL-1 production via
blocking NF-κB signaling in macrophages [274]. Tannic acid (25 μM) attenuates TGF-1-induced EMT
in lung epithelial cells [275].
Withaferin A from the Solanaceae family attenuates bleomycin-induced scleroderma by targeting
FoxO3a and NF-κB signaling [276]. Withaferin A (0.5μM) can inhibit the EMT of NSCLC cells [277]. It (2
μM) can also inhibit the EMT of MCF10A cells and suppress vimentin expression in breast tumors [278].
Extracts of root in Withania somnifera can suppress mammary EMT and cancer metastasis [279].
4.2. Reversal of EMT by Natural Pro-resolving Lipids
Pro-resolving lipids can be useful agent against cancer and EMT of cancer has been studied since
cancer is understood as a non-resolving disease [6,280]
Here, we briefly introduced the effect of pro-resolving lipids on EMT of cancer cells and emphasized
natural sources of pro-resolving lipids (Table 2).
Table 2. Pro-resolving lipids. * Antagonist.
















18S-RvE1 5S,12R,18S-trihydroxy-6Z,8E,10E,14Z,16E-EPA CMKLR1,BLT *
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Table 2. Cont.














































* antagonist; +(?) confirmed in non-cancer cells.
Pro-resolving lipids are generally known to act via GPCR receptors such as BLT1, CMKLR1,
FPRL1 (ALX/FPR2), GPR18, and GPR3 [41,281]. CMKLR1 is a receptor with high affinity for RvE1, as
measured via radioligand-binding assay (Kd = 11.3–5.4 nM) [282,283]. BLT1 is also a receptor with
low affinity for RvE1, as measured via radioligand-binding assay (Kd = 45 nM) [284]. CMKLR1 has
not been reported to be associated with EMT in cancer cells but seems to be associated with EMT in
diabetic nephropathy [285]. FPRL1 (ALX/FPR2) not only possesses an annexin A1 [286] protein but
also LxA4 (Kd = 1.7 nM, radioligand binding) [287], AT-RvD1 (EC50 = 1.8 × 10−10, -arrestin receptor
system [288], RvD1 (Kd = 0.17 ± 0.06 nM, radioligand assay; EC50 = 4.5 × 10–11, -arrestin receptor
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system) [288], RvD3 (activation of FPRL1 at 100 nM) [289] and other similar proteins as a ligand. FPRL1
mediates EMT inhibition by LxA4 and RvD1 [290,291].
GRP18 has been reported as a receptor for RvD2 on performing GPCR–arrestin-based screening (Kd
of 9.6± 0.9 nM, radioligand binding) [292]. GPR32 is known as the receptor of RvD1 (EC50 = 3.6 × 10−12,
-arrestin receptor system) [293] and RvD5 (activation of GPR32 at the range of 10−13–10−9 M) [294].
GPR32 is also activated by RvD3 and AT-RvD3 (0.1 pM–10 nM) [295]; it mediates EMT Inhibition by
RvD1 [291]. RvD1 also promotes wound healing in pulmonary epithelial cells and mediates EMT
inhibition [296].
LxA4 (0.1–0.8 μM) can suppress TGF-1 signaling in pancreatic cancer cells, reverse mesenchymal
features and block invasion and migration via a FPR2 [297]. LxA4 (0.01–0.1 μM) can also suppress
estrogen-induced EMT via LxA4 receptor-dependent manner in endometriosis [298]. LxA4 (0.2 μM)
and its analogue can suppress EMT, migration and metastasis of HCC by regulating integrin-linked
kinase axis [299].
100 nM of RvD1 and RvD2 can inhibit TGF-1-induced EMT of A549 lung cancer cells through
FPR2/ALXR and GPR32 [291]. GPR32 can recognize RvD1 (EC50 = 8.8 pM from -arrestin receptor
system) as an endogenous ligand [293]. Aspirin-triggered RvD1 (10 ng/mL) can block TGF-1-induced
EMT of A549 lung cancer cells via suppression of the mTOR pathway by reducing the expression
of pyruvate kinase M2 [300]. RvD1 (400 nM) prevents EMT of HCC cells by inhibiting paracrine of
cancer-associated fibroblast-derived cartilage oligomeric matrix protein [301].
MaR1 (0.1–10 ng/mice), a docosahexaenoic acid-derived pro-resolution lipid, can protect skin
from inflammation and oxidative stress caused by UVB irradiation [302]. Receptor for MaR1 is yet
unknown. The effect of MaR1 on EMT of cancer cells has not been reported yet except one study
has shown that incubating DHA with A549 lung cancer cells can produce MaR1 (1.58 ng/mL) and
PD1 (1.67 ng/mL) [303]. MaR1 (10 nM) can inhibit TGF-1-induced proliferation, migration, and
differentiation in human lung fibroblasts [304].
PD1 has anti-inflammatory and survival effects on neuronal diseases such as Alzheimer’s
disease and retinal degenerations [305]. PDX (1–100 nM), one of PD1 derivatives, can suppress
bleomycin-induced lung fibrosis through blocking EMT [6,306]. However, it is hard to find reports
about the effect of PDs on the EMT of cancer cells [6,306]. However, it is hard to find reports about the
effect of PDs on the EMT of cancer cells.
Pro-resolving lipid classes are mainly originated from ω-3 fatty acids which constitute a group of
essential fats that humans cannot synthesize endogenously [307]. Several pro-resolving lipids can be
obtained by total synthesis. Studies on derivatives are in progress.
It is possible to produce pro-resolving lipids by biological methods. EPA and DHA are the major
long chain ω-3 fatty acids in the diet. Algae are the major producers of EPA and DHA in the ecosystem.
Therefore, fish that consumes algae contains a lot of EPA and DHA [307]. Accordingly, algae or fish
might be a starting point for isolating or producing pro-resolving lipids in industrial scale. Brain cells
of rainbow trout (Oncorhynchus mykiss) can produce novel DHA-derived Rvs and PDs (Table 2) [308].
However, baking reduces proportions of PG, Rv, and hydroxy-fatty acid in farm-raised Atlantic salmon
(Salmo salar; Table 2) [309].
Infectious organisms can produce pro-resolving lipids to control host inflammation. Thus,
supraphysiological levels of LxA4 are generated during infection by Toxoplasma gondii, which in turn
reduces IL-12 production by dendritic cells, thus dampening Th1-type cell-mediated immune responses
(Table 2) [310].
Candida albicans can modulate host defense by biosynthesizing the pro-resolving lipid RvE1 [311].
C. albicans can biosynthesize nanogram quantities of RvE1 from EPA without collaboration of other
cellular partners. It can also biosynthesize PDs (Table 2) [311]. Trypanosoma cruzi is a protozoan
parasite that causes Chagas disease and produces the RvD1, RvD5, and RvE2 (Table 2) [312].
These reports suggested that algae, fish, and some infectious organisms might be applied to produce
pro-resolving lipids.
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5. Perspectives
Several natural compounds have anti-inflammatory activities and/or anti-EMT activities. However,
few reports have explained their anti-EMT activity by anti-inflammatory or pro-resolving mechanisms.
Therefore, examining anti-EMT activities of natural compounds based on their anti-inflammatory or
pro-resolving activities and assuring their anti-EMT activities in vivo might be important in the future.
Especially, it might be a reasonable way to study the anti-EMT activity of natural products through
interaction with the tumor microenvironment [255].
The flux of inflammatory or pro-resolving lipids from arachidonic acid related pathway (Figure 2)
could change if one pathway is blocked by natural anti-inflammatory or pro-resolving compounds.
Therefore, prevention of the production of these lipids might influence levels of other inflammatory and
pro-resolving lipids. Thus, further studies on effects of anti-inflammatory compounds or pro-resolving
lipids on EMT of cancer might require entire profiles of lipid metabolites affecting the EMT.
6. Conclusions
Expansion of studies about other pro-resolving lipids and nature-derived pro-resolving compounds
to inhibit EMT are needed. To do this, various types of pro-resolving lipids and new compounds from
natural sources should be procured and diffused to researcher without barrier. Thus, collaboration of
natural chemistry researchers with other fields is also required.
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Abstract: Persistent organic pollutants (POPs) bioaccumulate in the food chain and have been
detected in human blood and adipose tissue. Experimental studies demonstrated that POPs can
cause and promote growth of breast cancer. However, inconsistent results from epidemiological
studies do not support a causal relationship between POPs and breast cancer in women. To identify
individual POPs that are repeatedly found to be associated with both breast cancer incidence and
progression, and to demystify the observed inconsistencies between epidemiological studies, we
conducted a systematic review of 95 studies retrieved from three main electronic databases. While no
clear pattern of associations between blood POPs and breast cancer incidence could be drawn, POPs
measured in breast adipose tissue were more clearly associated with higher breast cancer incidence.
POPs were more consistently associated with worse breast cancer prognosis whether measured in
blood or breast adipose tissue. In contrast, POPs measured in adipose tissue other than breast were
inversely associated with both breast cancer incidence and prognosis. Differences in biological tissues
used for POPs measurement and methodological biases explain the discrepancies between studies
results. Some individual compounds associated with both breast cancer incidence and progression,
deserve further investigation.
Keywords: breast cancer; persistent organic pollutants; breast cancer risk; breast cancer prognostic;
systematic review
1. Introduction
Persistent organic pollutants (POPs) are a group of chemical substances of synthetic origin used for
industrial, agricultural or domestic purposes, that persist in the environment and bioaccumulate in the
food chain due to their lipophilic properties [1,2]. POPs have been detected in human blood, adipose
tissue and human milk and have been linked to the increase in the incidence of hormone-dependent
breast cancers [1,3–8].
Given the abundance of adipose tissue in the human breast, mammary epithelial cells exposure to
POPs sequestered in breast adipose tissue may promote carcinogenesis and progression of mammary
cancers [9]. In fact, numerous in vitro studies have demonstrated that some POPs stimulate the
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growth of estrogen receptor (ER)-positive breast cancer cells [10–12]. In animal studies, exposure
to some POPs, particularly during the perinatal period, impairs breast tissue development and
increases its susceptibility to carcinogens and the incidence of precancerous and cancerous breast
lesions [13]. In addition to their endocrine disrupting effect either as agonists or as antagonists
of endogenous hormones [14], POPs can interfere with estrogen synthesis by disrupting adipose
tissue functioning [15,16], interact with transcription factors [17], induce genotoxic enzymes [17] and
cytochrome 450 leading to increased levels of reactive oxygen species [18], and induce trans-generational
phenotypic changes by altering the epigenome [19].
Although experimental studies demonstrate that POPs can cause and promote growth of breast
cancer, several observational studies conducted in humans yielded inconsistent results regarding the
implication of POPs in women breast cancers [20–26]. Observational studies are known to be prone to
different biases that vary according to studies designs [27]. To draw meaningful conclusions about
a causal relationship between POPs and breast cancer in women, a systematic comparison of the
strengths and weaknesses of studies should be performed to triangulate their findings to provide
assurance that the observed findings are actually real [27]. Thus, the objective of the present systematic
review of the literature was to evaluate the observed associations between POPs and breast cancer
risk and prognosis to identify individual POPs that are repeatedly found to be associated with both
breast cancer incidence and progression, and to provide an explanation to the observed inconsistencies
between studies.
2. Materials and Methods
A systematic review was conducted following a pre-established protocol and according to the
general methodology of Cochrane reviews [28]. Considering the expected methodological diversity
and heterogeneity between eligible studies, the great susceptibility of observational designs to selection
bias and the variability in methods used to control for confounding, no quantitative synthesis was
planned [28].
2.1. Search Methods for Identification of Studies
An electronic search of the following databases was performed, from inception to December 2018:
MEDLINE (via PubMed), EMBASE and CENTRAL (Cochrane Central Register of Controlled Trials).
Search strategies were developed for each of these databases with text words and index terms referring
to POPs, breast cancer risk and breast cancer prognosis, and excluding animal studies (Table S1). No
language or publication date restrictions were applied. Reference lists of relevant reviews and of
included studies were scanned for any additional relevant studies not otherwise identified.
2.2. Criteria for Considering Studies for This Review
2.2.1. Types of Studies
Any observational or intervention study that evaluated the association between POPs and breast
cancer risk, survival or a meaningful breast cancer prognostic factor, whatever the design was eligible
for inclusion. No restrictions were applied regarding language or type (articles, short reports and
abstracts) of publication.
2.2.2. Types of Participants
Women included in the studies before or after breast cancer diagnosis, regardless of age,
menopausal status, breast cancer type, disease stage and treatment regimen, were eligible. No
participants were excluded based on ethnicity.
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2.2.3. Types of Exposures
Studies that measured exposure to any lipophilic POP, in a lipid rich biological human sample
(peripheral blood and adipose tissue), whatever the method of measurement, were eligible.
2.2.4. Types of Outcomes
Breast cancer risk, measured by breast cancer incidence, prevalence or breast mammographic
density (a recognized breast cancer risk factor) and breast cancer survival, including overall survival
(all-cause mortality), breast cancer-specific survival (breast cancer-specific mortality), and breast
cancer-free survival (breast cancer recurrence), were the primary outcomes. Studies that assessed the
association of POPs with meaningful breast cancer prognostic factors (age, stage, tumor size, lymph
node involvement, histological type, grade and molecular subtype) were also eligible.
2.3. Data Collection and Analysis
2.3.1. Selection of Studies
The references identified by the search strategy were reviewed by one author (K.E-I.) in a two-step
process. First, the title and abstract of each study were screened to exclude obviously non-eligible
studies and second, the full text of retained articles was examined and subjected to evaluation using
the predefined eligibility criteria. Whenever required, a second review author (C.D.) was consulted.
When required, further information was sought from the authors by email.
2.3.2. Data Extraction
Data extraction was performed using an exhaustive standardized form designed for this review.
Information about study design (inclusion criteria, sample size and methodology), participants and
tumors characteristics at diagnosis (age, menopausal status, tumor invasiveness, tumor ER status),
exposure assessment (timing, tissue sample, method of measurement, lipid-adjustment, list of all
contaminants evaluated, treatment of non-detectable values), measured outcomes and reported results
(any reported measure of association, adjustment variables, and statistical model selection procedure)
were collected. For observational studies, special attention was paid to distinguishing between adjusted
and unadjusted results, and to the variable selection method used in multivariate analyses. Studies
definition of each characteristic or variable retained was recorded. In the case of multiple publications
related to the same study, the publication reporting the outcomes of interest to the present review or
the one with the longest follow-up of these outcomes was considered as the reference, and information
was supplemented by secondary publications as required. Abstracts with insufficient information and
data to permit inclusion were excluded from the qualitative synthesis (Table S2). Data were extracted
twice over the course of several days to ensure their consistency.
2.3.3. Assessment of Risk of Bias in Retained Studies
Based on the “STrengthening the Reporting of OBservational studies in Epidemiology.” (STROBE)
statements [28], and the rating approach of the “Risk Of Bias in Non-randomized Studies-of
Interventions” (ROBINS-I) tool [27], the following domains were evaluated for risk of bias of included
studies: selection of participants into the study, exposure measurement, outcome measurement,
potential confounding accounted for, missing data, and selective reporting.
Assessment of the risk of bias was performed twice by a review author (K.E-I.), both for the risk
of bias in each study and for the overall risk of bias across studies. When required, a second reviewer
(C.D.) was consulted.
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2.3.4. Assessment of Heterogeneity
Differences between studies, including study design, participant characteristics (age and
menopausal status), tumor characteristics (invasiveness, ER status, and treatment received), exposure
measurement (timing, type of tissue sample) and different levels of risk of bias were considered for
exploring possible sources of heterogeneity.
2.3.5. Data Synthesis
Given that high heterogeneity between studies was expected, quantitative synthesis of data was
not considered appropriate. A systematic qualitative synthesis of study characteristics and results
was performed for risk, mortality, and prognostic factors associations with POPs exposure, and
separately for each type of tissue sample. The results were considered adjusted only when all important
confounders were considered into the models. For breast cancer risk, authors should have considered
at minimum age, body mass index or any other estimation of body fat, and breastfeeding or parity
as potential confounders. For breast cancer mortality, authors should have adjusted at minimum for
age. In addition, studies of breast adipose POPs should have considered breastfeeding or parity as
potential confounders. A positive association was defined as an observed higher risk or mortality with
higher POPs exposure whereas a negative association was defined as an observed inverse association.
3. Results
3.1. Results of the Search
Of the 11,015 references retrieved by electronic search, 95 met eligibility criteria (Figure 1), of
which 85 reported breast cancer incidence or prevalence outcomes [29–113], six reported mortality
outcomes [41,45,114–117] and nine reported breast cancer prognostic factors [66,90,116,118–123]. The
majority of studies of breast cancer risk were case-control studies (n = 81) whereas studies of breast
cancer prognosis included five cohort studies for mortality and nine cross-sectional studies for breast
cancer prognostic factors. Overall, POPs were measured in peripheral blood in 63 studies, in breast
adipose tissue in 32 studies, in adipose tissue other than breast in five studies and in breast tumors in
four studies (Figure 1).
3.2. Description of Studies
The 95 included studies were published between 1976 and 2018, and involved between five and
902 breast cancer patients (median = 113).
3.2.1. Studies of Breast Cancer Risk
Characteristics of the 61 studies that examined associations between peripheral blood POPs
and breast cancer risk are summarized in Table 1. These studies included breast cancer patients
between 40 and 66 years of mean age with varying proportions of premenopausal and postmenopausal
patients. Ten studies included at least 80% of postmenopausal patients, of which three studies included
exclusively postmenopausal patients. The proportion of invasive breast cancers was not reported in 35
studies and varied in the remaining 26 studies between 62 and 100%. Twenty studies included at least
80% of invasive breast cancers of which 13 studies included exclusively invasive breast cancers. The
proportion of estrogen receptor (ER) positive breast cancers was not reported in 40 studies and varied
in the remaining 19 studies between 32% and 87%. Two studies included at least 80% of ER-positive
breast cancers (Table 1 and Table S3).
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Figure 1. Flow Diagram according to PRISMA (Preferred Reporting Items of Systematic Reviews and
Meta-Analyses) [PRISMA], with modifications. *One cohort study on breast cancer mortality also
reported cross-sectional analyses of prognostic factors.
Characteristics of the 26 studies that examined associations between breast adipose tissue POPs
and breast cancer risk are summarized in Table 2. All these studies were hospital-based case-control
studies with hospital-controls and included breast cancer patients between 40 and 63 years of mean age
with varying proportions of premenopausal and postmenopausal patients. Only one study included at
least 80% of postmenopausal patients. The proportion of invasive breast cancers was not reported in
11 studies and varied in the remaining 15 studies between 76% and 100%, with eight studies including
exclusively invasive breast cancers. The proportion of ER-positive breast cancers was not reported in
15 studies and varied in the remaining 11 studies between 45% and 90%. No study included at least
80% of ER-positive breast cancers (Table 2 and Supplementary Table S4).
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Table 1. Summary characteristics of studies of peripheral blood POPs and breast cancer risk (n = 61).
Design
Cohort studies: n = 1
Case-cohort studies: n = 1
Cohort nested case-control studies with incidence density (risk-set) sampling: n = 13
Cohort nested case-control studies with cumulative density (exclusive) sampling: n = 3
Population-based case-control studies not nested in a defined cohort: n = 9
Hospital-based case-control studies with community controls: n = 8
Hospital-based case-control studies with both community-controls and hospital-controls: n = 4
Hospital-based case-control studies with hospital-controls: n = 19
Case-control studies (unclassified): n = 1
Cross-sectional studies: n = 2
Breast cancer
patients
Number of breast cancer patients: 20 to 902
Mean age: 40 to 66 years; NR in 13 studies.
Postmenopausal patients: 0% to 100%, median = 61%; two studies exclusively in
premenopausal patients; NR in 19 studies.
Invasive breast cancers: 62% to 100%, median = 99.5%; NR in 35 studies
Estrogen receptor positive breast cancers: 32% to 87%, median 64%; NR in 40 studies
POPs
Measurement method:
GC-ECD: n = 43
HPLC-MS-MS: n = 5
GC-MS: n = 4
GC-ID-HRMS: n = 3
HPLC/FD: n = 2
LC-MS-MS: n = 1
GC-IDMS: n = 1
GC: n = 3
MS: n = 1
NR: n = 2
Lipid adjustment: n = 39; NR in 18 studies
Measured POPs:
PCBs: n = 38
Organochlorines: n = 48
Dioxins: n = 2
PFAS: n = 3
Phthalates: n = 1
Parabens: n = 1
BPA: n = 2
PBBs: n = 1
n: number of studies; NR: not reported; POPs: persistent organic pollutants; MS: mass spectrometry; GC-ECD: gas
chromatography with electron Capture Detector; HLPC-MS-MS: high-performance liquid chromatography-tandem
mass spectrometry; HPLC/FD: high-performance liquid chromatography with fluorescence detection; LC-MS-MS:
liquid chromatography–tandem mass spectrometry; GC-MS-MS: gas chromatography-tandem mass spectrometry;
GC-IDMS: gas-chromatography isotope-dilution mass-spectrometry; GC-ID-HRMS: gas chromatography-isotope
dilution high-resolution mass spectrometry; HR-GC-ECD: high-resolution gas chromatography with micro-electron
capture detection; GC: gas chromatography; PCBs:. polychlorinated biphenyls; PFAS: perfluoroalkyl substances;
BPA: bisphenol A; PBBs: polybrominated biphenyls.
Table 2. Summary characteristics of studies of breast adipose tissue POPs and breast cancer risk (n = 26).
Design Hospital-based case-control studies with hospital-controls: n = 26
Breast cancer
patients
Number of breast cancer patients: 5 to 304
Mean age: 40 to 63 years; NR in three studies.
Postmenopausal patients: 49% to 82%, median = 56%; NR in 16 studies.
Invasive breast cancers: 76% to 100%, median = 100%; NR in 11 studies
Estrogen receptor positive breast cancers: 45% to 79%, median 64%; NR in 15 studies
POPs
Measurement method:
GC-ECD: n = 14
GC-MS: n = 9
GC: n = 4
Lipid adjustment: n = 23; NR in three studies
Measured POPs:
PCBs: n = 16
Organochlorines: n = 21
Dioxins: n = 2
PBDEs: n = 1
n: number of studies; NR: not reported; POPs: persistent organic pollutants; GC-ECD: gas chromatography with
electron Capture Detector; GC-MS: gas-chromatography mass-spectrometry; GC: gas chromatography; PCBs:
polychlorinated biphenyls; PFAS: perfluoroalkyl substances; PBDE: polybrominated diphenyl ethers.
Four studies examined associations between POPs in breast tumors and breast cancer risk, of
which three included breast tissue surrounding malignant tumors for cases. Two studies compared
malignant tumors of cases to benign tumors of controls whereas the two other studies compared
malignant tumors of cases to normal tissue of controls. All these four studies were hospital-bases
case-control studies with hospital controls, in which cases were on average 50 to 60 years old in the
two studies that reported age at diagnosis. One study included exclusively invasive cancers, whereas
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the three other studies did not report proportion of invasive cancers. No study reported proportion of
menopausal patients or the proportion of ER-positive breast cancers (Table S4).
Two studies examined associations between POPs in buttock adipose tissue and breast cancer risk.
The recent one was a cohort-nested case-control study with incidence density (risk-set) sampling and
included 409 postmenopausal breast cancer patients aged 58 years old in average, of which 78% had
ER-positive breast cancers. The proportion of invasive tumors was not reported. The other study was
a hospital-based case-control study with community controls including 265 breast cancer patients aged
62 years old in average. The proportions of postmenopausal patients, invasive tumors and ER-positive
tumors were not reported (Table S5).
3.2.2. Studies of Breast Cancer Prognosis
Characteristics of the 14 studies that examined the association between POPs and breast cancer
prognosis are summarized in Table 3.
Table 3. Summary characteristics of studies of POPs and breast cancer prognosis (n = 14).
Design
Studies of mortality: n = 6
Cohort studies n = 5
Ecologic study: n = 1
Studies of prognostic factors: n = 10
Cross-sectional studies: n = 10
Breast cancer
patients
Studies of mortality: n = 6
Number of breast cancer patients: 161 to 633
Mean age: 58 to 66 years; NR in one study.
Postmenopausal patients: 66% to 100% (in two studies); NR in three studies.
Invasive breast cancers: 71% to 86% (in two studies); NR in three studies
Estrogen receptor positive breast cancers: 72% to 78% (in three studies); NR in three studies
Studies of prognostic factors: n = 10
Number of breast cancer patients: 40 to 409
Mean age: 52 to 65 years
Postmenopausal patients: 41 % to 100%, median = 63%; NR in four studies.
Invasive breast cancers: 85% to 100%, median = 100%; NR in three studies
Estrogen receptor positive breast cancers: 50% to 86%, median 68%
POPs
Studies of mortality: n = 6
Type of sample:
Peripheral blood: n = 3
Breast adipose tissue: n =1
Adipose tissue other than breast: n = 2
Measurement method:
GC-ECD: n = 4
GC-MS: n = 1
NR: n = 1
Lipid adjustment: n = 5; NR in 1 study
Measured POPs:
PCBs: n = 4
Organochlorines: n = 5
Studies of prognostic factors: n = 10
Type of sample:
Peripheral blood: n = 3
Breast adipose tissue: n = 6
Adipose tissue other than breast: n = 1
Measurement method:
GC-ECD: n = 6
GC-MS: n = 3
HLPC-MS-MS: n = 1
Lipid adjustment: n = 9; NR in 1 study
Measured POPs:
PCBs: n = 4
Organochlorines: n = 6
n: number of studies; NR: not reported; POPs: persistent organic pollutants; GC-MS: gas-chromatography
mass-spectrometry; GC-ECD: gas chromatography with electron Capture Detector; HLPC-MS-MS: high-performance
liquid chromatography-tandem mass spectrometric; PCBs: polychlorinated biphenyls.
Six studies examined mortality outcomes, with three measuring POPs in peripheral blood, one
measuring POPs in breast adipose tissue and two measuring POPs in adipose tissue other than
breast. Patients were aged between 58 and 66 years old in average with only two studies reporting
the proportion of postmenopausal women (66% and 100% respectively), and two studies reporting
proportion of invasive cancers (71% and 86% respectively). The proportion of ER-positive breast cancers
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varied between 72% and 78% in the three studies that have reported patients ER status (Tables S5
and S6).
Ten studies examined breast cancer prognostic factors, with three measuring POPs in peripheral
blood, six measuring POPs in breast adipose tissue and one measuring POPs in adipose tissue other
than breast. Patients were aged between 52 and 65 years old in average with varying proportions of
premenopausal and postmenopausal women and none with at least 80% of postmenopausal patients.
The proportion of invasive cancers varied between 85% and 100% and the proportion of ER-positive
breast cancers varied between 50% and 86% with only two studies including at least 80% of ER-positive
breast cancers (Table S8).
3.3. Risk of Bias in Retained Studies
Overall, studies reporting associations between peripheral blood POPs and breast cancer risk
ranged from moderate to critical risk of bias, whereas studies reporting associations between adipose
tissue POPs and breast cancer risk were more likely to be at serious or critical risk of bias.
Overall, studies reporting associations between POPs, measured in peripheral blood or in adipose
tissue, and mortality outcomes were at serious risk of bias, whereas studies reporting associations with
prognostic factors ranged from serious to critical risk of bias.
3.4. Systematic Data Synthesis
3.4.1. Studies of Breast Cancer Risk
Among the 61 studies that examined associations between peripheral blood POPs and breast cancer
risk, 30 reported a positive association with at least one POP, six reported a negative association with
at least one POP, and 20 reported no association. Cohort-nested case-control studies with cumulative
density (exclusive) sampling, population-based case-control studies not nested in a defined cohort and
hospital-based case-control studies with both community- and hospital-controls were more likely to
observe an association. Studies that included at least 80% of postmenopausal patients were more likely
to observe an association whereas studies that included less than 80% of postmenopausal patients were
more likely to observe no association. Studies that included at least 80% of invasive cancers and those
with non-reported proportions of invasive breast cancers were more likely to observe an association.
Studies with non-reported proportions of ER-positive breast cancers were more likely to observe an
association whereas studies including less than 80% ER-positive breast cancers were slightly more
likely to observe no association (Table S3).
Among the 26 studies that examined associations between breast adipose tissue POPs and
breast cancer risk, 10 reported a positive association with at least one POP, two reported a negative
association with at least one POP, and seven reported no association. Studies reporting the proportion
of invasive breast cancers were slightly more likely to observe an association. Studies with non-reported
proportions of ER-positive breast cancers were more likely to observe a positive association. The four
studies of POPs in breast tumors did not report minimally adjusted estimates of risk (Table S4).
The two studies that examined associations between POPs in buttock adipose tissue and breast
cancer risk reported negative associations (Table S5).
3.4.2. Studies of Breast Cancer Prognosis
All three studies that examined peripheral blood POPs reported positive associations with both
breast cancer all-cause and specific mortality, of which one study also reported a negative association
with all-cause mortality (Table S6). The only study of breast adipose tissue POPs and breast cancer
mortality reported a positive association with breast cancer recurrence. The two studies of POPs in
adipose tissue other than breast reported negative associations with all-cause and breast cancer specific
mortality respectively, of which one study reported a positive association with breast cancer specific
mortality (Table S7).
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Among the three studies that examined peripheral blood POPs and breast cancer prognostic factors,
one study reported a positive association with tumor size and lymph-node involvement. Among the
six studies of breast adipose tissue POPs, three studies examined associations with meaningful breast
cancer prognostic factors but none of them reported minimally adjusted estimates. The only study of
buttock adipose tissue POPs and breast cancer prognostic factors did not report minimally adjusted
estimates (Table S8).
3.4.3. Individual POPs and Breast Cancer Risk and Prognosis
One to 71 individual POPs were measured in studies of breast cancer risk (median = 9).
Organochlorines were measured in 69 studies, of which 43 in blood, 21 in breast adipose tissue,
two in adipose tissue other than breast and three in breast tumor. Polychlorinated biphenyls (PCBs)
were measured in 57 studies, of which 38 were in blood, 16 in breast adipose tissue, one in adipose
tissue other than breast and two in breast tumors. Dioxins were measured in four studies, of which
two in blood and two in breast adipose tissue. Perfluoroalkyl substances (PFAS) were measured in
three studies in blood. Bisphenol A (BPA) was measured in two studies in blood, polybrominated
flame retardants (PBBs and PBDEs) in one study in blood and one study in breast adipose tissue
whereas mono-ethyl phthalate (MEP) and parabens were measured in blood in one study respectively
(Table S9).
One to 35 individual POPs were measured in studies of breast cancer prognosis (median = 25).
Organochlorines were measured in five studies of breast cancer mortality, of which three were in blood,
one in breast adipose tissue and two in adipose tissue other than breast, whereas six studies measured
organochlorines in relation to prognostic factors, of which three were in blood, four in breast adipose
tissue and one in adipose tissue other than breast. PCBs were measured in four studies of breast cancer
mortality, of which three were in blood, one in breast adipose tissue and one in adipose tissue other
than breast, whereas four studies measured PCBs in relation to prognostic factors, of which two in
blood, four in breast adipose tissue and one in adipose tissue other than breast (Tables S9 and S10).
Parabens were measured in breast adipose tissue in one study in relation to prognostic factors.
The magnitude of the reported associations between POPs and breast cancer risk and mortality
are summarized in Table 4.
Table 4. Main results summary of studies reporting positive * associations between POPs and breast
cancer risk and mortality.
Type of Tissue Sample
Studies with Positive *
Associations/Total Studies
Range of Associations **
Estimate [95% CI]
Breast cancer risk
Blood 29/61 From OR = 1.1 [1.0–1.2] (Heptachlor, continuous)to OR = 7.6 [1.1–51.4] (PCBs group 1a, variable form NR)
Breast adipose tissue 10/26 From OR = 1.1 [1.0–1.3] (PCB 180, quart 4 vs. quart 1)to OR = 10.5 [2.0–55.3] (β-HCH, >0.1 mg/kg vs. <0.1 mg/kg)
Adipose tissue other than breast 0/2 NA
Breast cancer mortality
Blood 3/3
From HR = 1.9 [1.1–3.4] (15-year breast cancer mortality
PCB 174, tert 3 vs. tert 1)
to HR = 5.8 [1.6–20.5] (breast cancer recurrence and/or death,
Dieldrin, quart 4 vs. quart 1)
Breast adipose tissue 1/1
From HR = 2.6 [1.0–7.1] (Breast cancer recurrence, PCB 153,
tert 3 vs. tert1)
to HR = 4.0 [1.3–4.9] (PCB 118, Breast cancer recurrence,
tert 3 vs. tert1)
Adipose tissue other than breast 1/2 MRR = 1.3 [1.1–1.5] (Breast-cancer specific mortality,Dieldrin, linear estimates per inter-quartile range)
POPs: persistent organic pollutants; CI: Confidence interval; NA: Not applicable; NR: not reported; * positive
association: an observed higher risk or mortality with higher POPs exposure; ** Adjusted for all important
confounders; OR: odds ratio; MRR: mortality rate ratio; PCB: Polychlorinated biphenyls; HR: hazard ratio, β-HCH:
β-Hexachlorocyclohexane.
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When considering POPs positively associated with breast cancer risk in at least 10% of studies and
at least two studies and no reported negative associations, eight individual POPs were consistently
positively associated with breast cancer risk in blood: p,p’-Dichlorodiphenyldichloroethylene (p,p’-DDE),
total or not specified DDE, β- Hexachlorocyclohexane (β-HCH), Dieldrin, PCB 118, PCB 138, PCB
170, PCB 180. Three individual POPs were consistently positively associated with breast cancer risk
in breast adipose tissue: p,p’-DDE, total or not specified DDE, PCB 105. When considering POPs
positively associated with breast cancer risk in at least one study and no reported negative associations,
six individual POPs were positively associated with breast cancer risk in both blood and breast adipose
tissue: p,p’-DDE, total or not specified DDE, Hexachlorobenzene (HCB), β-HCH, PCB 118 and PCB 180
(Tables S11 and S12).
When considering POPs positively associated with breast cancer mortality in at least 10% of
studies and no reported negative associations, total PCBs and four individual POPs were positively
associated with breast cancer mortality in blood: p,p’-Dichlorodiphenyltrichloroethane (p,p’-DDT),
Dieldrin, PCB 174, PCB 177. Total PCBs and three individual POPs were positively associated with
breast cancer mortality in breast adipose tissue: PCB 118, PCB 153, PCB 167 (Tables S13 and S14).
Six individual POPs were positively associated with breast cancer prognostic factors in blood, in at
least one study and with no reported negative associations: p,p’-DDE, Oxychlordane, trans-Nonachlor,
β-HCH, PCB 138, PCB 153 (Table S16).
Three individual POPs were positively associated with both breast cancer risk and prognosis
either in blood or in breast adipose tissue: p,p’-DDE, β-HCH and PCB 118 (Tables S11–S15).
4. Discussion
The present systematic review of POPs and breast cancer indicates that studies of blood POPs
and breast cancer risk accounted for much of the observed inconsistencies of epidemiological studies
results. POPs measured in breast adipose tissue were more clearly associated with higher breast cancer
risk. POPs were more consistently associated with worse breast cancer prognosis, whether measured
in blood or breast adipose tissue, whereas POPs measured in adipose tissue other than breast were
inversely associated with both breast cancer risk and prognosis. Some individual POPs measured
in blood and breast adipose tissue were consistently associated with higher breast cancer risk and
worse prognosis. However, the overall strength of evidence is weak, since few studies contributed to
estimations of associations and the overall risk of bias in these studies ranged from moderate to critical.
The inconsistencies between studies of blood POPs and breast cancer risk could be explained
by methodological biases. In fact, more than half of these studies have measured POPs at the
time of diagnosis which does not necessarily reflect the cumulative lifetime exposure to POPs and
early-life exposures during critical windows of vulnerability [124]. Even though the majority of
population-nested case-control studies and the only cohort study have measured POPs several months
to many years before breast cancer occurrence, a point measurement of blood concentration of POPs is
more likely to reflect recent dietary intakes and liver function [125,126] and can be affected by various
events over time, such as weight loss or gain, pregnancies and breastfeeding [124–126]. The complex
misclassification of POPs exposure resulting from blood measurements could have biased the observed
associations toward the null, i.e., toward the observation of weaker associations or no associations
at all.
In this regard, adipose tissue, as a storage compartment for lipophilic POPs [127], is a more
appropriate medium for estimating lifetime exposure to POPs. The observation of consistently positive
associations with breast cancer risk in studies of breast adipose tissue POPs but consistently negative
associations with POPs measured in adipose tissue other than breast is in line with the existent
evidence of a protective function of adipose tissue in the wildlife and points toward the metabolic and
toxicokinetic differences between different types of adipose tissue [127]. By accumulating POPs, adipose
tissue away from breast decreases their availability to other tissues, thereby limiting their toxicity to
the breast, whereas accumulation of POPs in breast adipose tissue exposes breast epithelial cells to
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their chronic local release. In fact, ultrastructural methods revealed regional differences in morphology
of human subcutaneous tissues [128]. Abdominal adipose tissue, classified as deposit white adipose
tissue, having large adipose cells and a poor collagenic component whereas adipocytes of breast
adipose tissue, classified as structural white adipose tissue, are covered by a relatively dense connective
capsule [128]. These regional differences in morphology explain the known regional differences in
the metabolism of subcutaneous fatty depots that are related to their various functions. Thus, our
results suggest that differences between adipose tissue subtypes may also have a toxicocokinetic impact
on POPs.
Moreover, more than half of studies of blood POPs and breast cancer risk included more
premenopausal than postmenopausal breast cancer patients. Although environmental exposures may
be involved in premenopausal breast cancer occurrence, these cancers are primarily driven by a strong
genetic susceptibility and are more often ER-negative cancers [129]. Furthermore, the increase in
breast cancer incidence over the last decades reflects the increase in the incidence of postmenopausal
breast cancers, which are more often ER-positive breast cancers [130], and thus more susceptible to the
hormone-disrupting effects of POPs [8]. The selection bias created by inclusion of large proportions of
premenopausal breast cancers, which are less likely to be related to POPs exposure, could have biased
the observed associations toward the null. In fact, we observed that studies that included less than 80%
of postmenopausal patients and those including fewer than 80% ER-positive breast cancers were more
likely to observe no association.
Another important issue was related to statistical methods used for selecting potential confounders.
If the majority of studies of blood POPs and breast cancer risk have considered important confounders in
their statistical models, methods used for selecting potential confounders were not always appropriate.
In particular, the majority of case-control studies used the change in estimate method, which is not
appropriate for accurate estimations of associations. Changes in estimates may be observed when
adjusting for colliders (i.e., non-confounders that introduce a selection bias) and when non-collapsible
effect measures such as odds ratios are used [131]. The bias introduced by this method can be difficult to
predict when numerous variables are tested for confounding and can lead to discrepant studies results.
The strengths of the present systematic review include the use of the Cochrane Reviews rigorous
methodology, the extensive and highly sensitive search strategy to retrieve as many relevant studies as
possible, the use of a pre-established protocol, the assessment of the risk of bias, and the systematic
analysis of results, in addition to considering sources of heterogeneity between studies results.
Limitations include the lack of high-quality evidence inherent in observational study designs and the
overall critical risk of bias in included studies.
Finally, although the present systematic review has identified some individual POPs associated
with both breast cancer risk and prognosis that deserve further investigation, it should be emphasized
that different POPs have different metabolic profiles and can have synergistic or antagonistic effects,
and that proportions of different POPs may vary from one person to another. Thus, approaches
considering the simultaneous exposure to different POPs may be more relevant than the isolated
analysis of individual POPs.
5. Conclusions
Over the past three decades, numerous epidemiological studies have attempted to assess the
association between exposure to POPs and breast cancer. Despite the apparent inconsistencies between
studies, which were mainly due to methodological biases and to differences in the biological sample
used for exposure measurement, when considering all studies (peripheral blood and adipose tissue)
and all outcomes together (risk and prognosis), there was a trend toward a positive association between
exposure to POPs and breast cancer that deserves further investigation. Future studies need to use
rigorous methodology by including the relevant study population, using an appropriate biological
sample for POPs measurement, controlling properly for confounding and assessing combined effects
of POPs.
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Abstract: There has been a renewed interest in the identification of natural products having premium
pharmacological properties and minimum off-target effects. In accordance with this approach, natural
product research has experienced an exponential growth in the past two decades and has yielded a
stream of preclinical and clinical insights which have deeply improved our knowledge related to the
multifaceted nature of cancer and strategies to therapeutically target deregulated signaling pathways
in different cancers. In this review, we have set the spotlight on the scientifically proven ability of
berberine to effectively target a myriad of deregulated pathways.
Keywords: berberine; signaling pathways; oncogenic cascades; TRAIL; microRNAs; cancer therapy
1. Introduction
Berberine, a natural alkaloid compound, is found in several medicinal plants. Typically, berberine
is commercially produced from a Chinese medicinal plant Coptis chinensis. Berberine has captivated a
substantial proportion of appreciation because of its remarkable pharmacological properties. Recent
advancements in high-throughput techniques have helped us to demystify various hierarchically
organized signaling complexes which play an instrumental role in cancer development and progression.
Basic reviews related to the ability of berberine to improve worsening conditions in different diseases
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have previously been published, so our aim is not to summarize pharmacological importance of
berberine in different diseases, but we have restricted our discussion specifically to berberine mediated
targeting of signaling cascades in different cancers. In this review, we present current views related to
how berberine effectively targets different deregulated oncogenic cascades and highlight key practical
and conceptual questions that will be helpful to shape the next dimension of investigation into the
ability of berberine to efficiently target different signaling cascades. We will start our overview
with one of the most widely investigated cancer killing molecules: TNF-related apoptosis-inducing
ligand (TRAIL).
2. Berberine Mediated Restoration of TRAIL-Mediated Apoptosis
There has always been a quest to identify the molecules having significant cancer killing activity
and minimal off-target effects. In accordance with this view, the discovery of TRAIL revolutionized the
field of molecular oncology [1,2]. However, initial claims were partially challenged by contemporary
researchers because TRAIL was ineffective against different cancers. In-depth studies revealed that
TRAIL transduced the signals intracellularly through death receptors (DR4, DR5) [3,4]. However, loss
of cell surface appearance of death receptors was a frequently noted mechanism in TRAIL-resistance
cancers. Moreover, imbalance of pro- and anti-apoptotic proteins was also reported in TRAIL resistant
cancers. The advent of high-throughput technologies has helped us to uncover the highly orchestrated
nature of TRAIL mediated signaling, which is initialized through extrinsic and intrinsic pathways.
In this section, we will summarize recent developments and discuss unresolved and outstanding
research questions.
Berberine has been shown to potently induce AMP-activated protein kinase (AMPK) in cancer
cells [5]. Expectedly, berberine mediated apoptosis inducing effects were severely impaired in
AMPKα-dominant negative (DN) expressing or AMPKα knockdown cancer cells. Knockdown of DR5
significantly abrogated TRAIL-berberine-induced apoptosis [5]. TRAIL and berberine combinatorially
enhanced p38-MAPK phosphorylation [6]. p38-MAPK inhibition enhanced apoptosis in EGFR
(epidermal growth factor receptor)-overexpressing MDA-MB-468 TNBC cells [6].
TRAIL and berberine significantly activated caspase-3 and cleavage of PARP in TRAIL-resistant
MDA-MB-468 BCa cells [7]. In a murine 4T1 BCa model, berberine potentiated the efficaciousness of
the anti-DR5 antibody and effectively blocked tumor growth and lung metastases [7]. Mcl-1 and c-FLIP
have been shown to negatively regulate TRAIL-mediated apoptosis. Berberine dose-dependently
induced degradation of Mcl-1 and c-FLIP [8]. However, treatment with a proteasome inhibitor MG132
interfered with berberine-mediated downregulation of Mcl-1 and c-FLIP [8].
While great efforts over the past few years have advanced our understanding of the berberine
mediated regulation of the TRAIL-mediated pathway, much of this work has focused on preliminary
information about the ability of berberine to improve TRAIL-induced killing activity. There are still
many questions which need detailed research, for example, how berberine mechanistically regulates
expression of death receptors in different cancers. Does it inhibit receptor degradation, or does it
interfere with epigenetic silencing to restore expression of death receptors? How does berberine
improve formation of death inducing signaling complex (DISC) while simultaneously targeting
negative regulators which inhibit DISC formation? In the following section, we will discuss how
berberine modulates the WNT/β-catenin pathway to inhibit cancer.
3. Regulation of WNT Pathway by Berberine
Levels of cytoplasmic β-catenin are controlled by a multi-proteins destruction complex which
induces β-catenin phosphorylation, which is required for β-catenin ubiquitination and its subsequent
degradation by proteasomes [9]. Berberine efficiently inhibited nuclear accumulation of β-catenin.
Co-immunoprecipitation studies revealed that berberine increased the interaction between APC
(adenomatous polyposis coli) and β-catenin [9] (shown in Figure 1). These findings shed light on the
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ability of berberine to stimulate the expression of APC and negatively regulate β-catenin by increasing
physical interaction between these proteins.
Figure 1. (A) WNT/ β-catenin mediated intracellular signaling. β-catenin moved into the nucleus
to stimulate expression of target genes. (B) Berberine promoted interaction of β-catenin and APC to
enhance degradation of β-catenin. (C) Berberine also promoted interaction of β-catenin with c-Cbl
in nucleus that also induced degradation of β-catenin. (D) Berberine inhibited phosphorylation of
LRP5/6 and GSK-3β. Abbreviations: c-Cbl (CASITAS B-lineage lymphoma protooncogene), LRP5/6
(Low density lipoprotein receptor-related protein), CK (Casein Kinase), GSK-3β (Glycogen synthase
kinase), RXR (Retinoid X-receptor), WNT (Wingless/Integrase), SAMP (Ser-Ala-Met-Pro motif), RING
(Really interesting new gene).
There is evidence of mechanistic regulation of the WNT pathway by berberine in hepatocellular
carcinoma cell line (SMMC-7721). However, these findings should be tested in other cancers. In a
report, researchers demonstrated that berberine worked synergistically with HMQ1611, a taspine
derivative and suppressed the phosphorylation of LRP5/6 and GSK3β [10]. Berberine and HMQ1611
combinatorially downregulated WNT5A, Frizzled8, CK1 (casein kinase 1) and APC. Overall this
study uncovered distinct steps of β-catenin phosphorylation and degradation by berberine and
HMQ1611 [10]. Importantly, berberine was unable to significantly inhibit tumor growth individually
in mice xenografted with SMMC-7721 cells.
Berberine decreased levels of WNT5A and cytoplasmic β-catenin in both SGC7901 and AGS
cells [11]. Treatment with berberine and galangin decreased β-catenin and WNT3A in esophageal
carcinoma cells [12]. Berberine concentration-dependently downregulated mRNA expression of
β-catenin in colon cancer cells [13]. RXRα (retinoid X receptor α) agonists have been shown to promote
RXRα binding to β-catenin to induce ubiquitination and degradation of β-catenin [14]. Berberine
275
Cancers 2019, 11, 478
dose-dependently enhanced physical association of RXRα with β-catenin. Berberine induced nuclear
translocation of E3 ubiquitin ligase c-Cbl which modulated degradation of β-catenin [14] (shown in
Figure 1). Overall, these findings clearly suggested that berberine enhanced degradation of β-catenin
by promoting its interaction with c-Cbl.
It seems clear that berberine has potential to regulate the WNT pathway in different cancers, but
it needs to be tested tactically in xenografted mice. Future studies must converge on identification
of the modes opted by berberine to inhibit the WNT pathway in different cancers. Does it interfere
with importin and exportin proteins to inhibit nuclear accumulation? Are there further previously
unexplored ubiquitin ligases which can target β-catenin? Can berberine effectively target LRP5/6 and
Frizzled receptors in other cancers to also efficiently inhibit cancer proliferation? In the upcoming
section we will highlight how berberine regulates the Janus kinases-signal transducer and activator of
transcription proteins (JAK-STAT) pathway in different cancers.
4. Targeting of JAK-STAT Pathway
Kinases of the Janus kinase (JAK) family and transcriptional factors of the STAT (signal transducer
and activator of transcription) family form a highly dynamic and orchestrated membrane-to-nucleus
signaling module that has been extensively investigated, and an overwhelmingly increasing list of
scientific reports have provided evidence of natural products mediated targeting of the JAK-STAT
pathway in different cancers. More importantly and excitingly, coupling of massively parallel DNA
sequencing with chromatin-immunoprecipitation has enabled researchers to capture thousands of
STAT-binding sites.
Berberine reduced protein levels of STAT3 and inhibited the phosphorylation at 705th tyrosine
and 727th serine in cholangiocarcinoma cell lines [15] (shown in Figure 2). Berberine exerted inhibitory
effects on constitutive and IL-6-triggered activation of STAT3 in NPC (nasopharyngeal carcinoma)
cells [16]. TAFs (tumor-associated fibroblasts) secreted IL-6 and the conditioned media harvested from
the fibroblasts induced STAT3 activation in NPC cells. Activation of STAT3 by conditioned media of
TAFs was blocked by berberine [16].
Figure 2. JAK-STAT signaling. Berberine has been shown to inhibit phosphorylation of STAT3 and
STAT5. Berberine markedly reduced mRNA levels of STAT3. Functionally active STAT3 moved into the
nucleus and stimulated expression of miR-21. Abbreviations: STAT (signal transducer and activator of
transcription), JAK (Janus kinase), PIAS (Protein inhibitors of activated STATs), PTP (Protein-tyrosine
phosphatase), SHP-2 (Src homology phosphatase-2).
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Berberine significantly decreased the phosphorylated levels of JAK2 and STAT3 in colorectal
cancer cells [17]. Interestingly, p-JAK2 and p-STAT3 were found to be remarkably enhanced in COX2
(cyclooxygenase-2) overexpressing colorectal cancer cells. COX2 overexpression induced activation of
JAK-STAT signaling further upregulated matrix metalloproteinases (MMP)-2 and MMP-9 in colorectal
cancer cells. However, berberine effectively interrupted COX2/JAK/STAT signaling [17].
Colonization of Fusobacterium nucleatum in the intestine may contribute to colorectal cancer
(18). Levels of p-STAT3 and p-STAT5 were found to be enhanced after inoculation of F. nucleatum
in C57BL/6-APCMin/+ mice and wild-type C57BL/6 mice. Moreover, F. nucleatum-induced increases
in quantities of p-STAT3 and p-STAT5 were found to be considerably reduced in mice treated with
berberine [18] (shown in Figure 2).
Doxorubicin, a widely used chemotherapeutic drug has been shown to induce activation of
STAT3 in lung cancer cells [19]. However, berberine markedly inhibited doxorubicin-triggered STAT3
activation. Besides, berberine promoted degradation of STAT3 by enhancing ubiquitination [19].
Berberine also enhanced killing effects of 5-fluorouracil by STAT3 inactivation and repressing the
expression of survivin in gastric cancer cells [20].
5. Targeting of the mTOR Pathway: Could Berberine Modify Extracellular Vesicle-Composition?
The mammalian target of rapamycin (mTOR), a serine/threonine kinase of the PI3K
(phosphoinositide 3-kinases)-related kinase family, is conserved on an evolutionary scale that
coordinates different cellular processes. mTOR forms two structurally and functionally active
complexes: mTOR complex 1 (mTORC1) and 2 (mTORC2). These two multi-component complexes are
involved in physiological and pathological functions, such as macromolecules synthesis, homeostasis
maintenance, cytoskeleton remodeling, angiogenesis, survival, response to stress and autophagy [21].
Considering the key role of mTOR in cell proliferation and differentiation, its deregulation contributes
to cancer onset and progression [22].
The cellular metabolism mediated by mTOR is involved in the connections between cancer cells
and tumor microenvironment during cancer advance and drug resistance acquisition, indicating the
potential benefits of PI3K-Akt (protein kinase B)-mTOR pathway blockage. This inhibition contributes
to reduce proliferation, migration, and survival of cancer cells, and increase tumor immunosurveillance
through down-regulation of immunosuppression and anti-tumor immune stimulation [23]. mTORC1
is a downstream component in several pathways frequently altered in cancer, including the PI3K/Akt
and MAPK (mitogen-activated protein kinases) pathways, that induces mTORC1 hyperactivation in
many human cancers. Besides, mTORC2 signaling has a key role in tumors for its role in Akt activation,
that induces tumor growth mechanisms such as glucose metabolism and apoptosis inhibition [24].
Recent reports show that mTOR is involved in lipid metabolism [25]; the critical step of this signaling
cascade is the activation of proteins by phosphorylation at different sites. An important upstream
target of mTOR is ERK (extracellular signal-regulated kinases), that regulates mTOR negatively and
in turn enhances autophagy. ERK, a protein of MAPK cascade, is a central integrator of extracellular
signals which are transduced by single cytokines or hormones or activated by cellular mechanical
stresses that influence lipid metabolism [26,27].
The mTOR inhibitors, called “rapalogs,” used as anti-cancer drugs belonged to a class of rapamycin
derivatives. The first rapalog, approved for advanced renal carcinoma management was temsirolimus,
followed by everolimus. These rapalogs did not show significant results in clinical practice as compared
to the results obtained in pre-clinical studies. The rapalogs and catalytic mTOR inhibitors were useful
in immunosuppression in a small number of cancers [28,29].
Several natural compounds such as berberine, resveratrol, curcumin, quercetin and others can
modulate the mTOR pathway [30–32]. Recent studies have revealed that berberine has anti-tumor
effects, through inhibition of the mTOR-signaling pathway. Berberine, anisoquinoline alkaloid
isolated from Berberis vulgaris L, has anti-diarrheic, anti-inflammation, and anti-microbial activities [33].
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Nowadays, several studies have shown that berberine is effective against glioma, colorectal, lung,
prostate and ovarian cancer [26].
Berberine can modulate different pathways, such as cellular glucose metabolism and the HIF-1α
(hypoxia-inducible factor 1α)-mTOR axis. In this context, Wang et al. [26] indicated that berberine
modulated the metabolism of glioblastoma multiforme cells, induced autophagy and reduced
glucose metabolism. These changes reduced tumor growth and invasiveness, induced apoptosis, by
AMPK/mTOR/ULK1 (Unc-51 like autophagy activating kinase) pathway inhibition. Berberine reduced
cancer progression in vivo, which clearly indicated the potential clinical benefits of alkaloids extract
from plants in cancer therapy [26].
Mao et al. provided evidence that berberine played a central role in regulation of cellular glucose
metabolism in colon cancer cells [34]. They studied the effects of berberine in colon cancer cell lines
and findings revealed that berberine inhibited glucose uptake and reduced the transcription of genes,
such as GLUT1 (glucose transporter 1), LDHA (lactate dehydrogenase A) and HK2 (hexokinase 2),
involved in glucose metabolism of colon cancer cells. This mechanism is mediated by HIF-1α protein
synthesis inhibition through mTOR pathway suppression. The molecular study indicated that HIF-1α
protein expression, a well-known transcription factor critical for dysregulated cancer cell glucose
metabolism, was considerably inhibited in berberine-treated colon cancer cell lines [34]. It was reported
that berberine activated AMPK that in turn inhibited mTOR, in in vitro studies and in mouse models
of colon carcinogenesis in early stages of tumorigenesis. Berberine also interfered with the NF-κB
(nuclear factor kappa-light-chain-enhancer of activated B cells) pathway and effectively inhibited colon
cancer progression [33].
Berberine may also induce autophagy in human liver carcinoma cell lines, through activation
of Beclin-1 and inhibition of mTOR signaling by suppressing the activity of Akt and up-regulating
P38 MAPK signaling [35,36]. The role of berberine in mTOR pathway modulation has been also
demonstrated in hematological malignancies. Ma and collaborators showed the synergism of TPD7 and
berberine in leukemia Jurkat cell growth inhibition through ephrin-B2 signaling modulation [37]. There
are direct pieces of evidence which shed light on synergistic antitumor activities of rapamycin and
berberine treatment in hepato-carcinoma cell lines. There was a marked decrease in phosphorylated
p70S6 kinase 1 protein levels, a downstream effector of mTOR in cells combinatorially treated with
rapamycin and berberine as compared to cells treated with rapamycin or berberine alone [38]. It
was also demonstrated that berberine and cinnamaldehyde reduced the susceptibility of mice to
lung carcinogenesis induced by urethane, and reversed the urethane-induced AMPK, mTOR, AQP-1
(aquaporin 1) and NF-κB expression patterns [39]. Overall these reports advocated the role of berberine
as a new compound for cancer therapy.
Recent findings indicate that extracellular vesicles (EVs) play a key role in different steps of
cancer progression, transporting oncogenic proteins and nucleic acids [40–42]. EVs are named in
different ways based on their origin, diameter and mechanism of release. The two population of EVs
better characterized are exosomes and micro-vesicles [43,44]. Hypoxia induces wide changes in the
tumor microenvironment, and several reports show EVs central role in this mechanism [45]. Besides
HIF-1, other pathways such as PI3K/Akt/mTOR are induced in tumor cells under hypoxia. It was
demonstrated that hypoxia promoted prostate cancer progression and hypoxis-induced-exosomes
remodeled the cancer microenvironment [46]. Moreover, exosomes released by mesenchymal stem
cells (MSC) dose-dependently reduced VEGF (vascular endothelial growth factor) expression and
secretion mainly through interfering with the mTOR/HIF-1α axis in breast cancer cells. MSC-derived
exosomes, enriched in miR-100, were taken up by breast cancer cells [47]. microRNA-100 efficiently
downregulated VEGF in breast cancer cells.
This evidence suggests the possible role of berberine in modifying EV-composition, as has already
been demonstrated for other natural compounds such as curcumin. It is exciting to note that exosomes
released by curcumin-treated CML cells contained considerably higher levels of miR-21. Consequently,
these miR-21 loaded exosomes were taken up by HUVECs (human umbilical vein endothelial cells)
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and it was mechanistically shown that miR-21 directly targeted MARCKS (myristoylated alanine-rich
C-kinase substrate) and inhibited angiogenic phenotypes [48]. Curcumin also induced selective
packaging of miR-21 in exosomes and played a central role in reshaping post-transcriptional network
in recipient cells [49]. Furthermore, in CML cells, curcumin modulates other molecular pathways thus
altering the metabolism of glucose that in myeloproliferative disease is a consequence of non-hypoxic
activation of HIF-1α [50]. It was demonstrated that curcumin promoted miR-22 mediated targeting of
importin 7 that resulted in a significant reduction in nuclear accumulation of HIF-1α [51].
It will be interesting to see if berberine demonstrated potent activity to promote release of exosomes
loaded with tumor suppressor microRNAs and proteins.
6. Regulation of Epigenetic Modulators by Berberine
Histone marks are motives enabling the recruitment of chromatin complexes that activate or repress
transcription. Histone modifications such as acetylation and methylation at specific positions are signals
recognized by these complexes. Berberine was shown to upregulate some histone deacetylases (HDAC)
of class II, such as sirtuin SIRT1 (sirtuin 1), producing an antiatherogenic effect, and suppression of
foam cell formation in THP-1-derived macrophages treated with oxidized low-density lipoprotein [52].
RNA silencing of SIRT1 or AMPK blocked the berberine action.
Rel proteins have emerged as complex modulators of carcinogenesis and we still have to
explore their functionalities in malignancies and response to cancer therapeutics [53]. Set9 (lysine
methyltransferase) induced methylation of the RelA/p65 subunit, which inhibited nuclear accumulation
of NF-κB and repressed transcriptional upregulation of miR-21. Berberine dose-dependently induced
generation of ROS, arrested cancer cells in G(2)/M phase and induced apoptosis in U266 cells [53].
Overall, the findings clearly suggested that berberine promoted Set9 mediated methylation of p65 to
limit shuttling of NF-κB into the nucleus. Berberine mediated inhibition of translocation of NF-κB into
the nucleus resulted in inhibition of miR-21 and B-cell lymphoma 2 (Bcl-2).
The protective effects of berberine against metabolic syndrome might rely on increasing
mitochondrial SIRT3 activity and stimulating glycolysis, independent of AMPK activation [54,55].
The growth arrest and DNA damage-inducible protein GADD45α (growth arrest and DNA damage
45α) is a DNA demethylation regulator recruited by TCF21 antisense RNA inducing demethylation
(TARID) lncRNA to enable transcription of the TCF21 gene coding for tumor-suppressor gene
transcription factor 21 [56]. As detailed in the next paragraphs, administration of Coptidis rhyzoma
aqueous extract, resulted in a higher expression of miR-23a, and in up-regulation of GADD45a, a
chromatin relaxer, decreasing DNA methylation through recruitment of the 5-hydroxymethylcytosine
(5hmC) hyperproducing enzyme TET, and thymine DNA glycosidase (TDG) [57–59].
Berberine induced a decrease in activity of two DNA methylases, DNMT1 (DNA
(cytosine-5)-methyltransferase 1) and DNMT3, that, through DNA hypomethylation, induced an
increase of p53 [60]; p53 activation was observed following the increase in miR-23a, through repression
of Nek6, in HCC cells in response to Rhizoma Coptis aqueous extract [60].
Various long noncoding RNA (lncRNAs), through their tertiary structure, work as scaffolds
to recruit protein complexes such as chromatin modifiers, polycomb repressive complex (PRC),
and transcriptional regulators to euchromatin regions: many lncRNAs have been associated with
pharmacological drugs as well as to cisplatin treatment [61]. In various studies, berberine has been
able to induce or repress some lncRNA [62].
7. Regulation of microRNAs by Berberine
Many bioactive compounds have been proposed for their regulatory effects on non-coding RNAs,
either long ncRNAs (lncRNA), or small RNAs such as microRNAs [63–65]. These miRNAs have
added new layers of complexity in the context of post-transcriptional regulation, controlling the
availability of mRNAs, and selection of the mRNAs that they recognize as targets by complementary
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seed sequences to initialize the degradation process of mRNAs. miRNAs exert a regulatory role in the
post-translational process.
OncomiRs are oncogenic due to their ability to support cell proliferation, apoptosis inhibition, cell
stemness, while tumor suppressor miRNAs are involved in nodes or networks leading to differentiation,
cell cycle inhibition and growth arrest and apoptosis.
There are feedback loops and feedforward loops, sustaining the oncogenic activity of ncRNAs: for
instance, a feedback loop has been described in lymphoma between miR-17-92, MYC, the protein kinase
Chk2 and hu antigen R (HUR) [66]. Transcription factors can induce the expression of protein-coding
genes as well as of miRNAs, that can target the mRNAs of the induced genes, in a feedforward loop. In
lymphoma cells, miR-17-92 regulates MYC mRNA levels through the inhibition of Chk2, causing the
depression of RNA-binding protein HUR, and its binding to MYC mRNA, preventing MYC translation.
Thus, berberine suppresses the growth of multiple myelomas, either by down-regulation of three
oncogenic miRNA clusters and other mRNAs, or by involvement of p53 and MAP kinases [67].
Several researchers pointed out to a correlation between berberine treatment and expression of
non-coding RNAs, either lncRNAs or microRNAs. In cancer studies, treatment of multiple myeloma
cells with berberine, significantly suppressed three oncogenic miRNA clusters, miR-17-92, miR-106-25,
and miR-99a-125b. Berberine mediated downregulation of miR-99a-125b was found to be correlated
with the regulation of p53, MAP Kinases and ErbB oncogene, leading to cell cycle arrest in the G2-phase
and to apoptosis [63].
In colon cancers, berberine was effective in downregulating miR-429, with increase in its target,
SOX-2; berberine up-regulated miR-296-5p and effectively interfered with the Pin1–β-catenin–cyclin
D1 signal transduction cascade. Berberine inhibited the growth of HepG2 cells and induced the
upregulation of miR-22-3p. miR-22-3p directly targeted SP1 and suppressed expression of its target
genes, BCL2 (B-cell lymphoma 2) and CCND1 (cyclin D1) [68] (shown in Figure 3).
It was shown that berberine suppresses interleukin 6 (IL6), a factor required for cell growth in
multiple myeloma cells (U266), through negative regulation of the signal transducer and activator of
transcription 3 (STAT3), and this induces inhibition of miR-21 expression [69]. STAT3 regulates miR-21
expression through binding to STAT3 binding sites in the promoter (shown in Figure 2). Additionally,
in ovarian cancer cells (SKOV3), berberine sensitized to cisplatin treatment through inhibition of
miR-21, and subsequent activation of PDCD4, a tumor suppressor.
It is not straightforward to determine the role of miRNAs in tumor promotion or suppression, that
depends on the context-specific, cell-type specific dual role of certain miRNAs [66]. This depends on
the varieties of targets of miRNAs. There are miRNAs, such as miR-25 and miR-125b, that act as tumor
suppressors in some tumor types and as oncogenes in others. In particular, in stem cells, miRNAs
that in other cell types are regulated and respond to the bioactive supplements, may not decrease
in levels, for their role in cell stemness. Berberine, in the form of a Rhizoma Coptis aqueous extract,
resulted not effective in decreasing miR-21 levels, while it supported a higher expression of miR-23a,
by up-regulating p21/GADD45a tumor suppressor gene (shown in Figure 3), causing HCC cells to
arrest the growth in G2/M phase [19,70]. Furthermore, miR-23a was shown to repress Nek6 and to
regulate p53 transcriptional activity.
Autophagy influences glucose and lipid metabolism in adipocytes. Berberine was shown to
decrease miR-30a and miR-376b, preventing basal autophagy in 3T3-L1 adipocytes. MiR-30 interacts
with the 3′-untranslated region of Beclin 1 (BECN1), thus the reduction in miR-30a levels increased
BECN1 to form BECN1 complexes that induce autophagy (beclin homolog in yeast, Atg6, is known
as autophagy promoting factor) [71]. This leads to reduced fat deposits and an increase in brown
fat tissue.
Berberine was shown to exert an anti-apoptotic role in development of preimplantation embryos
in vitro, by maintaining high levels of miR-21. Berberine up-regulated Bcl-2, in 2- and 4-cell embryos
and blastocysts, and down-regulated caspase-3 and PTEN.
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When the pre-miRNA is processed by the RISC complex, the guide strand is considered the
mature, active miRNA, while the complementary passenger strand (termed miRNA*) is thought to be
devoid of function. However, some miRNA star has been related to a function, some have a feedback
role to regulate the RISC processing, and some have been shown to have anti-oncogene activity. This
seems the case for miR-21*, or miR21-3p, affecting cancer cell growth [72]. In HepG2 hepatocellular
carcinoma cells, berberine increased the levels of miR-21-3p, with a role in tumor growth inhibition
and induction of apoptosis. In hepatic cancers, miR-21* antitumor activity relies on inhibition of
MAT2A and MAT2B methionine adenosyltransferases mRNAs, with consequent increased levels of
S-adenosyl-methionine (SAM). Methionine adenosyltransferase (MAT) played a central role in growth
of hepatoma cells. miR-21-3p had previously been shown to directly target MAT2A and MAT2B
in HepG2 cells. Berberine induced apoptosis in HepG2 cells mainly through miR-21-3p mediated
targeting of MAT2A and MAT2B [72].
Figure 3. Regulation of non-coding RNAs by berberine. (A) CASC2 interacted with AUF1 and prevented
its binding to AU rich sequences present within mRNA of Bcl-2. (B,C) AP-1 transcriptionally upregulated
miR-101. miR-101 directly targeted COX-2. (D–G) P53 induced transcriptional upregulation of miR-23a.
Additionally, miR-23a worked synchronously and stimulated the expression of GADD45a and p21.
miR-22-3p directly targeted SP1. SP1 mediated upregulation of CCND1 and BCL2. Abbreviations:
AUF1 (AU-rich element RNA-binding protein-1), BCL2 (B-cell CLL/lymphoma-2), GADD45α (Growth
arrest- and DNA damage-inducible gene), CCND1 (Cyclin D1), CASC2 (long non-coding RNA), SP1
(specificity protein-1), AP-1 (Activator protein-1).
Ovarian cancer cells resistant to cisplatin, such as A2780 and A2780/DDP lines, were incubated
with berberine combined with cisplatin, showing a significantly lower survival rate [73]. This effect was
found to be related to inhibition of miR-93 expression, that translated in re-expression of PTEN tumor
suppressor and recovery of AKT signaling [73]. Bcl-w has been shown to be targeted by miRNAs. In
gastric cancers [60], berberine upregulated miR-203 and restored cisplatin-sensitivity in gastric cancer
cells [74].
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In liver cancers, berberine inhibited cell proliferation and viability in HepG2, Hep3B, and SNU-182
lines. Berberine treatment increased the expression of tumor suppressor such as Kruppel-like factor 6
(KLF6), activating transcription factor 3 (ATF3) and p21, a cell cycle inhibitor, and down-regulated
the oncogene E2F transcription factor 1 (E2F1). A possible mechanism of the upregulation of protein
coding genes may be hypothesized through downregulation of the respective miRNAs.
Berberine supplementation led to the miR29-b suppression, increasing insulin-like growth
factor-binding protein (IGFBP1) expression in the liver; miR29-b suppression caused an increase in
AMPK activity and a reduction of lipid storage in diabetic and obese patients [60]. Activation of AKT
positively affected glucose uptake, reducing the glucose levels in blood.
LncRNAs are deregulated after berberine treatment in hepatocellular cancer, similarly to the effects
seen after curcumin treatment on lncRNAs and on epigenetic changes seen in hepatocellular cancer [75].
A lncRNA, ANRIL, expressed at increased levels in type 2 diabetic (T2D) patients, causing an increase
of CREB (cAMP response element-binding protein) expression, may be affected by berberine. Berberine
down-regulated miR-122 and this caused a decrease in SREBP-1 levels in palmitic acid-treated HepG2
cells. Berberine was able to reduce the levels of glucose in T2D patients and in nonalcoholic fatty
liver disease, by down-regulating lncRNA052686 and miR-122 [61,62,71,76,77]. The hyperlipidemic
effect of berberine was linked to the inhibition of C/EBPα and PPARγ2 expression through inhibition
of phosphorylated CREB binding to C/EBPβ promoter. MRAK052686, a lncRNA downregulated in
diabetes, was induced by berberine. MRAK052686 co-localize at the 3′UTR of Zbtb20, coding for a
protein regulating glucose homeostasis. The co-expression of MRAK052686 and Zbtb20 increases the
level of the protein, improving glucose homeostasis [62].
8. Nanotechnological Strategies to Improve the Delivery of Berberine
Due to its outstanding antitumoral properties, many efforts have been devoted in designing carriers
for berberine delivery as an anti-cancer therapeutic agent. Both inorganic and organic nanomaterials
have been exploited for this purpose (shown in Figure 4).
Figure 4. Berberine delivery strategies. On the left, inorganic nanocarriers are shown: Ag, Silver
nanoparticles; ZnO, zinc oxide nanoparticles; IO, Iron oxide nanoparticles. On the right, organic
nanocarriers are shown: SLN, solid lipid nanoparticles; NLC, nanostructured lipid carriers; Liposomes;
Dendrimers; Lipopolymeric nanoparticles.
Silver nanoparticles proved successful in delivering berberine to human tongue squamous
carcinoma SCC-25 cells, blocking cell cycle and increasing Bax/Bcl-2 ratio gene expression, thus
indicating activation of pro-apoptotic pathways triggered by mitochondrial dysfunction [78].
Interestingly, silver nanoparticles carrying berberine displayed elevated cytotoxicity in different
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breast cancer cell lines and inhibition of tumor growth in vivo [79]. The same research group
fabricated citrate-capped silver nanoparticles loaded with berberine and conjugated to polyethylene
glycol-functionalized folic acid and demonstrated that they were able to induce apoptosis and variations
in gene expression in breast cancer cells. In MDA-MB-231 athymic nude mice models, a significative
reduction of tumor progression was observed [80].
Zinc oxide nanoparticles carrying berberine were recently synthesized for lung cancer therapy.
They displayed antiproliferative activity in A549 cells and no significant toxicity in vivo. Moreover,
due to the intrinsic properties of ZnO, these materials have been exploited as photothermal therapy
(PTT) agents, leading to thermal ablation of cancer cells [81].
An innovative approach has been recently adopted by creating iron oxide nanoparticles complexed
with hypoxic cell sensitizer sanazole together with berberine, able to target hypoxic tumors in vivo.
Hypoxia is known to induce expression of HIF-1-alpha and consequent activation of angiogenesis
related genes. Interestingly, after administration of nanoparticles, transcriptional downregulation of
these and many genes linked to cell proliferation and metastasis was observed and clearly correlated
with a reduction of tumor volume in vivo [82].
Many studies have demonstrated the feasibility of designing organic nanoparticles for berberine
delivery. Solid lipid nanoparticles have been synthesized with good stability, high berberine loading and
huge entrapment efficiency, essential parameters for successful clinical evaluation. These nanomaterials
inhibited cell proliferation of MCF-7, HepG2, and A549 cancer cells inhibited cell cycle progression
and apoptosis in MCF-7 cells [83].
Nanostructured lipid carriers efficiently delivered berberine to H22 hepatocarcinoma cells with
high antitumor efficacy [84]. Lipid nanoparticles covered with the self-tumor targeting polymers
lactoferrin and hyaluronic acid were fabricated for berberine and rapamycin delivery to lung cancer
cells and displayed improved internalization and selective cytotoxicity. Detectable reduction in the
number of lung foci and vascular endothelial growth factor levels were further observed [85]. The
same approach was adopted by administering inhalable nanoparticles to in vivo models of lung cancer,
achieving a significant decrease in lung weight, reduction in lung adenomatous foci number and
diameter and in angiogenic markers expression [86].
Amine terminated G4 PAMAM have been developed with conjugated berberine and demonstrated
specific cytotoxicity in different human breast cancer cell lines [87]. Lipopolymeric micelles have been
developed that greatly improved berberine water solubility up to 300% with low toxicity and induced
apoptosis in treated monolayer and spheroid cultures of human prostate carcinomas [88]. Finally,
berberine loaded folate acid modified chitosan nanoparticles demonstrated effective in inhibiting
proliferation and migration and inducing apoptosis and necrosis in human nasopharyngeal carcinoma
cells CNE-1 [89].
9. Conclusions
Berberine has emerged as an excellent natural product having significant biological activity [90]. It
has demonstrated premium activity against different cancers. Increasingly sophisticated cutting-edge
research has uncovered tremendous chemopreventive ability of berberine to modulate signaling
pathways [91,92].
In the last few years, many studies have been focused on unraveling intrinsic properties of berberine
and its ability to interfere with intracellular pathways. In particular, there is an increasing interest in
exploiting this natural compound as an effective anticancer drug. Although some issues remain to
be solved, such as its poor water solubility/stability and low bioavailability, many nanotechnological
approaches have allowed the design of ad hoc delivery systems, making berberine application for
cancer treatment feasible. Many different nanocarriers, based both on inorganic and organic materials,
have been developed and proven to be effective in overcoming some of the above-mentioned issues
and in delivering berberine in an extremely efficient manner in many different cancer experimental
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models. In the near future, further research will provide crucial answers needed to pave the way to
berberine clinical application.
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Abbreviations
Breast cancer cells MDA-MB-231, MCF-7, MDA-MB-468
hepatocellular carcinoma cells SNU-182, HepG2, Hep3B, H22 SMMC-7721
gastric cancer cells SGC7901, AGS
lung carcinoma A549
myeloma U266 cell line
ovarian cancer cell line SKOV3
Akt protein kinase B
AMPK AMP-activated protein kinase
AQP-1 aquaporin 1
APC adenomatous polyposis coli
Bcl-2 B-cell lymphoma 2
CCND1 cyclin D1
c-FLIP cellular FADD like interdeukin-1-p-converting enzyme inhibitory protein
CK1 casein kinase 1
COX2 cyclooxygenase-2
CREB cAMP response element-binding protein
DISC death inducing signaling complex
DNMT1 DNA (cytosine-5)-methyltransferase 1
DR death receptor
EGFR epidermal growth factor receptor
ERK extracellular signal-regulated kinases
EVs extracellular vesicles
GADD45α growth arrest and DNA damage 45α
GLUT1 glucose transporter 1
HIF-1α hypoxia-inducible factor 1α
HK2 hexokinase 2
HUVECs human umbilical vein endothelial cells
IO iron oxide
JAK-STAT Janus kinases-signal transducer and activator of transcription proteins
LDHA lactate dehydrogenase A
lncRNAs long noncoding RNA
LRP low-density lipoprotein receptor-related protein
MAPK mitogen-activated protein kinases
MARCKS myristoylated alanine-rich C-kinase substrate
MMP matrix metalloproteinases
mTOR mammalian target of rapamycin
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells




RXRα retinoid X receptor α
SIRT1 sirtuin 1
SLN solid lipid nanoparticles
T2D type 2 diabetes
TAFs tumor-associated fibroblasts
TARID TCF21 antisense RNA inducing demethylation
TNF tumor necrosis factor
TRAIL TNF-related apoptosis-inducing ligand
ULK1 Unc-51 like autophagy activating kinase
VEGF vascular endothelial growth factor
ZnO zinc oxide.
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Abstract: Radiotherapy is used extensively in cancer treatment, but radioresistance and the metastatic
potential of cancer cells that survive radiation remain critical issues. There is a need for novel
treatments to improve radiotherapy. Here, we evaluated the therapeutic benefit of λ-carrageenan
(CGN) to enhance the efficacy of radiation treatment and investigated the underlying molecular
mechanism. CGN treatment decreased viability in irradiated cancer cells and enhanced reactive
oxygen species accumulation, apoptosis, and polyploid formation. Additionally, CGN suppressed
radiation-induced chemoinvasion and invasive growth in 3D lrECM culture. We also screened target
molecules using a gene expression microarray analysis and focused on Rac GTPase-activating protein
1 (RacGAP1). Protein expression of RacGAP1 was upregulated in several cancer cell lines after
radiation, which was significantly suppressed by CGN treatment. Knockdown of RacGAP1 decreased
cell viability and invasiveness after radiation. Overexpression of RacGAP1 partially rescued CGN
cytotoxicity. In a mouse xenograft model, local irradiation followed by CGN treatment significantly
decreased tumor growth and lung metastasis compared to either treatment alone. Taken together,
these results suggest that CGN may enhance the effectiveness of radiation in cancer therapy by
decreasing cancer cell viability and suppressing both radiation-induced invasive activity and distal
metastasis through downregulating RacGAP1 expression.
Keywords: carrageenan; invasion; metastasis; RacGAP1; radiotherapy
1. Introduction
Radiotherapy is a standard treatment to eliminate cancer cells by inducing a variety of cellular
events, including the accumulation of reactive oxygen species (ROS) [1] and apoptotic cell death [2].
In clinical practice, radiotherapy is used as a post-operative treatment after resection, treatment for
Cancers 2019, 11, 1192; doi:10.3390/cancers11081192 www.mdpi.com/journal/cancers291
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inoperable tumors, and may even replace surgery where organ preservation is desired [3,4]. Although
radiotherapy is an effective anticancer therapy, differences in radiation response among different types
of cancers [5,6], along with the side effects of high dose or large field IR [7], limit its efficacy. To increase
its clinical impact, various chemotherapeutic drugs are administered with radiotherapy. However,
these drugs can have their toxicity to normal tissues [8]. Therefore, novel therapies that are free from
side effects but at the same time can improve radiotherapy by increasing cancer cell death and reducing
distal metastasis are highly desirable.
Lambda-carrageenan (CGN), a family of linear sulfated polysaccharides, has diverse biological
activities, which include anti-coagulant [9], anti-viral [10], and anti-tumor effects [11]. In addition,
carrageenans are safely used as a food additive under FDA regulations in the United States [12].
Recently, several studies have reported the anti-tumor effects of CGN by stimulating an immune
response in mice [11,13]. However, the effect of CGN in combination with IR on cancer treatment and
its molecular mechanisms are not known. Considering the safety profile of this agent, we evaluated
the effect of CGN as an adjuvant treatment to radiotherapy.
In several types of cancer, recent studies have identified upregulated expression of RacGAP1
(also known as MgcRacGAP or hCYK-4), a member of the guanine triphosphatase (GTPase) activation
protein (GAP) family and suggested its potential role in promoting tumor progression [14–16]. RacGAP1
regulates the activation of Rho GTPase, which is reported to drive tumor growth [17] and to act as
an oncogene in basal-like breast cancers [18]. Moreover, RacGAP1 is required for integrin-related
invasive cell migration in the three-dimensional extracellular matrix (3D ECM) [19]. In clinical studies,
RacGAP1 has attracted increasing attention as a predictive biomarker for metastasis and prognosis in
several types of cancer [15,20].
In this study, we investigated the effect of CGN combined with ionizing radiation (IR) on cancer
treatment and determined underlying molecular mechanisms. We found that CGN treatment after IR
decreased cancer cell survival and invasiveness. Gene expression analysis showed that RacGAP1 was
upregulated after IR treatment, and significantly suppressed by CGN treatment. Furthermore, CGN
treatment after IR significantly suppressed tumor growth and lung metastasis in an in vivo model.
These results indicate that CGN is a potential therapeutic adjuvant to radiotherapy, improving its
therapeutic effect by suppressing RacGAP1.
2. Results
2.1. CGN Treatment Decreases the Cell Viability in Irradiated Cancer Cell Lines
The possibility of using polysaccharides as an adjuvant to improve the anti-tumor efficacy of
traditional chemotherapy has been raised [21,22]. In this study, we determined the anti-tumor effects
of CGN combined with IR in the MDA-MB-231 breast cancer, FaDu head and neck cancer, PANC-1
pancreatic cancer, and 4T1 murine breast cancer cell lines. In each case, when compared to IR alone,
cell number decreased significantly when IR and CGN were combined. The result also showed that
CGN alone caused damage to cancer cells (Figure 1A). To further analyze the decrease in cell number
in each condition, we next stained the cells with propidium iodide (PI) and Annexin V. CGN treatment
following IR led to a significant increase in PI-positive cells (Figure 1B) and Annexin V-positive cells
(Figure 1C) compared to the IR alone group. Annexin V/PI double staining analysis showed that late
apoptosis was increased in cells treated with IR and CGN compared to those treated with IR alone
(Figure S1). These results suggest that CGN combined with IR decreases viability in several cancer
cell lines by induction of apoptotic cell death. We evaluated the effect of CGN and IR treatment in
non-malignant epithelial cell line MCF10A (Figure S2A–C). The CGN-induced toxicity following IR
treatment in MCF10A cells was not higher than that in other malignant cells.
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Figure 1. λ-carrageenan (CGN) treatment decreases cell viability and increases apoptosis in irradiated
cancer cell lines. Cells were treated with 4 Gy IR, followed by CGN on the next day, and then analyzed
72 h after IR. (A) Cell viability was quantified by cell counting in MDA-MB-231, FaDu, PANC-1,
and 4T1 cell lines. (B) The percentage of dead cells was measured by PI staining, followed by flow
cytometry. The proportion of dead cells was quantified by gating the population of PI-positive cells.
(p-values: MDA-MB-231, 0.0056; FaDu, 0.0129; PANC-1, 0.0489; 4T1, 0.0468.) (C) Apoptotic cells were
measured by Annexin V-FITC staining, followed by flow cytometry. Mean fluorescence intensity
of FITC was calculated and normalized to the untreated group. Columns, mean (n ≥ 3); bars, SE.
*, p < 0.05; **, p < 0.01.
2.2. IR Combined with CGN Treatment Increases ROS Accumulation in MDA-MB-231 Breast Cancer Cells
Elevation of ROS is an important factor in the control of cancer cell death in radiotherapy [23]. It is
known that IR induces ROS, which mediate apoptotic cell death and mitotic failure. Additionally, CGN
has been reported to increase the production of ROS in human colonic epithelial cells [24]. We analyzed
cellular ROS levels using DCFDA, which fluoresces when oxidized by ROS. Increased ROS levels were
observed in the IR and CGN treated cells, compared to IR alone (Figure 2A). CGN or IR alone also
showed an increase in ROS accumulation. High levels of ROS are known to activate caspase-3 and
caspase-8, which are the key proteins of apoptosis [25]. The activities of caspase-3 and caspase-8, but
not caspase-9, were elevated after IR followed by CGN in comparison to IR alone in MDA-MB-231 cells
(Figure 2B). Consistent with these results, an increase in cleaved caspase-3 level in the IR and CGN
treated cells, compared to the other groups, was also confirmed by western blot (Figure S3). These
results indicate that apoptosis-related cell death is efficiently induced by CGN following IR, which is
consistent with the PI and Annexin V staining (Figure 1).
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Figure 2. IR exposure in combination with CGN increases ROS accumulation in MDA-MB-231 cells.
Cells were treated with 4 Gy IR, followed by CGN on the next day, and then analyzed 72 h after IR. (A)
ROS was measured by DCFDA. Columns, mean (n = 5); bars, SE. *, p < 0.05. (B) Caspase-3, caspase-8,
and caspase-9 activities were detected by microplate reader at specific wavelengths: caspase-3 excitation
(Ex)/emission (Em) = 535/620 nm; caspase-8 Ex/Em = 490/525 nm; caspase-9 Ex/Em = 370/450 nm.
Columns, mean (n = 5); bars, SE. **, p < 0.01; ns, not significant. (C) Cells stained with α-tubulin (green)
and PI (red) after treatments. Bar, 25 μm. (D) To measure polyploid populations, cells were treated with
staining solution and PI and analyzed by flow cytometry. Columns, mean (n = 3); bars, SE. *, p < 0.05.
Besides apoptotic cell death, IR is known to cause mitotic catastrophe [26,27], a mechanism of
mitosis-linked cell death resulting in polyploid cell formation [28]. Generation of ROS is also reported
to permit inappropriate entry into mitosis and induce mitotic catastrophe [29]. To determine whether
mitotic catastrophe was induced by CGN combined with IR, we analyzed polyploid formation in the
cells by immunofluorescence. Under confocal fluorescence microscopy, abnormal polyploid giant cells
were observed in both the IR alone and combined treatment groups (Figure 2C). The proportion of
polyploid cells was significantly increased by combined treatment with CGN and IR compared to IR
alone (Figure 2D). These data suggest that CGN can increase ROS accumulation in irradiated cells,
which may further enhance caspase-mediated apoptosis and mitosis-related cell death.
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2.3. CGN Inhibits the Radiation-Induced Invasiveness of Breast Cancer Cell Lines
Cancer cells with high invasive capacity are correlated with poor prognosis [30,31]. Several groups
have reported that failure of tumor control by IR could be associated with cancer invasiveness and
subsequent distal metastasis [32,33], highlighting a potentially undesirable effect of radiotherapy. Our
previous studies showed that cancer cell invasiveness could be increased in the surviving population
after IR treatment through integrin-mediated pathways [34,35]. We, therefore, investigated CGN’s
effect on the invasiveness of surviving cells after IR. The invasive activity was increased in the breast
cancer cell lines after IR treatment, as we have reported previously [35].
Interestingly, the invasive ability of MDA-MB-231 (Figure 3A) and 4T1 (Figure 3B) breast cancer
cell lines was significantly lower in the combined treatment with IR and CGN compared to IR alone.
Cell viability was not affected during the invasion assay (Figure S4). These data indicate that CGN
suppresses the IR-related invasiveness of these cells. Compared to the results of cytotoxicity depicted
in Figures 1 and 2, CGN showed a higher anti-invasive effect which is specific in post-IR cells. This
effect was more obvious in MDA-MB-231 cells, which leads to a more significant reduction in invasive
ability than that of CGN alone, suggesting the possibility that CGN suppresses specific mechanisms,
which induced the increase in invasiveness in post-IR cancer cells. To further confirm the effect of
CGN in the invasive growth of cancer cells, we performed 3D laminin-rich ECM (lrECM) culture.
Culturing cells in 3D lrECM is a common method to assess the physiologically relevant morphogenesis
and oncogenic properties of non-malignant or cancerous mammary epithelial cells [36]. As shown in
Figure 3C, untreated MDA-MB-231 cells under 3D culture displayed aggressive invasive growth with
stellate protrusions extending into the lrECM. The formation of protrusions was reduced in cancer
cells that received the combination of CGN and IR treatment, indicating suppression of their invasive
capacity in 3D lrECM culture.
Figure 3. CGN inhibits the IR-induced invasive activity and 3D lrECM growth in breast cancer cells.
(A, B) The invasive activity was measured by Matrigel chemoinvasion assay after IR and/or CGN
treatments in MDA-MB-231 (A) and 4T1 (B) cells. Columns, mean (n = 4); bars, SE. **, p < 0.01;
***, p < 0.001. (C) MDA-MB-231 cells were cultured in 3D lrECM. Bar, 50 μm.
2.4. Upregulation of RacGAP1 Is Involved in Cancer Cell Survival and Invasion after IR
To determine the effects on molecular pathways, differential gene expression in each treatment
group was assessed by cDNA microarray. We selected the genes that were both upregulated by
IR treatment and suppressed by the following CGN treatment (Figure S5). From these genes, we
focused on RacGAP1 as a potential target (Figure 4A) because this protein is intimately connected
with integrin signaling, which we have been mainly working on [34,35,37]. Moreover, RacGAP1 is
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recently reported to have important roles in oncogenic activity [19], tumor progression [15,16], and
cancer invasion [38,39].
Figure 4. Upregulation of RacGAP1 is involved in cancer cell survival and invasion after IR. (A) Gene
expression was analyzed by cDNA microarray. RacGAP1 expression level is shown by the heat map.
The values were normalized to the untreated group. (B) RacGAP1 protein expressions with different
doses of IR were analyzed in MDA-MB-231, FaDu, PANC-1, and 4T1 cell lines. (C) MDA-MB-231
cells were transfected with siRNA duplexes targeting RacGAP1 (# 1 or # 2) or the control sequence, as
indicated. Cell lysates were subjected to western blot two days after transfection. (D–H) MDA-MB-231
cells were transfected with siRNAs and incubated for two days, and then treated with 4 Gy IR. Each
experiment was performed 24 h after IR treatment. Cell viability was quantified by cell counting (D).
Apoptotic cells were measured by Annexin V-FITC staining and flow cytometry (E). ROS was measured
by DCFDA (F). Cells were treated with staining solution and PI, and then the cell cycle was analyzed
by flow cytometry. The percentage of polyploid cells in each group was normalized with control group
(G). The invasive activity was measured by Matrigel chemoinvasion assay (H). Columns, mean (n ≥ 3);
bars, SE. *, p < 0.05; **, p < 0.01. Data shown in (D–H) were normalized to that of MDA-MB-231 cells
transfected with siRNA control. For the continuous full length-image of Western blot signals, please
refer to Supplementary Materials Figure S7.
To investigate its role in irradiated cells, protein levels of RacGAP1 were determined after IR
treatment in different types of cancer cell lines (Figure 4B). RacGAP1 was found to be upregulated
after IR treatment, suggesting that it plays a role in the cellular response to radiation. Compared to the
control group, knockdown of RacGAP1 by siRNA (Figure 4C and Figure S6) resulted in a significant
decrease in cell viability following IR treatment (Figure 4D). Knockdown of RacGAP1 also increased
the apoptosis, ROS accumulation, and polyploid formation after IR treatment in MDA-MB-231 cells
(Figure 4E–G). Furthermore, knockdown of RacGAP1 effectively suppressed the IR-induced invasion
activity of cancer cells (Figure 4H). These results indicate that RacGAP1 inhibition could increase
the effectiveness of IR by reducing both cell viability and IR-induced invasiveness, which was also
achieved by adding CGN after IR.
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2.5. RacGAP1 Expression Is Suppressed by CGN in MDA-MB-231 Cells
The cDNA microarray data suggest that CGN treatment suppresses RacGAP1 (Figure 4A).
Consistent with the gene expression data, we also confirmed that the protein expression of RacGAP1
was significantly downregulated by CGN (Figure 5A). Moreover, elevation of RacGAP1 protein levels
following IR, and its suppression after CGN treatment were also confirmed by western blot (Figure 5B).
Immunofluorescent staining showed that RacGAP1 mainly localized in the nucleus and that its nuclear
level was increased after IR and suppressed by CGN treatment (Figure 5C).
Figure 5. RacGAP1 expression is suppressed by CGN in MDA-MB-231 cells. (A) Protein expression of
RacGAP1 was analyzed after treatment with different concentrations of CGN in MDA-MB-231 cells.
Total cell lysates were subjected to western blot. (B) RacGAP1 protein expression was analyzed using
cell lysates after IR and/or CGN treatment in MDA-MB-231 cells. (C) Immunofluorescence images show
RacGAP1 (green), α-tubulin (red) and nuclei (blue). Bar, 25 μm. (D) RacGAP1-mVenus expression
was induced by doxycycline in MDA-MB-231 cells. RacGAP1 expression was analyzed by western
blot using anti-RacGAP1 antibody. Dox, doxycycline. (E) Cell number was quantified by cell counting.
Columns, mean (n = 3); bars, SE. *, p < 0.05; **, p < 0.01. For the continuous full length-image of Western
blot signals, please refer to Supplementary Materials Figure S7.
To further confirm that the downregulation of RacGAP1 is involved in the cytotoxic effect of
CGN, we generated a doxycycline-inducible overexpression system of RacGAP1 (Figure 5D). RacGAP1
overexpression partially reduced the cytotoxicity caused by CGN with or without IR treatment
(Figure 5E), which suggests that RacGAP1 is indeed an important molecular target in CGN treatment.
2.6. CGN in Combination with IR Decreases Tumor Size and Metastasis in a Mouse Xenograft Model
To determine the in vivo effect of adjuvant CGN treatment after IR, we used a 4T1 xenograft
animal model with the experimental schedule shown in Figure 6A. Tumor growth was significantly
decreased in the group treated with CGN after IR compared to either CGN or IR treatment alone
(Figure 6B). Similarly, the terminal tumor size at day 25 was smallest in the CGN and IR group
(Figure 6C). Local invasion is the initial step in the spread of cancer cells from a local site to distant
metastasis sites [30]. Therefore, we next determined the therapeutic effect of CGN in combination
with IR on distant metastasis. Compared to the other groups, combined treatment with IR and CGN
significantly inhibited lung metastasis (Figure 6D). We then confirmed RacGAP1 expression within
tumors. Consistent with the in vitro data shown in Figure 5, RacGAP1 was suppressed in 4T1 tumors
treated by either CGN alone or CGN in combination with IR (Figure 6E). Taken together, these results
indicate that adjuvant CGN treatment effectively suppresses primary tumor growth and reduces
metastatic potential, which may be the result of RacGAP1 suppression.
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Figure 6. Radiation followed by CGN treatment decreases tumor size and metastasis in a 4T1 mouse
xenograft model. (A) Treatment schedule of each group. Mouse 4T1 cells were injected into Balb/c
mice (n = 6–7 in each group). (B) 4T1 tumor sizes were measured and normalized to size at day 12 in
each group. (C) Relative tumor size for each group was measured on Day 25. Scatter plot; mean ± SE.
*, p < 0.05. (D) Representative H&E images of lung sections. Bar, 500 μm. Arrow, metastatic lung
nodules. The number of metastatic lung nodules was counted (right panel). Scatter plot; mean ± SE.
*, p < 0.05. (E) Sections from 4T1 tumors were subjected to IHC staining with antibodies against
RacGAP1. Bar, 100 μm. RacGAP1 expression level was determined by scoring, as described in the
methods (right panel). Scatter plot; bars, mean (n = 5). *, p < 0.05.
3. Discussion
In this study, we tested CGN as an adjuvant therapy to improve the effectiveness of radiotherapy.
Administration of CGN to IR treatment increased cancer cell death. Furthermore, CGN treatment
resulted in notable suppression of IR-induced cancer cell invasion. RacGAP1 signaling is a possible
molecular mechanism of CGN effect after IR treatment on cancer cells. In the 4T1 xenograft model,
combined treatment of IR and CGN significantly suppressed the tumor growth and lung metastasis.
Although local radiotherapy improves cancer treatment outcomes, recurrence or distant metastases
following local treatment remain major therapeutic challenges. Local recurrences or distant metastases
could be partially due to the enhancement of invasive properties in surviving cancer cells after IR [33].
We and others have shown that integrins are involved in the acquisition of cancer cell invasion
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after IR [34,35,40]. Several studies have reported that α5β1-integrin trafficking regulates RacGAP1
activation, which is essential to promote pseudopod extension and cancer cell invasion [19,38]. Here,
we show that upregulation of RacGAP1 after IR is accompanied by increased invasion activity, and
depletion of RacGAP1 significantly suppressed IR-induced cancer cell invasion (Figure 4). Moreover,
CGN suppresses IR-induced invasiveness, which is partially restored by overexpression of RacGAP1
(Figure 5). These findings suggest that upregulation of RacGAP1 in cancer cells after IR treatment may
be one of the pivotal mechanisms contributing to IR-induced invasiveness. The detailed regulatory
mechanisms of RacGAP1 on IR-induced invasion should be investigated in future studies.
Previous studies suggest that RacGAP1 is a potential therapeutic target for the treatment of highly
aggressive cancers. The clinical significance of RacGAP1 has been widely reported, and its expression
in tumors is associated with more aggressive phenotypes in many cancers, including high-grade breast
cancer, epithelial ovarian cancer, gastric cancer, colorectal cancer, and hepatocellular carcinoma in the
transition from low- to high-invasive disease [15,20,39,41,42]. Besides, RacGAP1 is implicated in the
resistance to doxorubicin treatment in squamous cell carcinoma [43]. To our knowledge, this is the first
report to connect RacGAP1 to radiation resistance. In addition, we reveal a novel method for targeting
RacGAP1 by administering CGN after radiation therapy, which may lead to future clinical application.
Besides RacGAP1, other genes were also found to be upregulated by IR and suppressed by
the following CGN treatment (Figure S5). Within these genes, AKAP9, CENPE, PRKCI, RDX,
RECQL, and USO1 have also been reported to be associated with cancer progression [44–55].
AKAP9 (encodes A-kinase anchor proteins-9) is involved in the development of metastasis of several
cancers, including colorectal cancer [44], breast cancer [45], lung cancer [46], melanomas [47], thyroid
carcinomas [48]. Inhibition of CENPE-encoded protein CENPE (Centromere-associated protein E),
a kinetochore-associated mitotic kinesin, has been shown to induce cancer cell apoptosis and tumor
regression [49]. PRKCI (encodes protein kinase C, iota) is overexpressed in ovarian cancer [50] and
was suggested to promote immune suppression [51]. RDX (encodes radixin) is overexpressed in
many tumor tissues and was suggested to enhance colon cancer cell invasion [52]. RECQL-encoded
RecQ helicase-like protein is a DNA helicase which plays a vital role in the DNA damage response,
and the mutation of RECQL has been suggested as a plausible candidate breast cancer susceptibility
gene [53]. Knockdown of USO1 (encodes general vesicular transport factor p115) was shown to
inhibit cell proliferation and induce cell apoptosis in multiple myeloma cells [54] and colon cancer
cells [55]. Although these molecules have various functions in cancer cells, they may be involved in
radioresistance or radiation-induced invasion that can be targeted by CGN adjuvant treatment. Roles
of these molecules and related mechanisms could be investigated in the future.
In our study, an increase in the proportion of polyploid cells was noted after the combined treatment
with IR and CGN. Polyploid cells are considered the result of enhanced mitotic catastrophe [27,56].
Eriksson et al. revealed that IR treatment leads to a dose-dependent induction of morphological
mitotic catastrophes and polyploid formation [28], which is accompanied by delayed DNA damage
from IR [26]. The proportion of polyploid cells in HeLa Hep2 cells increases from 2.8 ± 1.3% to
17.6 ± 2.1% following treatment with 10 Gy [28]. Our data show that the proportion of polyploid cells
in MDA-MB-231 cells was 5.6 ± 2.7% in the untreated group, 12.9 ± 1.7% in the CGN group, 17.6 ± 3.3%
in the 4 Gy IR group, and 26.1 ± 1.9% in the IR and CGN group. Our results show that IR followed by
CGN led to a higher proportion of polyploid cells, indicating that CGN could enhance the induction of
cellular mitotic catastrophe following IR treatment. Aside from CGN, a variety of anticancer drugs
are also known to induce mitotic catastrophe by influencing the stability of microtubule spindles or
defective cell cycle checkpoints [57]. Mansilla et al. reported the result of mitotic catastrophe caused
by the chemotherapeutic agent doxorubicin and the anthracycline antibiotic WP631 in MDA-MB-231
cells and MCF-7/VP cells [58]. In their study, treating cells with both agents resulted in increased
polyploid formation, followed by increased cell death. The activation of the caspase-3-related apoptotic
pathway was only observed in MDA-MB-231 cells treated with doxorubicin, indicating that caspase is
not mandatory for cell death induced by mitotic catastrophe. In our study, cells cultured with CGN
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increased caspase-3 activity as well, suggesting that different patterns of cell death are also caused
by CGN.
In Figure 6, single IR or CGN failed to control the tumor growth and metastasis in vivo. In this
mouse model, we chose a low dose of IR treatment on a big tumor (about 500 mm3) to elucidate the
adjuvant effect of CGN with IR. IR was treated from day 12 after injection of 4T1 cells. In fact, on day
12, the tumor size is already too big to be affected by 2 Gy × 4 dosages. In our preliminary experiments,
when we treat the mice with higher doses (2 Gy × 5) on the smaller tumor (less than 100 mm3),
we observed the effect by IR alone as compared with the untreated group. Several studies have
reported the utilization of CGN in cancer immunotherapy. CGN promotes dendritic cell maturation
through toll-like receptor 4 signaling [13]. CGN-treated dendritic cells significantly inhibited the tumor
growth of murine lung tumor TC-1 compared with the control group [13]. In addition, a previous
report showed that intratumoral injection of CGN decreases tumor growth in the B16-F10 or 4T1 tumor
model in vivo by stimulating immune responses [11]. They treated with CGN every two days in the
early stage of the subcutaneous 4T1 tumor growth, which decreased significantly 25 days after tumor
inoculation in the CGN-treated group compared to the control group. In contrast, we showed that
CGN treatment alone did not inhibit in vivo 4T1 tumor growth (Figure 6B), while it decreased cell
viability in vitro (Figure 1A). We started CGN injection in the late stage of tumor growth and limited
the treatment to three injections to better assess the adjuvant effect of CGN for radiation therapy.
Therefore, the different in vivo results for CGN alone may be due to the differences in starting time
and a total number of CGN injections. It has also been reported that radiation affects immune cells
surrounding the irradiated tumors [59], but its role in either stimulating or dampening anti-tumor
responses is not fully understood. To effectively induce the immune response by CGN combined with
IR, the treatment condition should be optimized. Further investigation into the alteration of infiltrating
immune cell subsets following treatment with IR and CGN may lead to a better understanding of their
combined cytotoxic effects.
Carrageenan has been considered to cause inflammatory events of the gastrointestinal tract,
which may limit the utilization to use in clinical treatment. Early studies reported that CGN
administered in drinking water or diet could cause intestinal inflammation and ulcers in animals [60,61].
This phenomenon has been exacerbated in animal studies where CGN injected into confined spaces in
an animal’s body, such as the hind paw, pleural space, or peritoneal cavity [62,63]. However, safety
studies conducted over the last 15–20 years in which CGN was administered to test animals through
the diet have not shown any adverse effects [64]. These conflicting results are thought to be due to
the difference in the purity of “carrageenan” [65]. McKim et al. found that commercial CGN can be
diluted with sugars (dextrose or sucrose) and, thus, the potential to inadvertently add contaminants,
such as bacteria, is high. In our study, the purity of CGN we used is 88.72 ± 2.21%, which is higher
than the previous study used [65]. On the other hands, the amount of glucose was 4.23 ± 0.62% of the
initial weight. These results suggest that high purity CGN which we used would be difficult to cause a
pro-inflammatory effect.
In our study, the expression of RacGAP1 was found to be significantly suppressed by CGN
treatment. Although the detailed mechanism is still unclear, other studies suggest possible pathways.
For instance, Signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor which
has been reported to activate the transcription of RacGAP1 in hepatocellular carcinoma cells [42].
Several studies reported that some polysaccharides from plants could induce biological effects in cells
via suppression of STAT3-related pathways [66,67]. Therefore, it is reasonable to the hypothesis that
CGN, as a natural polysaccharide, regulates the expression of RacGAP1 via STAT3-related pathway.
These studies may provide us the clues about the mechanism of how CGN regulates RacGAP1, which
are worth further investigation.
Taken together, our results suggest a possible therapeutic strategy involving CGN treatment as an
adjuvant to radiotherapy for the suppression of tumor growth and the reduction of distant metastasis.
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4. Materials and Methods
4.1. Cell Culture
MDA-MD-231 human breast cancer cell line (ATCC® HTB-26™), PANC-1 human pancreatic
cancer cell line (ATCC® CRL-1469™), FaDu human head and neck cancer cell line (ATCC® HTB-43™)
and 4T1 mouse mammary carcinoma cell line (ATCC® CRL-2539™) were purchased from American
Type Culture Collection (ATCC; Manassas, VA, USA). MDA-MB-231 and PANC-1 cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM; Nacalai Tesque, Kyoto, Japan) containing 10% fetal
bovine serum (FBS; HyClone, GE Healthcare Life Sciences, Logan, UT, USA). FaDu cells were cultured
in minimum essential medium eagle (Sigma-Aldrich, St Louis, MO, USA) containing 10% FBS. 4T1
cells were cultured in RPMI-1640 (Sigma-Aldrich) containing 10% FBS.
4.2. Carrageenan
Lambda-carrageenan plant mucopolysaccharide (Sigma-Aldrich, Lot number BCBP8978V) was
dissolved in Milli-Q water at a concentration of 10 mg/mL. The typical molecular weight ofλ-carrageenan
was reported as 1054 kDa [68]. The purity of carrageenan used in this study was 88.72 ± 2.21%, which
was determined by EDTA/2-propanol recovery method [65]. The amount of glucose/dextrose dissolved
in the wash solution was also determined by Picoprobe Glucose Assay Kit (Abcam, Cambridge, UK),
and the results suggest that 4.23 ± 0.62% of the initial weight is accounted by glucose. To dissolve
CGN in water, the solution of CGN was gently shaking for 24 h in 37 ◦C. And then, CGN was filtered
through 0.45 μm filters (Advantec, Tokyo, Japan). Cells were treated with 2.5 mg/mL CGN or Milli-Q
water for 24 h after 4 Gy IR treatment.
4.3. Irradiations
Cells were irradiated with 4 Gy 130 kV X-rays using a CellRad X-ray generator (CellRad; Faxitron,
Tucson, AZ, USA). Mice were irradiated with a daily fraction of 2 Gy 125 kV X-rays for four days
(HITACHI).
4.4. Cell Viability Assay
Cells were seeded and treated with 4 Gy IR at 50–60% confluency. Twenty-four hours after IR,
cells were treated with 2.5 mg/mL CGN (approximately 2.2 mg/mL CGN is contained considering
purity mentioned above) or Milli-Q water for 48 h and then subjected to each experiment. Cell viability
and cytotoxicity were examined by cell counting using the trypan blue exclusion method and flow
cytometry after PI staining. The proportion of PI-positive cells was quantified by placing polygon gate.
4.5. Apoptosis Analysis
Annexin V staining was performed using an Annexin V-FITC Apoptosis Detection Kit (Abcam).
Cells more than 1 × 105 were harvested, resuspended in 500 μL binding buffer, and incubated with
Annexin V-FITC and PI for 5 min at room temperature in the dark. Fluorescence was analyzed using a
FACSAria III flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Mean fluorescence intensity
of FITC was calculated and normalized to the untreated group.
To determine caspase activity, caspase-3, caspase-8, and caspase-9 multiplex activity assay kit
(Abcam) was used. Briefly, cells were treated and seeded in 96-well plates at 2 × 104 cells/100 μL
FACS buffer (2% FBS in PBS). After incubation at 37 ◦C, 5% CO2 for 1 h, fluorescence was monitored
using a microplate reader (CLARIOstar; BMG LABTECH, Ortenberg, Germany) with the following
wavelengths: caspase-3 excitation (Ex)/emission (Em) = 535/620 nm; caspase-8 Ex/Em = 490/525 nm;
caspase-9 Ex/Em = 370/450 nm.
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4.6. ROS Detection Assay
To measure ROS levels in cells, treated cells were stained with 20 μM dichlorofluorescein diacetate
(DCFDA) for 30 min at 37 ◦C using a Cellular ROS detection assay kit (Abcam). Cells were then
analyzed using a FACSAria III flow cytometer.
4.7. DNA Content and Polyploidy Analysis
For polyploidy analysis, 70% of ethanol was added slowly to cell pellets. Cells were stored at
-80 ◦C overnight, and then cells were centrifuged and washed with cold PBS two times. Cells were
then resuspended in 300 μL staining solution (0.1% (v/v) Triton X-100, 2 mg RNase A (NIPPON GENE,
Tokyo, Japan) and 400 μL of 500 μg/mL PI (Setareh Biotech, Eugene, OR, USA) in 10 mL PBS. After
incubation at 37 ◦C for 15 min, samples were analyzed by a FACSAria III flow cytometer.
4.8. Immunofluorescence
Cells were fixed in 4% paraformaldehyde (PFA), permeabilized with 0.2% Triton X-100/PBS,
and then washed with PBS. For examination of polyploidy, cells were incubated with an α-tubulin
(Cell Signaling Technology, Danvers, MA, USA) antibody after blocking, and then washed with PBS,
followed by incubation with an Alexa Fluor secondary antibody. Cell nuclei were counterstained with
PI. For images of RacGAP1 localization, cells were stained with an anti-RacGAP1 antibody (Abcam),
an α-tubulin antibody and DAPI. Images were acquired by Leica True Confocal Scanning (TCS) SP8
microscope system (Leica Microsystems, Wetzlar, Germany).
4.9. Matrigel Invasion Assay
The Matrigel chemoinvasion assay was performed using Biocoat Matrigel invasion chambers
(Corning Inc., Corning, NY, USA) or 24-well hanging inserts 8.0 μm PET Millicell cell culture inserts
(Merck Millipore, Darmstadt, Germany) coated with Matrigel growth factor reduced (GFR) basement
membrane matrix (Corning Inc.). For coating Millicell inserts, 100 μL serum-free medium containing
400 μg/mL Matrigel was evenly distributed on the membrane of the Millicell insert chamber, followed
by incubation at 37 ◦C for at least 2 h. During the invasion assay, cells suspended in the DMEM with
0.1% BSA were seeded on the upper chambers, and the lower wells were filled with DMEM with
10% FBS. After incubation for 8 h, cells that migrated out onto the lower surface of the membranes
were fixed in 4% PFA and stained with 1% crystal violet. Data were collected from four independent
experiments and normalized to the results of the untreated group.
4.10. Western Blotting
Western blotting was performed as described previously [35]. Briefly, cell lysates were separated
by SDS-PAGE or Nu-PAGE Bis-Tris protein gels (Thermo Fisher Scientific, Waltham, MA, USA), and
then transferred onto a polyvinylidene fluoride (PVDF) membrane (Merck Millipore), and then blocked
with Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, NE, USA). Membranes were probed
with primary antibodies, anti-RacGAP1 (Proteintech, Rosemont, IL, USA or Abcam) or anti-β-actin
(Sigma-Aldrich, St Louis, MO, USA), and then washed with Tris-buffered saline Tween-20 (TBST). The
membranes were incubated with secondary antibodies and then washed with TBST. The signals were
detected with an Odyssey CLx Imager (LI-COR Biosciences).
4.11. Microarray Analysis
After treatment with CGN and IR, total RNA of MDA-MB-231 cells was isolated using a
NucleoSpin® RNA kit (MACHEREY-NAGEL, Düren, Germany). For the microarray analysis, the high
sensitivity 3D-Gene® Human oligo chip 25k version 2.10 (Toray Industries, Tokyo, Japan) was used.
The data were normalized and analyzed by Toray Industries. Gene expression values lower than 100
after global normalization were excluded. To focus on the effects of CGN, genes were selected by the
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following order (Figure S1). First, genes increased 1.25-fold or higher in the IR group compared to the
untreated group were selected. Second, genes reduced to one-eighth or less in IR and CGN treatment
groups, compared to untreated, were selected. The genes that meet both of these criteria were selected
as candidates for further analyses.
4.12. siRNA and Transfection
To knockdown RacGAP1, siRNAs with the following sequences were used: negative control:
5′-GUUUAUUGACAAGUUAAGAdTdT-3′ (sense), 5′-UCUUAACUUGUCAAUAAACdTdT-3′
(antisense); siRacGAP1 # 1: 5′-CAGGUGGAUGUAGAGAUCAAAdTdT-3′
(sense), 5′-UUUGAUCUCUACAUCCACCUGdTdT-3′ (antisense); siRacGAP1 # 2:
5′-CUAGGACGACAAGGCAACUUUdTdT-3′ (sense), 5′-AAAGUUGCCUUGUCGUCCUAGdTdT-3′
(antisense). The siRNA duplexes were synthesized by Hokkaido System Science. Cells were transfected
with siRNA duplexes using Lipofectamine RNAiMAX (Thermo Fisher Scientific).
4.13. Overexpression
For RacGAP1 overexpression, complementary DNA (cDNA) of RacGAP1 was obtained by
PCR from the first-strand cDNA of MDA-MB-231 cells. The RacGAP1 cDNA was subcloned into the
mVenus N1 vector and followed by subcloning into a PiggyBac transposon-based doxycycline-inducible
vector, pPB-TRE3G-MCS-CEH-rtTA3-IP [69]. Transfection of the resulting RacGAP1-mVenus plasmid,
together with a hyperactive PiggyBac transposase vector [69] to MDA-MB-231 cells was performed
by ViaFect transfection reagent (Promega, Madison, WI, USA), and cells were selected by puromycin.
The expression of RacGAP1-mVenus was induced by the addition of 200 ng/mL doxycycline.
4.14. In Vivo Study
One million 4T1 cells in 100 μL PBS were injected into the left thighs of six-week-old Balb/c mice
subcutaneously. Eleven days after inoculation, the mouse tumors were treated with a daily fraction of
2 Gy of X-rays for four days under anesthesia. Tumors were treated with 50 mg/kg CGN or PBS 3 times
by intratumoral injection one week after the first IR fraction. Tumor size was measured after radiation
and normalized to the tumor size measured on the first day after radiation. All animal procedures were
approved by the Institutional Animal Care and Use Committee of Hokkaido University (# 16-0137).
4.15. Immunohistochemistry
The tumor tissues were collected and placed in 4% PFA solution, fixed for 24 h, dehydrated through
a gradient of ethanol, and embedded into paraffin blocks for immunohistochemistry. The paraffin
blocks were cut to 4 μm sections and mounted onto microscope slides for analysis. For antigen retrieval,
the slides of tumor sections were incubated with antigen unmasking solution (Vector Laboratories,
Burlingame, CA, USA) at 80 ◦C for 1 h. Endogenous peroxidase activity was quenched using 3% H2O2
in 10% methanol. Each slide was incubated in 2% blocking buffer (Roche, Basel, Switzerland) for 1
h, and then incubated with a RacGAP1 primary antibody (Proteintech) overnight. Super Sensitive
IHC Detection Systems (BioGenex, Fremont, CA, USA) were used to amplify the signal. Sections were
stained with horseradish peroxidase (HRP) secondary antibodies. After two washes, the slides were
counterstained with hematoxylin (Muto Pure Chemicals, Tokyo, Japan). Positive staining was scored
using the following formula: (r3/t) × 3 + (r2/t) × 2 + (r1/t) × 1, where t is the total area of tumor tissue for
a whole tumor section, r3 is the total area of high-intensity staining (intensity 3), r2 is the total area of
medium intensity staining (intensity 2), and r1 is the total area of weak intensity staining (intensity 1).
4.16. Statistical Analysis
All in vitro results were confirmed by at least three independent experiments. Data were analyzed
by two-tailed Student’s t-tests. Graphs are presented in columns as mean values ± standard error of the
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mean (SEM). For in vivo experiments (n = 6–7 in each group), normality of the data sets was examined
by the Kolmogorov-Smirnov test, where p > 0.05 state in a normal distribution. After the judgment
of the equality of variance by the F-test, statistical significance was examined by the two-tailed t-test
for equal variance or t-test with Welch correction for unequal variances. For data with non-normal
distribution, statistical significance was examined by the Mann-Whitney test after confirming equal
variance by the F-test. Graphs are presented in scatter plots. Significant differences are indicated by
* p < 0.05, ** p < 0.01, *** p < 0.001 and n.s. for not significant.
5. Conclusions
In this study, we found that RacGAP1 expression is increased after irradiation and associated with
cancer cell invasion. We also found that CGN treatment following radiotherapy effectively suppressed
the expression of RacGAP1 in in vitro cell culture and in vivo mouse tumor model. Based on these
data, we conclude that CGN enhances the effect of radiotherapy by suppressing cancer cell survival
and invasiveness through the RacGAP1 pathway. We propose the novel application of CGN as an
adjuvant for radiotherapy in clinical use.
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